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Abstract 
The aim of this research study was the synthesis of an imaging agent, which could 
be used to non-invasively image atherosclerotic plaques via MRI. In order to 
achieve this, a library of peptide substrates designed to be substrate specific for 
either legumain or MMP-2/9 were synthesized. This was achieved via a 
combination of both solid and solution phase peptide synthesis. The first phase of 
the research study focused on the synthesis of a targeted MRI contrast agent 
designed to image legumain expressing atherosclerotic plaques. This was achieved 
by using a Fluorescent Resonance Energy Transfer (FRET) active system to 
evaluate the substrate specificity of synthesized peptide sequences for legumain. 
The self quenched FRET substrates were engineered to carry a legumain sensitive 
bond in between the donor (5(6)-carboxyfluorescein) and quencher 
(aminoanthraquinone) moiety. Legumain mediated activation of the FRET 
substrates was measured via fluorescence spectroscopic analysis which showed 
the release in fluorescence that was initially quenched by the anthraquinone 
moiety. Optimized peptide sequences were then covalently coupled to the 
gadolinium chelate (Gd-DOTA) so that, upon enzymatic cleavage, the contrast 
agent could be released at the site of activation. Mass spectrometric analysis on 
the post enzyme digested samples (incubated with recombinant human legumain) 
showed that the substrates were fragmented by the activated enzyme in vitro. The 
targeted MRI contrast agent and FRET substrates were successfully synthesized 
and then characterized by low/high resolution mass spectrometry. Additionally 
cytotoxic studies on selected compounds and a model of the enzyme-digested 
product [Lys(DOTA-Gd)-Sp-AQ] via MTT assay demonstrated that the compounds 
did not affect the cell viability of MDA-MB-231 cell line.  
The second phase of this project was the synthesis of an aminoanthraquinone 
peptide substrate coupled to a contrast agent (CA). This substrate was designed 
to be specific to MMP-2/9. Although the synthetic strategy was successful, 
subsequent reaction optimization will be required (increasing yield) before in vitro 
CA release could be evaluated. Thus, the targeted MRI CAs synthesized during this 
research study provide a starting point for novel imaging agents. These agents, 
which upon successful in vitro and in vivo trials could potentially be used to image 
legumain expression or MMP (2/9) expression or atherosclerotic plaques.  
Keywords: Atherosclerosis; MMPs; Contrast agent; FRET; Legumain; Gd-DOTA. 
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HPLC  High performance liquid column chromatography 
Hrs 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ICAM-1 Intercellular adhesion molecule-1 
IL   Interleukin  
Ile 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i-Pr-OH  Isopropyl alcohol  
IVUS  Intravascular ultrasound 
kDA  Kilo Daltons 
LDL   Low density lipids  
Leu   Leucine 
LSAM  Legumain stabilization and activity modulation 
m/z   Mass/charge   
MeOH  Methanol 
Met  Methionine 
MI   Molecular imaging  
MMP   Matrix metalloproteinase  
MRI   Magnetic resonance imaging  
MT-MMPs  Membrane type MMPs  
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NIRF  Near infrared fluorescence  
Nva   Norvaline   
NSF   Nephrogenic systemic fibrosis 
OCT  Optical coherence tomography 
PAMAM  Polyamidoamine  
PDGF   Platelet-derived growth factor  
PEG  Polyethylene glycol 
PET   Positron emission tomography 
Phe  Phenylalanine  
ppm  Parts per million 
Pro   Proline   
PS-SPL Positional scanning-synthetic peptide library. 
PSV  Protein storage vacuole 
PVD   Peripheral vascular disease  
PyBOP  Benzotriazol-1-yl-oxytripyrrolidinophosphoniumhexafluoro 
                   phosphate 
RER  Rough endoplasmic reticulum 
Rt   Room temperature   
Ser   Serine   
SMC   Smooth muscle cells  
SP  Signal peptide 
SPECT  Single-photon-emission computed tomography  
SPPS   Solid phase peptide synthesis  
TA   Thioanisole  
tBoc   Tertiarybutoxycarbonyl  
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TBTU  O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluroniumtetrafluoro 
borate 
TETA          1,4,8,11-Tetraazacyclotetradocane-N, N’, N’’, N’’’-tetraacetic acid 
TFA   Trifluoroacetic acid 
Thr   Threonine   
TIMPs  Tissue inhibitors of metalloproteinase  
TLC    Thin layer chromatography 
TNF   Tumor necrosis factor 
Tyr  Tyrosine 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VCAM-1 Vascular cell adhesion molecule-1 
VPE  Vacuole processing enzyme 
VSMCs  Vascular smooth muscle cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 1 - 
 
Contents 
 
 
Abstract 
Declaration 
Dedication 
Acknowledgement 
Abbreviations 
1. Introduction  
        
1.1. Atherosclerosis        …1  
1.1.1. Morphology of atherosclerosis     …2 
1.1.2. Clinical impacts of atherosclerosis     …4  
1.1.3. Risk factors developing atherosclerosis    …5 
1.1.4. Current therapies to treat atherosclerosis   …6 
1.2. Matrix metalloproteinase (MMPs)     …10 
1.2.1. Parameters for the regulation of MMPs    …11 
1.2.2. Structure of a MMP       …12 
1.2.3. MMPs and their role in atherosclerosis    …13 
1.2.4. MMP-2 and MMP-9       …15 
1.2.5. MMP-9/2 and its substrate specificity    …16 
1.2.6. Legumain in MMP activation and plaque progression  …19 
1.3. Legumain        …20  
1.3.1. Structure and role of legumain in mammals   …21 
1.3.2. Legumain expression in atherosclerosis    …23 
1.3.3. Legumain – substrate specificity     …25 
1.4. Molecular imaging       …28 
1.4.1. Atherosclerosis and molecular imaging    …29 
1.4.2. Magnetic resonance imaging (MRI)    …33 
1.4.2.1. Contrast agents (CAs)     …37 
1.4.2.2. Paramagnetic gadolinium (Gd) - based CAs  …38 
1.5. Fluorescence resonance energy transfer (FRET)   …41 
1.5.1. FRET construct       …43 
1.5.1.1.  Anthraquinone as quencher     …44 
1.5.1.2.  5(6)-Carboxyfluorescein (5,6-CBF) as donor  …45 
  1.6.  Aim           …47 
1.6.1. Rationale         …47 
1.6.1.1. Peptide synthesis      …51 
1.6.1.2. Coupling, protection and deprotection procedure …52 
1.6.1.3. Choice of chelating agents and contrast agent …56 
 
 
 
- 2 - 
 
2. Results and Discussion 
 
2.1. Library of FRET peptide substrates designed to be specific to  
legumain         …59 
 2.1.1. Synthesis of FRET peptide substrates (JC series- 1st batch) …61 
 2.1.1.1. Step 1: Synthesis of proline/β-alanine labelled amino  
            acids (donor unit) (2, 4)     …62 
2.1.1.2. Step 2: Synthesis of anthraquinone-spacer conjugate                   
(acceptor unit) (5)      …65 
2.1.1.3. Step 3, 4 and 5: Synthesis of FRET tetra peptide  
 substrates (1st batch- JC series)    …67 
    I. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Leu-Spacer-AQ (8) …70 
    II. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Leu-Spacer-AQ (11) …72 
    III. Synthesis of 5(6)-CBF-Pro-Leu-Asn-Leu-Spacer-AQ (14) …72 
    IV. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Leu-Spacer-AQ (17) …73 
    V. Synthesis of 5(6)-CBF-β-Ala-Leu-Asn-Leu-Spacer-AQ (20) …74 
    VI. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Leu-Spacer-AQ (25) …74 
        A. Synthesis of intermediate compound H2N-Leu-Spacer 
   -AQ (21)        …76 
        B. Synthesis of intermediate compound H2N-Asn(Trt)-Leu 
   -Spacer-AQ (22)       …78 
        C. Synthesis of intermediate compound H2N-Gly-Asn(Trt) 
   -Leu-Spacer-AQ (23)      …80 
        D. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Leu-Spacer-AQ  
   (25)        …81 
2.1.1.4. Fluorescence measurements     …82 
2.1.1.5. Legumain activity assay     …84 
2.1.1.6. Synthesis of FRET peptide substrates (JC series-2) …87 
A. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Lys-Spacer-AQ (31) …91 
        I. Synthesis of intermediate compound H2N-Lys(Boc) 
  -Spacer-AQ (26)       …91 
 II. Synthesis of intermediate compound H2N-Asn(Trt)-Lys 
     (Boc)-Spacer-AQ (27)      …92 
 III. Synthesis of intermediate compound H2N-Gly-Asn(Trt) 
      -Lys(Boc)-Spacer-AQ (28)     …92 
 IV. Synthesis of intermediate compound HN-Pro-Gly-Asn 
      (Trt)-Lys(Boc)-Spacer-AQ (29)    …93 
 V. Synthesis of 5(6)CBF-Pro-Gly-Asn-Lys-Spacer-AQ (31) …94 
B. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Lys-Spacer-AQ (34) …96 
C. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Lys-Spacer-AQ (38) …96 
D. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Lys-Spacer-AQ (41) …97 
E. Synthesis of 5(6)-CBF-β-Ala-Pro-Ala-Asn-Leu-Spacer-AQ  
    (46)         …97 
2.1.1.7. Fluorescence measurements (JC- 2nd series)  …98 
2.1.1.8. Legumain activity assay (JC- 2nd sereis)   …99 
- 3 - 
 
2.1.2. MRI based contrast agents for imaging atherosclerotic  
         plaques (JS series)       …101 
2.1.2.1. Synthesis of Gadolinium-DOTA-Peptide substrates- JS 
            Linear sequences       …104 
A. Synthesis of Gd(III)DOTA-Pro-Ala-Asn-Leu-Spacer-AQ (49) …106 
I. Synthesis of intermediate compound DOTA(tBu)-Pro-Ala 
   -Asn(Trt)-Leu-Spacer-AQ (47)     …106 
II. Synthesis of intermediate compound DOTA-Pro-Ala-Asn 
   -Leu-Spacer-AQ (48)      …106 
III. Synthesis of Gd(III)DOTA-Pro-Ala-Asn-Leu-Spacer-AQ  
      (49)        …107 
B. Synthesis of Gd(III)DOTA-Pro-Gly-Asn-Leu-Spacer-AQ (53) …108 
2.1.2.2. Synthesis of Gadolnium-DOTA-Peptide substrates- JS 
             Lysine series       …109 
2.1.2.2.1. Synthesis of Gadolinium complex using 1,4,7,10 
               -Tetraaza cyclododecane-1,4,7,10-tetraacetic acid  
               (58)        …111 
I. Synthesis of Fmoc-Lys(Boc)-Spacer-AQ (54)   …111 
II. Synthesis of Fmoc-Lys-Spacer-AQ [TFA] (55)  …112 
III. Synthesis of H2N-Lys(DOTA-tBu)-Spacer-AQ (56)  …114 
IV. Synthesis of H2N-Lys(DOTA)-Spacer-AQ (57)  …115 
V. Synthesis of H2N-Lys(DOTA-Gd3+)-Spacer-AQ (58) …116 
2.1.2.2.2. Synthesis of JS-Lysine series of tetra peptide 
               substrates       …117 
A. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-Gd3+)-Spacer 
    -AQ (62)        …118 
I. Synthesis of Fmoc-Pro-Gly-Asn(Trt)-OH (59)  …118 
II. Synthesis of Fmoc-Pro-Gly-Asn(Trt)-Lys(DOTA-tBu) 
    -Spacer-AQ (60)      …118 
 III. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-OH) 
       -Spacer-AQ (61)      …119 
IV. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-Gd3+) 
       -Spacer-AQ (62)      …120 
B. Synthesis of Fmoc-β-Ala-Gly-Asn-Lys(DOTA-Gd3+) 
    -Spacer-AQ (66)       …121 
C. Synthesis of Fmoc-Pro-Ala-Asn-Lys(DOTA-Gd3+)-Spacer 
    -AQ (70)        …122 
D. Synthesis of Fmoc-β-Ala-Ala-Asn-Lys(DOTA-Gd3+) 
    -Spacer-AQ (74)       …123 
2.1.2.3. Legumain activity assay for JS series   …124 
2.1.2.3.1. Mass spectrometric results for compound 49 
               (JS-Linear series)      …125 
2.1.2.3.2. Mass spectrometric results for compound 70 
               (JS-Lysine series)      …126 
- 4 - 
 
2.1.2.4. Cytotoxicity assay      …127 
2.1.2.4.1. MDA-MB-231 cells      …129 
2.1.2.4.2. Cytotoxicity studies in MDA-MB-231 cells  …129 
2.1.3. Conclusion        …132 
2.1.4. Limitations        …134 
      2.1.5. Future work                …135 
2.2. MMP (2/9) targeted gadolinium based contrast agents for MR  
       Imaging of atherosclerotic plaques     …137 
2.2.1. Synthesis of peptide substrates designed to be specific to  
          MMP-2/9 (JJ series) via solid phase peptide synthesis  
(SPPS)         …138 
I. Synthesis of Fmoc-Ala-Pro-Leu-Gly-Ala-Ser-Gly-OH (75) …140 
II. Synthesis of Fmoc-Ala-Ala-Leu-Ala-Nva-Leu-Gly-OH (76) …141 
III. Synthesis of Fmoc-Lys-Pro-Ala-Gly-Nva-Ala-Gly-OH (77) …142 
IV. Synthesis of Fmoc-Gly-Pro-Arg(Mtr)-Glu(OtBu)-Ile-Thr (tBu) 
     -Ala-Gly-OH (78)       …142 
V. Synthesis of Fmoc-Ile-Pro-Arg(Mtr)-Thr(tBu)-Leu-Thr(tBu) 
    -Ala-Gly-OH (79)       …143 
VI. Synthesis of Fmoc-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr(tBu) 
     -Ala-Gly-OH (80)       …144 
2.2.2. Synthesis of Gadolinium-DOTA-Peptide substrate designed  
          to be specific to MMP-2/9      …145 
2.2.2.1. Attempted synthesis of JD-(Gd(III)-DOTA-Gly-12-amino     
            dodecanoicacid-Ala-Ala-Leu-Ala-Nva-Leu-Gly-OH)  …145 
I. Synthesis of 12-((((9H-fluoren-9-yl)methoxy)carbonyl)amino) 
    dodeca noic acid (81)      …146 
II. Synthesis of H-12-aminododecanoic acid-Ala-Ala-Leu-Ala 
     -Nva-Leu-Gly-2-ClTrt resin (82)     …147 
III. Synthesis of H-Gly-12-aminododecanoic acid-Ala-Ala-Leu 
      -Ala-Nva-Leu-Gly-2-ClTrt resin (83)    …148 
IV. Synthesis of HO-DOTA-Gly-12-aminododecanoic acid-Ala 
     -Ala-Leu-Ala-Nva-Leu-Gly-OH (84)    …148 
2.2.2.2. Synthesis of JL (87)      …149 
I. Synthesis of DOTA-tris(tBu)-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu 
   -Thr(OtBu) -Ala-Gly-Lys-Spacer-AQ (85)    …151 
II. Synthesis of HO-DOTA-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr 
    -Ala-Gly-Lys-Spacer-AQ (86)     …152 
III. Synthesis of Fmoc-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr 
      -Ala-Gly-Lys (DOTA(Gd3+))-Spacer-AQ (JL-87)  …152 
2.2.3. Conclusion        …153 
2.2.4. Limitations        …155 
2.2.5. Future work        …155 
- 5 - 
 
2.3 Structure library        …157 
 
3. Experimental         …181  
         
3.1. Chemicals and reagents       …181 
3.2. Analytical methods        …181 
3.2.1. Chromatography       …181 
3.2.2. UV-Visible spectrophotometer     …181 
3.2.3. Mass spectrometry (MS)      …181 
3.2.4. High Performance Liquid Chromatography (HPLC)  …182 
3.2.5. Proton nuclear magnetic resonance (1H NMR)   …184 
 
3.3. General synthetic methods      …184 
3.3.1. Solid phase peptide synthesis     …184 
3.3.2. Solution phase peptide synthesis     …185 
 
3.4. Synthesis of 1st batch-FRET tetra peptide substrates (JC series 
       -Leucine)         …186 
3.4.1. Synthesis of fluorescent labelled amino acids   …186 
    I. Synthesis of 5(6)-carboxyfluorescein-Pro-OtBu (1)  …186 
   II. Synthesis of 5(6)-carboxyfluorescein-Pro-OH (2)  …186 
   III. Synthesis of 5(6)-carboxyfluorescein-β-Ala-OtBu (3)  …187 
      IV. Synthesis of 5(6)-carboxyfluorescein-β-Ala-OH (4)  …187      
3.4.2. Synthesis of anthraquinone-spacer conjugate (5)  …187 
3.4.3. Synthesis of FRET tetra peptide substrates (JC series-1st 
batch)         …188 
3.4.3.1. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Leu-Spacer-AQ  
            (8)         …188 
 I. Synthesis of 5(6)-CBF-Pro-Ala-Asn(Trt)-Leu-OH (6)  …188 
 II. Synthesis of 5(6)-CBF-Pro-Ala-Asn(Trt)-Leu-Spacer-AQ  
  (7)         …189 
    III. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Leu-Spacer-AQ (8) …189 
3.4.3.2. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Leu-Spacer-AQ 
      (11)        …189 
I. Synthesis of 5(6)-CBF-Pro-Gly-Asn(Trt)-Leu-OH (9)  …189 
    II. Synthesis of 5(6)-CBF-Pro-Gly-Asn(Trt)-Leu-Spacer-AQ  
     (10)         …190 
III. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Leu-Spacer-AQ (11) …190 
3.4.3.3. Synthesis of 5(6)-CBF-Pro-Leu-Asn-Leu-Spacer-AQ  
      (14)        …190 
I. Synthesis of 5(6)-CBF-Pro-Leu-Asn(Trt)-Leu-OH (12) …190 
    II. Synthesis of 5(6)-CBF-Pro-Leu-Asn(Trt)-Leu-Spacer-AQ  
         (13)         …191 
III. Synthesis of 5(6)-CBF-Pro-Leu-Asn-Leu-Spacer-AQ (14) …191 
3.4.3.4. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Leu-Spacer-AQ 
             (17)        …191 
- 6 - 
 
     I. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Leu-OH (15)  …191 
     II. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Leu-Spacer-AQ (16) …192 
    III. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Leu-Spacer-AQ  
   (17)         …192 
3.4.3.5. Synthesis of 5(6)-CBF-β-Ala-Leu-Asn-Leu-Spacer-AQ 
      (20)        …192 
I. Synthesis of 5(6)-CBF-β-Ala-Leu-Asn-Leu-OH (18)  …192 
II. Synthesis of 5(6)-CBF-β-Ala-Leu-Asn-Leu-Spacer-AQ (19)…193 
III. Synthesis of 5(6)-CBF-β-Ala-Leu-Asn-Leu-Spacer-AQ  
     (20)         …193 
3.4.3.6. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Leu-Spacer-AQ 
            (25)        …193 
 I. Synthesis of intermediate compound H2N-Leu-Spacer 
-AQ (21)        …193 
      II. Synthesis of intermediate compound H2N-Asn(Trt)-Leu 
 -Spacer-AQ (22)       …194 
      III. Synthesis of intermediate compound H2N-Gly-Asn(Trt) 
  -Leu-Spacer-AQ (23)      …195 
      IV. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn(Trt)-Leu-Spacer 
      -AQ (24)        …196 
     V. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Leu-Spacer-AQ  
      (25)         …196 
3.4.4. Synthesis of 2nd batch-FRET tetra peptide substrates  
          applying solution phase peptide synthesis (JC series-lysine) …196 
3.4.4.1. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Lys-Spacer-AQ  
     (31)        …196 
        I. Synthesis of intermediate compound H2N-Lys(Boc) 
  -Spacer-AQ (26)       …196 
 II. Synthesis of intermediate compound H2N-Asn(Trt)-Lys 
     (Boc)-Spacer-AQ (27)      …197 
 III. Synthesis of intermediate compound H2N-Gly-Asn(Trt) 
      -Lys(Boc)-Spacer-AQ (28)     …198 
 IV. Synthesis of intermediate compound HN-Pro-Gly-Asn 
      (Trt)-Lys(Boc)-Spacer-AQ (29)    …198 
 V. Synthesis of 5(6)CBF-Pro-Gly-Asn(Trt)-Lys(Boc)-Spacer 
     -AQ (30)                                …198 
VI. Synthesis of 5(6)CBF-Pro-Gly-Asn-Lys-Spacer-AQ (31) …199 
3.4.4.2. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Lys-Spacer-AQ  
          (34)        …199 
 I. Synthesis of intermediate compound H2N-β-Ala-Gly-Asn 
    (Trt)-Lys(Boc)-Spacer-AQ (32)     …199 
 II. Synthesis of intermediate compound 5(6)-CBF-β-Ala- 
      Gly-Asn-(Trt)-Lys(Boc)-Spacer-AQ (33)   …200 
       III. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Lys-Spacer-AQ  
- 7 - 
 
         (34)        …200 
3.4.4.3. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Lys-Spacer-AQ  
      (38)        …200 
 I. Synthesis of intermediate compound H2N-Ala-Asn(Trt) 
    -Lys(Boc)-Spacer-AQ (35)     …200 
 II. Synthesis of intermediate compound HN-Pro-Ala-Asn 
     -(Trt)-Lys(Boc)-Spacer-AQ (36)     …201 
      III. Synthesis of 5(6)-CBF-Pro-Ala-Asn(Trt)-Lys(Boc)- 
            Spacer-AQ (37)       …201 
      IV. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Lys-Spacer-AQ (38) …202 
3.4.4.4. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Lys-Spacer-AQ  
            (41)        …202 
  I. Synthesis of intermediate compound H2N-β-Ala-Ala-Asn 
    (Trt)-Lys(Boc)-Spacer-AQ (39)     …202 
 II. Synthesis of intermediate compound 5(6)-CBF-β-Ala- 
      Ala-Asn-(Trt)-Lys(Boc)-Spacer-AQ (40)   …202 
       III. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Lys-Spacer-AQ  
         (41)        …203 
3.4.4.5. Synthesis of 5(6)-CBF-Ala-Pro-Ala-Asn-Lys-Spacer-AQ  
            (46)        …203 
 I. Synthesis of intermediate compound H2N-Ala-Asn(Trt)- 
     Leu-Spacer-AQ (42)      …203 
 II. Synthesis of intermediate compound HN-Pro-Ala-Asn 
      (Trt)-Leu-Spacer-AQ (43)     …204 
 III. Synthesis of intermediate compound H2N-Ala-Pro-Ala 
      -Asn(Trt)-Leu-Spacer-AQ (44)    …204 
 IV. Synthesis of 5(6)-CBF-Ala-Pro-Ala-Asn(Trt)-Leu 
     -Spacer-AQ (45)       …204 
       V. Synthesis of 5(6)-CBF-Ala-Pro-Ala-Asn-Lys-Spacer-AQ  
      (46)         …205 
3.5. Synthesis of Gadolinium-DOTA-Peptide substrates [Leucine-JS  
       Linear sequences]        …205 
A. Synthesis of Gd(III)DOTA-Pro-Ala-Asn-Leu-Spacer-AQ (49) …205 
I. Synthesis of intermediate compound DOTA(t-Bu)-Pro-Ala 
    -Asn(Trt)-Leu-Spacer-AQ (47)      …205 
II. Synthesis of intermediate compound DOTA-Pro-Ala-Asn 
    -Leu-Spacer-AQ (48)        …206 
III. Synthesis Gd(III)DOTA-Pro-Ala-Asn-Leu-Spacer-AQ (49) …206 
B. Synthesis of Gd(III)DOTA-Pro-Gly-Asn-Leu-Spacer-AQ (53) …206 
I. Synthesis of intermediate compound HN-Pro-Gly-Asn(Trt) 
   -Leu-Spacer-AQ (50)       …206 
II. Synthesis of intermediate compound DOTA(t-Bu)-Pro-Gly  
    -Asn(Trt)-Leu-Spacer-AQ (51)     …207 
- 8 - 
 
III. Synthesis of intermediate compound DOTA-Pro-Gly-Asn 
     -Leu-Spacer-AQ (52)       …207 
IV. Synthesis of Gd(III)DOTA-Pro-Gly-Asn-Leu-Spacer-AQ (53) …208 
3.6. Synthesis of Gadolinium-DOTA-Peptide substrates- JS Lysine  
      Sequence         …208 
3.6.1. Synthesis of Gadolinium complex using 1,4,7,10-Tetra 
         azacyclodo decane-1,4,7,10-tetraacetic acid (58)  …208 
I. Synthesis of Fmoc-Lys(Boc)-Spacer-AQ (54)   …208 
II. Synthesis of Fmoc-Lys-Spacer-AQ trifluoroacetate salt (55) …209 
III. Synthesis of H2N-Lys(DOTAtBu)-Spacer-AQ (56)  …209 
IV. Synthesis of H2N-Lys(DOTA-OH)-Spacer-AQ (57)  …210 
V. Synthesis of H2N-Lys(DOTA-Gd3+)-Spacer-AQ (58)  …210 
3.6.2. Synthesis of JS-Lysine series of tetra peptide substrates …211 
A. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-Gd3+)-Spacer-AQ  
    (62)         …211 
I. Synthesis of Fmoc-Pro-Gly-Asn(Trt)-OH (59)   …211 
II. Synthesis of Fmoc-Pro-Gly-Asn(Trt)-Lys(DOTA-tBu) 
    -Spacer-AQ (60)       …211 
III. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-OH)-Spacer 
  -AQ (61)        …212 
              IV. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-Gd3+)-Spacer 
                   -AQ (62)        …212 
B. Synthesis of of Fmoc-β-Ala-Gly-Asn-Lys(DOTA-Gd3+)-Spacer 
    -AQ (66)         …212 
I. Synthesis of Fmoc-β-Ala-Gly-Asn(Trt)-OH (63)  …212 
II. Synthesis of Fmoc-β-Ala-Gly-Asn(Trt)-Lys(DOTA-tBu) 
    -Spacer-AQ (64)       …213 
III. Synthesis of Fmoc-β-Ala-Gly-Asn-Lys(DOTA-OH)-Spacer 
  -AQ (65)        …213 
IV. Synthesis of of Fmoc-β-Ala-Gly-Asn-Lys(DOTA-Gd3+) 
     -Spacer-AQ (66)       …213 
C. Synthesis of of Fmoc-Pro-Ala-Asn-Lys(DOTA-Gd3+)-Spacer-AQ 
    (70)         …214 
I. Synthesis of Fmoc-Pro-Ala-Asn(Trt)-OH (67)   …214 
II. Synthesis of Fmoc-Pro-Ala-Asn(Trt)-Lys(DOTA-tBu)- 
    Spacer-AQ (68)       …214 
III. Synthesis of Fmoc-Pro-Ala-Asn-Lys(DOTA-OH)-Spacer 
     -AQ (69)        …214 
IV. Synthesis of of Fmoc-Pro-Ala-Asn-Lys(DOTA-Gd3+)-Spacer 
     -AQ (70)        …215 
D. Synthesis of of Fmoc-β-Ala-Ala-Asn-Lys(DOTA-Gd3+)-Spacer 
    -AQ (74)         …215 
I. Synthesis of Fmoc-β-Ala-Ala-Asn(Trt)-OH (71)  …215 
- 9 - 
 
II. Synthesis of Fmoc-β-Ala-Ala-Asn(Trt)-Lys(DOTA-tBu) 
    -Spacer-AQ (72)       …215 
III. Synthesis of Fmoc-β-Ala-Ala-Asn-Lys(DOTA-OH)-Spacer 
     -AQ (73)        …216 
IV. Synthesis of of Fmoc-β-Ala-Ala-Asn-Lys(DOTA-Gd3+) 
     -Spacer-AQ (74)       …216 
3.7. MMP (2/9) targeted gadolinium based contrast agents for MR  
      imaging of atherosclerotic plaques     …216 
3.7.1. Synthesis of peptide substrates designed to be specific to  
         MMP-2/9 via solid phase peptide synthesis (JJ series)  …216 
I. Synthesis of N-Fmoc-Ala-Pro-Leu-Gly-Ala-Ser-Gly-OH (75) …216 
II. Synthesis of N-Fmoc-Ala-Ala-Leu-Ala-Nva-Leu-Gly-OH (76) …218 
III. Synthesis of N-Fmoc-Lys-Pro-Ala-Gly-Nva-Ala-Gly-OH (77) …218 
IV. Synthesis of N-Fmoc-Gly-Pro-Arg(Mtr)-Glu(OtBu)-Ile-Thr(tBu) 
     -Ala-Gly-OH (78)       …219 
V. Synthesis of N-Fmoc-Ile-Pro-Arg(Mtr)-Thr(tBu)-Leu-Thr(tBu) 
    -Ala-Gly-OH (79)       …219 
VI. Synthesis of N-Fmoc-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr(tBu) 
     -Ala-Gly-OH (80)       …220 
3.7.2. Synthesis of Gadolinium-DOTA-Peptide substrate designed to  
         be specific to MMP-2/9      …220 
3.7.1.1. Attempted synthesis of JD- (Gd(III)-DOTA-Gly-12-amino 
           dode canoicacid-Ala-Ala-Leu-Ala-Nva-Leu-Gly-OH)  …220 
I. Synthesis of 12-({[(9H-fluoren-9-yl)methoxy]carbonyl} 
   amino)dode canoicacid (81)     …220 
II. Synthesis of HO-DOTA-Gly-12-aminododecanoicacid-Ala-Ala 
    -Leu-Ala-Nva-Leu-Gly-2-ClTrt resin (84)   …221 
3.7.1.2. Synthesis of JL (87)      …222 
I. Synthesis of DOTA-tris(tBu)-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-  
   Thr (OtBu)-Ala-Gly-Lys-Spacer-AQ (85)   …222 
II. Synthesis of HO-DOTA-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr 
    -Ala-Gly-Lys-Spacer-AQ (86)     …222 
III. Synthesis of DOTA(Gd3+)-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu- 
     Thr-Ala-Gly-Lys-Spacer-AQ (JL-87)    …222 
3.8. UV-Vis Absorption Spectra      …223 
3.8.1. Materials        …223 
3.8.2. Method         …223 
3.9. Fluorescence measurements      …223 
3.9.1. Materials        …223 
3.9.2. Method         …223 
3.10. Legumain activity assay       …223 
- 10 - 
 
3.10.1. Materials        …224 
3.10.2. Legumain assay on JC series of peptide substrates  …224     
3.10.3. Legumain assay for JS linear/JS lysine series of peptide  
       Substrates        …225 
3.11. Cytotoxicity assay        …225 
3.11.1. MDA-MB-231 cells       …225 
3.11.2. Maintenance of MDA-MB-231 cells    …225 
3.12.3. Colourimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-(diphenyltetra 
          -zolium bromide) (MTT) assay     …225 
4. Reference          …227 
5. Appendix          …250 
6. Supporting studies        …267 
- 1 - 
 
1. Introduction 
 
1.1. Atherosclerosis  
Atherosclerosis can be defined as a disease related to the arterial networks 
characterised by the deposition of lipids, calcium, matrix components, 
inflammatory cells and smooth muscle cells inside the intima of a blood vessel 
(Homeister and Willis 2010). These deposits are known as plaques and are prone 
to cause several complications, for example:  
 Plaques block the space inside the arteries and interrupt the flow of blood 
either partially or completely.  
 The rupture of the plaque, due to thinning of the fibrous cap leading to 
formation of a blood clot or thrombus (Cipollone et al. 2005). 
 They can also cause the arteries to weaken leading to formation of a 
localized blood-filled sac from the dilation of blood vessels, which is defined 
as an aneurysm (Ross 1993). The rupture of this sac leads to severe internal 
bleeding.  
Cullen et al., (2007) stated that the term ‘atherosclerotic artery’ was first described 
by Leonardo da Vinci (1452-1519) as a broadening of vessel walls due to ‘excessive 
nourishment’ drawn from blood. The phrase arteriosclerosis, which is now often 
used interchangeably for atherosclerosis, was first coined by a German-born 
French surgeon and pathologist Johann G.C.F.M Lobstein in 1833, but the actual 
term ‘atherosclerosis’ was introduced by Felix J. Marchand, a German physician. 
Lobstein related atherosclerosis to a hardened arterial wall formation due to 
alterations in tissues in correlation with factors such as age, stress and metabolic 
dysfunction.  
Research into atherosclerosis started as early as the 18th century, but most of the 
results were not supported by experimental data. In 1856, the insudation theory 
by Virchow provided information on atherosclerotic lesions, but this work was also 
purely based on microscopic pictures of plaques at autopsy (Steinberg 2005). 
Approximately 50 years later, it was Anitschkow who demonstrated that the very 
first visible sign of a lesion would be seen only when the space between 
endothelium and the underlying inner elastic membrane was filled with lipid 
substances, which were polyblactic or monocytic in nature (Anitschkow and 
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Cowdry 1933). Experiments conducted by Timothy Leary in 1934, in lesions of 
rabbits with a high cholesterol diet, showed structural similarities to the lesion of 
human coronary arteries (Leary 1943). In 1951, it was found that the contents of 
atherosclerotic lesions in both animal models and human extracts were mostly of 
lipid origin and cholesterol (Duff and McMillan 1951). 
1.1.1. Morphology of atherosclerosis  
The first distinguishable form of the lesion is known as ‘intimal xanthoma’ or ‘fatty 
streak’ which generally is a very flat non-destructive collection or build-up of foam 
cells. These foam cells are normally present in most individuals in their middle age, 
but may not cause any health related problems. However, there are certain types 
of lesions, normally known as progressive or developing lesions, which tend to 
occur during the advanced stages of the disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Pictorial representation of a normal artery and an artery damaged by 
atherosclerotic plaque (Hicks 2009). 
 
These are characterized by a much more diverse and convoluted morphology, 
which may cause life-threatening problems (figure 1). Thus, based on various 
studies and knowledge about atherosclerotic plaques they can be broadly classified 
as (Virmani et al. 2000):  
 Pathologic intimal thickening lesions: These lesions contain 
proliferative smooth muscle cells (SMC) within an extracellular lipid 
environment rich in a proteoglycan matrix.  
 Fibrocalcific plaques: These lesions have fewer inflammatory cells but are 
generally rich in collagen and have a necrotic centre. 
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 Fibrous cap atheromas: These are similar to pathologic intimal thickening 
lesions, but they also contain macrophages derived from foam cells and 
inflammatory cells. They are characterized with a fibrous cap, rich in 
collagen, followed by a necrotic centre filled with extracellular lipid and 
apoptotic cellular debris. Thus, they are said to present features of instability 
such as a thin fibrous cap and a profuse amount of inflammatory cells 
(Homeister and Willis 2010). These lesions may be associated with lethal or 
non-lethal clinical manifestations.  
Pathologic intimal thickening lesions and fibrocalcific plaques are more stable 
when compared to fibrous cap atheromas and are therefore rarely associated 
with a thrombosis that may lead to a heart attack or stroke. Conditions of 
chronic angina pectoris and claudication are the clinical indicators of fibrocalcific 
plaques, which are caused by the reduction in the flow of blood due to the 
unusual protrusion of these plaques into the lumen of the blood vessel. 
Sometimes the inner walls of pathologic initimal thickening lesions undergo 
minor damage (fissures) or total ulceration, which assists in acute thrombosis 
(Homeister and Willis 2010). Most of the fatal consequences of atherosclerotic 
conditions are caused by fibrous cap atheromas, which are otherwise called 
vulnerable or unstable plaques. The disruption of the plaque wall is mainly due 
to an increase in inflammatory cell proteases being released continuously or 
due to plaque neovascularisation triggering intraplaque haemorrhage (O’Brien 
et al. 2004). Further studies on plaque growth shed more light on the 
remodelling strategy of these plaques into positive or negative remodelling 
(figure 2). When the inner space of the artery remains uncompromised with 
the arterial wall swelling outwards it is defined as positive remodelling (Glagov 
phenomenon). Such plaques do not cause angina and are generally progressive 
in development. They normally don’t intrude the luminal space until 40% of the 
cross sectional area is being used and only after which they start to restrict 
blood flow. Thus they grow for years and ultimately form the bulk of unstable 
plaques that normally rupture causing several complications in humans (Boudi 
and Ahsan 2010). 
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Figure 2: Pictorial representation of positive and negative remodelling of plaques (Boudi 
and Ahsan 2010). 
 
Most of these positive remodelled plaques, on reaching maximum outward dilation, 
start to grow inward into the luminal space thus progressing into negative 
remodelling phase. These negative alterations develop steady angina and also 
cause rupture of unstable plaques and thrombosis (Boudi and Ahsan 2010).    
1.1.2. Clinical impacts of atherosclerosis  
Several pathological findings in both human and animal samples have described 
atherosclerosis as ‘response-to-injury’ due to endothelial dysfunction (Cullen et al. 
2005). These abnormalities in the endothelium caused due to injuries trigger 
imbalanced reactions, which change the regular homeostatic conditions of the 
endothelium. These injuries initiate the inflow of leukocytes or platelets and also 
influence the endothelium to concentrate procoagulant properties instead of anti-
coagulants forming cytokines, growth factors and vaso-active molecules. If the 
response to the endothelial dysfunction is not neutralized or controlled it increases 
the concentration of these inflammatory molecules leading to the formation of 
plaques or lesions, which gradually thicken the walls of the arteries (Ross 1999). 
These lesions further mature by developing into fibrous plaques structured by 
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SMCs and connective tissues enclosing a lipid-rich centre in patients who are more 
vulnerable to develop a plaque.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Progress and the types of atherosclerotic effect in humans (Hong 2010). 
The plaques then undergo vascularisation, haemorrhage, and ulceration ultimately 
leading to several disorders in humans such as heart attack, stroke and peripheral 
vascular diseases depending upon the organ they affect as shown in figure 3. Thus 
the characteristic features of plaques, which are prone to rupture, are said to be 
large, showing active remodelling along with a large lipid centre almost covering 
40% of the plaque space (Ross 1999). 
1.1.3. Risk factors developing atherosclerosis 
Historically, the major causes or risk factors for atherosclerosis have been thought 
to be mainly smoking, alcohol in-take, age, sex, diet, diabetes, high blood pressure 
or obesity (Kannel et al. 1961). However, with the vast improvement in our 
knowledge about the pathogenesis of the disease more interest in understanding 
the novel risk factors of the disease has emerged (Ross 1999). In an article by 
Hackam and Anand (2003) about risk factors in atherosclerosis, they have 
described four factors, which are said to be predictors of this disease even in people 
with very few chances of developing atherosclerosis.  
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Atherosclerosis is a complex multifactorial disease that presents a lot of risk 
factors, both of genetic and environment origin. These factors can be classified as 
modifiable and non-modifiable, factors such as sex, age and family history are 
grouped as non-modifiable factors whereas smoking, alcohol intake, diabetes, 
obesity, hypertension are classified as modifiable factors (Tolfrey 2002). The 
probability of occurrence of atherosclerosis remains high with the high occurrence 
of these risk factors. Understanding these risk factors helps prevent the severity 
of the disease and also serves as a guide to treat susceptible patients at the early 
stage of the disease (Kullo and Ballantyne 2005). 
1.1.4. Current therapies to treat atherosclerosis 
The aim in treating atherosclerosis is to decrease morbidity and mortality and to 
deter any further complications (Boudi and Ahsan 2014). The prevention and 
management of this condition requires control over adaptable life style, as well as 
monitoring and treating certain clinical conditions such as hypertension, 
hyperlipidemia and diabetes mellitus (Boudi and Ahsan 2014). Since the vascular 
characterization and anatomy of atherosclerosis is well studied, this has led to the 
development of novel therapies that identify the potential targets of this disease. 
Therapies, such as amino acid supplementation, antiplatelet agents, angiotensin-
receptor blockers, angiotensin converting enzymes (ACE) and antioxidant 
therapies have shown to slow the development of atherosclerosis (Boudi and 
Ahsan 2014).  
A number of pharmacological agents haven been used to treat angina. Agents such 
as beta-blockers restrain sympathetic stimulation of the heart inhibiting heart rate 
and heart muscle contractility. This ultimately reduces myocardial oxygen 
consumption and hence relieves angina. In the same way, nitrates such as glyceryl 
trinitrate, isosorbide mononitrate and erythrityl tetranitrate also work to reduce 
myocardial oxygen uptake by decreasing systemic vascular resistance (Boudi and 
Ahsan 2014). Calcium channel blockers are substances that restrict calcium entry 
into myocytes and vascular smooth muscle cells. These agents increase systemic 
vasodilation which in turn increases coronary blood flow. They also bring down 
arterial pressure and systemic vascular constriction and produce a negative 
inotropic effect (Boudi and Ahsan 2014). Fibric acid derivatives such as fenofibrate, 
benzafibrate and gemfibrozil work by increasing lipoprotein lipase activity and 
boost the metabolic breakdown of triglyceride-rich lipoproteins (figure 4).  
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Figure 4: Chemical structure of fibrates.  
These proteins are normally required for a rise in HDL concentration. It has been 
stated that fibrates usually decrease triglycerides volume by 20-50% and enhance 
HDL concentration by 10-15% (Boudi and Ahsan 2014). Other drugs that are 
normally taken by atherosclerotic patients minimise the concentration of lipid 
contents in blood. These drugs, such as statins and niacin, work by controlling the 
production of cholesterol and triglycerides. Other antithrombotic drugs such as 
warfarin, aspirin (lower strength), clopidogrel and prasugrel work by thinning the 
blood, therefore preventing any further deposit of plaques, reducing the injuries 
triggered by blood clots due to atherosclerosis.   
However, these drugs might not be effective for people who are allergic to any of 
these chemical compounds and hence there is always a demand for 
complementary treatment (Baker 2008). Studies on hormonal therapies in clinical 
and animal analysis have demonstrated that the occurrence of coronary 
atherosclerosis can be highly reduced by estrogen, which works by inhibiting ACE 
(Brosnihan et al. 1999). Moreover, this hormone also increases the production of 
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endothelium-derived nitric oxide, which inhibits the proliferation of vascular 
smooth muscle cells (VSMCs) and prevents adhesion of leukocytes. 17-β-Estradiol 
(figure 5) is a naturally occurring estrogen hormone in humans which methylates 
to form 2-methoxyestradiol (2-ME) and this compound inhibits VSMC proliferation 
and thus prevents the progression of atherosclerosis (Barchiesi et al. 2006).  
 
 
 
 
 
 
 
Figure 5: Structure of 17-β-Estradiol. 
Studies on respiratory infection have shown that they might also enhance the 
condition of atherosclerosis in susceptible people (Meier et al. 1999). Evidence 
states that the occurrence of myocardial infarction is quite high during the cold 
seasons (The Eurowinter Group 1997) and during the spread of the influenza A 
virus. It has been stated that the virus causing influenza A also helps in the process 
of atherosclerosis by incubating and infecting the lesions (Haidaria et al. 2010). In 
a study conducted by the FLUVACS study group (Saskia and Kuiper 2011), it has 
been stated that mortality was reduced in people with cardiovascular conditions 
when they received the vaccine for the influenza A virus for two years. However, 
it has also been stated, that the use of vaccines to control cholesterol, oxidized 
LDL, endothelial cells, cytokines/growth factors and metabolic factors which 
generally reduces atherosclerotic progression could at the same time also increase 
plaque progression (Saskia and Kuiper 2011). The potential role of the immune 
system, in the pathogenesis of atherosclerotic plaques, has been studied by Chyu 
and colleagues (2011) where they explained the activity of lymphocytes and 
dendritic cells and their role in atherosclerotic plaque formation.  
Moreover, clinical procedures involving the administration of immunoglobulin 
intravenously to treat immune mediated inflammatory conditions such as 
autoimmune disease suggest the idea of administering polyclonal immunoglobulin 
to treat atherosclerotic inflammations and pre-clinical evaluations on the same 
have provided promising results (Nicoletti et al. 1998). Surgical procedures such 
as partial ileal bypass have been practised since the 1960s to treat hyperlipidemia. 
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In this procedure, the length of ileum is shortened to reduce circulating cholesterol 
volume, which can also be thought of as a means of treating the atherosclerotic 
condition (Boudi and Ahsan 2014). In a recent study, Rajoria and colleagues 
(2011) demonstrated the down regulatory effect of MMP-2 and MMP-9 (which are 
normally overexpressed in atherosclerotic plaques) by a natural dietary complex 
3,3’-diindolylmethane (DIM) present in cruciferous vegetables. This finding 
suggests that DIM could be used for reducing atherosclerosis plaque progression. 
Another means of treating the atherosclerotic condition is by the use of prodrugs.  
Huttunen and colleagues (2011) defined prodrugs as a chemically caged derivative 
of the active drug which is programmed to be released via a chemical or enzymatic 
reaction in vivo.  The rationale behind this concept was to enhance the 
physicochemical properties of the drug, such as drug stability and solubility; to 
enhance drug pharmacokinetic/pharmacologic characteristic, such as oral 
absorption and selectivity and also to prevent unwanted side effects or non-specific 
toxicity to healthy cells/tissues (Rautio et al. 2008). In this manner, prodrugs are 
designed to target proteases as they are involved in many diseases. Proteases 
present an important and fundamental role in several biological and pathological 
functions by their regulatory mechanism, proteolysis (Choi et al. 2012). By their 
highly restricted functioning, proteases control DNA replication and transcription, 
cell growth and differentiation, neurogenesis, angiogenesis, stem cell mobilization, 
immunity, necrosis and apoptosis (Lopez-Otin and Bond 2008). Hence any 
abnormal modifications in the proteolytic function cause diseases such as cancer, 
atherosclerosis and neurodegenerative disorders (Choi et al. 2012) and therefore 
making these attractive targets for prodrugs. For protease activated prodrugs 
(PAPs) to be efficient the bond between the therapeutic/prognostic agent and the 
promoiety must be stable while in the blood stream and then degrade upon 
reaching the target protease (Rautio et al. 2008). This can be achieved by using 
peptide sequences which remain stable in blood but are highly specific towards the 
protease of interest have been developed (Choi  et al. 2012). In their study on 
PAPs Choi and colleagues (2012) demonstrated that the synthesized peptide 
prodrugs were 97% stable after 24hrs in serum and plasma. They also suggested 
that the stability of the peptide substrates can be enhanced by the use of 
macromolecular structures such as dextran.    
MMPs are one such target protease for prodrugs and are also one of the well-
studied protease family. Mainly because of their pericelluar and extracellular 
location on cells they serve as valuable targets for delivering prodrugs to 
atherosclerotic and cancer microenvironments. Prodrugs have been synthesized 
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which are cleaved in vivo by MMPs to deliver compounds to atherosclerotic sites. 
Some of the known prodrugs that are specifically cleaved by MMP-2 are: melitin, 
TNF and Dox micelle whereas FITC based prodrugs and SeV are cleaved by MMP-
9 (Edward 2008). However, with the growing number of atherosclerotic incidences 
there is a need for a transition from the therapeutic state of primarily treating the 
cardiovascular defects to one which identifies plaques even before they could 
progress to the stage of rupture, and this can be achieved by molecular imaging 
(Hwang et al. 2011). As discussed in previous sections, atherosclerosis can be 
described as lipid-driven chronic inflammatory progression involving the 
remodelling of the ECM within blood vessels, which subsequently result in plaque 
formation (Hansson et al. 2006). Moreover, it has been demonstrated that MMPs 
were over expressed in atherosclerotic plaques and were also involved in the 
degradation of all components of the ECM (Wagsater et al. 2011). 
1.2. Matrix metalloproteinase (MMPs) 
Matrix metalloproteinases, normally known as MMPs, belong to the family of 
proteins dependent on zinc and calcium (Borkakoti 2004). MMPs are involved in 
physiological functions such as healing of wounds, ovulation, development of the 
skeletal system and the development of the mammary gland involutions in adult 
reproductive tissues (McCawley and Matrisian 2001). One major function of MMPs 
is the production and degradation of the extracellular matrix generally known as 
ECM. This is done under tight control of the, naturally available endogenous 
inhibitors: α-2-macroglobulins (Nagase and Woessner 1999) and tissue inhibitors 
of metalloproteinases (TIMPs) (Hansen et al. 1993). MMPs are broadly classified 
into four groups depending on their sequence homology and substrate specificity:  
 Collagenases  
 Gelatinases  
 Stromelysins and  
 Membrane type MMPs (MT-MMPs) 
MMP-1 (interstitial collagenase), MMP-8 (neutrophil collagenase) and MMP-13 
(collagenase III) are the group of MMPs that belong to the collagenases. These 
MMPs are capable of cleaving fibrillar collagens I, II and III. MMP-2 and 9 belong 
to the second group representing gelatinases, and are known for their ability to 
disintegrate gelatins. Type IV collagen is also degraded by these gelatinases in the 
basement membrane. MMP-3, 10 and 11 belong to the third group of MMPs 
denoted as stromelysins. These MMPs are capable of degrading a broad range of 
ECM component, taking into account proteoglycans, laminis, fibronectin, 
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vitronectin and certain classes of collagenases as well. The final group of MMPs- 
the MT-MMPs are capable of degrading many of the ECM components and 
additionally they also have the capacity to activate other MMP types (Creemers et 
al. 2001). Some distinctive features of MMPs as elucidated by Denis and Verweij 
(1997); Nagase and Woessner 1999; Hansen and co-workers (1993) and 
Westermarck and Kahari (1999) are:  
 MMPs are generally in their inactive form. They are produced as pre pro-
enzymes and released as pro-enzymes.  
 They have a distinct sequence made of 80 amino acids in the propeptide 
domain-PRCG(V/N)PD.  
 MMPs have two catalytic zinc atoms of which one is present at the active 
site.  
 The stability of the enzyme is sustained by two calcium ions. 
 There is a highly conserved region between the catalytic domain and the 
propeptide N-terminal domain in the primary region. 
 α-macroglobulin and TIMPs are the natural inhibitors of MMPs.  
1.2.1. Parameters for the regulation of MMPs 
Natural inhibitors such as α-macroglobulin and TIMPs regulate the functioning of 
this family of enzymes and when these regulations are disrupted they are said to 
cause various disorders in living organisms (McGeehan et al. 1994). Such disorders 
include rheumatism and osteoarthritis, tumor growth, angiogenesis and 
atherosclerosis leading to brain injuries, periodontal diseases, acute lung injury 
and acute respiratory distress syndrome (McCawley and Matrisian 2001; 
Westermarck and Kahari 1999).  
The pro-MMPs are said to be in an inactive form due to the electrostatic interaction 
between the free thiol in the prodomain and the zinc atom, which is ligated to 
histidine in the catalytic pocket as shown in figure 6. This electrostatic interaction 
can be disrupted either by proteases or by non-proteolytic means ultimately 
activating the MMPs. During this process of activation the prodomain may not be 
removed completely, however the enzyme still remains active because the 
presence of the prodomain does not interfere with the activation of the enzyme 
and can be removed later either by autolysis intra or intermolecularly (Fu et al. 
2008). This process of activation was termed as ‘cysteine-switch’ by Van Wart and 
Hansen (1990), which makes the MMPs catalytically active by any of the following 
three mechanisms: 
- 12 - 
 
 Alteration of the free thiol by physiological or non-physiological compounds.  
 Activation by interacting with another proteinase leading to disruption of the 
prodomain.  
 Allosteric interference causing inter or intramolecular autolytic cleavage of 
the prodomain.  
 
Figure 6: Activation of a latent MMP by proteolytic or non-proteolytic mechanism (Fu et 
al. 2008). 
In healthy tissues and normal cells the concentration of MMPs are generally low 
and are said to be over expressed when stimulated by various factors like cell 
matrix, growth factors, cytokines, cell-cell interactions, oncogeneic 
transformations, physical stress or tumor promoters (Westermarck and Kahari 
1999). Once the MMPs are activated, they continuously degrade the ECM and 
hence it is very important that their functioning is kept under tight control. 
1.2.2. Structure of a MMP 
MMPs normally have three domains (figure 7), the signal peptide (1) which 
operates as the signalling tool for secretion, a pro-peptide domain (2), which 
detaches itself when the enzyme is activated, and finally a catalytic domain (3) 
(Nguyen et al. 2001). The MMPs remain inactive because of the presence of the 
cysteine switch which is ~80 amino acids long (Himelstein et al. 1994-95). The 
MMPs are activated by the removal of the amino terminal domain from the enzyme 
in a proteolytic fashion (Denis and Verweil 1997). 
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Figure 7: Structure of a MMP (adapted from Hidalgo and Eckhardt 2001). 
It has been demonstrated that the reduction in the components of the matrix, 
(particularly that of fibrillar collagens in the fibrous cap) lead to thinning of the cap 
wall (Shah 2003). Increased breakdown of the matrix is a characteristic feature of 
a particular group of MMPs involving MMP-1, MMP-2, MMP-3 and MMP-9. These 
MMPs are expressed by the inflammatory cells and, to a smaller quantity, by SMCs 
and endothelial cells in atherosclerotic plaques (Galis et al. 1995). Since most of 
the properties of these proteases are well studied with a clear knowledge about 
their chemistry in most diseases they can be efficiently used as targets for drug 
design. With progress in the fields of molecular imaging and the use of fluorescent 
probes such as near infrared fluorescent probes (NIRF) (Zucker and Cao 2001), 
these proteases (MMPs) can be characterised in their natural environment of action 
and may also be exploited as diagnostic tools to detect atherosclerosis or tumour 
at a much early stage of progression (Neefjes and Dantuma 2004). 
1.2.3. MMPs and their role in atherosclerosis 
MMPs play a vital role in the development, decay and rupture of atherosclerotic 
plaques (Galis et al. 1994). Aspects of which are listed below: 
 The damage of the intimal ECM is the main reason for the rupture of the 
plaque initiated by proteases.  
 MMPs are normally found to be active at neutral pH, which is the most 
desirable condition for vascular ECM remodelling to occur.  
 MMPs have at least one component of the ECM as a recognized substrate.  
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 The thickening and growth of the injured blood vessels cause the 
accumulation of new cells derived by VSMCs (Newby 2005).  
Atherosclerotic plaques are said to be in a dynamic state undergoing constant 
remodelling of the ECM, to maintain the stability of the plaque (Loftus et al. 2000). 
There is evidence to show the over expression of MMPs in such plaques along with 
their involvement in aneurismal and degradation process (Thompson et al. 1995). 
Overexpression of these MMPs in atherosclerotic lesions leads to unstable plaques, 
which are prone to rupture resulting in clinical conditions such as thrombosis, 
occlusion, heart attack or stroke (Galis and Khatri 2002). One major source of 
MMPs is the foam cells, which are derived from macrophages. These macrophages 
are normally said to be highly concentrated in human and animal atherosclerotic 
plaques (Galis et al. 1995). The early stage of the growth of the plaque is initiated 
by VSMCs, which cause the migration, and over expression of MMP-2 at the site of 
injury (Galis et al.1994). Over expression of MMP-2 and 9 is detected in injured 
arteries as they play a vital role in remodelling (Chesler et al. 1999). There is also 
accumulation of other MMPs including MMP-1, 3 and 9 as a result of the signalling 
of inflammatory cytokines and tumour necrosis factor-α at the site of injury (Yanagi 
et al. 1992). Furthermore immune activation also leads to increased production of 
MMP-1, 3, 8 and 9 in the vascular SMCs by the addition of T-lymphocytes and 
recombinant CD40 ligands (Schonbeck et al. 1999).  
Work carried out by Loftus and colleagues (2000), has shown an increase in the 
expression of MMP-9 in most of the unstable carotid plaques and has also 
demonstrated that most of the plaques with the characteristic features of 
instability such as the presence of cerebral particulate embolization, plaque 
rupture and intraplaque haemorrhage have all demonstrated increased 
concentration of MMP-9. It has been previously stated that the site of plaque burst 
is concentrated with inflammatory infiltrates, which are mostly characterized by 
macrophages, foam cells and T-lymphocytes (Moreno et al. 1994). Buja and 
Willerson (1994) have shown that these inflammatory infiltrates play a vital role 
in plaque rupture. 
Welgus and his colleagues (1990) explained that macrophages were effective 
producers of MMP-9 and also the increased expressions of MMP-3 and MMP-1 in 
carotid plaques was related with macrophage and mast cell infiltration (Nikkari et 
al. 1995). All these studies demonstrate that MMPs are up regulated at the site of 
injury to enhance the repairing process of the injured site. Thus the occurrence of 
MMPs does not only have a role in the pathogenesis of atherosclerosis, but it is 
also a strong indication of the stability of the plaques (Galis 2004). With increased 
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knowledge about the structural chemistry of MMPs and available peptide 
substrates specific for particular MMPs, they can be effectively used as diagnostic 
tools for studying atherosclerotic plaques by using them as markers for molecular 
imaging in MRI or fluorescent probes techniques. Hence MMPs can be used as 
targets for both therapy and imaging (Lancelot et al. 2008).  
1.2.4. MMP-2 and MMP-9 
Several research studies have demonstrated that MMPs particularly MMP-2 and 
MMP-9 have a potential involvement in angiogenic lesions of both atherosclerotic 
and tumour origin and in their progression (Kurizaki et al. 1998). MMP-2 and MMP-
9 are generally termed as gelatinases because they can cleave gelatin, which is a 
denatured form of collagen. The one and main difference between gelatinases and 
other MMPs is the presence of three fibronectin type II repeats which is the key 
reason for enhanced binding affinity towards collagen (Kridel et al. 2001). 
Gelatinases are similar in structure having the three-fibronectin units placed in the 
catalytic domain. They also have similar specificities for substrates like collagen, 
type X, VII, V and IV, fibronectin, fibrin, interleukin-I and α-1 proteinase inhibitor 
(Xu et al. 2005).  
The major difference between the two MMPs is their mechanism of activation (table 
1): 
 The mesenchymal cells are responsible for the activation of MMP-2 
(Lozito et al. 2014) and they are finally activated by membrane type 
MMP (MT-MMP) and more recently it has been found that they are also 
activated by legumain (Mattock et al. 2010). 
 Cells such as neutrophils and eosinophils are said to produce MMP-9 
and they are ultimately activated by MMPs such as MMP-3 (Xu et al. 
2005).  
Similar to other MMPs, both MMP-2 and 9 have a hemopexin domain separated 
from the catalytic domain by a fibronectin motif. Moreover, MMP-9 has a domain 
similar to collagen. As mentioned previously this hemopexin unit at the C- terminal 
region favours binding of MMP to substrates and may also be involved with TIMP 
activities (Nguyen et al. 2001). 
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Common names Gelatinase A, Gelatinase B, 
Nomenclature MMP-2 MMP-9 
Substrate specificity 
Gelatin type I, IV, V, 
collagen, elastin 
Gelatin type I, IV, V, 
collagen, elastin 
Molecular mass 72kDa 92kDa 
Molecular mass of 
active units 
64kDa, 62kDa 82kDa, 67kDa 
Physiological activators 
Type I collagen, 
lipopolysaccharide, 
hepatocyte growth 
factor, thrombin, APC, 
legumain and MT1-
MMP. 
Serine proteases 
Latent form binds to 
TIMP 
TIMP-2 TIMP-1 
 
Table1: Features of gelatinase A and B (Nguyen et al. 2001). 
1.2.5 MMP-9/2 and its substrate specificity 
Overexpression of MMPs in vascular and cardiac tissues has been associated in the 
pathogenesis of several cardiovascular disorders such as atherosclerosis. 
Development of atherosclerotic plaques, also known as negative remodelling, 
requires the production and migration of smooth muscle cells (SMCs) within the 
arterial wall, and this progression is largely dependent on MMPs, particularly MMP-
2 and MMP-9, which can degrade reticular type IV and V collagen surrounding SMC 
(Guo et al. 2009). Experiments conducted on Ldlr-/-Apob100/100 mice demonstrated 
that MMP-2 and MMP-9 were the two main proteases overexpressed in 
atherosclerotic mice model (Wagsater et al. 2011). Based on this evidence part of 
this project involved the synthesis of MMP-2 and MMP-9 specific peptide 
substrates. The rationale was to exploit the peptide hydrolysis ability of MMP-2/9 
to deliver a prognostic chemical agent in the atherosclerotic microenvironment, 
which in this project was a gadolinium-DOTA chelate. In order to avoid any false 
signals or unspecific loading of the chemical agent disturbing the healthy cells, it 
is essential for the imaging agent/ therapeutic drug to be selectively deposited at 
the site of plaque formation. Hence, the stability and selectivity of the peptide 
substrate is vital for the design of such prodrugs. Thereby the peptide substrate 
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should have the potential to carry the prognostic/therapeutic agent to the desired 
site while still being stable in the circulatory system.     
Figure 8: A representation of scissile bond. 
The synthesis of peptide substrates activated by MMP-9/2 to release the required 
therapeutic drug or imaging agent can be done, by mimicking the available 
resources of natural substrates (figure 8). The peptide substrates are constructed 
in a way to mirror the subsites/pockets of the corresponding enzyme into which 
the side chain residues of the relevantly positioned amino acid projects (Atlas et 
al. 1970).  A peptide sequence around the active site would be labelled as P3-P2-
P1-P1’-P2’-P3’ and the region of cleavage or ‘hot-spot’ is present between P1-P1’ 
positions (Lim et al. 2010). The symbol P denotes the position of amino acids in 
the sequence. On drawing the peptide structure in a conventional way as in a 
scissile bond, the arrangement will have the N-terminus to the left followed by 
labelling the amino acids as P1 and those amino acids towards the right are labelled 
as P1’ (figure 8). The major amino acids for proteolytic hydrolysis by the enzyme 
(MMP-2/9) are placed within P3-P3’ position. 
In MMP-2 and MMP-9, the S1’ subsite has a deep hydrophobic pocket, that prefers 
a leucine or isoleucine residue at this location. Normally MMP-2 tolerates 
hydrophobic amino acids on the carboxyl side of the sequence (right side of scissle 
bond) much better than on the other side (Massova et al. 1997; Murphy and 
Nagase 2008). Synthetic hydrophobic amino acid residues such as norvaline or 
norleucine with straight and long side chains and also naturally available branched 
H2N
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amino acids such as valine, leucine and isoleucine are favoured at the S1’ subsite. 
Moreover MMP-9 can tolerate further branching at the β and γ-carbon. Compared 
to S1’, the S1 subsite is shallow in nature with limited preference for amino acids 
residues at this position. However, it was demonstrated that glycine was the most 
preferred amino acid at this position (McGeehan et al. 1994).  
The S2’ subsite has a small hydrophobic surface, and with MMP-9 this position 
accepts amino acids with a small hydrophobic side chain or with a large hydrophilic 
side chain. The S3 subsite is characterized with a deep hydrophobic pocket and 
also creates a deviation from linearity into the active site cleft.  Hence an amino 
acid similar to proline; which has a five membered ring structure, is well tolerated 
at this position (Kridel et al. 2001). Chen and co-workers demonstrated that the 
S2 position was the main area of difference in selectivity between MMP-2 and MMP-
9.  
 
MMP 
 
P3 
 
P2 
 
P1 
 
P1’ 
 
P2’ 
 
Hydrophobic 
pocket 
Long side 
chain amino 
acids 
Small 
subsite 
Amino acids 
with 
hydrophobic 
side chains. 
Very broad 
specificity for 
amino acids 
residues  
MMP-
2 
Proline 
Serine, 
lysine, 
alanine and 
glutamic acid 
Alanine 
and 
glycine 
Leucine and 
isoleucine 
Valine, 
leucine and 
isoleucine 
MMP-
9 
Proline 
Arginine and 
aspartic acid 
Glycine 
Leucine, 
isoleucine 
and 
norvaline 
Serine and 
threonine  
 
Table 2: Summary of preferred amino acids for MMP-2/9. 
 
For example, if glutamic acid in the sequence was substituted for aspartic acid 
then the substrate specificity for MMP-2 would be switched to MMP-9 (Chen et al. 
2002). Normally the selectivity and sensitivity of cleavage by MMP-9 can be 
enhanced by placing amino acids with large side chain groups at position P2. The 
presence of arginine at P2 position was found to be well tolerated by MMP-9. 
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Furthermore the positon of arginine at this location improved the proteolytic effect 
of MMP-9 whereas; this had unfavourable hydrolysis for MMP-2 (Murphy et al. 
2002; Chen et al. 2002). Additional studies have shown the successful cleavage of 
a prodrug (EV1-FITC) by MMP-9 with a straight chain residue at the α-carbon of 
norvaline which was found to perfectly occupy the S1’ pocket of the enzyme (Van 
Valckenborgh et al. 2005) (Table 2). 
1.2.6. Legumain in MMP activation and plaque progression  
Papaspyridonos and colleagues (2006), in their findings on gene expression as a 
novel tool for detecting unstable atherosclerotic plaques, demonstrated the up 
regulation of MMPs in atherosclerotic lesions. Moreover, it lead to important 
information about a novel gene, termed legumain, as a potent activator of MMPs 
at protein level (Papaspyridonos et al. 2006). RT-PCR, western blot and affymetrix 
analysis demonstrated consistent up regulation of legumain in vulnerable plaques 
at both transcript and protein levels. Although this enzyme has not been correlated 
with atherosclerosis previously, studies by Hashimoto and colleagues (1999) has 
highlighted the expression of legumain by macrophages and its involvement in 
activation of MMPs and cathepsins as vital to the role of this enzyme in 
atherosclerosis (Shirahama-Noda et al. 2003). It was also shown that the 
occurrence of legumain was associated, significantly, with the expression of CD68-
macrophage markers providing clear evidence that macrophages largely expressed 
legumain (Papaspyridonos et al. 2006).  
Liu and colleagues (2003) also demonstrated the involvement of legumain with 
the invasion and metastasis of tumour; largely by increased ECM destabilization. 
This function could have been possible by the initiation of progelatinase A (MMP-
2), which already has a vital role in ECM degradation. Moreover, the activation of 
MMP-2 involves hydrolysis of an asparaginyl bond which is the universal hot-spot 
for legumain recognition (Nagase 1997). Liu also confirmed that there was an 
increase in the concentration of the active form of MMP-2 (62kDa) when the 
concentration of legumain was increased while incubation with the inactive 72kDa 
MMP-2. It was also demonstrated that there was very little or zero response when 
pro MMP-9 were incubated with legumain even though MMP-9 is a functionally 
similar protease to MMP-2 in tumour and atherosclerotic plaque progression (Liu 
et al. 2003; Chen et al. 2001). Moreover, it was demonstrated that normal cells 
expressing legumain were not affected by legumain-based prodrugs used in 
treating cancer, indicating that these kinds of therapeutics or diagnostics require 
conditions that are not similar to normal tissues. Thus there is every possibility of 
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legumain effecting the remodelling of ECM through processing of other proteases 
specifically MMPs (Morita et al. 2007) explaining their involvement in human 
atherosclerosis.    
1.3. Legumain  
Asparaginyl Endopeptidase (AEP), otherwise known as legumain (EC 3.4.22.34) is 
a distinct member of the cysteine peptidases. The name legumain was first used 
by Kembhavi and colleagues (1993). It was given to an endopeptidase that was 
initially isolated and characterized from leguminous seeds and Vigna aconitifolia 
(moth beans). Legumain is expressed in a diverse range of organisms such as 
parasites, plants and mammals (Halfon et al. 1998). They are involved in functions 
such as processing stored vacuole proteins in plants, digestion of haemoglobin in 
blood flukes, processing precursor polypeptides site-specifically during protein 
maturation and also protein degradation (Halfon et al. 1998). Legumain belong to 
a very large family of proteolytic enzymes known as cysteine proteinases (CPRs) 
that can be further categorized into 30 individual sub-families based on their 
variations in molecular structure. Initially, only three families of CPRs, were 
assumed to be represented in mammals-consisting of: 
 C1- Papain family, including cathepsins-B, H, L, S that are predominantly 
lysosomal in nature, responsible for lysosomal/endosomal system 
proteolysis but can also be processed to act extracellularly.   
 C2- Calpain 
 C14- Caspase; C2 and C14 were secreted in the cytosolic fraction of cells 
and were involved in restricted proteolysis of cytosolic substrates.  
However, Chen and colleagues (1997) were later able to demonstrate the presence 
of legumain (C13) along with other mammalian CPRs. According to MEROPS 
database, legumain was further grouped along with four other sub-families of CPRs 
comprising of clostripain (C11), caspases (C14), gingipain (C25) and separin (C50) 
to form a distinct cluster characterized as clan CD, (Rawlings and Barrett 1999; 
Chen et al. 1998) mainly based on the amino acid sequence of their catalytic motif.  
In 1991, Hara-Nishimura and colleagues were able to extract Asn-specific CPRs 
from sprouting seeds of castor beans and soybean cotyledons (Scott et al. 1992). 
These enzymes were found to transform precursor polypeptides of 2S albumin and 
11S globulin into mature proteins by catalysing, restricted proteolysis of Asn 
residues in vitro. The proteinase sequence as in Schistosoma mansoni-an 
invertebrate published by Klinkert and colleagues as early as in 1989 was found to 
be similar to the legumain family. It is also being stated that legumain is a vital 
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enzyme for matrix degradation (Morita et al. 2007), antigen processing (Maehr et 
al. 2005), atherosclerosis (Clerin et al. 2008), tumorigenesis (Liu et al. 2003; Luo 
et al. 2006) and is also associated with several pathological disorders (Lee and 
Bogyo, 2010). The functions of legumain vary according to the conformational 
state of the corresponding substrate protein. For example, with access to the 
regular processing sites in a precursor polypeptide they can only act as VPE, but 
when the substrate is open for unrestricted proteolysis due to any mutated 
conformation, then it can function as a degradative enzyme. The sensitivity and 
quality of these reactions appears to be the effect of co-evolution of enzyme and 
substrate (Muntz et al. 2002). 
1.3.1. Structure and role of legumain in mammals 
Chen and colleagues (1997) were able to demonstrate that this enzyme was also 
present in humans by expressed sequence tags (ESTs), which coded the presence 
of sequence similarity to legumain. The first mammalian legumain was isolated 
from the kidney of pigs (Chen et al. 1997). It was also demonstrated that this 
enzyme regulated the biosynthetic process of lysosomal enzymes such as 
cathepsin B, L and also activated proMMP-2 (Shirahama-Noda et al. 2003; Smith 
et al. 2012). Legumain is expressed in a number of mammalian tissues (kidney, 
placenta, spleen, liver and testis); however, their activity was found to be 
predominant in the kidneys (Morita et al. 2007).  
Figure 9: Structure of prolegumain and active legumain (adapted from Dall and 
Brandstetter, 2013). 
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Legumain is a well conserved sequence from plant to mammals, including humans 
and it was found that they were localized intracellularly in endosome/lysosomal 
structures and is involved in protein degradation intracellularly (Chen et al. 1998). 
However, it was proved that they were also present extracellularly, linked with 
matrix, cell surfaces and efficient in tumour microenvironments at reduced pH (Wu 
et al. 2006).  Legumain is generally produced as inactive forms- prolegumains (50-
60kDa) and upon activation at pH 4.5 they are converted to active form (46kDa) 
by auto cleavage at carboxyl end of asparagine. Further activation at acidic 
conditions produces the mature enzyme (36kDa) known as active human legumain 
(Stern et al. 2009). Chen and co-workers (2000) have determined 4.5pH to be the 
optimal pH for prolegumain activation, which was comparable with the pH range 
of lysosomal units as in macrophages, kidney cells and fibroblasts (Ling et al. 
1998; Kundra and Kornfeld 1999). Any further increase in pH after the release of 
the active enzyme would lead to inactivation due to denaturation of the enzyme 
(Chen et al. 2000). The crystal structure of legumain was well studied by Dall and 
Brandstetter (2013). The structure of active legumain showed the presence of a 
six-stranded β-sheet located centrally and bordered by 5 major α-helices, as 
shown in figure 9[A]. They also confirmed the presence of a unique ~30aa inset 
between β2 and α2 helix which regulates zymogen activation (Fuentes-Prior and 
Salvesen, 2004). Although the mechanism of action, localization and pH dependent 
activation and maturation are similar to cathepsins, legumains show no sequence 
similar to the above making them completely unique from other CPRs (Dall and 
Brandstetter 2012). The crystal structure of prolegumain indicated the presence 
of a helical ‘pro-domain’ placed at the top of the protease domain blocking access 
to the active site of the enzyme, as shown in figure 9[B]. The presence of this pro-
domain regulates the conformational stability and dormant nature of the enzyme 
prior activation. The pro-domain contains legumain stabilization and activity 
modulation (LSAM) domain otherwise known as C-terminal death domain (Asp324- 
Tyr433) and activation peptide (Lys287-Asn323), as shown in figure 9[B] (Dall and 
Brandstetter 2013).  
Any interaction with the protease is mainly electrostatic in nature involving both 
activation peptide and LSAM domain. The positively charged pro-domain interface 
balances the highly negatively charged protease surface ultimately clarifying the 
rationale behind: 
1) Stability of prolegumain at neutral pH. 
2) Release of pro-domain upon protonation of protease surface. 
3) Stability of the activated AEP at acidic pH. 
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4) Denaturation of active AEP at pH >6.0 (Fuentes-Prior and Salvesen 2004). 
Dall and Brandstetter (2013) also showed the presence of an electrostatically 
encoded stability switch near the activation peptide, which can be activated by pH 
or ligands explaining the reason why legumains are pH-sensitive. Further analyses 
of legumain have explained its potential role in various disease states including 
parasitic infections, matrix degradation, antigen processing, atherosclerosis, and 
tumours (Lee and Bogyo 2012). With mounting evidence illustrating the role of 
legumain in triggering extracellular matrix turnover in several disease states, it 
has also been demonstrated that they play a vital role in many tumour 
development and metastasis (Liu et al. 2003) and in growth of atherosclerotic 
plaques (Papaspyridonos et al. 2006). Morita and co-workers (2007) were able to 
clearly present the degradation of fibronectin- a vital element of extracellular 
matrix protein in renal proximal tubes to be caused by legumain. Moreover many 
peptidases such as matrix metalloproteinase (MMP-2/9), serine proteases and 
cathepsins which are generally involved in matrix degradation and remodelling are 
synthesized by tubulointerstitial cells of the renal system (Jernigan and Eddy, 
2000), thus increasing the possibility of legumain, (which is said to be over 
expressed in the renal proximal tubules) in controlling matrix remodelling by 
activating these peptidases (Morita et al. 2007). 
In their findings Mattock and co-workers (2010) demonstrated that active 
legumain was found to be over expressed in unstable regions of plaques. This is 
one of the key factors for atherosclerotic plaque progression, thus confirming the 
association between legumain and atherosclerosis. It was also shown that the 
enzyme was found to be co-localized in the endothelial cells of mature plaques in 
coronary arteries of humans but no presence of the enzyme was noticed in normal 
arteries or during the early stage of plaque development (Clerin et al. 2008). 
Legumain was also found to be expressed in fibrin rich regions of unstable plaques 
presenting a probability that it is involved in extracellular matrix remodelling 
(Morita et al. 2007). These results also demonstrate the fact that the enzyme 
requires an acidic surrounding for activation similar to the lysosome, macrophage 
microenvironment and plaque microenvironment, where areas of acidic pH are 
correlated with regions which are rich in lipids, inflammatory cells and 
metabolically active (Naghavi et al. 2002). 
1.3.2. Legumain expression in atherosclerosis  
Amongst the various proteases involved in atherosclerosis, MMPs and serine 
proteases have been shown to be more active in this pathological condition. Recent 
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studies have shed light on the potential role of lysosomal CPRs in atherogenesis 
by demonstrating legumain expression in stable and unstable human 
atherosclerotic plaques (Clerin et al. 2008; Papaspyridonos et al. 2006). Liu and 
co-workers (2003) were able to suggest that the role of extracellular legumain 
may actively be associated with the metastatic behaviour of tumour cells. Wu and 
colleagues (2006) were also able to show the presence of legumain in the tumour 
microenvironment linked with the tumour cell surface.  Moreover, Choi and 
colleagues (1999) in their findings were able to demonstrate that legumain could 
also function in a protease independent fashion inhibiting osteoclast formation and 
bone resorption. In experiments conducted by Clerin and colleagues (2008) in 
mouse models of atherosclerosis, they were able to characterize the gene and 
protein expression of legumain as well as increased legumain concentration in 
human samples of atherosclerotic tissues. They also proposed that legumain 
expressed by macrophages could lead to atherogenesis by protease regulated as 
well as protease independent pathways. Foam cells, macrophages and their 
precursors (monocytes) are the main cell types that expressed legumain in both 
mouse and human atherosclerotic arterial tissue (Clerin et al. 2008).  
Studies have shown that differentiated macrophages presented high concentration 
of legumain secreted extracellularly (Clerin et al. 2008). However, the pro-form of 
legumain secreted extracellularly can be converted to mature forms by pH driven 
autocatalytic activation in the acidic microenvironment of the cell. These active 
forms in turn could activate other proteases such as MMPs, cathepsins-L and S 
that have already been shown to be involved in atherosclerosis and are present in 
the cell microenvironment (Liu et al. 2006). Plaque instability and rupture is highly 
increased by continuous ECM destabilization and tissue remodelling which is said 
to be enhanced by legumain which activates and regulates elastolytic or 
collagenolytic enzymes such as MMP-2 (Chen et al. 2001).   
Besides this protease dependent activity of legumain in atherosclerosis, they can 
also induce chemotaxis of monocytes. They perform this by initially acting as a 
chemo attractant of monocytes and then conduct a chemotactic effect on the same 
(Clerin et al. 2008). Choi and colleagues (2001) have also shown a similar 
behaviour of legumain in inhibiting the differentiation of monocytes to osteoclast 
by its C-terminal peptide (17kDa). Thus this characteristic feature of legumain 
could cause ECM destabilization by a protease dependent mechanism and at the 
same time can also function as a chemo attractant recruiting monocytes into 
atherosclerotic plaques and retaining macrophages in the lesions (Clerin et al. 
2008). Therefore, they may play a dual role in atherosclerosis by acting both as a 
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protease and a chemo attractant. Moreover, legumain are also found to be 
expressed by endothelial cells of mouse and human atherosclerotic tissues. These 
endothelial legumain are expressed only by advanced stage plaques of both human 
and mouse atherosclerotic models (Clerin et al. 2008). The presence of legumain 
expressed by inflammatory cells in areas of plaque neovascularization of coronary 
arteries in humans proposes a crucial role of legumain in angiogenesis (Clerin et 
al. 2008). On the basis of all these findings, this research study also focused on 
the synthesis of a library of peptide substrates that could be site specifically 
cleaved by legumain and hence could act as a diagnostic tool for detecting 
atherosclerotic plaques. In summary, legumain produced by macrophages 
overexpressed in atherosclerotic lesions could contribute to neovessel 
development by initiation and migration of endothelial cells, invasion and 
propagation (Clerin et al. 2008). All this evidence supports the fact that legumain 
can be exploited in various ways as a vital diagnostic tool for identifying, 
characterizing and treating atherosclerosis.    
1.3.3. Legumain–substrate specificity 
Inspite of the numerous findings in exploiting legumain as an important 
therapeutic target, the available procedures to characterize the role of legumain 
in disease states still depends on genetic alterations and antibodies. These 
elements make it a challenge to study the enzyme in its natural state (Lee and 
Bogyo 2012). Hence, there is a need for small chemical probes with high sensitivity 
and selectivity for the enzyme, which can monitor its function and parameters in 
a wide range of biological systems. When compared to other cysteine proteases, 
which generally exhibit broader specificity, proteases belonging to clan CD have a 
specific requirement at the P1 position of the amino acid sequence with legumain 
having strict specificity for asparagine at the P1 amino acid position (Mathieu et al. 
2002). Mathieu and colleagues (2002) proved the specificity of legumain for 
asparagine at P1 by performing a variable library screen test. They constructed a 
library with 19 wells corresponding to 19 different amino acids at P1 of a tripeptide 
sequence and results confirmed that asparagine was the only amino acid tolerated 
by legumain at the P1 site. Knowledge about substrate specificity for legumain 
apart from the P1 position is not available; hence determining specific amino acids 
ideal for binding would also serve the same purpose of studying the enzyme 
(Backes et al. 2000). Mathieu and colleagues (2002) using a positional scanning 
synthetic combinatorial library (PS-SCL) having asparagine constant at P1 and the 
respective P2 and P3 positions randomized using 19 amino acids were able to find 
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the most suitable substrates for legumain. The result of these studies 
demonstrated that Pro-Thr-Asn was the ideal sequence for human legumain.  
Another study by Manoury and colleagues (1998) stated that tetanus toxin antigen 
of microbial origin when processed by mammalian legumain, cleaved the sequence 
at the carboxyl side of asparagine. They further confirmed that human legumain 
could not tolerate His or Tyr at P2 or P3 positions and has a very low reactivity 
towards substrates containing Asn, Glu, Gln, Phe or Trp at these positions. Chen 
and colleagues (1997) conducted experiments by treating legumain with a range 
of oligopeptides and concluded that Asn was the hot spot for substrate recognition 
and cleavage (figure 10). They also stated that there was no data available for any 
other protease apart from legumain and other variants species of legumain with 
such high specificity for asparagine. In another similar study by Dando and 
colleagues (1999) on substrate specificity for legumain isolated from pig kidney, 
the role of amino acids on other positions apart from P1 was evaluated.  
 
 
 
 
 
 
  
Figure 10: Asn as the required hot spot for legumain cleavage of peptide substrates 
(Chen et al. 1997). 
They concluded that there was no distinctive necessity for a particular amino acid 
in any subsite apart from P1. However they also presented evidence of Pro and Ala 
at P3 and P2 subsites in most of the substrates cleaved by the enzyme proposing 
the idea that this might be an important detail while designing a substrate for 
legumain. To date there are two prodrugs designed based on legumain activity for 
tumor studies. One of which has a peptide substrate: N-Suc-Ala-Ala-Asn-Leu-
doxorubicin (LEG-3) cleavable by legumain (figure 11), which releases Leu-
Doxorubicin at the tumour microenvironment (Wu et al. 2006).  
Neurotensin 
pGlu-Leu-Tyr-Glu-Asn----Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu 
  
Human VIP 1-2 
His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn----Tyr-Thr-Arg 
  
Chicken VIP 16-28 
pGlu-Met-Ala-Val-Lys-Lys-Tyr-Val-Asn----Ser-Val-Leu-Thr-NH2 
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Figure 11: Structure of LEG-3, Legubicin (Liu et al. 2003). 
Table 3b 
 
P3 
 
P2 
 
P1 
 
P1’ 
Hydrophobic 
pocket 
Hydrophobic, 
non-polar amino 
acids with varying 
side chains 
Strict 
specificity for 
an asparagine 
residue 
Positive, 
hydrophilic 
amino acids 
Proline, β-
Alanine 
Alanine, Glycine 
and Leucine 
Asparagine 
Lysine, Histidine 
and Arginine 
Table 3a and 3b: Most preferred substrate sequences for legumain (Mathieu et al. 2002). 
Table 3a 
P3 P2 P1 Km (μM) Vmax (μM s-1) 
Ala Ala Asn 80 ± 6 4.4 ± 0.5 
Thr Ala Asn 128± 10 5.7 ± 0.6 
Pro Thr Asn 122 ± 13 6.9 ± 0.6 
Phe Tyr Asn n/a n/a 
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The second one is a legumain based DNA vaccine constructed to down regulate 
tumour development and metastasis (Luo et al. 2006; Lewen et al. 2008). Thus 
based on the available literature (Table 3a and b), peptide substrates suitable for 
legumain have been synthesized using both solid phase and solution phase peptide 
synthesis in this research study. Research and advancements have enhanced the 
knowledge on disease etiology resulting in effective therapeutic schemes. Despite 
these improvements heart failure causes 300,000 deaths per year (Leuschner and 
Nahrendorf 2011). Hence the need for new diagnostic approaches that identify 
individuals with atherosclerotic plaques and enable personalized treatment before 
irreversible damage occurs is in demand. For instance, molecular imaging can be 
used to locate an inflamed plaque at the event of rupture and initiate significant 
action in order to prevent any further complication (Fuster et al. 2005). Moreover 
molecular imaging could also help in prioritising the lesions that need treatment 
from those that can be left alone hence avoiding unwanted problems and re-
interventions (Leuschner and Nahrendorf 2011). Hence, there is a significant need 
in combining experimental evaluations with molecular imaging to improve the 
process of developing therapeutic and diagnostic tools for atherosclerotic plaques.   
1.4. Molecular imaging 
The in vivo characterization and evaluation of biological events at cellular and 
molecular level without any surgical biopsies is known as molecular imaging (MI) 
(Weissleder and Mahmood 2001). One of the objectives of molecular imaging is to 
detect specific targets for various molecular pathways, in order to study 
fundamental biological events and also activities of cells in their natural living 
environments (Weissleder and Mahmood 2001). This multi-disciplinary field is of 
extreme importance to researchers of molecular biology and chemistry with its 
significant applications rooted in chemical, biological and imaging sciences (Jaffer 
et al. 2007). Imaging modalities require probes, which are highly specific and 
sensitive in their purpose of detection incorporating two important features. A 
high-resolution output source, capable of interpreting even the weak signals sent 
out from the target compound and a target specific imaging moiety that 
distinguishes the required molecular or cellular region. The major challenge for 
synthesizing these imaging agents will arise when the target compound is of low-
abundance or is remote (Jaffer et al. 2007). Molecular imaging of subjects can be 
enhanced by, using appropriate probes with: 
 High specificity and affinity 
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 Strength to withstand biological barriers  
 Increased selectivity  
 Quick response to stimulus and clarity in imaging (Jurasz 2003). 
Some examples of probes for detecting signals include fluorophores used in near 
infrared fluorescence imaging, paramagnetic (gadolinium) and super paramagnetic 
(iron oxides) ligands used in MRI, radioisotopes used in PET and single-photon-
emission computed tomography (SPECT) and micro bubbles used in ultrasound 
imaging (Jurasz 2003). These probes can be further categorized into 3 classes: 
 Compartmental probes: These probes are used for evaluating 
physiological functions, for example flow and perfusion. In this type of 
imaging the target is not exactly a molecular process but a surrogate as in 
diffusion MRI (dMRI). 
 Targeted probes: These probes are designed for a very specific target such 
a particular molecule, receptor or enzyme. 
 Smart probes: These probes are tailored to become active only in the 
presence of the target molecule. In this type of imaging the presence of 
background noise is significantly reduced enhancing the resolution when 
compared to targeted probe imaging (Perez et al. 2003). 
1.4.1. Atherosclerosis and molecular imaging 
Various advancements in this field of molecular imaging have reformed the quality 
of medical science by offering reasonable and adequate anatomical details that 
improve diagnostic proficiency and also help monitor therapeutic interventions 
(Quillard et al. 2011).  The biological and anatomical origination and development 
of atherosclerosis has been studied applying various advanced techniques in 
molecular biology, from genetically modified mice and also from meticulous 
observations of human pathological samples. All these findings have provided a 
complex picture of the disease and the diverse targets responsible for the condition 
as shown in figure 12. It is hoped that eventually, this will lead to the development 
of specific probes. These probes coupled with various imaging platforms have 
widened ventures for medical imaging and preclinical research (Sadeghi et al. 
2010).  
Both cells and the endothelial surface within the arterial vessel wall in 
atherosclerosis release a number of molecular targets. Notably there is differential 
accumulation or release of these targets right from early plaque formation up to 
advanced stages such as susceptible plaques and thrombotic complications 
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(Choudhury and Fisher 2009). Some examples of molecular targets for recognizing 
premature or early artherogenesis consists of endothelial cell adhesion molecules 
such as vascular cell adhesion molecule-1 (VCAM-1), P and E selectin and 
intercellular adhesion molecule-1 (ICAM-1). 
 
Figure 12: A pictorial representation of an artery presenting potential molecular targets 
for imaging and hence detecting atherosclerotic development (Libby et al. 2010). 
 
These molecular targets are responsible for mononuclear leukocyte concentration 
to endothelial activation and subsequent migration towards the subendothelial 
space (Galkina and Ley 2007; Cybulsky MI and Gimbrone Jr 1991). These 
endothelial adhesion molecules have always been on the forefront of molecular 
imaging mainly because they are overexpressed in a wide range of diseases such 
as atherosclerosis, cancer, ischemic stroke and ischemia-reperfusion (McAteer et 
al. 2010). Vascular imaging is less complicated compared to neurological imaging, 
as targets are available in the circulating blood stream. However, it has its own 
limitations such as, the location of blood vessels deep inside the body; impeding 
access for low penetrance techniques similar to fluorescent and ultrasound imaging 
(Choudhury and Fisher 2009). Moreover, the small size of these plaques and 
movement due to cardiac and respiratory function, along with challenges to 
concentrate contrast agents due to the shear force on blood stream applied from 
the blood vessel walls, impose further restrictions on imaging (Choudhury and 
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Fisher 2009). The main reason for imaging such targets will help to serve two 
purposes: 
 In understanding the course of treatment to the patient and will also aid in 
monitoring the progress of the treatment. 
 In synthesizing novel drugs for the disease (Overall and Kleifeld 2006). 
Techniques Advantages Disadvantages 
Optical 
Use of non-ionizing radiations, high 
resolution, for imaging soft tissues, can 
be applied for longitudinal studies, aid in 
imaging structures over a diverse range 
of size and category, comparatively 
cheap and less time consuming. 
Low penetrance, invasive in 
procedure. 
Ultrasound 
Real-time, no harmful radiation, less 
expensive, readily available, non-
invasive and quick. 
Skilled operator required, 
chances for false-positive 
results are quite high 
leading to further 
evaluation, less 
quantitative. 
Computer 
Tomography 
More detailed compared to ultrasound, 
quick, 3-dimensional resolution, painless 
and quick. 
Use of strong radiation, low 
resolution for soft tissues 
and on inflammations, 
allergic reactions. 
Nuclear 
Functioning of body parts can be 
imaged, painless, highly sensitive 
technique, quantitative. 
Exposure to ionizing 
radiation may cause allergic 
reactions, quite high-
priced. 
Magnetic 
resonance 
imaging 
Non-invasive, painless, no harmful 
radiation used, can be applied for a 
diverse range of disorders, highly 
sensitive, both spatial and temporal 
resolution obtained. 
Expensive, quite a lengthy 
procedure, not 
recommended for people 
with metal implants, advice 
required for people with 
renal problems. 
 
Table 4: Advantages and disadvantages of popular imaging procedures for vascular 
disorders (Leuschner and Nahrendorf 2011). 
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A wide range of imaging modalities are available to image vulnerable plaques, 
including invasive techniques such as, virtual histology, IVUS, OCT, thermal 
heterogeneity and integrated backscatter, are being evaluated ex-vivo and are 
now under clinical evaluation. A few non-invasive imaging techniques such as, MRI, 
PET and CT are applied to analyse metabolic activity and also unstable plaques 
(Fayad and Fuster 2001). Some advantages and disadvantages of these imaging 
techniques are listed and compared in Table 4. 
Of these various imaging procedures only nuclear imaging has been used for 
medical purposes. FDG (2-[18F]fluoro-2-deoxy-d-glucose) a 18Fluorine agent has 
been used in PET scans for imaging inflammatory regions in atherosclerotic 
conditions by exogenous administration. Moreover, it has been demonstrated that 
FDG-PET can successfully detect inflamed and metabolically active plaques 
(McAteer et al. 2010). The major advantages of PET scans are that they are highly 
sensitive and have quantitative outputs. By synthesizing novel radio-ligands which 
can then detect molecular targets such as MMPs (Wagner at al. 2006), serine 
proteases (Li et al. 2008) and apoptosis (Korngold et al. 2008) PET can be used 
beyond macrophage imaging and also to visualize the response to treatments in 
high risk patients (McAteer et al. 2010). Another means of enhancing molecular 
imaging of plaques will be the use of multimodality imaging. This involves 
evaluation of several vascular regions at the same time. To achieve this, the 
required molecular probe is administered into the body intravenously and allowed 
to aggregate at the specific region (Sadeghi et al. 2010).  
 
 
 
 
 
 
 
 
 
Figure 13: Comparison of spatial resolution and sensitivity of imaging techniques. 
(Sadeghi et al. 2010).  
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Upon optimizing the conditions for a positive target to background signal, the 
highly sensitive nuclear procedure (SPECT, PET) which, exhibits sensitivity up to 
picomolar scale along with superior spatial and temporal resolution of CT and MRI 
(figure 13) will be the source behind hybrid imaging platforms. Hybrid procedures 
such as PET/CT and PET/MRI are becoming popular (Sadeghi et al. 2010). 
Compared to other imaging modalities, MRI provides well-defined information on 
both anatomy and plaque configuration. Furthermore, coupling the imaging agents 
with specific molecular probes that target the biomarkers of atherosclerotic 
plaques (Sadeghi et al. 2010) will further enhance the resolution of the image 
captured via a MRI scanner. These imaging techniques provide very promising 
application in studying the various causes and events in atherosclerosis. But 
clinical manifestation will require a safe, low-molecular weight, non-toxic and cost 
effective probe and imaging technique. This research study is focused on the use 
of chemical agents for MRI, which is one of the efficient techniques for vascular 
imaging. MR imaging produces no harmful radiation and hence can be applied for 
longitudinal studies and can also provide high spatial and temporal resolution 
required for studying vascular injury by atherosclerosis (Fayad and Fuster 2001). 
Moreover, its proficiencies are further improved by the application of increasingly 
refined contrast agents that can specifically target molecular markers, cells and 
biological progressions (McAteer et al. 2010).   
1.4.2. Magnetic resonance imaging (MRI)  
Magnetic resonance imaging is a diagnostic tool that penetrates deep into soft 
tissues of the body and can produce images of resolution up to submillimeter scale 
(Hasegawa and Zaidi 2006). It has been developed as a sensitive technique for 
non-invasively imaging thrombosis within the carotid artery (Flacke et al. 2001). 
With its property of non-invasive imaging MRI produces precise three-dimensional 
images of the structures that are scanned. A very brief comparison between MRI 
and other non-invasive imaging techniques (table 5) rationalizes that MRI 
produces images with enhanced contrast and resolution. Because it gives clear 
analysis on anatomy, function and metabolic activity of tissues it is readily applied 
in musculoskeletal, neurological, cardiovascular and cancer studies (Strijkers et al. 
2007). As previously discussed MRI requires no ionizing radiation and moreover 
the contrast agents (CA) used for improving the clarity of imaging are far less toxic 
when compared to CT contrast agents (Sand and Levitin 2004). MRI with high 
resolution helps to detect and characterize atherosclerotic plaques and also mature 
lesions. It also helps in distinguishing between thin and broken fibrous cap (figure 
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15) with an intact and thick fibrous cap in vivo. Along with the available CAs the 
required molecular specificity could be easily attained by MR imaging (Caravan 
2009). In a study on MRI by Corti (2006) it was stated that magnetic resonance 
imaging is a promising technique for studying plaques. The procedure for this 
imaging technique is mainly based on the signal emitted from the experimental 
subject under a strong magnetic field in accordance to the concentration of water 
and also the relaxation times (T1 and T2).  
Imaging 
procedure 
Energy used Spatial 
resolution 
(mm) 
Acquisition 
time per 
frame (s) 
Required 
probe 
quantity 
(ng) 
Depth of 
tissue 
penetration 
(mm) 
PET Annihilation 
photons 
1-4(A), 4-
5(C) 
1-300 1-100 >300 
SPECT Gamma rays 0.5-5(A), 7-
15 (C) 
60-2000 1-100 >300 
Fluorescence 
imaging 
Visible to 
infrared light 
2-10 10-2000 103-106 1-20 
MRI Radio-
frequency 
waves 
0.025-
0.1(A), 0.2 
(C) 
60-3000 103-106 >300 
Ultrasound High-
frequency 
sound waves 
0.05-0.5(A), 
0.1-1 (C) 
0.1-100 103-106 1-200 
CT X-rays 0.03-0.4(A), 
0.3-1(C) 
1-300 N/A >300 
Table 5: Comparison between various non-invasive imaging tools (Camici 2012). 
The rapid spinning of the positively charged protons around the nucleus creates a 
magnetic field. Therefore, when they are placed inside a MRI scanner emitting 
strong magnetic field strength, these protons align themselves with the external 
magnetic field. When specific radio waves are passed through them some of these 
protons are raised to a higher or excited energy level and while returning to their 
original frequency in the absence of the radio wave, termed as relaxation, these 
protons emit radiofrequency signals. These signals are then detected by a receiver 
or antenna in the MRI device producing clinical images (Ibanez et al. 2009; Singer 
2012) as shown in figure 14. 
The time taken by the protons to return to its original longitudinal energy state 
after the radio wave is switched off is marked as T1 and technically denoted as 
spin-lattice relaxation whereas the time taken to return to its transverse state to 
- 35 - 
 
release energy is marked as T2 and technically denoted as spin-spin relaxation 
(Singer 2012). The T1 and T2 values are said to vary according to various tissues; 
for example water has a longer relaxation time when compared to fat and hence 
the characteristic features can be studied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: A pictorial representation of the behaviour of protons when exposed to a 
strong magnetic field to radio frequency signal (adapted from, Singer 2012). 
 
Since the human body contains a lot of hydrogen atoms, which is the underlying 
basis for MR imaging, it helps in producing a clinically significant image. The mode 
of MR imaging is based on the biophysical and biochemical aspects, which include 
molecular change, chemical composition, water content and physical conditions. 
The first human atherosclerotic plaque sample to be viewed in vivo was that of the 
coronary lesions by Fayad and colleagues (2000).  
BO
Random movement of protons in the absence of a magnetic field 
Alignment of protons in the presence of a strong magnetic field 
Realignment of protons in the presence of radio-frequency wave 
When the radio frequency is switched off, the protons return to their 
original position and release energy 
Rf wave 
Release of 
energy 
BO
BO
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Figure 15: Automated segmentation of high-spatial resolution, multi contrast, bright and 
black blood in vivo magnetic resonance imaging. (Chu et al. 2010). 
 
This procedure was further improved by Botnar and colleagues (2000) to give a 
better image of the coronary plaque during free breathing conditions. Since then 
the clinical applications of MRI have been exploited in studying plaques in human 
carotids (Yuan et al. 2001), aortic (Corti et al. 2001), peripheral (Coulden et al. 
2000) and diseases of the coronary artery (Fayad et al. 2000). Thus many 
researchers have concluded that MRI is a sensitive diagnostic technique for 
studying the progress of the plaque (Corti 2006) and also has the potential to 
explain the thickness of the lesion, the growth rate along with the composition of 
the atherosclerotic plaques (figure 15) (Fayad et al. 2000). In most imaging 
situations the generally evaluated tissue-proton spin density and T1/T2 relaxation 
times are normally sufficient to provide the required images (figure 15). However 
under certain pathological conditions when the changes in local relaxation times 
are not enough to distinguish between the normal and abnormal regions of the 
tissue, the need for a better contrast between them becomes necessary (Singer 
2012). This can be brought about by using CAs, which work by altering the normal 
relaxation times and thus, enhance the resolution of the target location (Strijkers 
et al. 2007). This combination between MRI and contrast agents will enhance 
understanding about various diseases including arthritis, tumour related conditions 
and atherosclerosis.  
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Further work on MRI contrast agents, for example, small iron oxide particles that 
can be easily ingested by macrophages accumulated in plaques producing better 
images and quickening the process of diagnosing high risk plaques (Kooi et al. 
2003) are in progress. Advancements in the clinical setting of MRI with the release 
of 3-T and 7-T scanner have further increased the opportunities for distinguishing 
and studying atherosclerotic disease (Yuan et al. 2012). High spatial resolution 
black-blood techniques (figure 15) might enhance non-invasive imaging of human 
coronary and carotid arteries thus helping in early evaluation of atherosclerotic 
conditions (Fayad and Fuster 2000). These progressions in MRI and contrast 
agents will help in developing an accurate and early diagnostic tool for susceptible 
patients of atherosclerosis (Ostergaard et al. 1999). 
1.4.2.1. Contrast agents (CAs) 
For molecular imaging, the selection of an appropriate contrast agent (CA) is 
important to produce the required contrast between the abnormal and normal 
regions. CA’s constructed for any particular target generally consist of two main 
elements:  
 A unit, which is highly specific to the overexpressed molecular marker 
similar to proteins, peptides, carbohydrates, small molecules, antibodies 
and fragments of antibodies. 
 An imaging tag that can send significant signals to an external imaging 
device of choice such as fluorophores (NIRF), radio-isotopes (SPECT/PET), 
sonic enhancers (US) or magnetic groups (MRI) (Jaffer et al. 2006). 
However, the choice of a CA mainly depends on the location, concentration and 
nature of the corresponding molecular target more than the imaging modality. For 
instance, ECM proteins such as collagen, elastin and fibrins are normally expressed 
in high concentrations when compared to other molecular targets and hence low 
molecular weight CA’s equivalent to a few nanometres can be used to image them. 
Imaging such molecular targets enables greater accumulation of CAs leading to 
the use of imaging devices with comparatively low intrinsic sensitivity. On the other 
hand molecular targets of very low concentrations such as 10-9 to 10-13 mol/g 
require different targeting procedures (Nunn et al. 1997). 
As stated earlier, image quality of the MRI scan can be improved by the use of 
appropriate contrast agents, which work by altering the relaxation time of the 
tissue water. In a recent evaluation 35% of MRI examinations are said to use 
contrast agents to provide high-resolution imaging (Li et al. 2008). In a review by 
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Sosnovik and Caravan (2009) it has been stated that the CAs for MRI have been 
broadly classified into paramagnetic gadolinium (Gd)-based CAs and super 
paramagnetic (iron-oxide) nanoparticles. CAs in general alter both T1 and T2 but 
it is always important to distinguish them into transverse relaxation agents (1/T2) 
or longitudinal relaxation agents (1/T1). The 1/T2 agents function by increasing 
transverse rate (1/T2) to the same extent as the longitudinal rate (1/T1) increase 
and they are denoted as T1 emitting a positive scan with an increase in signal 
intensities. When there is a large increase in the transverse rate (1/T2) alone then 
they are denoted as T2 agents causing a reduction in signal intensity and are 
denoted as negative contrast agents. Ferromagnetic iron oxide CAs are denoted 
as T2 agents and paramagnetic Gd CAs are examples of T1 agents. There are 
several other contrast agents available but the gadolinium based paramagnetic 
CAs are more widely used in several clinical analyses (Caravan 2006). 
1.4.2.2. Paramagnetic gadolinium (Gd)-based contrast agents 
Gadolinium complexes are used as extracellular contrast agents for MRI in 
recognizing and treating a wide range of vascular dysfunction. Since they are 
classified as T1 contrast agents they produce positive images with good signal 
intensities such as Gd-DTPA (Mohs et al. 2004; McAteer et al.2010) as shown in 
figure 16. Most of the Gd based analyses are pre-clinical with the exception of EP-
2104R, which is a fibrin targeted probe (Spuentrup et al. 2008). Contrast agents 
targeted to MMPs (Lancelot et al. 2008), high-density lipoproteins (Frias et al. 
2004) and also non-targeted complexes such as gadofluorine-M (Meding et al. 
2007) and long chain fatty acids coupled to Gd (Lipinski et al. 2006) have imaged 
plaque growth in rabbit and mouse models for atherosclerosis.  
 
 
 
 
 
 
 
 
 
 
 
Figure 16: MRI image (T1) of blood-brain barrier defect due to stroke. The image on the 
left has no CAs but the one on right has CAs. 
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Some of the commercially available Gd-based contrast agents are Gd-DTPA (figure 
17-A), Gd-DOTA or Gd-BOPTA (figure 18-A) which are known for their low toxicity 
but at the same time posses low molecular weight leading to immediate clearance 
from the blood stream producing poor signals for imaging (Mohs et al. 2004). 
However, this problem can be solved by coupling them to a polymeric carrier for 
example Gd-DTPA and Gd-DOTA coupled to polyamidoamine (PAMAM) dendrimers 
(Nwe et al. 2010), Gd-DTPA coupled to dextran (Li et al. 1992), Gd-DTPA coupled 
to albumins (Spanoghe et al. 1992), Gd-DTPA coupled to polyethylene glycol. 
These CAs reduce the toxicity of the metal ion, increases their retention time in 
the blood stream, act as carriers of therapeutic compounds and also can increase 
the specificity of the CA by carrying a probe specific to the target of interest 
(Mulder et al. 2005). Thus these macromolecular agents act as blood pool contrast 
molecules delivering more information on vascular anatomy, capillary 
permeability, and blood volume. Moreover, pathological information pertaining to 
myocardial infarction, inflammation, plaque deposits, break-down of blood brain 
barrier and tumour can also be evaluated.  
Free gadolinium metal ion is toxic and therefore it is always bound to chelating 
agents such as DTPA or DOTA. Many factors are assured to impact the stability of 
these complexes such as charge, number, basicity of co-ordinating groups, 
conformational effects and ligand field including intrinsic energy and entropy 
(Frullano and Meade 2007). The gadolinium (III) complex of diethylenetriamine 
pentaacetic acid (Gd-DTPA/Gadopentetate dimeglumine/Magnevist) is one 
popularly used MRI contrast agent. This water-soluble complex is stable and 
nontoxic with a very high demetallation (KGd) stability constant (breaking of a bond 
between the substrate and metal atom) of logKGd = 22.4 and is approved for both 
experimental and medical research. Gd-DTPA aggregates in tissue by perfusion-
controlled routes and has been permitted for use in adult patients since June 1988 
(Frullano and Meade 2007). Revealing abnormal vascularity and imaging 
disruptions of blood-brain barrier triggered by lesions are well documented by 
using such image enhancing contrast agents (Hayes et al. 2002). Laboratory 
analyses of animals and humans involving a Gd(III) complex of DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetra acetic acid) a macrocyclic ligand has proved 
its conformational rigidity and demetallation stability constant to be 25.3 and also 
has a very low dissociation constant at physiological pH. This CA has also been 
approved for medical examinations (Frullano and Meade 2007). Further research 
in this field of MRI contrast agents have categorised CAs into four major groups: 
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 Targeting CAs: Tailored to spot specific receptors or organs and hence 
aggregate at the target site. 
 Activatable CAs: Designed to undergo modification in relaxivity 
corresponding to changes in specific physiological factors  
 Blood pool agents: In contrast to other CAs they have longer residence time 
and also find application in magnetic resonance angiography. 
 Chemical exchange saturation transfer agents (CEST): These novel agents 
work using an irradiated group of protons ultimately leading to their 
activation. Their reaction is controlled by few variables such as chemical 
shift and exchange rate between their proton group and water protons 
(Zhang et al. 2003; Frullano and Meade 2007).    
Generic name 
 
Trade name 
 
Gadopentetate dimeglumine 
 
Magnevist (Gd-DTPA) 
 
Gadoterate meglumine 
 
Dotarem 
 
Gadodiamide 
 
Omniscan 
 
Gadoteridol 
 
ProHance 
 
Gadobutrol 
 
Gadovist 
 
Gadoversetamide 
 
Optimark 
 
Gadobenate disodium 
 
MultiHance 
 
Gadoxetate disodium 
 Primovist/Eovist 
Gadofosveset trisodium 
 
Vasovist/Ablavar 
 
Table 6: List of clinically approved contrast agents (Singer 2012). 
Some of the approved CAs, in use, intravenously in the United States and European 
Union are shown in table 6 (Li et al. 2008). Based on the chemical structure of the 
chelating agent they can be classified as macrocyclic and linear contrast agents 
(figure 17 and 18).  
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Figure 17: Structure of (A) Magnevist (Gadopentetic acid; Gd-DTPA) and (B) ProHance 
(Gd-HP-DO3A; Gadoteridol) (Kunnemeyer at al. 2009).  
 
 
Figure 18: structure of (A) macrocyclic and (B) linear contrast agents (Singer 2012). 
Theoretically macrocyclic chelates are more stable than the linear counterpart as 
they bind securely to the metal ion and hence the chance for disassociation of the 
metal is low (Kei and Chan 2008). Some of these CAs are inexpensive in production 
and have a very good safety profile allowing use even in children (Caravan 2006). 
However, the use of these agents in people with renal disorder needs special 
consideration as they might cause severe renal failure leading to death, also 
pregnant women will require the advice of their doctors as CAs are prone to cross 
the blood-placenta barrier (Webb et al. 2009).  
1.5. Fluorescence resonance energy transfer (FRET) 
The enormous growth in magnetic resonance imaging has already widened its 
application from medical diagnosis to consistent cellular analysis and imaging 
A B 
A B 
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(Frullano and Meade 2007). However, along with MRI techniques, optical imaging 
procedures are also being suggested as a potent tool for both in vivo and in vitro 
molecular imaging because of their excellent sensitivity and selectivity (Chen et 
al. 2014). Optical imaging effectively helps in the study of interactions and 
structural modifications along with microscopic visualization and subcellular 
localization of biochemical reactions (Schmid and Sitte 2003). FRET is one of the 
most widely suggested techniques for studying live interactions between molecules 
without causing any damage to the native biological evolutions in living cells (Kalab 
and Soderholm 2010).  
Figure 19: Pictorial representation of fluorescent energy transfer. 
FRET is a technique used to measure distance between molecules even at the 
nanometre range, thus helping to predict any changes between the molecules 
(Selvin 2000). This procedure can be defined as the transfer of energy from an 
excited fluorophore, which is the donor molecule to another fluorophore denoted 
as the acceptor molecule as in figure 19 (Schmid and Sitte 2003). It is commonly 
known as Forster resonance energy transfer due to the fact that the expression 
‘fluorescence resonance energy transfer’ evokes the idea of resonance energy 
transfer or transfer of energy due to photon effect which would completely mislead 
any lay person (Kalab and Soderholm, 2010). This technique helps to image 
localized proteins and other surrounding molecules with 3-dimensional resolution 
compared to conventional optical techniques.  
The efficiency of FRET is based on optimising a few parameters such as: 
 10-100nm has been proposed as the required distance between donor and 
acceptor pair (Hayward et al. 2010). 
 The excitation spectrum of the donor and acceptor pair should produce an 
overlap (Zaccolo 2004). 
Fluorescent 
donor 
FRET 
Non-Fluorescent 
acceptor 
 
Decrease in 
donor emission  
Sensitized 
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 The direction of the fluorophore otherwise denoted as the dipole moments 
(Selvin 2000). 
In FRET, many different combinations of fluorescent dyes have been examined and 
used for both transfer of energy and labelling macromolecules. Some of the most 
prevalently used dyes as FRET pair are fluorescein/rhodamine, Cy3/Cy5 (cyanine 
dyes) and also combinations of Alexa Fluor® dyes are used (Schmid and Sitte 
2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: A pictorial expression of FRET between FITC and rhodamine (Sapsford et al. 
2006). 
The spectra in figure 20, shows the relative absorption (Abs) and emission (Em) 
of a commonly used FRET pair, where fluorescein is the donor and rhodamine is 
the acceptor unit. The energy transfer rate kt between the donor/acceptor pair 
depends on the distance ‘r’ and is generally denoted as ‘R0’. This is defined as the 
distance between the donor and acceptor unit during which 50% of the excited 
molecules at the donor side deteriorate and cause an increase in the acceptor 
molecule emission (Sapsford et al. 2006; Selvin 2000). The efficacy of a FRET 
process can be evaluated using the equation: E= 1/ [1+r/R0)6] (Buntru et al. 
2009).  
1.5.1. FRET construct 
FRET is a technique widely used for various bio analyses mainly due to its intrinsic 
sensitivity towards nanoscale alterations in donor-acceptor pairs. This can be 
achieved only by designing a suitable FRET construct based on experimental 
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needs. The components for making a FRET design can be categorised into three 
divisions: organic materials such as traditional fluorophore dyes, dark quenchers 
and polymers (Widengren 2010); inorganic substances such as metals and semi-
conductors (Medintz et al. 2003) and finally biological origin fluorophore similar to 
fluorescent proteins (FP), amino acids and gene-based compounds that would 
fluoresce by particular enzyme catalytic reactions (Touryan et al. 2009). These 
components may either be used as a donor or as an acceptor or can be both 
depending upon the experimental set up (Sapsford et al. 2006). 
1.5.1.1. Anthraquinone as quencher 
The acceptor molecule used in this present study was 1-((2-(2-(2-amino 
ethoxy)ethoxy)ethyl)amino)anthracene-9,10-dione (figure 21). The acceptor unit 
is otherwise denoted as the quencher, which has the same meaning as an acceptor.  
  
 
 
 
 
 
 
Figure 21: Structure of 1-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)anthracene-9,10-
dione. 
 
Labelling of oligonucleotides with fluorescent elements has become popular and 
also a large number of non-fluorescent quenchers varying from gold nanoparticles 
to nucleotides are being used as probes (Marras et al. 2002). Substituted 
anthraquinones are suggested to be efficient quenchers because of their non-
fluorescent properties, which make them effective dark quenchers. As they do not 
fluoresce like many other quenchers they can effectively absorb heavy fluorescent 
emissions. They have a broad absorption wavelength, which closely matches many 
fluorescein emissions with wavelengths between 490nm to 520nm (Nakayama et 
al. 2003). They can be easily purified and also in certain cases, isolation using 
reverse phase HPLC results in a highly purified compound (Laikhter et al. 2004). 
These quenchers are popular because of the ease in handling the compound and 
also because of the cost when compared to other radioactive labelling procedures. 
One such example is 15mer linear oligo DNA probe with fluorescein as donor and 
O
O
HN
O
O
NH2
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anthraquinone as quencher (Kodama et al. 2006); where anthraquinone was found 
to efficiently quench the fluorescent moiety.  
Anthraquinone has favourable characteristics as an effective quencher, as found 
by May and colleagues in their research work (2005), studying most FRET pairs.  
Anthraquinones have been used efficiently as quenchers in many experimental 
analyses (Laikhter et al. 2004) mainly due to their broad wavelength capacity. The 
use of efficient quenchers in a FRET construct has become vital because of the 
reduction in background fluorescence (Sapsford et al. 2006). Quenchers are used 
to study the binding and separating process with ease and also save much time, 
for processes that would otherwise be very difficult to follow (Walter and Burke 
1997). Marras and colleagues (2002) have demonstrated that quenching of 
fluorophore can be made more efficient with effective binding between the 
quencher and fluorophore (relating to the dipole moment). Also in certain DNA 
related studies, quenchers are used as probes in combination with organic dyes 
(Zuo et al. 2010). Van Valckenborgh and colleagues (2005) have also proven the 
effective quenching of a fluorophore (FITC) by anthraquinone in their research 
studies. Thus taking advantage of all these properties 1-((2-(2-(2-
aminoethoxy)ethoxy)ethyl)amino)anthracene-9,10-dione was used as the 
quencher for the FRET construct in this research work.  
 
1.5.1.2. 5(6)-Carboxyfluorescein (5(6)-CBF) as donor 
5(6)-CBF is a mixture of 5 and 6-carboxy substituted fluoresceins. Grignon and 
colleagues (1989) have used 5(6)-CBF to study cell:cell fusion and intercellular 
transport in plants. They have also demonstrated that 5(6)-CBF was successfully 
used as a tracer element to monitor phloem sap in real time, in short and long 
term experiments. 5(6)-CBF is one of the most popular organic dyes used in many 
fluorescent based analyses mainly because of its favourable characteristics such 
as availability of instrumentation for interpreting results, comparatively low price 
and compatibility with living cells (Fischer et al. 2003). Carboxyfluorescein (CBF) 
has been the most preferred compound of choice for synthesising fluorescent-
labelled peptides requiring hydrolytic stability and for protein conjugates (Weber 
et al. 1998).  
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Figure 22: Chemical structure of 5(6)-carboxyfluorescein.  
Mordon and colleagues (1994) in their studies on imaging tumor tissue using a 
fluorescent probe have stated that 5(6)-CBF is widely used in pharmacological and 
cellular studies without significant toxicity and its biocompatibility has been well 
documented. Taking advantage of 5(6)-CBF’s sensitivity towards variations in pH 
Mordon and colleagues were able to differentiate between normal and cancerous 
tissues. 5(6)-CBF is less vulnerable to photo-bleaching and is more stable, 
moreover it has also been demonstrated that its fluorescence emission (max: 
515nm) is directly proportional to increase in pH stating that it is active in acidic 
to near neutral pH (5.0-7.8) (Bidmanova et al. 2012) and also has two 
wavelengths of maximum absorbance (465 and 490nm) (Mordon et al. 1992). In 
this research study 5(6)-CBF (figure 22) has been used as the donor unit by 
coupling to the required peptide sequences. It reacts with the primary amine 
forming an amide bond and this chemistry is more stable and better yielding 
(Fischer et al. 2003). In a study to image the movement of pepducin in living cells 
using the principle of FRET, Tsuji and colleagues (2013) have used 5,6-CBF as the 
donor reagent for the FRET construct and have shown positive results. Bidmanova 
and colleagues (2012) have studied the photo stability and temperature response 
and demonstrated that CBF’s showed less or no significant changes to these 
conditions. Thus considering these advantages 5(6)-carboxyfluorescein was 
preferred as the donor compound in the FRET construct for this research study.   
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1.6 Aim 
 
The aim of this research project was the design, synthesis and evaluation of 
selective, non-invasive imaging agents for atherosclerotic plaques. To achieve the 
aim the study was split into three objectives. 
The first objective was the design, synthesis, purification and characterization of a 
small library of FRET peptide substrates specific to legumain (JC- 1st and 2nd 
series). The sensitivity of the FRET compounds was evaluated by incubation with 
the protease (rhLegumain) to observe the release in fluorescence. The results were 
measured fluorometrically using a multi-mode microplate reader. The successful 
compounds were then used as templates for the synthesis of a peptide based 
contrast agent with the potential to be used for MR imaging (JS series).  
 
The second objective was the synthesis of a library of compounds carrying the 
diagnostic contrast agent (Gd-DOTA). The design of these compounds (JS linear 
and JS lysine series) followed a similar pattern as in the JC library. Upon synthesis, 
purification and characterization of the JS library of compounds, they were 
incubated with the Recombinant Human Legumain/Asparaginyl Endopeptidase 
(rhLegumain). The end products of the enzyme treated compounds were purified 
and characterized by ESI mass spectrometry. The cytotoxicity of the JS series of 
compounds was also evaluated.     
 
The final objective was the synthesis, purification and characterization of a small 
discrete library of peptide motifs, which were designed to be peptide substrate 
specific to MMP-2 and MMP-9 (JJ series). The substrates were then conjugated to 
the contrast agent via N-terminal conjugation (compound: JD) or by coupling to 
the side chain of a lysine residue (compound: JL-87). This synthesis involved both 
solid and solution phase peptide synthesis. Upon successful synthesis of these 
compounds they were incubated with the protease to evaluate the release of the 
contrast agent in vitro.      
 
1.6.1. Rationale 
Atherosclerosis causes the death of more people than any other disease in the 
Western world (American heart association). Atherosclerotic plaques contain 
significantly higher quantities of activated MMP-2 than normal tissue extracts 
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(Galis et al. 1994) and subjects with acute coronary syndrome have increased 
plasma levels of MMP-1,2 and 9 (Alberto et al. 2006). Their expression is not only 
a part of atherosclerotic lesions but also predictive of plaque instability (Galiz 
2004). McGeehan and colleagues initially characterized peptide substrates specific 
to MMP-1 and MMP-9 in 1994. Since then its function has been exploited to not 
only deliver site specific pharmacological products in a range of disease states both 
in vitro and in vivo (Van Valckenborgh et al. 2005) but also as a device to localise 
imaging agents (Lancelot et al. 2008). An experiment by Ishizaki and colleagues 
(2010) has demonstrated the over expression of both MMPs and legumain in stroke 
caused by atherosclerosis. Legumain is a distinctive late cysteine endopeptidase 
found in many mammalian tissues (Chen et al. 1998). Legumain is found to be 
active under acidic environments in an autocatalytic manner (Li et al. 2003) 
expressing specificity to an asparagine residue at the P1 position of a substrate 
sequence (Chen et al. 1997; Ishizaki et al. 2010). Legumain is also involved in a 
number of pathological conditions such as tumour, atherosclerosis and 
inflammation, though their biological function in these conditions is not clearly 
understood (Chen et al. 2014). It has also been demonstrated that legumain may 
assist in plaque development by activating other proteases such as MMP-2, 
cathepsin-L, whose functioning has already been strongly linked with 
atherosclerotic plaque progression (Mattock et al. 2010).  
More recently a peptide model of MRI contrast agent (Gd-NBCB-TTDA-Leg (L)) and 
a near infrared fluorescent probe (CyTE777-Leg (L)-CyTE807) were successfully 
synthesized to specifically target the over expressed legumain in the tumour 
microenvironment (Chen et al. 2014). A more or less similar approach has been 
undertaken in this research project to specifically and efficiently target legumain 
activity in vitro (table 7, 8 and 9). Thus synthesising highly specific and potent 
substrates for legumain will not only be effective for demonstrating the expression 
of legumain in atherosclerosis, but will also be valuable for therapeutic 
interventions of atherosclerosis in the future (figure 23-A).  
Prodrugs that are synthesized to be specifically activated in the presence of over 
expressed or exclusively expressed enzymes in conditions such as cancer or 
atherosclerosis were not significantly successfully in clinical research. This was 
mainly due to the lack of a clear understanding about the enzyme activity and 
expression in vivo (Bagshawe 1993; Connors and Knox 1995). Hence in order to 
specifically image these enzymes (overexpressed in abnormal regions) it will be 
effective, to have a relatively non-invasive procedure which will enable real time 
evaluation of enzyme activity. Therefore, prodrugs attached to molecular imaging 
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agents may be advantageous in the improvement of enzyme-activated prodrugs 
(Gabriel et al. 2011). As discussed in previous sections, there are a number of 
imaging techniques to detect enzymatic activity, among which MRI and optical 
imaging (FRET) were the main focus of study in this research project. It has already 
been demonstrated that MRI could be used to monitor vulnerable plaques using 
molecular probes (Sirol et al. 2004). Molecular imaging may substantially improve 
the accuracy of MRI by selectively revealing markers of instability. As previously 
discussed MMPs and legumain can be exploited to site specifically deposit these 
contrast agents/therapeutic drugs specifically via enzyme cleavage in vulnerable 
plaques.  
To achieve this, the synthesis of a paramagnetic gadolinium chelate covalently 
linked to a small peptide (typically 7-9 amino acids in length for MMPs and a 
tetrapeptide for legumain), where the peptide is a tailored substrate for specific 
MMP/legumain which are found to be over expressed in vulnerable plaques will be 
attempted which is the main aim of this research project (figure 23-B). Lancelot 
and colleagues have already reported the use of MMP inhibitor, rather than a 
substrate for non-invasive imaging in 2008. However, a reduction in biological 
clearance time and also an increase in MRI contrast can be enhanced by the use 
of a MMP-substrate/gadolinium chelate conjugate in a method analogous to that 
of Jastrzebska and colleagues (2009). The authors in their work have developed a 
novel solubility-switchable contrast agent for the in vivo imaging of tumours. 
The aim of this research program was the synthesis and characterization of two 
main series of compounds reported as the Legumain series (table 7, 8 and 9) and 
the MMP series (table 10). Each library of compounds was synthesized via 
combination of both solid and solution phase peptide synthesis. The synthesis of 
these compounds could lead to site-specific deposition of the paramagnetic 
contrast agent by successful cleavage of the peptide substrates via the 
corresponding proteases (MMP/Legumain) for imaging atherosclerotic plaques.    
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Figure 23: A pictorial representation of peptide substrate cleaved by legumain (A)/MMPs 
(B) to aggregate metal ions for imaging. 
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1.6.1.1. Peptide synthesis  
The amino acids were coupled sequentially to one another through amide bonds 
to synthesize the peptide substrates. These substrates were designed to be specific 
to the enzyme of interest, which in this research study was MMP-2/9 and legumain. 
The arrangement of amino acids along the sequence was done to mimic the 
corresponding enzyme subsites or pockets so that the positioned amino acid 
projects into the relevant spaces. The peptide sequence containing the active site 
is normally labelled as P3-P2-P1-P1’-P2’-P3’ and the corresponding enzyme cleaves 
the sequence around the region between P1-P1’ (Lim et al. 2010) denoted as the 
hot spot of the sequence.  
 
Figure 24: A- tertiarybutyloxycarbonyl (tBoc) group, B- 9-fluorenylmethyloxycarbonyl 
(Fmoc) group. 
 
The amino acids chosen for the peptide synthesis included a wide range of 
aliphatic, aromatic, hydrophobic and neutral functional groups. In order to prevent 
any unwanted side chain reactions or polymerization all amino acids were N-
protected either by the tertiarybutyloxycarbonyl (tBoc) group or the 9-
fluorenylmethyloxycarbonyl (Fmoc) group (figure 24). Solid phase peptide 
synthesis is a process by which a desired peptide sequence can be synthesised by 
the sequential addition of amino acids on to a solid support. This method was first 
developed by Bruce Merrifield in 1984 for the synthesis of polypeptides. Some of 
the major advantages of this procedure when compared to conventional synthesis 
are easy work-up, stable, quick and simple isolation procedures (Merrifield 1963; 
Erickson and Merrifield 1976; Leznoff 1978). In synthesizing longer sequences, 
solution phase peptide synthesis may become labour-intensive due to the 
repetition of coupling and deprotection cycles and may also require isolation of 
peptide intermediates. Peptide substrates for MMPs were synthesized manually 
applying the SPPS procedure and a 2-chlorotrityl resin (figure 25A) preloaded with 
glycine was used as the solid support.  
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Figure 25: A: 2-chlorotrityl resin preloaded with glycine (H-Gly-2-ClTrt); B: Novasyn TGT 
resin preloaded with N-Fmoc protected asparagine (Fmoc-Asn(Trt)-Novasyn TGT). 
 
The 2-chlorotrityl resin was chosen as polymeric support because it is acid-labile 
and the rate of racemisation is highly reduced when using Fmoc protected amino 
acids (Barlos et al. 1989). The stability of the resin is good under storage 
conditions of 2-6ºC in DCM and final cleavage of the peptide sequence from the 
resin was done using trifluroacetic acid (TFA) in dichloromethane (DCM). The 
tetrapeptide substrates for legumains were synthesized manually applying 
standard fluorenylmethoxycarbonyl (Fmoc) SPPS procedure on preloaded Fmoc-
Asn(trt)/Leu-Novasyn TGT resin (figure 25B). The chemical properties of this resin 
are similar to that of 2-chlorotrityl resin but also have other advantages such as 
highly polar poly ethylene glycol (PEG) and polystyrenes (PEG-PS) matrix and have 
good solvation properties (Kates et al. 1998). 
1.6.1.2. Coupling, protection and deprotection procedure 
Coupling agents were used during both solid and solution phase peptide synthesis. 
This was done to activate the carboxyl group of the corresponding amino acid prior 
to coupling to the sequence. The formation of a peptide bond is the vital step in 
peptide synthesis, which involves amide bond formation (figure 26). For this 
reaction to take place, coupling reagents are required for activating the carboxylic 
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unit of the amino acid. The formation of a peptide bond is a nucleophilic 
substitution reaction of an amino group (nucleophile) at a carboxyl group via a 
tetrahedral intermediate. Carboxylic acids react with ammonia or amines at rt to 
produce an ammonium salt instead of a carboxamide. Hence the carboxyl 
component of an amino acid has to be activated prior to a peptide bond formation 
by introducing electron-accepting moieties. The following reaction between the 
activated intermediate and amine unit is defined as the coupling reaction and the 
reagents used for activation are termed as coupling reagents (Han and Kim 2004).  
 
Figure 26: Schematic representation of a coupling reaction. 
There are a number of coupling agents available of which the most commonly used 
are uronium and phosphonium salts and hydroxybenzotriazole (HOBt) (Miranda 
and Alewood 2000). The coupling agents used during this research project 
consisted of TBTU/HOBT and DIPEA or PyBOP/DIPEA, which were used 
interchangeably. The synthesis of the intact peptide sequences for conjugation to 
the aminoanthraquinone conjugate/Gadolinium conjugate was done following the 
procedure for solid phase peptide synthesis (figure 27). While sequentially 
arranging amino acids onto the solid support it is always important to protect any 
reactive side chain groups together with the primary amine. The temporary 
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protecting groups on the primary amine were removed at each stage after the 
coupling and the side chain protecting groups were removed along with the final 
cleavage of the sequence from the resin (Kent 1988). The most commonly used 
protecting groups are tBoc/Bzl and Fmoc/tBu (Chan and White 2000) mainly 
because they can be removed easily using an acid, base or by hydrogenolysis 
respectively.  
Figure 27: Representation of steps involved in SPPS. 
Moreover these groups provide better orthogonality, are cost effective and many 
amines are available commercially with these protecting groups (Sheppeck et al. 
2000). In the tBoc/Bzl system, the primary amine is protected by the tBoc group 
and the benzyl or cyclohexyl group protects the side chains. Similarly for Fmoc/tBu, 
the primary amine is protected by the Fmoc group and the side chains are 
protected by the tert-butyl group (Albericio 2000). 
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Figure 28: Schematic representation of Kaiser test (Friedman, 2004). 
 
In order to monitor the successful completion of coupling and deprotection of 
amino acids in a SPPS system, the Kaiser test was undertaken to analyse the colour 
changes. This test is based on the reaction of ninhydrin with the primary amine 
(Kaiser et al. 1970) giving rise to an intense blue colour. The intensity of the colour 
developed depends on the terminal amino acid (figure 28). After the final coupling, 
the peptide sequence was removed from the resin and characterized using mass 
spectrometry. Some of the peptide substrates for the legumain series of 
compounds were synthesized following the procedure for solution phase peptide 
synthesis.   
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Figure 29: Structure of coupling agents used in this project. 
 
An aminoanthraquinone unit conjugated to a PEG like spacer acted as a soluble 
support for immobilization of the amino acids. Coupling of the desired N-protected 
amino acids was performed in DMF using activating/coupling reagents such as 
HOBt/TBTU and DIPEA or the PyBOP and DIPEA system (figure 29). Both TBTU 
and HOBt were used to accelerate the process of coupling but the presence of 
HOBt was also found to suppress racemisation by forming less reactive HOBt 
esters. This additive also inhibited dehydration of the carboxamide side chain of 
Asn residues (Stawikowski and Fields, 2002). An excess of the activated amino 
acid in the range of 1.1 to 2 folds compared to the anchoring support 
(anthraquinone moiety) was used to drive the coupling reaction to completion.  
 
1.6.1.3. Choice of chelating agents and contrast agent 
In order to produce a sharp contrast between the normal and abnormal tissues MR 
imaging depends on the use of contrast agents (CAs). This clarity in images can 
be produced by increasing the electronic retention time of the imaging agent and 
the magnetic moment of the complex, which can be achieved by the use of 
chelated gadolinium complexes (Gd-DOTA/Gd-DTPA). As previously discussed the 
use of macrocyclic (DOTA) and linear (DTPA) chelating agents have long been 
recognized as efficient conjugates for MRI contrast agents (Nwe et al. 2011). 
Gadolinium (Gd), a rare lanthanide known for its unique magnetic property has 
been one of the most prominently used contrast agents for MR imaging (figure 
30). However, there are a few other contrast agents such as iron particle CA and 
manganese (II) chelate, but Gd is preferred due to the nature of the metal ion and 
also the requirement of MR imaging (Caravan et al. 1999). 
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Figure 30: Various paramagnetic ions and their influence on proton relaxation time (Pople 
et al. 1959). 
However, due to the toxic nature of the free metal ion, it has to be chelated to 
ligands such that they remain intact inside the body and can also be excreted 
without dissociation from the complex. For example, as in Magnevist 
[Gd(DTPA)(H2O)]2- a clinically approved and commercially available CA is found 
not to enter cells and does not have any intercalating groups to damage DNA 
(Caravan et al. 1999). Of the available ligands, DOTA is considered to possess 
good thermodynamic stability and kinetic resistance when compared to DTPA 
although both DOTA and DTPA are commercially used as chelating agents for MRI 
contrast agents (Duncan et al. 1994; Loncin et al. 1986). Gd-DOTA has been 
successfully used as a contrast agent for evaluating intracranial lesions of the 
central nervous system and results show that they have been well tolerated in-
vivo. (Parizel et al. 1989).  
A ligand should be designed in such a way that it would increase the number of 
inner-sphere water molecules (q) in the complex, causing a very slow tumbling 
rate (1/ζr) and finally less water residence time (ζm) as shown in figure 31 
(Raymond and Pierre 2005). In order to increase the sensitivity of contrast agents, 
they are coupled to proteins or receptor molecules or small peptide sequences 
which in turn increases the specificity by binding to the corresponding target 
molecule. This coupling also increases the concentration and retention of the entire 
complex in the target region leading to increased relativity and also reduced 
background noise (Caravan et al. 1999), for example, Gd-DOTA-Gal80 specific 
peptide is unique for binding to galactose regulatory protein Gal80 (Li et al. 2002). 
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Figure 31: Features influencing relativity (Raymond and Pierre 2005). 
Based on the same idea, a small library of Gd-DOTA-peptide conjugates was 
synthesized with the peptide sequence having the favourable cleavage site for the 
corresponding enzyme of interest, which was MMP-9/2 and legumain during this 
research program. Upon cleavage by the target enzyme the contrast agent (Gd-
DOTA) is anticipated to quicken water exchange and increase relativity leading to 
enhanced contrast between the target and the surrounding region (Meade and 
Allen 2004).  
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2. Results and discussion 
 
 
 
2.1. Library of FRET peptide substrates designed to be specific to legumain   
This section explains the design, synthesis, characterization and preliminary 
biological evaluation of a library of peptide fluorogenic substrates. Each peptide 
sequence was designed to be a specific substrate for legumain and consisted of 
four amino acids with the anticipated cleavage site (*) being on the carboxyl end 
of an asparagine residue.  
 JC-series: consisted of a fluorescent probe (5(6)-CBF) conjugated to a 
peptide substrate: 5(6)-CBF-Z-Y-Asn-(*)-Lys/Leu-Spacer-AQ; [where Y and 
Z denoted the amino acids used in the sequence and the spacer consisted 
of a PEG like diamino chain] (Figure 32). 
 
Figure 32: Structure of JC (1st and 2nd) series of peptide substrates. 
Two batches of FRET peptide substrates designed to be specific to legumain were 
synthesised (JC series 1 and 2). Fluorescently tagged amino acids have been 
exploited as powerful tools for the evaluation of biological events such as receptor-
ligand binding, enzyme activities and protein structures (Ozawa and Umezawa 
2002). Fluorescent labeling is rapidly replacing radiolabelling for production of kits 
for binding and enzyme assays with the application of FRET techniques and 
fluorescent polarization. Use of fluorescent labeling involving the FRET principle 
has become increasingly attractive due to advantages such as high stability, quick 
detection and ease of instrumentation. Also the disadvantages, involved with the 
use of radioactive isotopes can be avoided (Tung 2004). The aim of this research 
study was the synthesis of  imaging agents which could specifically identify 
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atherosclerotic plaques with the aid of biomarkers such as legumain that are 
overexpressed in the microenvironment of the plaques.  In order to achieve this, 
a FRET peptide library was designed in such a way that the positioning of the amino 
acids along the sequence was done to mimic the subsites of the enzyme of interest, 
which in this study was legumain. Hence, the purpose for the synthesis of the FRET 
compounds was to identify those peptide substrates that could be readily cleaved 
by legumain which was confirmed by the release of fluorescence via a legumain-
based assay. In this manner, the successful peptide substrates can be used to 
carry the contrast agent that could then be deposited site specifically on 
atherosclerotic plaques, which could possibly improve the quality of image 
obtained from a MRI scanner. The design outline for this library of peptide 
substrates will follow the template as shown in figure 32.   
The fluorophore was 5(6)-carboxyfluorescein whilst the acceptor moiety was an 
aminoanthraquinone derivative with a hydrophilic diamino chain (PEG like 
structure). Some of the advantages of the 5(6)-CBF and PEG-like diamino chain 
was the improved solubility during synthesis; the carboxylic group on the 
fluorophore can form an amide bond with the adjacent amine, such amides are 
resistant to hydrolysis, which coupled to the non-toxic nature of the fluorophore 
makes it biocompatible for in-vitro studies. Peptides and nucleotides labelled with 
FITC tend to deteriorate more quickly when compared to 5(6)-CBF conjugates 
(Banks and Paquette. 1995). Another advantage of 5(6)-CBF was its sensitivity at 
acidic and near-neutral pH making it suitable for the rh-legumain assay where the 
release in fluorescence is studied in similar conditions (Bidmanova et al. 2012). 
Moreover, 5(6)-CBF can be used for both solid and solution phase peptide 
synthesis and is cost effective when compared to other fluorescein derivatives such 
as fluorescein isothiocyanate and carboxyfluorescein-N-succinimidyl ester (Fisher 
et al. 2003; Fernandez-Carneado and Giralt 2004). The design of the JC series had 
the fluorophore at the N-terminus of the tetrapeptide and the aminoanthraquinone 
conjugate at the carboxyl terminus. From the available information on legumain 
substrate specificity it was decided to place the asparagine residue at the P1 
position and the P3 position was occupied by either proline or β-alanine (Mathieu 
et al. 2002; Sexton et al. 2007; Liu 2009). The FRET properties of the peptide 
fluorogenic substrates were evaluated using a spectrophotometer prior to 
demonstrating the release of fluorescence when incubated with the rh-legumain.  
 
 
- 61 - 
 
2.1.1. Synthesis of FRET peptide substrates (JC series-1st batch)       
From previous discussions (section-1.3.3) it can be demonstrated that legumain is 
one promising biomarker for the identification of atherosclerotic plaques. 
Therefore, synthesizing compounds that could be recognized by legumain and 
subsequently release the diagnostic/therapeutic agent could be the next step 
towards early detection of atherosclerotic plaques (Papaspyridonos et al. 2006). A 
library of peptide substrates designed to be specific to legumain were synthesized 
in order to study the efficiency in fluorescence release upon incubation with the 
enzyme. The successful peptide substrates were then used as a template for the 
synthesis of peptide coupled contrast agents which could perhaps be used for the 
imaging of atherosclerotic plaques via MRI.  
 
Comp. 
 no. 
 
Fluorophore 
 
P3 
 
P2 
 
P1 
 
P1’ 
 
Donor unit 
8  
 
 
 
 
5(6)-CBF 
Pro Ala Asn Leu  
 
11 Pro Gly Asn Leu 
14 Pro Leu Asn Leu 
17 β-Ala Ala Asn Leu 
20 β-Ala Leu Asn Leu 
25 β-Ala Gly Asn Leu 
   
Table 7: List of FRET peptide sequence for JC series-1. 
 
This section details the design, synthesis and characterization of the 1st batch of 
JC series of FRET peptide substrates. An overview of the 1st batch of FRET 
compounds is shown in table 7. The complete synthesis of the JC series (1st) of 
peptide substrates will involve the intermediate and target compounds as detailed 
in figure 33.   
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Figure 33: An overview of the intermediate and target compounds for the JC series-1 of 
FRET peptide substrates. 
2.1.1.1. Step 1: Synthesis of proline/β-alanine labeled amino acids (donor 
unit) (Compound 2, 4) 
In this study fluorescein labeled amino acids were initially synthesized as part of 
the tetra peptide sequence. The fluorescein labeled compound was then coupled 
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to the amino terminus of the tripeptide sequence containing the donor unit (AQ) 
of the FRET pair.  
 
Scheme 1: Synthesis of fluorescein labeled amino acids. Conditions and reagents: (a) 
DMF, DIPEA, PyBOP (Proline/β-alanine), rt. (b) TFA, rt. 
The tert-Butyl protected fluorescein conjugates (1 and 3) were synthesized by the 
reaction of 5(6)-carboxyfluorescein with H-Pro-OtBu hydrochloride or H-β-Ala-OtBu 
hydrochloride in DMF as shown in scheme 1(a). The mixed isomer 5(6)-
carboxyfluorescein was activated using PyBOP in DMF prior to coupling with proline 
(1) or β-alanine (3) (scheme 1a). Reaction progress was monitored by TLC 
analysis, using a chloroform extract of the reaction mixture, which was referred 
against the starting material (5(6)-CBF). The TLC plate showed two components 
with a bright yellow fluorescein band corresponding to the product (with a Rf value 
of 0.9 demonstrating the less polar nature of the compound due to the protected 
proline/β-alanine residue) and a pale yellow band corresponding to the unreacted 
5(6)-CBF. The crude product was then partitioned between chloroform and an 
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aqueous solution of citric acid in order to facilitate the extraction of the product 
into the organic solution. The organic solution was then washed with water several 
times until the aqueous solution was colorless or pale yellow. The organic solution 
was then purified by column chromatography, using 10% MeOH in chloroform to 
elute the first pale fraction followed by a gradient elution using MeOH in 5% 
increments (up to 20%) to elute the major band.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Mass spectrometry result for compound 1. RP-HPLC elution profile of 
compound 1 (0.5mg/mL in methanol); Conditions: Flow rate, 0.5mL/min; Detection, 
247nm; stationary phase: Eclipse XDB-C18 RP column; mobile phase A= 0.1%TFA/water; 
mobile phase B=0.1%TFA/methanol; gradient: low pressure gradient; 21min. 
The purity of compounds 1 (figure 34) and 3 were found to be 92% and 94% using 
a Shimadzu Prominence HPLC system equipped with an eclipse XDB-C18 RP 
column. Additionally the compounds were also characterized by high resolution 
ESI (+) mass spectrometry, which gave a signal at m/z 530.1804 (M+H)+ 
corresponding to a molecular mass of 529 relating to the proline conjugate (1-
figure 34). Similarly compound 3 containing the β-alanine conjugate was also 
characterized by high resolution ESI (+) mass spectrometry, which gave a signal 
at m/z 504.1642 (M+H)+ corresponding to a molecular mass of 503 (figure 35).  
In order to couple the labeled amino acid to the amino terminus of the tri-peptide 
sequence, the tert-butyl protected compounds 1 and 3 were deprotected using 
trifluoroacetic acid (scheme 1b). Reaction progress was monitored by TLC, which 
showed the presence of a single new component, with a low Rf value due to the 
polar nature of the deprotected product. The purity of the compounds 2 and 4 
were found to be 81% and 51% using a Shimadzu Prominence HPLC system 
(M+H)+ 
Compound 1 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 min
0
500
1000
1500
2000
2500
3000mVDetector A:247nm 
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equipped with an eclipse XDB-C18 RP column. The products (2 and 4) were then 
characterized by high resolution ESI (+) mass spectrometry, which displayed a 
signal at m/z 474.1179 (M+H)+ corresponding to a molecular mass of 473 relating 
to the proline conjugate (2). Similarly the β-alanine conjugate (4) was also 
characterized by high resolution ESI (+) mass spectrometry, which displayed a 
signal at m/z 448.1025 (M+H)+ corresponding to a molecular mass of 447 (figure 
35). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Mass spectrometry result for compounds 3 and 4 was confirmed using a high 
resolution-electrospray ionization mass spectrometry (ESI-MS).  
 
2.1.1.2. Step 2: Synthesis of anthraquinone-spacer conjugate (acceptor 
unit) (Compound 5) 
The synthesis of the aminoanthraquinone spacer conjugate (5) was attempted, 
following an adapted procedure by Turnbull (2003). 1-Chloroanthraquinone was 
reacted with 2,2’-(ethylenedioxy)bis(ethylamine) in DMSO (scheme 2). The 
mixture was heated over a water bath for 3 hours. A gradual color change from a 
pale yellow to an intense pink, characteristic of the modified anthraquinone 
chromophore was noticed. 
Compound 3 
Compound 4 
(M+H)
+ 
(M+H)
+ 
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Scheme 2: Synthesis of anthraquinone spacer conjugate.  
The reaction mixture was then cooled to room temperature and a large excess of 
water was added to facilitate precipitation of the aminoanthraquinone product. The 
product was loaded onto a chromatographic column followed by elution of a front 
running pale yellow impurity using DCM. The polarity of the solvent system was 
increased gradually by adding methanol in increments of 5% (up to 20%). Since 
the elution of the major red band was slow, triethylamine (TEA) was added to 
quicken the elution of the polar compound. Adding TEA prevents ionization of the 
free amine in the compound due to the slightly acidic nature of silica and thus 
reduces the retention time of the compounds on the silica gel column. The purity 
of the sample was found to be 83% using a Shimadzu Prominence HPLC system 
equipped with an eclipse XDB-C18 RP column. The product was then characterized 
using a high resolution ESI (+) mass spectrometry, which gave a signal at m/z 
355 (M+H)+ corresponding to a molecular mass of 354. Furthermore, the 1H NMR 
spectrum (d-DMSO) (figure 36) showed a 2-proton triplet signal at 2.65ppm and 
another 2-proton triplet signal at 3.39ppm which was assigned to 1’ and 2’ protons. 
Signals for 4-proton multiplet between 3.51 and 3.58ppm were assigned to 6’ and 
3’ protons. A two proton multiplet between 3.62ppm and 3.64ppm was assigned 
to 4’ protons. Signal for a 2-proton triplet at 3.72ppm was assigned to 5’ protons. 
The protons attached to the aromatic group were assigned as follows: H-2 and H-
4 gave a single proton doublet at 7.28ppm and a single proton double doublet at 
7.44ppm respectively and a 1-proton multiplet between 7.62ppm and 7.66ppm 
was assigned to H-3. Another two proton multiplet between 7.81ppm and 7.92ppm 
was assigned to H6 and H7 protons. The H-5 and H-8 gave a single proton double 
doublet signals each at 8.12ppm and 8.20ppm respectively. A triplet for a single 
proton at 9.78ppm was assigned to the anthraquinone amino group proton. To 
further confirm the assignment in the 1H NMR, a 2D-COSY spectrum of compound 
5 was also undertaken (appendix 1).   
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Figure: 36 1H-NMR in d-DMSO was recorded for compound 5  on a Bruker NMR 
spectrometer operating at 1H frequency of 400MHz.  
 
2.1.1.3. Step 3, 4 and 5: Synthesis of FRET tetra peptide substrates (1st 
batch-JC series) 
Upon successful synthesis, isolation and characterization of the donor and the 
acceptor molecule, the next step was the chemical synthesis of the peptide 
substrate via SPPS (scheme 3). The rationale for the selection of amino acids for 
the synthesis of the peptide substrates for legumain was based on the information 
available from the literature (Mathieu et al. 2002; Dall and Brandstetter, 2015). 
From experiments conducted by Mathieu and colleagues (2002) on substrate 
specificity for legumain it was demonstrated that the enzyme showed strict 
specificity towards asparagine at P1 position of the peptide chain. In the same 
study the authors demonstrated that amino acids such as Thr, Ala, Pro, Val and 
Gly were desirable at P2 and P3 positions and on the prime position amino acids 
with small side chains (Ala, Gly, Ser, Cys) were well tolerated, however proline at 
this position was found to be unfavorable. Moreover it was also demonstrated that 
except for the most conserved feature of Asn at P1 position, the rest of the amino 
acid positions varied between species. This was proven by the ideal cleavage 
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sequence for schistosoma legumain to be Thr-Ala-Asn (P3-P2-P1) whereas the 
human legumain preferred Pro-Thr-Asn (Dall and Brandstetter 2015).   
 
Scheme 3: Steps involved in synthesis of JC series-1. 
Information from the MEROPS database on the available legumain activity probes 
suggest that P2 position was well tolerated by amino acids such as threonine, 
alanine, glycine, leucine and serine (Rawlings et al. 2012). Considering these 
findings, the FRET peptide substrates for legumain were structured spanning the 
P3 to P1’ positions (table 7, pg. 62).  
The FRET tetra peptide substrates were synthesized according to a stepwise 
process, which included: 
I. Synthesis of the tetra-peptide chain was done by sequential addition of 
amino acids onto a leucine pre-loaded resin for solid phase peptide 
synthesis. The pre-loaded resin was reacted in cycles of coupling and 
deprotection with commercially available amino acids (scheme 3a,b). The 
N-Hydroxybenzotriazole (HOBt) esters are commonly used during peptide 
synthesis mainly because of their excellent racemization suppressing effect 
and coupling acceleration properties (Gutte 1995). For the final coupling a 
fluorescein labelled amino acid (5(6)-CBF-Pro-OH (2)/ 5(6)-CBF-βAla-OH 
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(4)) was conjugated to the N-terminal of the tri-peptide sequence. The 
fluorescein tagged tetra-peptide sequence was then removed from the resin 
using TFA in DCM (scheme 3c). The product was then characterized by high-
resolution mass spectrometry and the purity was determined using HPLC.  
II. The next step involved the coupling of the fluorescein labelled tetra-peptide 
sequence to the aminoanthraquinone conjugate using the coupling agents 
TBTU/HOBT and DIPEA (scheme 3d). The aminoanthraquinone conjugate is 
expected to quench the fluorescence emission from the 5(6)-
carboxyfluorescein in the absence of the target enzyme (legumain). The 
crude product was purified by column chromatography and then 
characterized by high-resolution mass spectrometry (ESI-HR). 
III. The final step involved removal of the γ-trityl protecting group from the 
asparagine residue. The rational for the side chain protection of the primary 
amide in the asparagine residue was to avoid any unwanted side reactions 
during the process of coupling and deprotection. Moreover unprotected 
asparagine had poor solubility which could delay reaction progress. The N-
trityl protection of the side chain in asparagine could prevent the 
dehydration of the amide structure to a nitrile group, thus keeping the 
asparagine residue intact and recognizable by legumain. This is important 
because of the strict specificity of legumain towards asparagine at the P1 
position of the peptide substrate. The trityl protecting group was used 
because of its stability during the cycles of coupling and deprotection and 
finally it can be removed by 95%TFA in DCM (Ding, 2014). This should allow 
the peptide substrate to be recognized by legumain leading to hydrolysis on 
the carboxyl end of asparagine. This hydrolysis of the peptide substrate 
leads to an increase in distance between the FRET pair (amino 
anthraquinone/5(6)-carboxyfluorescein) and the release in fluorescence can 
be measured fluorimetrically, which was the objective for synthesizing the 
FRET peptide substrate (scheme 3e).  
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I. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Leu-Spacer-AQ (Compound 8) 
Scheme 4: Steps involved in the synthesis of compound 8.  
 
A leucine pre-loaded resin was reacted in cycles of coupling and deprotection with 
Fmoc protected amino acids in the following order:  N-Fmoc-Asn(Trt)-OH,  N-
Fmoc-Ala-OH followed by coupling of the fluorescein labeled amino acid (2). 
Reagents and reaction conditions are as mentioned in scheme 4. Leucine (leu) at 
P1’ position of the peptide sequence was chosen based on the fact that most of the 
tumor related prodrugs targeting legumain expression (Liu 2009) were found to 
be tolerated by the enzyme. After the final coupling, the peptide sequence was 
removed from the resin with trifluoroacetic acid (5%) in DCM. 
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Figure 37: Expansion of the ESI (+) mass spectrum of compound 6 that shows the 
isotopic pattern of the molecular ion. 
HPLC was performed on a Shimadzu Prominence system equipped with UV-Vis 
detector using an eclipse XDB-C18 RP column and the purity of the sample was 
found to be 44%. The rest of the signals were accounted for as belonging to 
reagents and other unidentified mass. Product 6 was characterized by high 
resolution ESI (+) mass spectrometry, which gave a signal at m/z 1014.3917 
(M+H)+ corresponding to a molecular mass of 1013.38 (figure 37).  
The FRET peptide sequence 8 was synthesized by reacting compound 6 with 
compound 5 in DMF (scheme 4A) followed by liquid/liquid extraction and 
chromatographic purification as detailed in the previous section 2.1.1.3 (II). The 
yield of the product obtained after column chromatography was 53%. The resulting 
compound (7) was characterized by ESMS (+), which gave a signal at m/z 1350.4 
(M+H)+ corresponding to a molecular mass of 1349 and also a signal for the doubly 
charged ion at m/z 675.8 [(M+2H)/2]2+. Removal of the γ-trityl protecting group 
from the asparagine residue was achieved by treating compound 7 with TFA as 
detailed in section 2.1.1.3 (III) (scheme 4D). Deprotection progress was 
monitored by TLC analysis, which showed the presence of a new single component, 
which gave a low Rf value indicating the polar nature of the deprotected compound 
(8).  
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II. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Leu-Spacer-AQ (Compound 11) 
The FRET peptide sequence 11 was synthesized consisting of 5(6)-CBF at the N-
terminus of the tetra peptide and an aminoanthraquinone-spacer acceptor unit at 
the C-terminus of the sequence. The position of asparagine and proline were 
preserved from the previous sequence whereas alanine at P2 was replaced with 
glycine. This decision was based on the fact that glycine was also tolerated at the 
P2 position of the tetra peptide sequence (Mathieu et al. 2002). Moreover the 
current database on legumain active probes demonstrates that five of the probes 
had a glycine residue at the P2 position of the peptide sequence (Rawlings et al. 
2012). The synthesise of the target FRET peptide substrate 11 required the 
removal of the trityl protecting group from the side chain of Asn in order to be 
recognized by the activated legumain. The protecting group was removed by 
treating the compound with TFA (scheme 4b) to yield the deprotected compound 
11 as detailed in section 2.1.1.3 (III). 
III. Synthesis of 5(6)-CBF-Pro-Leu-Asn-Leu-Spacer-AQ (Compound 14) 
 
Synthesis of the FRET peptide substrate 14 followed the same protocol as 
compound 8. The positing of the amino acids from P3-P1’ including the FRET pair 
remained the same except for the amino acid at the P2 position of the sequence. 
Leucine (leu) was placed at P2 rather than ala or gly as in compounds 8 and 11. 
The choice of leu at that position was based on the information from the MEROPS 
database which demonstrates that three of the legumain peptide substrates had 
leu at this position. However, the coupling and deprotection methods remained the 
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same as detailed in scheme 4. Though TLC analysis indicated that the reaction had 
gone to completion by the presence of a new component close to the base line 
indicating the polar nature of the compound 14, it also showed the presence of a 
fluorescein band lying close to the red spot and hence it was decided to purify the 
sample by silica gel column chromatography. Various solvent systems were tried 
(ethyl acetate: hexane: MeOH-3:1:1; ethyl acetate: hexane- 4:1; ethyl acetate: 
DCM: isopropanol- 8:1.5:0.5; varying gradients of MeOH-3% up to 10% in DCM) 
to obtain a separation between the two bands and it was found that 10% MeOH in 
DCM was able to produce a separation between the front running red band 
presumed to be the deprotected product (due to the presence of the anthraquinone 
conjugation) and the fluorescein band. The sample was dissolved in 10% MeOH in 
DCM and loaded onto the silica gel column prepared using the same solvent 
mixture. However, the fluorescein band was found to overlap with the deprotected 
sample (red band) during the course of elution. Two fractions were eluted from 
this column with the first fraction being eluted with 10% MeOH in DCM and the 
other fraction was eluted with a higher percentage of MeOH in 5% increments (up 
to 30%). Upon TLC analysis of the first eluted fraction it still appeared to be a 
binary mixture of two close running spots (a reddish band and a fluorescein band), 
which could not be resolved by column chromatography. Mass spectrometric 
analysis on the first eluted fraction showed the presence of many unresolved 
signals.  Hence it was decided to repeat the peptide synthesis applying solution 
phase peptide synthesis, which involved purification after each coupling and 
deprotection cycle in the hope to isolate the desired product eliminating any 
undesired reagents after each coupling and deprotection cycles. Moreover, 
optimizing the equivalence of fluorophore to be coupled to the peptide sequence 
may also reduce the presence of excess/unreacted dye. 
IV. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Leu-Spacer-AQ (Compund 17) 
 
The FRET tetra peptide sequence (17) was synthesized following a procedure 
analogous to compound 8. The amino acids were coupled in the subsequent order: 
N-Fmoc-Asn(Trt)-OH, N-Fmoc-Ala-OH followed by coupling of the fluorescein 
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labeled amino acid (4). The position of asparagine residue was maintained at P1 
and the positon of alanine at P2 was also similar to sequence 8; however proline 
at P3 positon was replaced by β-alanine based on the information on legumain 
substrate specificity as discussed in section 2.1.1.3. TLC analysis of compound 17 
showed a binary mixture of two close running components with one corresponding 
to the deprotected sample perceived by the reddish brown stain due to the 
presence of the anthraquinone moiety and a bright yellow fluorescein spot which 
may be due to the presence of unreacted fluorescein residue, which upon column 
chromatography separation was not possible to be isolated.  
 
V. 5(6)-CBF-β-Ala-Leu-Asn-Leu-Spacer-AQ (Compound 20) 
 
Compound 20 was synthesized following a procedure analogous to compound 8. 
The amino acids were coupled in the subsequent order: N-Fmoc-Asn(Trt)-OH, N-
Fmoc-Leu-OH followed by coupling of the fluorescein labeled amino acid (4).  
However, the same problem as encountered with compound 15 and 17 was 
observed after deprotecting the sample with TFA. Hence it was decided to 
synthesize the next FRET peptide substrate via solution peptide synthesis in an 
attempt to investigate the purity, yield and homogeneity of the intermediates and 
target compound.  
VI. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Leu-Spacer-AQ (Compound 25) 
The aminoanthraquinone conjugate was used as a support for growing the amino 
acid sequence. The coupling of subsequent N-protected amino acids was 
performed in DMF along with activating/coupling agents such as TBTU and HOBT 
(scheme 5) in the presence of a base (DIPEA). The amino acids used for the 
peptide synthesis were N-protected by the Fmoc group except for asparagine, 
which also had a γ-trityl protecting group along with the Fmoc group at the N-α 
terminus. The Fmoc group was removed using 20%v/v piperidine in DMF and the 
general mechanism for Fmoc removal is detailed in figure 38. 
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Scheme 5: Synthesis of fluorescein labelled tetra-peptide compound via solution phase 
peptide synthesis. 
 
Following each coupling and deprotection reaction, the intermediates were purified 
by column chromatography and the isolated samples were characterized by low-
resolution and/or high-resolution mass spectrometry and some of the 
intermediates were also characterized via NMR. Upon successful synthesis of the 
FRET peptide sequence the γ-trityl protecting group from asparagine residue was 
removed using TFA (scheme 5). Some of the advantages of solution peptide 
synthesis are the isolation and characterization of the intermediates obtained after 
each coupling and deprotection reaction and hence every reaction cycle can be 
easily controlled (Chandrudu et al. 2013). Purification at each step is done by 
chromatography using a silica gel column which provided the intermediates in 
reasonable yield and purity (Dunn 2015). This is important because no matter how 
carefully the SPPS was done to avoid deletion compounds due to incomplete 
coupling, there are still possibilities for the presence of such molecules (Doonan 
2002). Moreover this technique is well suited for the synthesis of small peptides 
composed of few amino acid residues and is highly flexible with respect to the 
chemistry of coupling and the combination of amino acids (Guzman et al. 2007). 
N
H
O
O
(a) Fmoc-AA1-OH
TBTU/HOBT,
DIPEA in DMF (b) 20%v/v Piperidine
in DMF
(a) and (b) were performed
until the required
sequence was synthesized
Spacer
N
H
O
O
Spacer
N
H
O
O
SpacerN
H
O
O
SpacerNH2-AA3-AA2(Trt)-AA1-NH-
N
H
O
O
Spacer
(c) CBF-Labeled amino AA
HOBT/TBTU
DIPEA in DMF
N
H
O
O
Spacer
(d) 95% TFA- removal of
side chain protecting
group
Fluorescein labeled tetra peptide conjugate
where, AA1, AA2, AA3 and AA4 represent amino acids.
Fmoc-AA1-NH
NH2-AA1-NH-
CBF-AA4-AA3-AA2(Trt)-AA1-NH-
CBF-AA4-AA3-AA2(NH2)-AA1-NH-
- 76 - 
 
Figure 38: General mechanism for Fmoc group deprotection. 
Another advantage of this technique over SPPS is the reduced cost for synthesizing 
peptides. In this method amino acids, reagents, derivatives and coupling agents 
are generally used in a ratio of 1:1 and not in excess as in SPPS. Additionally other 
limitations in SPPS such as incomplete coupling and deprotection reactions, buildup 
of byproducts and finally because the peptide chain remains attached to the resin, 
it meant that if any coupling was incomplete then the final compound will have a 
population of molecules with missing amino acid residues. And the process of 
removing the deletion product is quite difficult (Chandrudu et al. 2013). The 
following sub-sections demonstrate in detail the synthesis of FRET peptide 
substrate 25.  
A. Synthesis of intermediate compound H2N-Leu-Spacer-AQ (Compound 
21) 
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The Fmoc-protected intermediate (Fmoc-Leu-Spacer-AQ) was synthesized by 
reacting N-Fmoc-L-Leucine with compound 5 (Spacer-AQ) in DMF. The reaction 
conditions were as mentioned in scheme 6. The carboxyl group of the N-protected 
amino acid was activated via an esterification reaction with TBTU/HOBt in the 
presence of the base (DIPEA) prior to addition to the aminoanthraquinone 
conjugate (5). Reaction progress was monitored by TLC, which showed the 
presence of a single new component different from the starting material. The Fmoc 
protecting group was then removed using piperidine in DMF followed by purification 
by column chromatography to produce compound 21. The yield of the compound 
after column chromatography was 81%. The purity of the sample was found to be 
98% via analytical HPLC performed on a Shimadzu Prominence system equipped 
with UV-Vis detector using an eclipse XDB-C18 RP column. The product 21 was 
then characterized by high resolution ESI (+) mass spectrometry, which gave a 
signal at m/z 468.2488 (M+H)+ corresponding to a molecular mass of 467. 
Furthermore, the 1H NMR spectrum (d-DMSO) showed, for example, a multiplet 
signal for the 6 protons at the δ carbon of the leucine side-chain between 0.80 and 
0.85ppm. Multiplet signal for the 2 protons at the β carbon was found between 
1.14 and 1.21ppm and 1.33ppm and 1.40ppm. Another multiplet for the 1 proton 
at the γ carbon was found between 1.63 and 1.70ppm. A quartet signal at 3.11ppm 
was assigned to the signal proton at the α carbon of leucine. A two proton multiplet 
signal between 3.18 and 3.30ppm and another two proton triplet at 3.46ppm was 
assigned to CH2-NH-COO and to CH2-CH2-NH-COO protons. A two proton quartet 
at 3.53ppm was assigned to CH2-NH-AQ protons. A multiplet signal between 
3.57ppm and 3.64ppm was assigned to O-CH2-CH2-O protons of the spacer arm. 
A two proton triplet at 3.73ppm was assigned to CH2-CH2-NH-AQ protons. The 
protons attached to the aromatic group were assigned as follows: H-2 and H-4 
gave a single proton double doublet at 7.29ppm and 7.45ppm and a single proton 
multiplet between 7.63ppm and 7.67ppm was assigned to H-3. A multiplet 
between 7.82ppm and 7.94ppm for three protons was assigned to H-6 and H-7 
and the amide proton of leucine. The H-5 and H-8 protons gave a double doublet 
signal at 8.12ppm and 8.20ppm respectively. The anthraquinone amino group 
proton gave a triplet at 9.79ppm. To further confirm the assignment in the 1H NMR, 
a 2D-COSY spectrum of compound 21 was also done (appendix 2).         
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B. Synthesis of intermediate compound H2N-Asn(Trt)-Leu-Spacer-AQ 
(Compound 22) 
 
Compound 22 was synthesized following a procedure analogous to compound 21. 
The yield of the sample after column chromatography was 94% and the purity of 
the sample was determined using analytical HPLC performed on a Shimadzu 
Prominence system equipped with UV-Vis detector using an eclipse XDB-C18 RP 
column which was found to be 91% (figure 42). The product 22 was characterized 
by high resolution ESI (+) mass spectrometry, which gave a signal at m/z 
824.4013 (M+H)+ corresponding to a molecular mass of 823.4013 (figure 39); the 
ESMS (-) mass spectrometry displayed a signal at m/z 822 corresponding to the 
proton abstraction product (M-H)- . 
Figure 39: Mass spectrometry result for compound 22. RP-HPLC elution profile of 
compound 22 (1mg/mL in methanol); Conditions: Flow rate, 1mL/min; Detection, 
247nm; stationary phase: Eclipse XDB-C18 RP column; mobile phase A= 0.1%TFA/water; 
mobile phase B=0.1%TFA/methanol; gradient: low pressure gradient; 23min. 
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Furthermore, the structure of the compound 22 was confirmed by 1H NMR 
spectroscopy (d-DMSO), which showed, for example, a 6 proton multiplet between 
0.80ppm and 0.85ppm was assigned to the two methyl group protons in leucine. 
A two proton multiplet signal between 1.37ppm and 1.48ppm was assigned to the 
protons at the β carbon of the leucine side chain. Another multiplet signal for the 
single proton at the γ carbon was found between 1.51ppm and 1.61ppm. A 2 
proton multiplet between 2.38 and 2.46ppm was assigned to the methylene group 
of the asparagine side chain. A two proton multiplet signal between 3.07 and 
3.18ppm was assigned to CH2-NH-Leu protons. Another signal for two protons 
between 3.34 and 3.41ppm was assigned to CH2-CH2-NH-Leu protons was seen as 
an overlap with the water signal which was further confirmed using 2D-analysis 
(see appendix 3). A multiplet for five protons between 3.45 and 3.53ppm was 
assigned to protons of CH2-NH-AQ, CH-CH2-CONH-trityl protecting group and CH2-
O-CH2-CH2-NH-AQ respectively. Another two proton multiplet between 3.58 and 
3.61ppm was assigned to Leu-NH-CH2-CH2-O-CH2 protons. A two proton triplet 
signal at 3.71ppm was assigned to CH2-CH2-NH-AQ. A quartet at 4.26ppm was 
assigned to the single proton at the α carbon of leucine. Signals for a 1 proton and 
a 15 proton multiplet between 7.17 and 7.30ppm were assigned to the H-2 proton 
of the aromatic ring along with the protons of the phenyl rings of the trityl 
protecting group. The protons attached to the aromatic group were assigned as 
follows H-4 gave a single proton double doublet at 7.45ppm and a multiplet 
between 7.62ppm and 7.66ppm was assigned to H-3. A single proton triplet of 
doublets at 7.83ppm was assigned to H6 followed by another single proton triplet 
of doublets at 7.89ppm was assigned to H7 proton. A multiplet for two protons 
between 7.95ppm and 8.02ppm was assigned to NH-spacer arm proton and the 
amide proton of leucine. The H-5 and H-8 protons gave a double doublet signal at 
8.13ppm and 8.20ppm respectively. A singlet at 9.23ppm was assigned to NH-
Trityl protecting group proton. Signal for a one proton triplet at 9.80ppm was 
assigned to the anthraquinone amino group proton. To further confirm the 
assignment in the 1H NMR, a 2D-COSY spectrum of compound 22 was also done 
(appendix 3).         
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C. Synthesis of intermediate compound H2N-Gly-Asn(Trt)-Leu-Spacer-AQ 
(Compound 23)  
Compound 23 was synthesized following a procedure analogous to compound 21. 
The yield of the sample was found to be 82% post column chromatography. The 
purity of the sample was determined using HPLC performed on a Shimadzu 
Prominence system equipped with UV-Vis detector using an eclipse XDB-C18 RP 
column which was found to be 88%. The product 23 was characterized by high 
resolution ESI (+) mass spectrometry, which gave a signal at m/z 881.4232 
(M+H)+ corresponding to a molecular mass of 880; the ESMS (-) low resolution 
mass spectrometry gave a signal at m/z 879 corresponding to the proton 
abstraction product (M-H)- and m/z 915 corresponding to the chloride adduct 
(M+Cl)-. Furthermore, the structure of the compound 23 was confirmed by 1H NMR 
spectroscopy (d-DMSO), which showed, for example, a 6 proton double doublet at 
0.82ppm which was assigned to the two methyl group protons in the side chain of 
leucine. A multiplet signal for the 3 protons at the β and γ carbons in leucine was 
found between 1.38 and 1.60ppm. A 2 proton multiplet between 2.65 and 2.76ppm 
was assigned to the methylene group protons of the asparagine side chain. A 2 
proton multiplet signal between 2.97 and 3.10ppm was assigned to CH2-NH-Leu 
and a singlet for two protons at 3.13 was assigned to CH2-NH2. A two proton triplet 
at 3.26ppm was assigned to CH2-CH2-NH-Leu protons. A multiplet signal for six 
protons between 3.47ppm and 3.59ppm was assigned to O-CH2-CH2–O and CH2-
NH-AQ protons. A triplet at 3.71ppm was assigned to the two protons of CH2-CH2-
NH-AQ protons. A multiplet between 4.17 and 4.23ppm was assigned for a single 
proton at the α carbon of leucine. A broad signal at 4.56ppm for a single proton 
was assigned the methine group proton of asparagine. Signals for a 1 proton and 
a 15 proton multiplet between 7.18ppm and 7.29ppm was assigned to the H-2 
proton of the aromatic ring along with the protons of the phenyl rings of the trityl 
protecting group. The protons attached to the aromatic group were assigned as 
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follows H-4 gave a single proton double doublet at 7.45ppm and a single proton 
multiplet between 7.62ppm and 7.66ppm was assigned to H-3. A multiplet for four 
protons between 7.81ppm and 8.03ppm was assigned to H-6 and H-7 protons 
along with the protons for NH-spacer-AQ and the amide proton of leucine. The H-
5 and H-8 protons gave double doublet signals at 8.13ppm and 8.21ppm 
respectively. Signal for a one proton singlet at 9.22ppm was assigned to NH-Trityl 
protecting group proton followed by another one proton triplet at 9.79ppm which 
was assigned to the anthraquinone amino group proton.  
D. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Leu-Spacer-AQ (Compound 25)       
 
The fluorescein tagged peptide sequence 24 was synthesized by reacting 
compound 23 with the fluorescein labeled amino acid (4) in DMF. The carboxyl 
group of the fluorescein labeled amino acid was activated via an esterification 
reaction with TBTU/HOBT in the presence of DIPEA as base.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: Mass spectrometry result for compound 24. 
(M+H)
+
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The compound was purified by column chromatography using MeOH: DCM by 
gradually increasing the polarity of the solvent system (up to 10% MeOH) to elute 
the product. The yield of the sample after column chromatography was found to 
be 50%. The compound (24) was characterized by high resolution ESI (+) mass 
spectrometry, which gave a signal at m/z 1310.5081 (M+H)+ corresponding to a 
molecular mass of 1309 (figure 40) and also a signal at m/z 1333 corresponding 
to the sodium adduct (M+Na)+; the ESMS (-) mass spectrometry gave a signal at 
1308 (M-H)- corresponding to the proton abstraction product and also a signal m/z 
653 (M/2-2H)2-.  Subsequent γ-trityl deprotection of the asparagine residue was 
achieved by treating the compound 24 with TFA to yield the corresponding 
deprotected compound 25 as detailed in section 2.1.1.3 (step:3-III). Upon TLC 
analysis, the γ-deprotected tetra-peptide sequence appeared to have a close 
running fluorescein band. The same problem as encountered with the previous 
compounds (14, 17 and 20) which were synthesized via SPPS was noticed which 
upon further column chromatography was not possible to resolve. It was decided 
to repeat the peptide synthesis by coupling the fluorescent dye directly to the tetra 
peptide sequence in future reactions. This idea was further supported by the work 
done by Fernandez-Carneado and Giralt (2004) on synthesizing fluorescently 
labelled peptides. The authors suggest that the method of fluorescent labeling 
could potentially be improved if the fluorophore was directly coupled on to an 
assembled peptide sequence. In the same study it was also mentioned that 5(6)-
CBF was demonstrated to react in a reproducible manner with amino groups 
producing highly fluorescent 5(6)-carboxy fluoresceinamido derivatives.    
2.1.1.4. Fluorescence measurements 
In this study, a library of FRET peptide substrates consisting, of an 
aminoanthraquinone/5(6)-CBF pair tagged to the C and N termini of a peptide 
sequence, designed to be recognizable by legumain have been synthesized 
(section 2.1.1.3 pg. 68). Legumain is one of the proteases which is found to be up 
regulated during atherosclerotic plaque progression. The role of this enzyme has 
been linked to atherosclerosis both directly by proteolytic breakdown of the ECM 
and indirectly by activation of other proteases that are associated with degradation 
of the ECM. Hence, the synthesis of suitable probes, which are designed to be 
specific to legumain that are found to be overexpressed in atherosclerotic plaques 
has been undertaken in this research project.   
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Figure 41: Pictorial explanation of FRET mediated quenching effect. 
 
In order to evaluate the efficiency of the FRET peptide library (JC series-1) of 
compounds, fluorescence spectra was recorded for compound 11. The 
fluorescence measurement was performed to demonstrate that the absorption 
spectra of the FRET compounds (with the acceptor/donor pair) would completely 
overlap with the emission spectrum of the fluorescein counterpart (donor) as 
described in figure 41. Hence the experiment was done by analyzing the 
fluorescence spectra of the peptide-fluorophore conjugate before and after 
coupling to the acceptor (quencher) moiety. The UV-Vis absorption spectrum of 
compound 11 (5(6)-CBF-Pro-Gly-Asn-Leu-Sp-AQ) had a maximum absorbance at 
490nm and the fluorescence emission spectrum of compound 9 (5(6)-CBF-Pro-
Gly-Asn-Leu-OH) showed a maximum fluorescence intensity wavelength at 
515nm, emission slit width: 10nm. From the data as seen in figure 42, it can be 
clearly understood that the relative fluorescence intensity of the compound 11 was 
almost completely quenched by the acceptor unit (AQ) which can be seen by a low 
lying curve (4). This result suggests that there is very little or no fluorescence 
detected prior to incubation with the activated enzyme.  
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Figure 42: Comparison of relative fluorescence intensities between 5(6)-CBF-Pro-Gly-
Asn-Leu-OH 9 (1μM) and the FRET substrate-compound 11 (1μM). 
 
2.1.1.5. Legumain activity assay 
The human genome comprises of 2% of the total genetic information related to 
members of the protease family which sum up to a total of 560 members 
(Edgington et al. 2011). One of the functions of this diverse family of proteases 
(serine, aspartate, metalloproteases, and cysteines) is to cleave peptide bonds 
that are specific to each family. Although this biological mechanism is vital to 
maintain normal cellular activities, it is also a serious regulatory process for several 
pathologies. Any unregulated proteolysis would be extremely detrimental to the 
stable cellular environment and hence the family of proteases is subjected to strict 
regulatory pathways. In order to have a clear understanding about both the normal 
and pathological functions of proteases, direct evaluation of the parameters for 
their enzymatic activities is essential (Edgington et al. 2011). 
Initially proteases were thought to degrade proteins completely to preserve the 
homeostasis of proteins in the molecular system but they also perform restricted 
proteolysis of substrates at only certain cleavage sites. This ability to cleave a 
substrate at a specific site is regulated by a number of factors such as 
concentration of target and protease; and tertiary structure however, in numerous 
cases this is controlled by specific amino acid chains surrounding the scissile bond 
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2] 5(6)-carboxyfluorescein 
3] 5(6)-carboxyfluorescein-Pro-Gly-Asn-Leu-OH (9). 
4] 5(6)-carboxyfluorescein-Pro-Gly-Asn-Leu-OH-Spacer-AQ (11). 
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(Edgington et al. 2011). Therefore, on developing this idea it may be possible to 
synthesize peptide sequences consisting of a fluorescein dye and a quencher 
tagged at opposite ends of the sequence (figure 41). These substrates on 
incubation with the corresponding enzyme can then be cleaved to release 
fluorescence. This method of enzymatic detection is known as substrate based 
probes. Another method involves the application of activity based probes which 
are designed to carry a reactive functional group (warhead) coupled to a protease 
recognizable sequence and a fluorogenic/radiolabelled tag for imagining purposes 
(Edgington et al. 2011). These probes function by covalently modifying the target 
enzyme leading to direct identification and quantification of the labeled enzyme. 
Moreover, contrasting the substrate based probes, these probes continue to be 
linked to the target enzyme enabling live cell imaging ultimately leading to 
dynamic analyses on enzyme activation and localization (Blum et al. 2005; Blum 
et al. 2007). This research study focused on the synthesis of FRET peptide 
substrate-based probes that could be activated by legumain.  
The rationale for the design of the JC library of compounds was to observe the 
increase in fluorescence intensity when incubated with legumain. Excitation at 
492nm and emission at 520nm based on the fluorescence properties of free 5(6)-
CBF was initially subdued by the aminoanthraquinone (absorbance 200nm-650nm) 
conjugate in the absence of the enzyme as demonstrated in section 2.1.1.4 and 
this model could be predicted to generate a means for efficient substrate cleavage 
detection.  
 
Figure 43: Relative fluorescence intensity upon incubation of probe 8 (10μM) with 
legumain (40ng in a final assay volume of 100μL per well) in legumain assay buffer, pH 
5.0 λex 492nm, λem 520nm. Data represents mean values ± SD from triplicates from one 
experiment recorded individually. 
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Figure 44: Relative fluorescence intensity upon incubation of probe 11 (10μM) with 
legumain (40ng in a final assay volume of 100μL per well) in legumain assay buffer, pH 
5.0 λex 492nm, λem 520nm. Data represents mean values ± SD from triplicates from one 
experiment recorded individually. 
 
 
Figure 45: Relative fluorescence intensity upon incubation of control (10μM) with 
legumain (40ng in a final assay volume of 100μL per well) in legumain assay buffer, pH 
5.0 λex 492nm, λem 520nm. Data represents mean values ± SD from triplicates from one 
experiment recorded individually. 
 
Six FRET peptide substrates were synthesized (8, 11, 14, 17 and 25 section: 
2.1.1.3) and these compounds were incubated individually with activated human 
recombinant legumain at 37°C for two hours. Increase in fluorescence due to 
increase in the distance between the FRET pair (AQ/5(6)-CBF) by hydrolysis of the 
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substrate in the presence of activated legumain was observed only in substrates 
8 and 11. Compounds 8 and 11 showed an increase in fluorescence emission when 
compared to the control (figure 43, 44 and 45). The control was the corresponding 
peptide sequences without the anthraquinone unit (acceptor) for example 
compounds 6 and 9 respectively. The other four compounds (14, 17, 20 and 25) 
did not produce the gradual increase in fluorescence as observed in compounds 8 
and 11. During the synthesis of compounds 14, 17, 20 and 25 it was observed 
that there was a close running fluorescence band near to the presumed product, 
which was not possible to separate using column chromatography. This could have 
also been one of the reasons for the background fluorescence noise even before 
incubating with the activated enzyme. Another observation from the legumain 
assay was that two of the six compounds (8 and 11) having proline at P3 positon 
were found to be readily cleaved by the enzyme which was consistent with the 
data that the preference for proline at this position was high compared to other 
amino acid residues (Sexton et al. 2007; Mathieu et al. 2002). Based on the results 
obtained from the legumain assay, the successful FRET peptide substrates (8 and 
11) were used as a model for the synthesis of the 2nd batch of JC FRET peptide 
substrates. The 2nd batch of FRET peptide substrates were synthesized in order to 
eliminate the problems encountered during the synthesis of the 1st batch of JC 
compounds.  
2.1.1.6. Synthesis of FRET peptide substrates (JC series-2)     
Schwarz and colleagues (2002) in their experiment to determine the substrate 
preferences of legumain (isolated from pig, schistosoma and humans) synthesized 
many peptide libraries. The results from these experiments indicate that 
Lys/Arg/His were well tolerated at P1’ position. The authors also demonstrated that 
the presence of amino acids such as pro, leu, asp and glu at P1’ was less effective 
when compared to other amino acid residues at that position. Based on this study 
the following peptide substrates in the JC- 2nd series had lysine at P1’ rather than 
leu as seen in the 1st batch of compounds. The FRET peptide substrates for 
legumain were structured spanning the P3 to P1’ positions except for compound 
46 which has an extra amino acid at P4 position. The most conserved feature of 
the FRET peptide library was the FRET pair (AQ/5(6)-CBF) which was similar to the 
previous series (JC series-1) along with the positioning of Asn at the P1 of the 
peptide sequence. The design for the 2nd batch of JC series followed the protocol 
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as detailed in section 2.1.1.3. This series of compounds included the selection of 
amino acids as shown in table 8.  
Table 8: List of tetra peptide sequence for JC series (II) of FRET peptide substrates. 
The adaptations made during this peptide synthesis were that the terminal amino 
acids (proline/β-alanine) were not initially labeled with the fluorescein dye. 5(6)-
CBF was directly coupled to the aminoanthraquinone-peptide conjugate in the 
hope that the close running fluorescein impurity as noticed in JC series-1 could 
potentially be avoided.  
Figure 46: General mechanism for Boc group deprotection. 
 
Comp. 
 no. 
 
Acceptor 
unit 
 
P4 
 
 
P3 
 
P2 
 
P1 
 
Hot 
spot 
 
P1
’ 
 
Donor unit 
31  
 
 
5(6)-CBF 
 Pro Gly Asn  Lys  
 
34  β-Ala Gly Asn  Lys 
38  Pro Ala Asn  Lys 
41  β-Ala Ala Asn  Lys 
46 β-Ala Pro Ala Asn  Lys 
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Moreover, it was decided to reduce the equivalence of the fluorophore while 
coupling to the aminoanthraquinone-peptide conjugate as a means to reduce the 
presence of any unreacted starting material. The final step involved the removal 
of the side chain protecting group from ε-lysine and γ-asparagine residues as 
explained in section 2.1.1.3 (III). The general mechanism of the Boc deprotection 
reaction is shown in figure 46. During the removal of the Boc protecting group 
using TFA, the tert-butyl carbamate becomes protonated leading to the loss of the 
tert-butyl cation resulting in a carbamic acid. Decarboxylation of the carbamic acid 
results in the release of the free amine and the final product, as the TFA salt results 
by the protonation of amine under acidic conditions as shown in figure 46. The 
rationale for the selection of amino acids for JC-2nd series was based on the 
information as discussed previously in section (2.1.1.3).  
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The synthesis of the 2nd batch of FRET tetra peptide substrates is shown in an 
abbreviated form in scheme 6.  
Scheme 6: A schematic representation of the synthesis of the compounds detailed in 
table 8. 
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A. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Lys-Spacer-AQ (Compound 31) 
I. Synthesis of intermediate compound- H2N-Lys(Boc)-Spacer-AQ 
(Compoud 26) 
 
The Fmoc-protected intermediate (AQ-Spacer-Lys(Boc)-Fmoc) was synthesized by 
reacting N-Fmoc-Lys(Boc)-OH with compound 5 (scheme 6/n1) in DMF. 
Subsequent liquid/liquid extraction followed by N-Fmoc deprotection was 
performed using piperidine in DMF (scheme 6/n1). The deprotected sample was 
purified by column chromatography using 5% MeOH in DCM as the initial solvent 
to elute the front running impurities and then gradually increasing the polarity of 
the solvent system by using methanol up to 10% to elute the required product. 
The yield of the sample after column chromatography was 90%. The deprotected 
product 26 was then characterized by low resolution ESMS (+) mass spectrometry, 
which gave a signal at m/z 583 (M+H)+ corresponding to a molecular mass of 582 
and also a signal at m/z 604 corresponding to the sodium adduct (M+Na)+. The 
ESMS (-) mass spectrometry gave a signal at m/z 581 (M-H)- corresponding to the 
proton abstraction product and also a signal at m/z 616 corresponding to the 
chloride adduct (M+Cl)-. Furthermore, the 1H NMR spectrum (d-DMSO) showed, 
for example, a multiplet signal for the 15 protons between 1.20ppm and 1.52ppm 
which was assigned to β, γ, δ and the Boc group protons. A two proton quartet 
signal at 2.86ppm was assigned to the ε-methylene group protons of the lysine 
side chain. A quartet at 3.06ppm was assigned to the single α-proton of the lysine 
side chain. A two proton multiplet signal between 3.21 and 3.26ppm and another 
two proton triplet at 3.46ppm was assigned to CH2-NH-COO and to CH2-CH2-NH-
COO protons. A six proton multiplet between 3.52 and 3.64ppm was assigned to 
CH2-NH-AQ and O-CH2-CH2-O protons of the spacer arm. A two proton triplet at 
3.73ppm was assigned to CH2-CH2-NH-AQ. A single proton triplet at 6.75ppm was 
assigned to NH-COO-Boc group. The protons attached to the aromatic group were 
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assigned as follows: H-2 and H-4 gave a single proton doublet and a double doublet 
at 7.30ppm and 7.46ppm and a single proton triplet at 7.66ppm was assigned to 
H-3. A multiplet between 7.82ppm and 7.92ppm for three protons was assigned 
to H-6 and H-7 and NH-spacer arm protons. The H-5 and H-8 protons gave a 
double doublet signal at 8.13ppm and 8.21ppm respectively. The anthraquinone 
amino group proton gave a triplet at 9.80ppm. To further confirm the assignment 
in the 1H NMR, a 2D-COSY spectrum of compound 26 was also performed 
(appendix 4).     
II. Synthesis of intermediate compound- H2N-Asn(Trt)-Lys(Boc)-Spacer-
AQ (Compound 27) 
Compound 27 (scheme 6/n2) was synthesized following a procedure analogous to 
compound 26 and the yield for the post chromatographic sample was found to be 
76%. The product 27 was then characterized by low resolution ESMS (+) mass 
spectrometry, which gave a signal at m/z 939 (M+H)+ corresponding to a 
molecular mass of 938; and the ESMS (-) mass spectrometry gave a signal at 937 
(M-H)- corresponding to the proton abstraction product. 
III. Synthesis of intermediate compound- H2N-Gly-Asn(Trt)-Lys(Boc)-
Spacer-AQ (Compound 28) 
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Compound 28 (scheme 6/n3) was synthesized following a procedure analogous to 
compound 26 and the yield for the sample after column chromatography was 
found to be 67%. The product 28 was characterized by low resolution ESMS (+) 
mass spectrometry, which gave a signal at m/z 996 (M+H)+ corresponding to a 
molecular mass of 995 and also a signal at m/z 1017 corresponding to the sodium 
adduct (M+Na)+; the ESMS (-) mass spectrometry gave a signal at 993 (M-H)- 
corresponding to the proton abstraction product and m/z 1029 corresponding to 
the chloride adduct (M+Cl)-. 
IV. Synthesis of intermediate compound HN-Pro-Gly-Asn(Trt)-Lys(Boc)-
Spacer-AQ (Compound 29) 
Compound 29 (scheme 6/n5) was synthesized following a procedure analogous to 
compound 26 and the yield for the sample was found to be 86%. The product  29 
was then characterized by low resolution ESMS (+) mass spectrometry, which gave 
a signal at m/z 1093 (M+H)+ corresponding to a molecular mass of 1092 and also 
a signal at m/z 1115 corresponding to the sodium adduct (M+Na)+; the ESMS (-) 
mass spectrometry gave a signal at 1091 (M-H)- corresponding to the proton 
abstraction product and m/z 1127 corresponding to the chloride adduct (M+Cl)-. 
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V. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Lys-Spacer-AQ (Compound 31) 
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Legumain recognition site
5(6)-CBF Pro Gly Asn Lys Spacer AQ  
The fluorescein labeled tetra peptide sequence (30) was synthesized by reacting 
5(6)-CBF with compound 29 in DMF (scheme 6/n7). The crude product was 
purified by column chromatography. The crude sample was dissolved in a polar 
solvent system (chloroform: MeOH: pyridine:35% ammonia- 20:55:15:10) and 
loaded onto a chromatographic column. The same solvent system was used to 
elute three fractions with the first and last fraction corresponding to impurities and 
unreacted fluorescein dye. The yield for the sample after column chromatography 
was found to be 82%. The second band consisting of a reddish brown solution was 
then filtered to remove silica and was characterized by low resolution ESMS (+) 
mass spectrometry, which gave a signal at m/z 1451 (M+H)+ corresponding to a 
molecular mass of 1450 and also a signal at m/z 1473 corresponding to the sodium 
adduct (M+Na)+; the ESMS (-) mass spectrometry gave a signal at 1449 (M-H)- 
corresponding to the proton abstraction product and m/z 1485 corresponding to 
the chloride adduct (M+Cl)-.     
Deprotection of the γ-trityl (asparagine) and ε-Boc (lysine) protected compound 
(30) with TFA gave the deprotected compound 31 after 3 hours reaction at rt 
(scheme 6/TFA). TLC showed the presence of a single new component close to the 
base line, due to the polar nature of the deprotected compound. Analytical HPLC 
was performed on a Shimadzu Prominence system equipped with UV-Vis detector 
using an eclipse XDB-C18 RP column and the purity of the sample was found to be 
93% (figure 47) and the yield of the compound (31) was 97%. Additionally the 
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target compound 31 was also characterized by high resolution ESI (+) mass 
spectrometry, which gave a signal at m/z 1109.4252 (M+H)+ (figure 47) 
corresponding to a molecular mass of 1108 and also a signal for the doubly charged 
ion at m/z 555 [(M+2H)/2]2+. The observed data was consistent with the 
theoretical isotope model confirming the structure of compound 31. It was noticed 
that the yield and purity of the target compound was high when compared to the 
1st batch of JC compounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47: Mass spectrometry result for compound 31. RP-HPLC elution profile of 
compound 31 (1mg/mL in methanol); Conditions: Flow rate, 1mL/min; Detection, 
275nm; stationary phase: Eclipse XDB-C18 RP column; mobile phase A= 0.1%TFA/water; 
mobile phase B=0.1%TFA/methanol; gradient: low pressure gradient; 23min. 
This could have been possible because of the switch to solution peptide synthesis 
which normally is the favourable technique for synthesis of peptide sequences less 
than 8 amino acids long. Moreover the isolation of intermediates after each 
coupling and deprotection cycle by column chromatography could have possibly 
removed any undesirable products. Furthermore Fernandez-Carneado and Giralt 
(2004) have demonstrated in their studies on fluorescent labeled peptides that the 
coupling of 5(6)-CBF into a solid support-attached peptide sequence was found to 
be difficult.  
(M+H)
+ 
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B. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Lys-Spacer-AQ (Compound 34) 
The entire chemical synthesis of the FRET peptide substrate (34) was similar to 
compound 31. The only difference was the replacement of proline with β-alanine 
at P3 position of the peptide sequence. The coupling and deprotection methods and 
the reaction conditions were the same as in compound 31 (scheme 6). HPLC for 
the FRET tetra peptide 34 was performed on a Shimadzu Prominence system 
equipped with UV-Vis detector using an eclipse XDB-C18 RP column and the purity 
of the sample was found to be 77% and the yield of the compound was 83%. The 
product 34 was also characterized by high resolution ESI (+) mass spectrometry, 
which gave a signal at m/z 1083.4097 (M+H)+ corresponding to a molecular mass 
of 1082 and also a doubly-charged signal at m/z 542 [(M+2H)/2]2+. 
C. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Lys-Spacer-AQ (Compound 38) 
The chemical synthesis of the FRET peptide substrate (38) was similar to 
compound 31. The only difference was the replacement of glycine with alanine at 
P2 position of the peptide sequence. The coupling and deprotection methods were 
similar to compound 31 as mentioned in scheme 6. HPLC for the target compound 
38 was performed on a Shimadzu Prominence system equipped with UV-Vis 
detector using an eclipse XDB-C18 RP column and the purity of the sample was 
found to be 82% and the yield of the compound was 92%. The deprotected product 
38 was characterized by high resolution ESI (+) mass spectrometry, which gave 
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a signal at m/z 1123.4411 (M+H)+ corresponding to a molecular mass of 1122 and 
also a doubly-charged signal at m/z 562 [(M+2H)/2]2+. 
D. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Lys-Spacer-AQ (Compound 41) 
The synthesis of the FRET peptide substrate followed the same procedure as 
compound 34. The major difference was the replacement of gly with ala at the P2 
positon of the sequence. The reaction conditions remained the same as mentioned 
in scheme 6. The purity of the target compound 41 was determined to be 84% via 
HPLC analysis performed on a Shimadzu Prominence system equipped with UV-Vis 
detector using an eclipse XDB-C18 RP column and the yield of the  compound was 
91%. The deprotected product 41 was characterized by high resolution ESI (+) 
mass spectrometry, which gave a signal at m/z 1097.4250 (M+H)+ corresponding 
to a molecular mass of 1096 and also a doubly-charged signal at m/z 549 
[(M+2H)/2]2+.  
 
E. Synthesis of 5(6)-CBF-β-Ala-Pro-Ala-Asn-Leu-Spacer-AQ (Compound 
46) 
The chemical synthesis of the FRET peptide substrate (46) was similar to 
compound 41. The major difference was the addition of another amino acid to the 
peptide sequence making it a penta-peptide substrate. This peptide sequence was 
synthesized in order to evaluate the influence of additional amino acids on the 
recognition of the peptide substrate by the enzyme. The coupling and deprotection 
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methods were similar to compound 31 as mentioned in scheme 6. The γ-trityl 
(asparagine) protected compound (45) was deprotected using trifluoroacetic acid 
(scheme 6/TFA). Reaction progress was monitored by TLC analysis, which showed 
the presence of a single new component with a low Rf value indicating the polar 
nature of the deprotected sample. HPLC for the target compound 46 was 
performed on a Shimadzu Prominence system equipped with UV-Vis detector using 
an eclipse XDB-C18 RP column and the purity of the sample was found to be only 
64% and the yield of the compound was 75%. The product 46 was characterized 
by high resolution ESI (+) mass spectrometry, which gave a signal at m/z 
1179.4674 (M+H)+ corresponding to a molecular mass of 1178 and also a doubly-
charged signal at m/z 590 (M/2+2H)2+.   
 
2.1.1.7. Fluorescence measurements for the 2nd series of JC library 
Earlier in this section (2.1.1) it was discussed that fluorescent-labeled peptide 
substrates were effectively used as sensitive tools for monitoring various biological 
events. Chen and colleagues (2014) in their work on fluorescent probes have 
demonstrated that the principle of FRET may be an effective technique to image 
legumain-expressing abnormal tissues for both diagnosis and targeted treatments. 
Hence, by applying the principle of FRET, a small library of peptide substrates 
designed to be specific to legumain was synthesized. It was hoped that these self-
quenched FRET substrates may release detectable fluorescence signals upon 
cleavage by legumain. Moreover the presence of a non-fluorescent quencher 
moiety (AQ) with a broad absorption wavelength of 550nm-700nm was found to 
be efficient in quenching 5(6)-CBF by eliminating much of the background 
fluorescence. Based on this idea the JC series of compounds were synthesized 
consisting of a tetra peptide substrate between the FRET pair. In order to evaluate 
the ability of the anthraquinone chromophore to quench the fluorescence emission 
of 5(6)-CBF an initial fluorescence measurement study was perform in a similar 
manner to that of compound 8. 
Compound 31 along with its corresponding peptide-fluorophore sequence was 
dissolved in water and the fluorescence spectrum was recorded using a 
luminescence spectrophotometer. From figure 48, the data for fluorophore 
quenching studies demonstrated that the relative fluorescence intensity of the 
compound 31 was almost completely quenched by the acceptor unit (AQ) which 
can be seen by a low lying curve (4) when compared to its fluorogenic-peptide 
conjugate (3). Thus the fluorescence measurement studies demonstrated that the 
relative fluorescence intensity of the fluorophore (5(6)-CBF) has been completely 
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quenched by the anthraquinone chromophore. Therefore any release in 
fluorescence that would be observed during the in vitro studies with rh legumain 
was not because of background fluorescence from the FRET compounds but only 
because of the release in fluorescence due to the increase in distance between the 
acceptor and donor pair as a result of proteolytic activity by the enzyme. 
 Figure 48: Comparison of relative fluorescence intensities between 5(6)-CBF-Pro-Gly-
Asn-OH (1μM) and the FRET substrate-compound 31 (1μM) in water. 
 
2.1.1.8. Legumain activity assay for the 2nd series of JC library 
The 2nd series of FRET peptide substrates contained five compounds labeled with 
5(6)-CBF. The compounds 31,34,38,41 and 46 had a design similar to 5(6)-CBF-
AA2–AA1-Asn-Lys-Spacer-AQ, where AA1 and AA2 corresponded to amino acids. 
The five compounds were incubated with activated legumain individually following 
a protocol similar to the previous assay conditions as in section 2.1.1.6. The FRET 
pair in each of the compounds was expected to quench the emission by the 
fluorophore. However, on cleavage of the peptide substrate by the enzyme, an 
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increase in the distance between the donor/acceptor pair would lead to 
fluorescence release (Chen et al. 2014). Thus release in fluorescence was noticed 
as soon as the compounds were incubated with the activated legumain. The 
relative fluorescence intensity reached a maximum after 120 minutes incubation 
(figure 49).  
 
Figure 49: Relative fluorescence intensity upon incubation of 31, 34, 46, 38 and 41  
(10μM) with legumain (40ng in a final assay volume of 100μL per well) in legumain assay 
buffer, pH 5.0 λex 492nm, λem 520nm. Data represents mean values ± SD from triplicates 
from one experiment done individually. 
 
The results indicated that the peptide substrates could be recognized by legumain 
and hence these compounds could potentially be used to synthesize diagnostic 
tools for targeting legumain, which is overexpressed in atherosclerotic plaques. 
From the legumain enzyme assay it was observed that compounds 31, 34 and 46 
produced a gradual increase in fluorescence intensity with time when incubated 
with the enzyme, whereas compounds 46 and 49 did not produce the gradual 
increase in fluorescence. Moreover, compound 34 having β-Ala at P3 position was 
found to release fluorescence which was in contrast to the results obtained from 
the 1st batch of JC compounds. This may suggest that compounds 17, 20 and 25 
did not produce the required result because of background fluorescence as well as 
the position of leucine at P1 (Schwarz et al. 2002) and not necessarily because of 
β-Ala at P3 position. More information that can be gained from the legumain assay 
was that, from the five successful compounds (8, 11, 31, 34 and 46) including 
the 1st-batch compounds, three of the compounds (11, 31 and 34) had Gly at P2 
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position and the other two compounds (8 and 46) had Ala at P2 position. This 
result may perhaps suggest that the preference for glycine could be higher than 
alanine, even though both the amino acids are thought to be favored at P2 position 
as suggested in the experiments conducted by Mathieu et al. 2002.  
Although compounds 14, 17, 20 and 25 suffered severe background fluorescence, 
this problem was rectified during the synthesis of compounds 31, 34, 38, 41 and 
46. The latter compounds, denoted as the 2nd batch of FRET peptides, were 
synthesized via solution peptide synthesis, which may possibly have influenced the 
purity and yield of the target compounds when compared to the 1st batch of FRET 
peptide substrates. As previously discussed legumain is a distinct enzyme, which 
has strict specificity towards an asparagine residue at the P1 position of the peptide 
sequence (Mathieu et al. 2002). It was also mentioned that the amino acids on 
positions apart from P1 did not influence enzyme specificity however, proline and 
alanine residues at the P3 position were found to be the most desired amino acids 
at that position (Mathieu et al. 2002). Moreover in order to analyze the influence 
of the length of the peptide sequence on enzyme recognition, a penta-peptide 
substrate (46) was also synthesized as part of the 2nd batch of FRET peptide 
substrates. The compounds 8, 11, 31, 34, 38 and 41 were adapted as the design 
template for synthesizing the library of JS series in the following section 3.1.2. The 
JS library of peptide substrates were complexed to a paramagnetic metal ion-
gadolinium linking to the aim of this research study, which was the synthesis of a 
contrast agent that would ultimately improve MR imaging, facilitating a non-
invasive means for detecting atherosclerotic plaques.   
 
2.1.2. MRI based contrast agents for imaging atherosclerotic plaques (JS 
series) 
Magnetic resonance imaging is a non-invasive technique that can provide 
information on the anatomy, function and metabolism of tissues in vivo. Apart 
from the basic contrast in MR images produced by the difference in the local water 
content, the signals from regional differences in the relaxation time T1 and T2 also 
dominate image contrast. However, the intrinsic contrast produced by the signals 
provided by water T1 and T2 about tissue pathology are often too limited for a 
sensitive and specific diagnosis (Strijkers et al. 2007). For this reason, MRI 
contrast agents such as gadolinium complexes of either DOTA or DTPA are 
increasingly used to alter and improve image contrast. Gadolinium is a positive-
contrast paramagnetic agent, which works by shortening the relaxation time (T1) 
of water protons in the tissue. Liu and colleagues (2012) in their studies have 
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demonstrated that the MR images acquired with the application of gadolinium 
complexes were able to expose tissue lesions, atheroma and metastases more 
clearly than the images without the contrast agent.  
A biocompatible molecule that can bind efficiently to a paramagnetic ion to produce 
a stable metal chelate is defined as a ligand. Many such gadolinium chelates (as 
discussed in the introduction chapter) are commercially available for research and 
clinical applications. Novel MRI contrast agents have been synthesized by 
covalently attaching them to suitable frameworks using dendrimers, nanoparticles, 
liposomes, proteins and bioactive peptides (Huang et al. 2013). In a study by Nwe 
and colleagues (2010) on contrast agents, they have synthesized gadolinium 
complexes either using DTPA or DOTA conjugated to G4 PAMAM dendrimers in 
order to evaluate MRI quality and contrast. Their findings suggested that 
gadolinium-DOTA complexes produced better quality images and also a faster 
blood clearance compared to Gd-DTPA.  
Another major limitation for the use of gadolinium contrast agents for clinical 
application is their low sensitivity. Hence the need for targeted contrast agents to 
specifically image regions of interest is desired. Many studies have suggested the 
use of folic acids, lactoferrin, nucleic acids, peptides and monoclonal antibodies as 
some of the targeting components of MRI contrast agents (Chen et al. 2014). Such 
targeted MRI contrast agents have proven useful in research and clinical diagnosis 
for highlighting specific metabolites and biomarkers (Liu et al. 2014). Chen and 
colleagues (2014) in their studies on MRI contrast agents have successfully 
synthesized a novel contrast agent and a near infrared fluorescent probe for both 
in vivo and in vitro detection of legumain, which is generally over expressed in 
unstable atherosclerotic plaques. The application of contrast agents conjugated to 
legumain activatable peptide substrates to detect legumain accumulation in 
atherosclerotic plaques using MR imaging was the basis for this current research 
study.  
The aim of this research study was to synthesize a small library of substrate based 
MRI contrast agents designed to specifically image atherosclerotic plaques by 
targeting some of the biomarkers (enzymes/proteases-legumain) that are over 
expressed in the microenvironment of the disease. Moreover, it can be anticipated 
that these MRI-images can give a better understanding about the type of 
therapeutic agent that could be effective for treating the plaques or the imaging 
agent can alternatively be used to deliver the therapeutic drug to the 
atherosclerotic plaques (Nelson 2012). This is one possibility for the future 
development of these substrate based contrast agents for therapeutic purposes. 
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In this way, the contrast agents can be used for both research and clinical 
evaluations as a novel means to diagnose and monitor drug administration and 
treatment. A targeted contrast agent, in context to this research study, can be 
defined as an agent, which is expected to produce little or zero signal until 
activated by the target enzyme. In this way the activity of the enzyme of interest 
can be monitored thus creating a platform for using them as diagnostic tools to 
locate plaques. The atherosclerotic plaques could potentially be imaged using a 
peptide substrate conjugated to MRI contrast agents analogous to the JS series of 
compounds. This library of compounds consisted of a paramagnetic gadolinium 
chelate covalently coupled to a peptide sequence designed to be specific to 
legumain. Hence, legumain driven cleavage of the peptide substrate can lead to 
accumulation of the contrast agent at the site of the plaque ultimately leading to 
better contrast MR images as described in figure 50 (Leuschner and Nahrendorf 
2011). Following the successful synthesis and characterization of JC series of FRET 
peptide substrates, the same method of synthesis was applied to construct a small 
library of MRI contrast agents conjugated to peptide substrates designed to be 
specific to legumain. The sequence design for the JS series was based on the 
results from the legumain assay on the JC FRET peptide library. Compounds 8 and 
11, which were readily hydrolysed in the presence of legumain, were chosen as 
the model for the JS linear series (figure 50). The linear sequences were 
synthesized via solution phase peptide synthesis. Similarly, based on the results 
from the second batch of JC FRET peptide library, the JS lysine series was designed 
and synthesized. The lysine sequences were synthesized via a combination of both 
solution and solid phase peptide synthesis (figure 50). 
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Figure 50: Template describing the JS series of compounds and the anticipated image 
enhancement on release of the CA when the MRI peptide CA is activated by legumain.  
  
2.1.2.1. Synthesis of Gadolinium-DOTA-Peptide substrates-JS Linear 
sequences 
The rationale for the synthesis of the gadolinium-DOTA-peptide substrates was to 
image atherosclerotic plaques by specifically identifying the biomarkers (legumain) 
over expression in these plaques. Hence two series of compounds were 
synthesized and this section explains in detail the chemical synthesis of the JS-
linear series. The linear series of JS compounds had a design: Paramagnetic 
gadolinium complex-AA4-AA3-AA2-AA1-Spacer-AQ, where AA represents amino 
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acids and the complex consisted of Gd-DOTA chelate. The linear sequences were 
synthesized following the procedure for solution peptide synthesis. The JS-linear 
library of compounds consisted of a hydrophobic group comprising of an 
aminoanthraquinone moiety, which was conjugated to the C-terminus of a tetra 
peptide sequence in order to, potentially, increase the retention time of the 
contrast agent (DOTA-Gd) within the atherosclerotic plaque environment. This 
increase in retention time of the contrast agent could perhaps enhance the 
quality/resolution of the image from a MRI scanner. The presence of a short 
diamino chain between the carboxyl end of the peptide sequence and 
anthraquinone moiety was incorporated to produce an amphiphilic compound in 
order to improve the solubility of the compound. Furthermore, the intense reddish-
pink colour of the aminoanthraquinone chromophore helped to identify the 
required compound on a silica gel chromatographic column; thus making the 
process of identifying the required fraction easier. The chelating agent-DOTA was 
either covalently attached to the side chain of a lysine residue (JS-lysine series) 
or to the terminal proline (JS-linear series). The rationale for such a design was 
based on the concept that the aminoanthraquinone-peptide-contrast agent 
conjugate can accumulate and bind to the extracellular protein moieties in the ECM 
and when cleaved by the target enzyme, the intact contrast agent may be released 
locally. The released contrast agent (DOTA-Gd), along with the hydrophobic site 
(proline, β-alanine, and AQ-spacer-lysine) attached to them, could increase the 
retention time of the CA. This may enhance the contrast between the normal and 
abnormal regions of investigation. As discussed in previous sections, DOTA is a 
favourable bifunctional chelating agent (BFCA) when compared to DTPA mainly 
because of its thermodynamic stability and kinetic inertness preventing in vivo 
dissociation of free metal ions into the blood stream. Furthermore, most of the 
clinically relevant MRI contrast agents are based on DOTA-gadolinium complexes 
such as Gadovist®, ProHance®, Dotarem® and Gadomer-17®. Several derivatives 
of DOTA-based BFCA’s are available commercially such as active DOTA esters, 
DOTA with a coupling unit present either at the α- site of one carboxylate arm 
(McMurry et al. 1992; James et al. 2012) or into the macrocycle (Kruper et al. 
1993) and protected DOTA species (Jamous et al. 2013). However, the protected 
DOTA derivative (DOTA-tris-tBu ester) has been used in this research project as it 
can be readily coupled to the peptide sequence following a standard coupling 
procedure during both solution and solid phase peptide synthesis. 
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A. Synthesis of Gd(III)DOTA-Pro-Ala-Asn-Leu-Spacer-AQ (Compound 49) 
I. Synthesis of intermediate compound DOTA(tBu)-Pro-Ala-Asn(Trt)-Leu-
Spacer-AQ (Compound 47)  
 
 
The tert-butyl protected compound (47) was synthesized by reacting DOTA-tris-
tBu-ester with compound 43 in DMF along with the in situ coupling agents: 
TBTU/HOBT and DIPEA. The crude sample was purified by column chromatography 
and the yield of the product (47) post column chromatography was 43%. After 
purification the compound 47 was characterized by high resolution ESI (+) mass 
spectrometry, which gave a signal at m/z 1568.8402 (M+Na)+ corresponding to 
the molecular mass of 1545 and also a signal at 784 [(M+Na)/2]2+.  
II. Synthesis of intermediate compound DOTA-Pro-Ala-Asn-Leu-Spacer-
AQ (Compound 48)  
 
The γ-trityl and tert-butyl protected aminoanthraquinone-tetra peptide sequence 
(47) was deprotected using trifluoroacetic acid. The reaction conditions and 
reagents were the same as detailed in section (2.1.1.3). Reaction progress was 
monitored by TLC analysis, which showed the presence of a single new component 
close to the base line confirming the polar nature of the deprotected sample. The 
residual TFA was evaporated under reduced pressure and any remaining solvent 
was re-evaporated with ethanol. The condensate was triturated with diethyl ether 
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followed by cooling on ice to facilitate further precipitation. The yield of the crude 
sample 48 was found to be 87%. The product (48) was characterized by high 
resolution ESI (+) mass spectrometry, which gave a doubly-charged signal at m/z 
568.7844 [(M+2H)/2]2+ corresponding to a molecular mass of 1135 and also a 
signal at m/z 587 corresponding to the potassium adduct [(M+H+K)/2]2+. 
 
III. Synthesis Gd(III)DOTA-Pro-Ala-Asn-Leu-Spacer-AQ (Compound 49)  
Synthesis of the target gadolinium complex of DOTA-tetrapeptide-amino 
anthraquinone spacer conjugate (49) was performed in accordance to the reaction 
conditions proposed by Digilio and co-workers (2010). The Gd complex was 
prepared in a neutral aqueous solution by reacting GdCl3(6H2O) with compound 
48.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51: Expansion of the ESI (+) mass spectrum of the Gd-DOTA-peptide sequence 
(49) that shows the isotopic pattern of the molecular ion (doubly charged at half mass). 
 
[(M+2H)/2]
2+
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The reaction pH was adjusted to 7 by adding a solution of ammonia 0.35% drop 
wise. After two hours the reaction progress was checked by TLC analysis using 
chloroform: MeOH: pyridine:35%ammonia (20:55:15:10), which showed the 
presence of two components with one corresponding to the starting material. After 
13 hours the reaction mixture was reduced to low volume by evaporation at room 
temperature and then purified by column chromatography using the same solvent 
system as for the TLC analysis. Analytical HPLC for the target compound 49 was 
performed on a Shimadzu Prominence system equipped with UV-Vis detector using 
an eclipse XDB-C18 RP column and the purity of the sample was found to be 72%. 
The product (49) was characterized by high resolution ESI (+) mass spectrometry, 
which gave a signal at m/z 1291 (M+H)+ corresponding to a molecular mass of 
1290 and also a signal at m/z 1313 corresponding to the sodium adduct (M+Na)+. 
A doubly-charged signal at m/z 646.2351 [(M+2H)/2]2+ was also observed (figure 
51). 
B. Synthesis of Gd(III)DOTA-Pro-Gly-Asn-Leu-Spacer-AQ (Compound 53) 
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Compound 53 was synthesized following a procedure analogous to compound 49. 
The only difference was the swapping of alanine with glycine at the P2 position of 
the peptide sequence. Analytical HPLC for the target compound (53) was 
performed on a Shimadzu Prominence system equipped with UV-Vis detector using 
an eclipse XDB-C18 RP column and the purity of the sample was found to be 77%. 
The product 53 was characterized by high resolution ESI (+) mass spectrometry, 
which gave a doubly-charged signal at m/z 661.2134 [(M+2Na)/2]2+ (figure 52) 
corresponding to a molecular mass of 1276 and also a signal at m/z 1299 
corresponding to the sodium adduct (M+Na)+. 
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Figure 52: Mass spectrometry result for compound 53. 
 
 
2.1.2.2. Synthesis of Gadolinium-DOTA-Peptide substrates-JS Lysine 
sequence 
Yang and colleagues (2014) in their study on MRI contrast agents have 
demonstrated that the relaxivity of the contrast agent- Gd-DO3A-Lys was found 
to be significantly higher than the commercially available macro cyclic MRI contrast 
agent-Dotarem and Gd-DTPA based CA’s. They also demonstrated that the CA 
conjugated to lysine was found to be sensitive enough for clinical evaluation on a 
3T human scanner. In the same study the authors have also demonstrated that 
when DOTA was conjugated to the side chain of a lysine residue, it produced a 
major difference in bio-distribution by lengthening the half blood-life (68.1 min) of 
the compound. Signal enhancement of the GD-DO3A-Lys contrast agent remained 
high even at 52 min post injection (Yang and Chuang 2012).  The authors also 
suggested that the mode of excretion was not only through the renal system but 
also via the reticuloendothelial system (RES- liver and spleen) and visceral organs 
such as the gastrointestinal (GI) tract (Yang et al. 2014; Shiraishi et al. 2010). 
Thus considering these findings, leucine was replaced by lysine in the following 
series of compounds.  
The JS lysine series of peptide substrates were synthesized via a combination of 
both solid and solution phase peptide synthesis; the gadolinium complex was 
covalently coupled to the side chain of a lysine residue rather than the terminal 
amino acid as in the JS-Linear series. In order to increase the retention time of the 
contrast agent within the atherosclerotic plaques, a hydrophobic unit consisting of 
an aminoanthraquinone moiety coupled to a small diamino chain was conjugated 
[(M+2Na)/2]
2+ 
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to the C-terminal of the lysine residue. Upon deprotection of the ε-Boc group from 
the lysine residue, the tert-butyl protected DOTA unit was coupled followed by 
removal of the capping unit from DOTA. The paramagnetic metal ion-Gadolinium 
(lll) was then complexed to the ligand. It was anticipated that upon peptide 
hydrolysis by legumain the contrast agent should retain the hydrophobic unit, 
which may then increase the retention time of the gadolinium complex at the site 
of activation.  
Scheme 7: Chemical synthesis of the MRI based peptide contrast agent-JS lysine series. 
The protocol for the synthesis of the following compounds involved (scheme 7): 
(i) The synthesis of the (DOTA)-Lys-Spacer-AQ conjugate. 
(ii) The synthesis of a tri-peptide sequence via solid phase peptide 
synthesis. 
(iii) The next step was the coupling of the tri-peptide sequence to the 
(DOTA)-Lys-Spacer-AQ conjugate. 
(iv) The target gadolinium-peptide substrate-AQ conjugate was synthesized 
by coupling Gd(III)Cl3(6H2O) to the peptide substrate.  
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2.1.2.2.1. Synthesis of Gadolinium complex using 1,4,7,10-Tetraaza 
cyclododecane-1,4,7,10-tetraacetic acid (Compound 58) 
I. Synthesis of Fmoc-Lys(Boc)-Spacer-AQ (Compound 54) 
 
The Boc-protected conjugate (54) was synthesized by reacting N-Fmoc-Lys(Boc)-
OH with compound 5 in DMF along with in situ coupling agents TBTU, HOBt and 
DIPEA. Reaction progress was monitored by TLC analysis; the crude product was 
then partitioned between DCM and water (x3), and washed with saturated sodium 
hydrogen carbonate (x3) and dried with anhydrous magnesium sulphate. The yield 
for the sample was found to be 81%.  
 
 
 
 
 
 
 
 
Figure 53: Mass spectrometry result for compound 54. 
 
The product 54 was characterized by high resolution ESI (+) mass spectrometry, 
which gave a signal at m/z 805.3811 (M+H)+ corresponding to a molecular mass 
of 804 (figure 53). Furthermore, the structure of the compound was confirmed by 
1H NMR (d6-DMSO) spectrum, which showed, for example, the presence of the 
tBoc-protecting group along with the γ-methylene group and the δ-methylene 
(M+H)
+
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group of the lysine side chain as a thirteen-proton multiplet between 1.17ppm and 
1.40ppm. Also a two-proton multiplet between 1.46 ppm and 1.62ppm was 
assigned to the β-methylene group of the lysine side chain. Signal for a two proton 
multiplet between 2.82ppm and 2.89ppm was assigned to the ε-methylene group 
protons of the lysine side chain. A two proton multiplet between 3.17ppm and 
3.29ppm was assigned to CH2-NH-Lys protons. A triplet at 3.45ppm was assigned 
the two protons of CH2-CH2-NH-Lys. A multiplet signal for six protons between 
3.49ppm and 3.61ppm were assigned to CH2-NH-AQ, O-CH2-CH2-O of the spacer 
arm. A two proton triplet at 3.70ppm was assigned to CH2-CH2-NH-AQ. A single 
proton multiplet between 3.90ppm and 3.95ppm was assigned to the α-H methine 
proton of the lysine side chain. A three proton multiplet between 4.17ppm and 
4.29ppm was assigned to CH2-CH-Fmoc group protons. A signal proton triplet at 
6.76ppm was assigned to NH-tBoc proton. A multiplet for three protons between 
7.26ppm and 7.33ppm was assigned to H2, H10 and H15 protons. Another 
multiplet between 7.36ppm and 7.45ppm for three protons was assigned to H4, 
H11 and H14. A multiplet for a single proton between 7.62ppm-7.66ppm was 
assigned to H3 proton of the anthraquinone group. A two proton multiplet signal 
between 7.70ppm and 7.73ppm was assigned to H9 and H16 protons. A five proton 
multiplet between 7.81ppm and 7.95ppm was assigned to H6, H7, H12 and H13 
protons along with NH-spacer arm protons. Two double doublet signals at 8.12ppm 
and 8.20ppm for one proton each was assigned to the H5 and H8 protons. Finally 
a single proton triplet at 9.78ppm was assigned to the anthraquinone amino group 
proton.    
II. Synthesis of Fmoc-Lys-Spacer-AQ trifluoroacetate salt (Compound 55) 
 
 
The Boc protected compound (54) was deprotected using trifluoroacetic acid. 
Reaction progress was monitored by TLC analysis, which showed the presence of 
a single new component, close to the base line of the TLC sheet suggesting the 
polar nature of the deprotected salt. The yield of the crude product was 54%. 
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Analytical HPLC for the compound (55) was performed on a Shimadzu Prominence 
system equipped with UV-Vis detector using an eclipse XDB-C18 RP column and 
the purity of the sample was found to be 95% (figure 54). The deprotected product 
55 was characterized by high resolution ESI (+) mass spectrometry, which gave 
a signal at m/z 705.3280 (M+H)+ corresponding to a molecular mass of 704 (figure 
54). Furthermore, the removal of the tBoc-protecting group was confirmed by 1H 
NMR (d6-DMSO) spectrum, which showed the absence of the signal for the tBoc 
protecting group which was seen in compound 54.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54: Mass spectrometry result for compound 55. RP-HPLC elution profile of 
compound 55 (1mg/mL in methanol); Conditions: Flow rate, 1mL/min; Detection, 
254nm; stationary phase: Eclipse XDB-C18 RP column; mobile phase A= 0.1%TFA/water; 
mobile phase B=0.1%TFA/methanol; gradient: low pressure gradient; 23min. 
A multiplet for two protons between 1.27ppm and 1.32ppm was assigned to the 
γ-methylene group protons of the lysine side chain. Another multiplet for four 
protons between 1.51ppm and 1.61ppm was assigned to the β and δ methylene 
group protons of the lysine side chain. A two proton multiplet between 2.74 and 
2.76ppm was assigned to the ε- methylene group protons. A two proton quartet 
at 3.24ppm was assigned to CH2-NH-COO protons. A triplet at 3.46ppm was 
assigned the two protons of CH2-CH2-NH-COO. A multiplet signal for six protons 
between 3.51ppm and 3.61ppm were assigned to protons of CH2-NH-AQ, O-CH2-
CH2-O of the spacer arm. A two proton triplet at 3.70ppm was assigned to CH2-
CH2-NH-AQ. A single proton multiplet between 3.92 ppm and 3.98ppm was 
assigned to the α-H methine proton of the lysine side chain. A single proton triplet 
 
 
(M+H)
+ 
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at 4.19ppm was assigned to CH-Fmoc proton and a two proton doublet at 4.26ppm 
was assigned to CH2-CH-Fmoc protons. A multiplet for three protons between 
7.26ppm and 7.33ppm was assigned to H2, H10 and H15. Another multiplet 
between 7.38ppm and 7.48ppm for three protons was assigned to H4, H11 and 
H14 protons. A multiplet between 7.62ppm and 7.73ppm was assigned to the H3 
proton of the anthraquinone group and H9 and H16 protons of the Fmoc group. A 
four proton multiplet between 7.81ppm and 7.91ppm was assigned to H6, H7, H12 
and H13 protons followed by a triplet at 7.94ppm for a single proton was assigned 
to NH-spacer arm-AQ. A double doublet at 8.13ppm and a doublet at 8.19ppm for 
one proton each were assigned to H5 and H8 protons. A single proton triplet at 
9.77ppm was assigned to the anthraquinone amino group proton.    
III. Synthesis of H2N-Lys(DOTA-tBu)-Spacer-AQ (Compound 56) 
N
H
O
O
H
N
O
O
NH2
O
H
N
(56)
N
N
N
N
O
O
O
O
O
O
O
 
The tert-butyl protected intermediate (Fmoc-Lys(DOTA-t-Bu)-Spacer-AQ) was 
synthesized by reacting compound 55 with DOTA-tri-tBu-ester in DMF along with 
the in situ coupling agents: TBTU/HOBT and DIPEA. After purification by column 
chromatography the Fmoc-protecting group was removed by treating the 
compound with piperidine in DMF at rt. Reaction progress was monitored by TLC 
analysis and on reaction completion the crude product was purified by column 
chromatography. The dried sample was re-dissolved in a slightly polar solvent 
system containing 5% MeOH in DCM. The same solvent system was used to elute 
the front running impurities. The major product was then eluted by gradually 
increasing the polarity of the solvent system (up to 10% MeOH in DCM). The yield 
of the sample was found to be 28%. The purity of the product 56 was found to be 
90% determined via analytical HPLC performed on a Shimadzu Prominence system 
equipped with UV-Vis detector using an eclipse XDB-C18 RP column. The product 
56 was also characterized by high resolution ESI (+) mass spectrometry, which 
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gave a signal at m/z 1059.6071 (M+Na)+ corresponding to a molecular mass of 
1036 (figure 55) and the low resolution ESMS(+) gave a signal at m/z 519 
[(M+2H)/2]2+; ESMS (-) mass spectrometry gave a signal at m/z 1035 (M-H)- 
corresponding to the proton abstraction product.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: Mass spectrometry result for compound 56. 
IV. Synthesis of H2N-Lys(DOTA)-Spacer-AQ (Compound 57) 
 
The tert-butyl protected compound (56) was deprotected using trifluoroacetic 
acid. Reaction progress was monitored by TLC analysis, and on completion the 
residual TFA was evaporated under reduced pressure. The purity of the product 
57 was found to be 95% determined via analytical HPLC performed on a Shimadzu 
Prominence system equipped with UV-Vis detector using an eclipse XDB-C18 RP 
column. The deprotected product 57 was characterized by high resolution ESI (-) 
mass spectrometry, which gave a signal at m/z 867.4259 (M-H)- corresponding to 
a molecular of 868 (figure 56).  
(M+Na)
+
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Figure 56: Mass spectrometry result for compound 57. 
 
 
The low resolution ESMS (+) mass spectrometry, which gave a signal at m/z 869 
(M+H)+ corresponding to a molecular mass of 868 and also a signal at m/z 435 
[(M+2H)/2]2+. 
 
V. Synthesis of H2N-Lys(DOTA-Gd3+)-Spacer-AQ (Compound 58) 
 
 
Synthesis of the target gadolinium complex of DOTA-Lysine-aminoanthraquinone 
spacer conjugate (58) was performed in accordance to the reaction conditions 
mentioned in scheme 7. The Gd complex was prepared in a neutral aqueous 
solution by reacting GdCl3(6H2O) with compound 57. The reaction pH was adjusted 
to 7 by adding a solution of ammonia 0.35% drop wise. Reaction progress was 
monitored by TLC analysis and the crude product was purified by column 
(M-H)
-
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chromatography. During purification it was observed that the compound was found 
to have very high affinity to the silica gel in the column and even by increasing the 
polarity of the eluting solvent system it failed to move through the silica gel. The 
silica slurry from the glass column was collected and washed several times with 
10% methanol in DCM to collect the sample. The filtered solution was dried at rt 
and then characterized by low resolution ESMS (+) mass spectrometry, which gave 
a signal at m/z 1024 (M+H)+ corresponding to a molecular mass of 1023; ESMS 
(-) mass spectrometry gave a signal at 1022 (M-H)- corresponding to the proton 
abstraction product and also a signal at m/z 1057 for the chloride adduct (M+Cl)- 
2.1.2.2.2. Synthesis of JS-Lysine series of tetra peptide substrates   
The design template for the JS lysine series was Fmoc-AA3-AA2-AA1-Lys(DOTA-
Gd)-Spacer-AQ, where AA represents amino acid. The synthesis of the JS-Lysine 
series of tetra peptide substrates is shown in an abbreviated form in scheme 7. 
The tripeptide sequence corresponding to positions P1, P2 and P3 were synthesized 
via SPPS. A NovoSyn®TGT resin preloaded with asparagine was used for SPPS 
because the peptide chain can be cleaved from the resin by treatment with 5% 
TFA in DCM. This is vital because higher concentration of TFA could cause the 
removal of the side chain protecting group from Asn before the synthesis of the 
target compound. Moreover, unprotected Asn could undergo a dehydration 
reaction on the free primary amide causing it to form a nitrile group. 
 
Table 9: List of tetra peptide sequence for JS-lysine series. 
 
This dehydration reaction could modify the structure of Asn in the final compound 
thus making it unproductive as the enzyme can only recognize and cleave at the 
Comp. 
no. 
P3 P2 P1 P1’  
 
 
 
 
 
62 Fmoc-
Pro 
Gly Asn Lys-(DOTA-
Gd) 
66 Fmoc-β-
Ala 
Gly Asn Lys-(DOTA-
Gd) 
70 Fmoc-
Pro 
Ala Asn Lys-(DOTA-
Gd) 
74 Fmoc-β-
Ala 
Ala Asn Lys-(DOTA-
Gd) 
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carboxyl end of asparagine. This JS-lysine series of compounds included the 
selection as shown in table 9.  
A. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-Gd3+)-Spacer-AQ 
(Compound 62) 
I. Synthesis of Fmoc-Pro-Gly-Asn(Trt)-OH (Compound 59) 
 
An asparagine pre-loaded resin was reacted in cycles of coupling and deprotection 
with Fmoc protected amino acids in the following order: N-Fmoc-Glycine and N-
Fmoc-L-Proline. After the final coupling, the peptide sequence was removed from 
the resin using trifluoroacetic acid (5%) in DCM. Analytical HPLC was performed 
on a Shimadzu Prominence system equipped with UV-Vis detector using an eclipse 
XDB-C18 RP column and the purity of the sample was found to be 70% and the 
yield was 75%. Product 59 was characterized by high resolution ESI (+) mass 
spectrometry, which gave a signal at m/z 751.3120 (M+H)+ corresponding to a 
molecular mass of 750. 
II. Synthesis of Fmoc-Pro-Gly-Asn(Trt)-Lys(DOTA-tBu)-Spacer-AQ 
(Compound 60) 
The tert-butyl protected aminoanthraquinone-tetra peptide sequence (60) was 
synthesized by treating the tri-peptide sequence (59) with compound 56 in DMF 
along with the coupling agents TBTU, HOBt and DIPEA (scheme 7). The crude 
product was purified by column chromatography. The yield after column 
chromatography was found to be 43%. 
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The compound 60 was characterized by low resolution ESMS (+) mass 
spectrometry, which gave a signal at m/z 1769 (M+H)+ corresponding to a 
molecular mass of 1770 and also a signal at m/z 885 [(M+2H)/2]2+; ESMS (-) 
mass spectrometry gave a signal at m/z 1803 corresponding to the chloride adduct 
(M+Cl)-. 
 
III. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-OH)-Spacer-AQ 
(Compound 61) 
  
The γ-trityl and tert-butyl protected aminoanthraquinone-DOTA-tetra peptide 
conjugate (60) was deprotected using trifluoroacetic acid (scheme 7). Reaction 
progress was monitored by TLC analysis, which showed the presence of a single 
new component lying close to the base line indicating the polar nature of the 
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deprotected product. The deprotected product was deemed sufficiently pure (by 
TLC) to be used without further purification and the yield of the crude sample was 
80%. The deprotected product 61 was characterized by low resolution ESMS (+) 
mass spectrometry, which gave a signal at m/z 1359 (M+H)+ corresponding to a 
molecular mass of 1358 and also a signal at 680 [(M+2H)/2]2+ and another signal 
at 1381 corresponding to the sodium adduct (M+Na)+; ESMS (-) mass 
spectrometry gave a signal at 1357 (M-H)- corresponding to the proton abstraction 
product.  
IV. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-Gd3+)-Spacer-AQ 
(Compound 62) 
 
Synthesis of the target gadolinium complex of DOTA-tetrapeptide-amino 
anthraquinone spacer conjugate (62) was performed in accordance to the reaction 
conditions mentioned in scheme 7. The Gd complex was prepared in a neutral 
aqueous solution by reacting GdCl3(6H2O) with compound 61. The reaction pH was 
adjusted to 7 by adding a solution of ammonia 0.35% drop wise. Reaction progress 
was monitored by TLC analysis. On completion the reaction mixture was reduced 
to low volume and then purified by column chromatography. Analytical HPLC was 
performed on a Shimadzu Prominence system equipped with UV-Vis detector using 
an eclipse XDB-C18 RP column and the purity of the sample was found to be 45%. 
The product 62 was characterized by high resolution ESI (+) mass spectrometry, 
which gave a signal at m/z 1514.5264 (M+H)+ corresponding to a molecular mass 
of 1513 and also a signal at m/z 1536.5082 corresponding to the sodium adduct 
(M+Na)+ (figure 57). A signal at m/z 779 [(M+2Na)/2]2+ was observed on the low 
resolution ESMS(+). 
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Figure 57: Mass spectrometry result for compound 62. 
 
B. Synthesis of Fmoc-β-Ala-Gly-Asn-Lys(DOTA-Gd3+)-Spacer-AQ 
(Compound 66) 
 
 
The chemical synthesis of compound 66 was similar to compound 62. The only 
difference was that proline at P3 was swapped for β-alanine and the rationale for 
this change has already been discussed in section 2.1.1.3. The coupling and 
deprotection methods and the reagents were the same as summarized in scheme 
(M+Na)
+
 
(M+H)
+
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7. The Gd complex was prepared in a neutral aqueous solution by reacting 
GdCl3(6H2O) with the intermediate compound 65. The reaction pH was amended 
to 7 by adding a solution of ammonia 0.35% drop wise. Reaction progress was 
monitored by TLC analysis. On reaction completion the residual solvent was dried 
at rt. A white precipitate was found along with the dry sample and hence water 
was added to remove the salt like deposits, which may be due to the use of 
ammonia in the reaction mixture. The solution was found to contain a few un-
dissolvable particles and hence on filtering the mixture it was decided to 
characterize both separately. The yield was found to be 33%. Low resolution ESMS 
mass spectroscopy on the red solution gave required peaks and hence it was 
decided to evaporate the filtered solution. It was also observed that the 
precipitates collected during filtration were not dissolvable in most solvents and 
hence it was left aside for further analysis. The dried solution was then 
characterized by low resolution ESMS (+) mass spectrometry, which gave a signal 
at m/z 1533 (M+2Na-H)+ corresponding to a molecular mass of 1487 and also a 
signal at m/z 1520 (M+CH3OH+H)+.  
 
C. Synthesis of Fmoc-Pro-Ala-Asn-Lys(DOTA-Gd3+)-Spacer-AQ 
(Compound 70) 
 
The chemical synthesis of compound 70 was similar to compound 62. The only 
difference was that glycine at P2 was swapped for alanine and the rationale for 
this change has already been discussed in section 2.1.1.3. The coupling and 
deprotection methods and the reagents were the same as summarized in scheme 
7. The target compound 70 was characterized by low resolution ESMS (+) mass 
spectrometry, which gave a signal at m/z 1528 (M+H)+ corresponding to a 
molecular mass of 1527 and also a signal at m/z 1550 corresponding to the sodium 
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adduct (M+Na)+. Signal at m/z 764.7751 [(M+2H)/2]2+ (figure 58) was observed 
on as high resolution ESI (+) mass spectrometry. The yield of the post column 
chromatographic product was 29%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: Expansion of ESI (+) spectrum of compound 70 that shows the isotopic 
pattern of the molecular ion (doubly-charged at half-mass). 
 
 
D. Synthesis of Fmoc-β-Ala-Ala-Asn-Lys(DOTA-Gd3+)-Spacer-AQ 
(Compound 74) 
 
 
 
The chemical synthesis of compound 74 was similar to compound 66. The only 
difference was that glycine at P2 was swapped for alanine and the rationale for 
choosing this amino acid has already been discussed in section 2.1.1.3. The 
coupling and deprotection methods and the reagents were the same as 
summarized in scheme 7. Analytical HPLC was performed on a Shimadzu 
[(M+2H)/2]
2+
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Prominence system equipped with UV-Vis detector using an eclipse XDB-C18 RP 
column and the purity of the sample was found to be 65%. The target compound 
74 was characterized by high resolution ESI (+) mass spectrometry, which gave 
a signal at m/z 1502.5225 (M+H)+ (figure 59) corresponding to a molecular mass 
of 1501. A signal at m/z 1524 corresponding to the sodium adduct (M+Na)+ and 
another signal at m/z 751 [(M+2H)/2]2+ was observed on the low resolution ESMS 
(+) mass spectrometry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59: Expansion of the ESI (+) mass spectrum of compound 74 that shows the 
isotopic pattern of the molecular ion. 
 
2.1.2.3. Legumain activity assay for JS series 
 
 
 
 
 
 
Figure 60: Assay conditions for JS series of compound. 
The legumain activity assay was performed to analyse if the compounds of the JS 
library (linear and lysine series) were recognized by legumain. The contrast agent 
conjugated tetra peptide compounds (49, 53, 62, 66, 70 and 74) were incubated 
(M+H)
+
 
Final volume in each eppendorf: 600µL 
 
 Assay buffer: 352.3µL 
 Substrate: 7.7µL 
 rh Legumain: 240µL 
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with activated legumain in sterile eppendorf tubes individually (figure 60). The 
volume in each tube was set to 600μL to reduce any purification and 
characterization difficulties due to volume. After two hours of incubation with 
activated legumain at 37°C, the enzyme digested product was basified using 
triethylamine and then extracted into chloroform and washed with water. This was 
done several times and the organic extracts were collected and combined. Both 
organic/aqueous extracts were dried at room temperature. The dried products of 
each sequence were then characterized by both low and high-resolution mass 
spectrometry to identify the molecular mass of the fragmented compound.   
2.1.2.3.1. Mass spectrometric results for compound 49 (JS-linear series) 
Figure 61: Schematic representation of compound 49 (JS-linear series) before and after 
enzyme assay. 
Compound 49 was incubated with activated legumain and the expected result is 
shown in figure 61. Mass spectrometric analysis on compound 49 was undertaken 
to identify the presence of molecular masses 468.25 (fragment without gadolinium 
complex) and 840.22 (fragment with gadolinium complex).  From the low-
resolution mass spectrometric analysis (ESMS), it was shown that the compound 
had been cleaved by legumain producing the required mass 841.4 (M+H)+ 
corresponding to a molecular mass of 840 as well as its sodium 863.2 (M+Na)+ 
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and potassium 880.6 (M+K)+ adduct. Negative mode ionization (low-resolution 
MS) for compound 49 also revealed the presence of the fragment with the 
gadolinium complex with the corresponding signals: 840 (M)-, 875.6 (M+Cl)-, 
886.6 (M+FA-H)-, 954.8 (M+TFA-H)- and also the fragment without the gadolinium 
complex was observed with the signals for 467 (M-H)- corresponding to a mass of 
468 as well as the chloride adduct 503 (M+Cl)-, and also 511.2 (M+FA-H)-. 
However, in contrast to the low-resolution mass spectrometry, the high-resolution 
mass spectrometry (ESI) analyzed by +ve MALDI using alphacyan 
hydroxycinnamic acid and DCTB matrices (targeting the peptide and organo-
metallic portions for ionization) did not yield the appropriate molecular ions using 
either matrix. At the same time, the high-resolution ESI-MS results did not show 
the presence of the intact compound suggesting that the tetra peptide sequence 
could have been cleaved by legumain. These results suggest the need for a better 
purification technique to isolate the enzyme-digested product.  
 
2.1.2.3.2. Mass spectrometric results for compound 70 (JS-lysine series) 
Similarly, low-resolution mass spectra for compound 70 also gave peaks 
corresponding to both the fragments. Compound 70 was analyzed for the presence 
of molecular masses 522.20 (fragment without gadolinium complex) and 1024.34 
(fragment with gadolinium complex) (figure 62). The low-resolution mass 
spectrum suggested that the compound had been cleaved by legumain producing 
the required signal at 511 [(M+2H)/2]2+ corresponding to a molecular mass 1024. 
Negative mode of ionization (low-resolution MS) for compound 70 also indicated 
the presence of the fragment with the gadolinium complex with the corresponding 
signals: 1023 (M-H)- and 1059 (M+Cl)- and also the fragment without the 
gadolinium complex with the peak for 521 (M-H)- corresponding to a molecular 
mass 522. However, the high-resolution mass spectrometric (ESI) results 
conflicted with the low-resolution mass spectrometric (ESMS) results.  For ESI the 
compound (70) was dissolved in Methanol and analyzed by nanospray on the 
Orbitrap, but did not yield the appropriate molecular ions. But the ESI mass 
spectrometric results showed no signals relating to the molecular mass of the 
intact compound, suggesting that the tetra peptide sequence was cleaved by 
legumain. Similar results were observed for compounds 62, 66, 74 and 53 
confirming the fragmentation of the peptide sequence by the enzyme but lacking 
confirmation of the presence of required molecular masses.  
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Figure 62: Schematic representation of compound 70 (JS-lysine series) before and after 
enzyme assay. 
From the results obtained it can be suggested that the compounds synthesized 
had been fragmented by legumain. This could be indicated by the presence of 
peaks corresponding to the enzyme-digested product, with and without the 
contrast agent (Gd-DOTA), spotted on the low-resolution mass spectrometric 
report. However, the high resolution ESI mass spectrometric analysis failed to 
show the presence of peaks relating to the enzyme digested product. This result 
may suggest that the enzyme could have hydrolysed the compounds (JS series) 
but the need for a better purification technique prior to mass spectrometric 
analysis was necessary. Some of the most commonly used methods for clean up 
to prepare a sample for analysis post enzyme assay are reversed-phase 
chromatography in a pipet tip (ziptips), spin column (ultramicrospin columns) or 
spring column setup (Sep-Pak cartridges) (Gundry et al. 2010).   
2.1.2.4. Cytotoxicity assay 
Studies on the ‘drug-like’ properties of newly synthesized chemical compounds, 
during the process of drug development, are important in order to avoid any drug 
failures during clinical trials (Hamid et al. 2004). Evaluation of toxicity of a drug 
candidate in different human cell lines is vital for its potential use as an imaging 
agent for biomedical studies (Chen et al. 2014). This can be performed using in 
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vitro cytotoxicity assays, which are available commercially and make the process 
of screening numerous drug libraries easy and quick. Cell viability and proliferation 
can be evaluated by a number of methods that can measure various cellular 
responses and effects (Cook and Mitchell 1989). The common assays to study in 
vitro toxicity are lactate dehydrogenase (LDH) release (Decker and Lohmann-
Matthes 1988), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT) metabolism (Mossmann 1983); neutral red uptake (Morgan et al. 1991) and 
adenosine triphosphate (ATP) content (Crouch et al. 1993).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63: Scheme depicting the conversion of MTT to the metabolized formazan product.  
Most modern assays have been adapted for microtiter plates (for example, 96 well 
plates) and these miniaturizations conveniently allow more than one sample, at a 
time, to be examined easily and quickly (Weyermann et al. 2005). Assays based 
on traits such as luminescence and colorimetric measurements allow samples to 
be assayed directly in a microtiter plate using an ELISA plate reader. In this 
research project, cytotoxicity was determined using the MTT assay. It is one of the 
most widely used techniques in the investigation of a compound’s toxicity mainly 
due to its simple, quick, sensitive and semi-automated characteristics (Mossmann 
1983; Denziot and Lang 1986).  MTT is a water-soluble tetrazolium salt, which 
when added to viable proliferating cells is reduced to insoluble purple formazan 
crystals (figure 63). These purple crystals are formed by the cleavage of the 
tetrazolium ring due to the presence of succinate dehydrogenase in the 
mitochondria of living cells (Fotakis and Timbrell 2005). The MTT metabolite 
formazan, which is impermeable to the cell membrane, accumulates in viable cells 
(Berridge and Tan 1992). This accumulation allows the formazan crystals to be 
solubilized and facilitates their quantification by spectrophotometry (Barron et al. 
2010). The absorbance value recorded is directly proportional to the number of 
viable cells (Isobe et al. 2001; Pozzolini et al. 2003).    
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2.1.2.4.1. MDA-MB-231 Cells 
Human breast epithelial cancer (MDA-MB-231) cells were isolated from a sample 
of pleural effusion taken from a patient who was undergoing a radical mastectomy 
in the early 1970s (Cailleau et al. 1974). MDA-MB-231 cells demonstrate invasive 
properties and are commonly used as a model for estrogen receptor negative 
breast cancer with a function in the evaluation of tumorigenicity, metastasis and 
cell invasion. These cells are categorized as triple negative/basal-B mammary 
carcinoma cells (Tate et al. 2012). The in-house MDA-MB-231 cells were selected 
for the MTT assay due to their immortal and proliferative nature and also to 
determine the effect of the synthesized compound on cell viability (Kong, personal 
communication).    
2.1.2.4.2. Cytotoxicity studies in MDA-MB-231 cells 
Figures 64, 65, 66 and 67 show the cell viability (%) of MDA-MB-231 cells when 
treated with compounds-62, 66, 70 and 58 (0-40μM) after 24 and 72 hours by 
using the MTT assay. 
 
 
 
  
 
 
 
 
 
 
 
Figure 64:  Cell viability of 62 in MDA-MB-231 cells after 24 and 72 hours at 37°C. Data 
are represented as mean ± SEM of 3 independent experiments (n=3), each 
experiment consisted of 6 replicates/concentration.   
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Figure 65: Cell viability of 66 in MDA-MB-231 cells after 24 and 72 hours at 37°C. Data 
are represented as mean ± SEM of 3 independent experiments (n=3), each experiment 
consisted of 6 replicates/concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66: Cell viability of 70 in MDA-MB-231 cells after 24 and 72 hours at 37°C. Data 
are represented as mean ± SEM of 3 independent experiments (n=3), each experiment 
consisted of 6 replicates/concentration. 
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Figure 67: Cell viability of 58 in MDA-MB-231 cells after 24 and 72 hours at 37°C. Data 
are represented as mean ± SEM of 3 independent experiments (n=3), each experiment 
consisted of 6 replicates/concentration. 
The results showed that 62, 66, 70 and 58 did not affect cell viability even at 
higher concentrations (up to 40μM) in MDA-MB-231 cells. Though compound 62 
did not affect cell viability, the values suggest a small variation between the 
experiments which may be due to experimental errors and hence the MTT assay 
for compound 62 should be repeated. Data for compound 58 which represents the 
part of the peptide sequence with the gadolinium chelate (contrast agent) released 
after the intact compound (for example, 62) was treated with legumain suggest 
that it does not affect cell viability. It can be concluded that the compounds 
synthesized during this research program were found not to affect cell viability of 
MDA-MB-231 cells. In similar work on synthesizing a peptide based MRI contrast 
agent and a fluorescent probe to detect legumain activity in tumors, Chen and 
colleagues (2014) have demonstrated that the MRI contrast agent of the structure 
Gd-NBCB-TTDA-Leg(L) and a fluorescent probe of structure CyTE777-Leg(L)-
CyTE807 were non-toxic to CT-26 and 3T3 cell lines. Similarly, the results of the 
MTT assay in this study have demonstrated that both the intact compounds (62, 
66, 70) and the paramagnetic gadolinium complex (58) which will be released 
upon cleavage by legumain, were found not to affect the viability of MDA-MB-231 
cells and hence can be used for further drug development as a diagnostic tool for 
atherosclerosis plaques.   
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2.1.3. Conclusion  
The last decade has seen a steady increase in the knowledge and understanding 
of legumain expression and activity leading to progression of atherosclerotic 
plaques. Evidence suggested that legumain was directly or indirectly involved in 
plaque progression either by ECM disruption in an uncontrolled manner or by 
activation of other proteases such as MMP-2 or cathepsin which also degraded the 
ECM. Moreover, it was also discussed that legumain showed strict specificity 
towards asparagine and was active only under acidic to near neutral pH. Hence 
any diagnostic interventions by exploiting these up-regulated legumains in 
identifying and treating atherosclerotic plaques would be beneficial. 
From the information available on legumain substrate specificity a library of FRET 
peptide compounds were designed. By utilizing the principle of FRET, which is 
based on the transfer of energy between a donor (5(6)-CBF) and acceptor (AQ) 
within close proximities a library of tetra peptide substrates (JC series) were 
synthesized in such a way that they had substrate specificity for legumain. The JC 
series of compounds was synthesized via a combination of both solid and solution 
phase peptide chemistry. Fluorophore quenching studies on selected compounds 
(11 and 31) demonstrated no release of fluorescence from the compounds in the 
absence of the enzyme (legumain) suggesting that they could be effective FRET 
compounds for legumain assay. In another study on FRET probes for detecting 
legumain activity, it was demonstrated that proline, glycine and asparagine at P3, 
P2 and P1 position of the peptide sequence produced results similar to the 
commercial available legumain substrate Z-Ala-Ala-Asn-AMC (Ding, 2014). Hence 
when the compounds from the JC library were incubated with activated legumain, 
a gradual increase in fluorescence release was recorded over time. This could have 
been due to the hydrolysis of the peptide substrate leading to the increase in 
distance between the FRET pair. The results demonstrated that some of the FRET 
peptide substrates synthesized during the study were recognizable by legumain. 
Results from the legumain assay further suggested that the second batch of JC 
compounds having lysine at P1’ was better substrate than the first batch of 
compounds which had leucine at that position. This result was also supported by 
the experiments conducted by Schwars et al. (2002) who showed that leucine at 
P1’ was less effective compared to lysine. Moreover results from the legumain 
assay also suggested that the preference for glycine at P2 was favourable over 
alanine. Finally compound 46 which was a penta-peptide was also found to be 
recognized by legumain by generating a maximum fluorescence intensity released 
between 800 to 1200 RFI which was comparable with compound 11. This result 
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suggested that the length of the peptide sequence has no effect on legumain 
specificity towards the peptide substrate. Although the results from the legumain 
assay demonstrate that the FRET peptide substrates were recognized by the 
enzyme there is a need for improvement in the purity of the compounds. This can 
be achieved by purifying the compounds by preparative HPLC, which could be an 
important technique to inform about the purity of the target compounds.      
The sequence design of the JC series of compounds was utilized as a model for 
synthesizing the library of JS compounds. This series of compounds comprised of 
a tetra peptide sequence (mimicking the JC library) covalently coupled to the MRI 
contrast agent (Gd-DOTA). This design was undertaken in order to achieve the aim 
of this research project, which focuses on the synthesis of a non-invasive contrast 
agent for imaging atherosclerotic plaques. The design of the JS series of 
compounds was based on the concept that enzyme cleavage of the peptide 
substrate may lead to the release of the CA and also enhance the hydrophobicity 
of the CA. Accumulation of the CA at the site of activation could improve the 
contrast of the surrounding region leading to better image resolution of the 
atherosclerotic plaques. The JS series of compounds were incubated with the 
activated enzyme (legumain) and the enzyme-digested product was characterized 
via mass spectrometric analysis. The results of the legumain assay demonstrated 
that the activated enzyme fragmented the peptide substrates. However, as 
mentioned in the previous paragraph, it is suggested that the target compounds 
have to be purified by preparative HPLC. In this manner, the success of the 
enzyme-substrate assay can be strictly related to the design of the compounds.   
Evaluating the cytotoxicity of a chemical drug is an important factor for using them 
in biomedical studies. Selected compounds (62, 66, 70 and 58) from the JS series 
were evaluated for cytotoxicity against MDA-MB-231 cells. The results of the 
toxicity assay demonstrated that the compounds did not affect the viability of the 
cells even at higher concentrations of the drug (40μM). However the need for a 
control to compare the results obtained is desirable. It could be suggested that 
these compounds may form a new platform of targeted contrast agents for imaging 
atherosclerotic plaques via the application of MRI by specifically targeting the 
biomarker over expressed in the plaque regions. Thus in this research study MRI 
contrast agent (Gd-DOTA) conjugated to peptide substrates specific to legumain 
that is over expressed in unstable atherosclerotic plaques have been successfully 
synthesized and characterized by spectroscopic analysis.  
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2.1.4. Limitations  
The main limitation of this work was the purity of the peptide sequences 
synthesized via SPPS. The purity of the compounds ranged between 44-80% 
(synthesized via SPPS) and the purity of the target compounds synthesized via 
fragment condensation and solution peptide synthesis ranged from 60-97%. Hence 
purification of the peptide substrates by preparative HPLC would be desirable. 
Another problem to explore during the fragment condensation technique is 
racemization of the amino acid residues. Racemization is a serious issue as it is 
not easy to detect and more importantly difficulties arise trying to separate 
residues containing R-amino acids from the S-amino acids. Though racemization 
suppressants such as HOBt were used during the synthesis process, it must be 
agreed that there is always a risk for racemization to occur during fragment 
condensation technique. However racemization cannot occur if the synthesis of the 
peptide chain proceeds from the C-terminal end, because the carboxyl group is 
protected by an unreactive group (Doonan 2002). Also, choosing appropriate 
amino acid residues at the C-terminal position during fragment condensation can 
also prevent racemization. This can be done by choosing glycine at the C-terminus 
since it is the only amino acid that lacks a chiral carbon and hence the formation 
of azlactone which is the main route to racemization by carboxyl activation is 
prevented (Nyfeler 1994). Proline can also be used at the C-terminus because the 
structure of proline provides resistance to base-catalysed racemization (Jones 
1992).  
The other limitation regarding the JS series of compounds was that the purification 
of the enzyme digest product did not show the presence of the required molecular 
mass of the product on high resolution mass spectrometry. This highlights the 
need for another purification technique besides the conventional solvent extraction 
method followed during the study. The process of purification is important to desalt 
and concentrate peptide mixtures before any analysis by mass spectrometry 
because these impurities may hinder peptide ionization and cause chemical noise 
in the mass spectra (Gundry et al. 2009). Some of the most commonly 
recommended methods are reverse phase chromatography in a pipet tip (Ziptip), 
spin column or syringe column format (SPE-solid phase extraction columns). For 
example, RP-SPE columns consist of a non-polar stationary phase and a 
moderately polar mobile phase can be used. The solution containing the analyte 
of interest is poured through the column and the interaction between the sample 
and the hydrophobic functional group on the silica surface causes retention of the 
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analyte in the column. The sample can then be eluted by using a non-polar solvent 
which breaks the interaction between the sample and the column. Similarly other 
separation methods based on charge (ion exchange chromatography), molecular 
size (gel chromatography), and specific binding group (affinity chromatography) 
can also be performed to address the problems encountered during analysis of the 
enzyme digest product in this research study. 
2.1.5. Future work   
Further work on the determination of the efficacy of the substrates (JS library) 
towards legumain is desirable. Upon determining the efficacy of the peptide 
substrate-contrast agent conjugates synthesized during this research study, they 
may then be utilized as powerful tools for the evaluation of atherosclerotic plaques. 
Furthermore, analysis on the release of the contrast agent in human 
atherosclerotic tissue extracts could be the next step in exploiting these 
compounds for in vivo imaging. Moreover, coupling these imaging units to 
therapeutic drugs could open a new approach for delivering drugs selectively to 
the diseased tissue and concurrently monitoring treatment progress and side 
effects.  
These small sized molecules (JS series) consisting of a plaque recognizable unit 
and a gadolinium chelate could benefit from easy and quick endocytosis by the 
plaques, fast blood clearance leading to excretion of the toxic metal ion and the 
reproducible nature of these substrate based contrast agents will be one of the key 
features for transition from lab to clinical analysis (Sosnovik and Caravan 2009). 
However, one major drawback with such small sized imaging molecules is that the 
biomarkers (legumain) around the microenvironment of the abnormal tissue are 
expressed in submicromolar levels. In order to produce signal enhancement the 
need for a self-assembly approach with multiple (1000s) gadolinium chelates along 
with a plaque recognizable unit is desirable. 
The substrate based probes synthesized during this research study could be used 
as prototypes to design activity based probes (ABPs) which function by covalently 
altering the proteases in an activity dependent manner (Edgington et al. 2011). 
These probes could be used for live cell imaging as the ABPs remains attached to 
the target biomolecule allowing dynamic analysis on enzyme function and 
localization. Furthermore the synthesized peptide substrates could be manipulated 
in such a way as to be used as dual imaging agents via the application of both MRI 
and optical imaging. The dual probe system could be designed to carry a FRET pair 
along with a contrast agent covalently coupled to the side chain of an amino acid 
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residue on a peptide sequence engineered to be specific to the protease/enzyme 
of interest (Puthenedam 2010). Finally, more biological analysis to understand the 
turnover kinetics and to evaluate the intercellular contrast agent release properties 
of the chemical compounds, along with cytotoxic studies (MTT, LDH, ATP content 
evaluation) on human tissue extracts of atherosclerotic lesions is desirable. This 
can be achieved by developing optimized assay conditions for treating legumain 
expressing cell lines such as HEK293 cells and HCT116 colorectal cells known for 
expressing active legumain (Smith 2014) with the synthesized chemical 
compounds.  
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2.2. MMP (2/9) targeted gadolinium based contrast agents for MR 
imaging of atherosclerotic plaques  
The aim of this part of the research study was the synthesis of contrast agents, 
which exhibited specificity towards enzymes/proteases that are overexpressed in 
atherosclerotic plaques. The production of excellent MRI contrast between the 
normal and diseased region depends on endogenous variances in water content 
and relaxation time of the CA. Several non-specific contrast agents are widely used 
for examining physiological parameters in clinical applications (Mishra et al. 2006; 
Calcagno et al. 2013). However, when it comes to monitoring specific 
functions/irregularities, the need for a functionalized/targeted CA is essential 
(Mishra et al. 2006) as in the case of atherosclerotic lesions. In order to achieve 
this (target specific/activatable CA’s), biomolecules could be conjugated to the 
gadolinium chelates (Gd-DTPA/Gd-DOTA). These targeted CAs could potentially be 
used to image pre-rupture atherosclerotic plaques by detecting the specific 
enzyme/ protease concentrated in the shoulder region of the plaques via a MRI 
scanner. The targeted CAs are said to localize to the target molecules of interest 
with great specificity and affinity, ultimately increasing the diversity of MR 
applications (Mishra et al. 2006). The targeted contrast agents can further increase 
the relaxation time by binding to specific targets (protein/enzyme) and inducing 
water proton relaxation rate enhancement (Caravan et al. 1999).  
Gadolinium based contrast agents with MMP recognizable substrates were 
synthesized potentially to increase sensitivity and delay blood clearance time 
assisting in accumulation of the CA at the site of activation. Upon activation by the 
specific MMP (2/9); these CA’s produce signal amplification by increasing the rate 
of relaxation of the surrounding water protons at the site of activation (Lepage et 
al. 2007). Chen and colleagues (2005) in their studies on the detection of MMP 
activity in atherosclerotic plaques successfully synthesized a fluorogenic probe to 
monitor protease activity via the application of optical imaging. The probe 
consisted of a peptide substrate cleavable by MMP-9, which was conjugated to a 
fluorophore (FITC). The probe was injected into mice, which suffered an induced 
infarction. The images obtained, highlighted the affected areas due to the 
accumulation of the fluorogenic probe when compared to the control. A similar 
kind of probe was used to detect gelatinase (MMP-2/9) activity in the aorta of Apo 
lipoprotein (ApoE-/-) deficient mice with atherosclerotic lesions. This probe 
produced fluorescence in the presence of the protease confirming MMP activity 
(Deguchi et al. 2006). In another study based on detecting protease activity in 
human atheromas, the authors were able to demonstrate the overexpression of 
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MMP-9 in atherosclerotic plaques using a protease sensing NIRF probe, which was 
auto-quenched at injection due to closely spaced fluorophores (FRET effect). Upon 
enzyme-specific protease driven cleavage of the substrate, the fluorophores were 
successfully dequenched and released fluorescence confirming the presence of 
MMP-9 at the site of activation (Kim et al. 2010). Furthermore, P947-a gadolinium 
based MMP activatable CA was found to produce signal enhancement via MRI of 
MMP-rich versus MMP-poor regions of a plaque. It was also demonstrated that this 
probe was not only able to detect MMPs in atherosclerotic plaques in vivo, but also 
other proteases that were overexpressed in unstable plaques (Calcagno et al. 
2013). 
Jastrzebska and colleagues (2009) were successful in synthesizing an enzyme 
activated, solubility switchable CA for detecting MMP-2 activity in vivo via the 
application of MRI. The contrast agent (Gd-DOTA) was conjugated to the N-
terminus of the peptide substrate (SPAY*YTAA) via a hydrophobic alkyl chain. The 
peptide substrate had a favorable cleavage site between Y*Y specifically for MMP-
2.  The water solubility of the intact probe was maintained by the addition of a PEG 
chain at the C-terminus of the peptide sequence as well as to lower the rate of 
elimination from the blood. The authors were able to successfully demonstrate, 
that upon cleavage by the enzyme the hydrophilic moiety (PEG chain) was 
separated from the sequence leading to the release of the contrast agent attached 
to the hydrophobic alkyl unit. This cleavage lead to retention of the contrast agent 
at the enzyme rich region for a longer time enhancing the contrast of the image 
produced. Based on this finding an attempt to synthesize a contrast agent 
covalently coupled to a peptide sequence specific to MMP (2/9) was undertaken. 
These findings suggest the application of substrate-based probes to be specific and 
efficient in detecting MMP-2/9 activity within the lesions leading to the imaging of 
atherosclerotic plaques with more accuracy and clarity.  
2.2.1. Synthesis of peptide substrates designed to be specific to MMP-2/9 
(JJ series) via solid phase peptide synthesis (SPPS) 
It is important to reduce/eliminate background noise in order to produce accurate 
MRI images of the region of interest. This can be achieved by avoiding unspecific 
binding of probes to areas around the target region. Hence by designing probes 
that are highly specific to the biomarkers (proteases/enzymes) which are 
overexpressed in the microenvironment of the disease, non-specific binding could 
potentially be reduced. Moreover, these probes should be stable and dormant until 
they reach the cells of interest and then become activated to release the carry load 
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(therapeutic/prognostic agent). In this section of the research study, emphasis 
towards the synthesis of peptide substrates that are highly specific to MMP-2/9 
was undertaken. In this way, the most desirable substrates for MMP-2/9 
identification can be used for imaging atherosclerotic plaques by conjugating the 
MRI contrast agents to the peptide substrates. The choice of amino acids for the 
oligopeptide sequences was based on their sequence specificity to MMP-2 and 
MMP-9 (Xu et al. 2005; Kridel et al. 2001). The P3 position of the peptide chain 
corresponding to the S3 sub-pocket of the enzyme having a hydrophobic cavity 
which created a deviation from linearity into the active site cleft. Hence this feature 
of the S3 sub-pocket was suitable for the proline residue, which had a ring 
structure that produced the bend necessary for the ideal substrate binding at this 
position (Kridel et al. 2001).  
A library of peptide substrates synthesized by Kridel and colleagues (2001) having 
arginine at P2 positon of the sequence was found to be readily recognized by MMP-
9. This was due to the hydrophilic nature of the Asp-410 side chain located in the 
S2 subsite, showing a good interaction with the guanidinium group of arginine. It 
was also found that arginine at this position was less effective with MMP-2 
recognition and also served as a significant region of differentiation between the 
two proteases which demonstrated a lot of sequence similarity (Murphy et al. 
2002). Additionally small amino acids residues such as Ser, Ala or Leu were found 
to be better tolerated at the P2 position for MMP-2. Another distinctive feature of 
MMP-2 subsite was that the presence of Ala at P3 position was significant when 
compared to proline as in MMP-9 (Chen et al. 2002). The S1 subsite was 
characterized with an extended hydrophobic surface and was found to 
accommodate a wide range of amino acids (Olson et al. 2000). However glycine 
at this position was highly favored by MMP-9/2 (McGeehan et al. 1994). The S1’ 
sub-pocket was a deep hydrophobic region and also served as another important 
substrate recognition point. This information supports the reason for the presence 
of amino acids with side chain residues such as ile, leu, nva and ala (Kridel et al. 
2002; McGeehan et al. 1994). Finally the S2’ sub-pocket was the last point of 
significant substrate recognition and interaction however interactions outside the 
significant (P3-P2’) is also common among MMP substrates. The S2’ subsite was 
found to favor amino acids residues such as val, leu and ile for MMP-2 and MMP-9 
tolerated amino acids such as ser and thr. Furthermore, information on MMP-2/9 
substrate design was discussed previously in section 1.2.5. (Table:2) which clearly 
lists the choice of amino acids for synthesizing a peptide substrate which is highly 
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specific to MMP-2/9. The JJ series of peptide substrates is shown in table 10. 
Compound 
name 
N P4 P3 P2 P1 P1’ P2’ P3’ P4’ 
75 Fmoc Ala Pro Leu Gly Ala Ser Gly  
76 Fmoc Ala Ala Leu Ala Nva Leu Gly  
77 Fmoc Lys Pro Ala Gly Nva Ala Gly  
78 Fmoc Gly Pro Arg Glu Ile Thr Ala Gly 
79 Fmoc Ile Pro Arg Thr Leu Thr Ala Gly 
80 Fmoc Gly Pro Arg Arg Leu Thr Ala Gly 
Table 10: List of amino acids for JJ series of peptide substrates. 
I. Synthesis of Fmoc-Ala-Pro-Leu-Gly-Ala-Ser-Gly-OH (75) 
 
 
 
 
 
A 2-Chlorotrityl resin preloaded with glycine was reacted in cycles of coupling and 
deprotection with Fmoc protected amino acids. The amino acids were coupled in 
the following order: N-Fmoc-L-Ser(tBu), N-Fmoc-L-Alanine, N-Fmoc-Glycine, N-
Fmoc-L-Leucine, N-Fmoc-L-Proline and N-Fmoc-D-Alanine. After the final coupling, 
the peptide sequence was removed from the resin using trifluoroacetic acid (1%) 
in DCM. The yield of the crude sample was found to be 59%. The crude product 
75 was characterized by high resolution ESI (+) mass spectrometry, which gave 
a signal at m/z 850.4349 (M+H)+ (figure 68) corresponding to a molecular mass 
of 849; low resolution ESMS (-) mass spectrometry gave a signal at m/z 848 (M-
H)- corresponding to the proton abstraction product. 
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Figure 68: Expansion of the ESI (+) mass spectrum of compound 75 which shows the 
isotopic pattern of the molecular ion. 
 
All these signals corresponded to the peptide chain with the tert-Butyl protecting 
group attached to the side chain of the serine residue. This was confirmed by low 
resolution ESMS (+) mass spectrometry on the product retreated with TFA, which 
gave a signal at m/z 816.4 corresponding to the sodium adduct (M+Na)+. ESMS 
(-) mass spectrometry also gave a signal at m/z 793 (M)- corresponding to the 
molecular mass of the peptide sequence without the tert-Butyl protecting group 
attached to the side chain of the serine residue. 
II. Synthesis of Fmoc-Ala-Ala-Leu-Ala-Nva-Leu-Gly-OH (76) 
 
Compound 76 was synthesized following a procedure analogous to compound 75. 
The amino acids were coupled in the following order: N-Fmoc-L-Leucine, N-Fmoc-
L-Norvaline, N-Fmoc-L-Alanine, N-Fmoc-L-Leucine, N-Fmoc-L-Alanine and N-
Fmoc-D-Alanine. The yield of the peptide sequence was found to be 22%. Product 
76 was characterized by low resolution ESMS (+) mass spectrometry, which gave 
(M+H)
+
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a signal at m/z (+) 836.4 (M+H)+ corresponding to a molecular mass of 835 and 
also a signal at m/z 859 corresponding to the sodium adduct (M+Na)+. 
III. Synthesis of Fmoc-Lys-Pro-Ala-Gly-Nva-Ala-Gly-OH (77) 
 
Compound 77 was synthesized following a procedure analogous to compound 75. 
The amino acids were coupled in the following order: N-Fmoc-L-Alanine, N-Fmoc-
L-Norvaline, N-Fmoc-Glycine, N-Fmoc-L-Alanine, N-Fmoc-L-Proline and N-Fmoc-
L-Lysine. The crude yield was found to be 81%. Product 77 was characterized by 
high resolution ESI (+) mass spectrometry, which gave a signal at m/z 821 (M+H)+ 
corresponding to a molecular mass of 820; low resolution ESMS (-) mass 
spectrometry displayed a signal at m/z 819 (M-H)- corresponding to the proton 
abstraction product.  
IV. Synthesis of Fmoc-Gly-Pro-Arg(Mtr)-Glu(OtBu)-Ile-Thr (tBu)-Ala-Gly-
OH (78) 
 
 
Compound 78 was synthesized following a procedure analogous to compound 75. 
The amino acids were coupled in the following order: N-Fmoc-L-Alanine, N-Fmoc-
Threonine (tBu), N-Fmoc-L-Isoleucine, N-Fmoc-L-Glutamate (OtBu), N-Fmoc-L-
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arganine (Mtr), N-Fmoc-L-Proline and N-Fmoc-Glycine. HPLC was performed on a 
Shimadzu Prominence system equipped with UV-Vis detector using an eclipse XDB-
C18 RP column. The purity of the crude sample was found to be 76% and the yield 
was 58%. Product 78 was characterized by high resolution ESI (+) mass 
spectrometry, which gave a signal at m/z 1346.6681 (M+H)+ corresponding to a 
molecular mass of 1345 and also a signal at m/z 673 [(M+2H)/2]2+; low resolution 
ESMS (-) mass spectrometry gave a signal at 1344 (M-H)- corresponding to the 
proton abstraction product.  
V. Synthesis of Fmoc-Ile-Pro-Arg(Mtr)-Thr(tBu)-Leu-Thr(tBu)-Ala-Gly-OH 
(79) 
 
 
 
 
 
 
 
 
Compound 79 was synthesized following a procedure analogous to compound 75. 
The amino acids were coupled in the following order: N-Fmoc-L-Alanine, N-Fmoc-
L-Threonine(tBu), N-Fmoc-L-Leucine, N-Fmoc-L-Threonine(tBu), N-Fmoc-L-
Arganine(Mtr), N-Fmoc-L-Proline and N-Fmoc-L-Isoleucine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69: Mass spectrometry result for compound 79. RP-HPLC elution profile of 
compound 79 (1mg/mL in acetonitrile); Conditions: Flow rate, 0.5mL/min; Detection, 
254nm; stationary phase: Eclipse XDB-C18 RP column; mobile phase A= 0.1%TFA/water; 
mobile phase B=0.1%TFA/acetonitrile; gradient: low pressure gradient; 28min. 
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HPLC was performed on a Shimadzu Prominence system equipped with UV-Vis 
detector using an eclipse XDB-C18 RP column. The purity of the crude sample was 
found to be 70% and the yield was 91%. Product 79 was characterized by high 
resolution ESI (+) mass spectrometry, which gave a signal at m/z 1374.7366 
(M+H)+ (figure 69) corresponding to a molecular mass of 1373 and also a signal 
at m/z 1396 corresponding to the sodium adduct (M+Na)+; low resolution ESMS 
(-) mass spectrometry gave a signal at 1372 (M-H)- corresponding to the proton 
abstraction product.  
 
VI. Synthesis of Fmoc-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr(tBu)-Ala-Gly-
OH (80) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 80 was synthesized following a procedure analogous to compound 75. 
The amino acids were coupled in the following order: N-Fmoc-L-Alanine, N-Fmoc-
L-Threonine(tBu), N-Fmoc-L-Leucine, N-Fmoc-L-Arganine(Mtr), N-Fmoc-L-
Arganine(Mtr), N-Fmoc-L-Proline and N-Fmoc-Glycine. HPLC was performed on a 
Shimadzu Prominence system equipped with UV-Vis detector and fluorescence 
detector using an eclipse XDB-C18 RP column and the purity of the crude sample 
was found to be 83% with a yield of 92%. Product (80) was characterized by high 
resolution ESI (+) mass spectrometry, which gave a signal at m/z 1529.7147 
(M+H)+ corresponding to a molecular mass of 1528. A signal at m/z 1551 
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corresponding to the sodium adduct (M+Na)+ and a signal at 765 (M/2+2H)2+ was 
observed on the low resolution ESMS (+) mode; low resolution ESMS (-) mass 
spectrometry gave a signal at 1527 (M-H)- corresponding to the proton abstraction 
product. 
Although substrates cleaved by gelatinases are still not fully identified, repetitive 
units with Pro-XX-Hy-(Ser/Thr), where X represents any amino acid residue and 
Hy represents a hydrophobic amino acid residue such as Ala, Ile, Leu, Val, Tyr, 
Trp, Met and Phe (Zitka et al. 2010) were found to be often cleaved by the 
protease. Peptide substrates with arginine residues were recognized by MMP-9 and 
also sequences with Gly-Leu-(Lys/Arg) were also found to be preferred by 
gelatinases (Kridel et al. 2001). Thus in accordance to the aim of this research 
study the peptide substrates were then covalently coupled to the paramagnetic 
contrast agent (Gd-DOTA). These specifically engineered contrast agents are 
anticipated to deliver the imaging agent site specifically upon cleavage by MMPs 
(2/9) potentially enhancing the underlying atherosclerotic lesion.    
2.2.2. Synthesis of Gadolinium-DOTA-Peptide substrate designed to be 
specific to MMP-2/9 
2.2.2.1. Attempted synthesis of JD-(Gd(III)-DOTA-Gly-12-
aminododecanoic acid-Ala-Ala-Leu-Ala-Nva-Leu-Gly-OH) 
Upon successful synthesis and characterization of the six-peptide substrates 
(section 3.2.1) designed to be specific to either MMP-9/2, it was decided to couple 
the substrates to the MRI contrast agent Gd-DOTA via the application of both solid 
and solution phase peptide synthesis. The synthesis of the peptide conjugated MRI 
contrast agent was undertaken in order to achieve the aim of this research study 
for specifically and accurately imaging atherosclerotic plaques. The synthesis of 
compound JD was attempted, following an adapted procedure by Jastrzebska and 
colleagues (2009). The experimental procedure was broken down to four stepwise 
processes (figure 70): 
(i) The first step was the synthesis and characterization of the Fmoc-protected 12-
aminododecanonic acid (81), a hydrophobic alkyl chain which may potentially 
increase the retention time of the contrast agent upon cleavage by MMP-9/2.  
(ii) The second step was the coupling of compound 81 to the peptide sequence 76 
after the removal of the Fmoc protecting group from the peptide sequence using 
20% Piperidine in DMF producing compound 82  
(iii) The third step was the coupling of the glycine residue to compound 82 after 
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the removal of the Fmoc protecting group from 12-Ado acid producing compound 
83.    
(iv) The intermediate compound 83 was then covalently attached to the chelating 
agent Tri-tert-butyl-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetra 
acetate(DOTA-tris[t-Bu]) (84). 
Figure 70: Step involved in the chemical synthesis of compound 84. 
 I. Synthesis of 12-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)dodeca 
noic acid (Compound 81) 
 
Scheme 8 (a): 12-aminododecanic acid, dioxane: water, 12hrs, rt. 
The synthesis of Fmoc-12-aminododecanoic acid 81 was undertaken following an 
adapted method by Espelt and colleagues (2003). This involved the reaction of 
Fmoc N-hydroxysuccinimide ester (Fmoc-OSu) and 12-aminododecanoic acid 
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(Ado) in dioxane and water (4:1) (scheme 8). After 12 hours the reaction mixture 
was concentrated and then extracted into DCM and washed with water (x3), 
saturated sodium hydrogen carbonate (x3) and dried with anhydrous magnesium 
sulphate. The organic layer thus obtained was concentrated and purified by column 
chromatography. The yield of the sample after column chromatography was found 
to be 33%. The structure of the product was confirmed by low resolution ESMS 
(+) mass spectrometry which gave a signal at m/z 438 (M+H)+ corresponding to 
a molecular mass of 437. The 1H NMR spectrum had; for example, a 14-proton 
broad singlet at 1.30ppm which was assigned to the methylene protons of the 
spacer arm numbered 3-10 (scheme 8). A 2-proton multiplet between 1.45 and 
1.52 and a 2-proton quintet signal at 1.65ppm which were assigned to CH2CH2NH 
and CH2CH2COOH respectively. A 2-proton triplet signal at 2.37ppm was assigned 
to CH2COOH and another 2-proton multiplet between 3.15 and 3.24pm was 
assigned to CH2NHFmoc. A single proton multiplet between 4.22ppm and 4.28ppm 
was assigned to the proton attached to the Fmoc protecting group and another 2-
proton multiplet between 4.42ppm and 4.47ppm was assigned to the methylene 
group protons of the Fmoc protecting group. The signals for the protons on the 
aromatic group were assigned as follows: a triplet of doublets for 2-protons at 
7.34ppm was assigned to H-2 protons. The H-3 protons gave a triplet signal at 
7.43ppm for two protons. A doublet for two protons at 7.62ppm was assigned to 
the H4 protons followed by another doublet signal at 7.79ppm was assigned to the 
H1 protons.    
II. Synthesis of H-12-aminododecanoic acid-Ala-Ala-Leu-Ala-Nva-Leu-
Gly-2-ClTrt resin (Compound 82) 
Compound 81 was coupled to compound 76 using the reagents and reaction 
conditions similar to that of coupling an amino acid via SPPS (TBTU, HOBt, DIPEA 
in DMF reacting at rt). The Kaiser test was performed to confirm the completion of 
the reaction. Subsequent Fmoc deprotection from 12-aminododecanoic acid was 
achieved using 20% Piperidine in DMF. Reaction completion was confirmed by the 
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blue color developed during the Kaiser test determining the presence of the 
primary amine.       
III. Synthesis of H-Gly-12-aminododecanoic acid-Ala-Ala-Leu-Ala-Nva-
Leu-Gly-2-ClTrt resin (Compound 83) 
Before coupling the peptide substrate to the chelating agent [DOTA-tris(tBu)], a 
glycine residue was coupled to compound 82 in order to enhance the yield and 
assist in the process of coupling the chelating agent to the alkyl unit (Jastrzebska 
et al. 2009). Therefore, compound 82 was coupled to Fmoc-protected glycine with 
the aid of coupling agents HOBt/TBTU and DIPEA in DMF and the mixture was left 
to react for two hours at rt (figure 70). The Kaiser test was undertaken to confirm 
the completion of the reaction. Upon removal of the Fmoc protecting group from 
the glycine residue, the chelating agent [DOTA-tris(tBu)] was then coupled to the 
peptide sequence.  
IV. Synthesis of HO-DOTA-Gly-12-aminododecanoic acid-Ala-Ala-Leu-Ala-
Nva-Leu-Gly-OH (Compound 84) 
The next step was the coupling of [DOTA-tris(tBu)] to compound 83 with the aid 
of coupling agents HOBt/TBTU and DIPEA in DMF for 2hrs at rt. The Kaiser test 
was undertaken to confirm the completion of the reaction. DOTA was used as the 
chelating agent in this research project because, Polyaza polycarboxylic 
macrocycles such as DOTA or 1, 4, 8, 11-tetraazacyclotetrado cane-N,N’,N’’,N’’’-
tetraacetic acid (TETA) are said to be more efficient when compared to similar but 
noncyclic chelates such as DTPA or EDTA mainly because of their kinetic inertness 
and thermo stability in vivo (Jastrzebska et al. 2009). The final cleavage of the 
resin from the sequence along with the removal of the tert-butyl protecting group 
from DOTA was achieved using the cleavage mixture containing TFA: H2O: EDT: 
TA. 1, 2-Ethanedithiol (EDT) and thioanisole (TA) were included in the reaction 
mixture in order to prevent any side chain reactions by acting as effective 
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scavengers of carbonium ions and other reactive species. The filtered solution was 
then added drop wise to diethyl ether by placing the reaction flask on ice to 
facilitate product precipitation. 
 
The crude product (84) was characterized by low resolution ESMS (+) mass 
spectrometry which gave a signal at m/z 628 [(M+2H)/2]+ corresponding to a 
molecular mass of 1253; ESMS (-) mass spectrometry displayed a signal at m/z 
1252.4 (M-H)- corresponding to the proton abstraction product and also a signal 
at m/z 1253.4 (M)- corresponding to the molecular mass of compound 84. 
However, the final step of complexing the paramagnetic metal ion to the DOTA 
construct was not possible due to the low yield of compound 84. Hence, it was 
decided to attempt another approach using an aminoanthraquinone unit for 
growing the peptide sequence-DOTA conjugate followed by complexing the metal 
ion to DOTA, via solution phase chemistry to attain a better yield.  
2.2.2.2. Synthesis of JL (Compound 87) 
Synthesis of the peptide conjugated MRI contrast agent was achieved by coupling 
peptide substrate 80 to compound 56, which was then complexed to the 
paramagnetic metal ion-gadolinium. The design for the JL-87 conjugate consisted 
of a hydrophobic amino anthraquinone moiety attached to the C-terminal of the 
peptide sequence via a short diamino chain. The rationale for this design was based 
on the concept, that upon enzymatic hydrolysis of the peptide substrate, the 
contrast agent remains attached to the hydrophobic aminoanthraquinone unit, 
which could ultimately enhance the retention time of the macrocyclic gadolinium 
complex at the site of activation. The experimental procedure was broken down to 
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three stepwise processes (scheme 9):  
 
Scheme 9: Steps involved in the chemical synthesis of compound JL-87. 
 (i) The first step involved coupling of the peptide substrate 80 to compound 56 
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to synthesize the AQ-DOTA-peptide conjugate 85. 
(ii) The next step involved the removal of the tert-butyl group from the chelating 
agent (DOTA) 86. 
(iii) The final step involved the synthesis of the target compound AQ-DOTA(Gd)-
peptide conjugate JL-87. 
I. Synthesis of DOTA-tris(tBu)-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr(OtBu) 
-Ala-Gly-Lys-Spacer-AQ (Compound 85) 
 
Compound 85 was synthesized by reacting peptide sequence 80 in DMF along with 
the in the situ-coupling agents TBTU/HOBT and DIPEA with compound 56 (scheme 
9a). Reaction progress was monitored by TLC analysis; the crude product was then 
extracted into DCM and washed with water (x3), saturated sodium hydrogen 
carbonate (x1) and evaporated to low volume. The product (85) was characterized 
by low resolution ESMS (+) mass spectrometry, which displayed a signal at m/z 
1274 [(M+2H)/2]2+ corresponding to a molecular mass of 2547 and also a signal 
at m/z 2547 (M)+ corresponding to the mass of the compound.   
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II. Synthesis of HO-DOTA-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr-Ala-Gly-
Lys-Spacer-AQ (Compound 86) 
 
The tert-butyl protected compound 85 was deprotected using trifluoroacetic acid 
(scheme 9b). Deprotection progress was monitored by TLC analysis, which showed 
the presence of a new component, with a low Rf value due to the polar nature of 
the deprotected sample. The residual TFA was evaporated under reduced pressure 
and any remaining solvent was re-evaporated with ethanol. The product (86) was 
characterized by low resolution ESMS (+) mass spectrometry, which gave a signal 
at m/z 1162 [(M+2H)/2]2+ corresponding to a molecular mass of 2323 and also a 
signal at m/z 2347 corresponding to the sodium adduct (M+Na)+.  
III. Synthesis of Fmoc-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr-Ala-Gly-Lys 
(DOTA(Gd3+))-Spacer-AQ (Compound JL-87) 
Synthesis of the target gadolinium complex of DOTA-peptide-aminoanthraquinone 
spacer conjugate JL-87 was performed in accordance to the reaction conditions 
proposed by Digilio and co-workers (2010). The Gd complex was prepared in a 
neutral aqueous solution by reacting GdCl3(6H2O) with compound 86. The reaction 
pH was adjusted to 7 by adding a solution of ammonia 0.35% drop wise (scheme 
9c). 
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Reaction progress was monitored by TLC analysis. The reaction volume was then 
reduced by evaporation at rt. The yield was found to be 56%. The product JL-87 
was characterized by low resolution by ESMS (+) mass spectrometry, which gave 
a signal at m/z 1239 [(M+2H)/2]2+ corresponding to a molecular mass of 2477 
and also a signal at m/z 2477 (M)+.  
 
2.2.3. Conclusion  
The aim of this research study was the synthesis of a library of targeted MRI 
contrast agents that could have the potential to be used as non-invasive imaging 
agents of atherosclerotic plaques. It was hoped that this could be achieved by 
exploiting the role of MMP-2/9 (generally over expression in these plaques). The 
functioning of these proteases is required for both normal physiological activities 
and is also a cause for several pathological conditions as discussed in the 
introduction. During this research study, work was focused on synthesizing a small 
library of peptide substrates designed to be specific to either MMP-2 or MMP-9. 
This was achieved by synthesizing six peptide sequences (75, 76, 77, 78, 79 and 
80) adopting solid phase peptide synthesis (McGeehan et al. 1994; Van 
Valckenborgh et al. 2005; Jastrzebska et al. 2009). The choice of amino acids for 
the peptide substrates was based on the information available from the literature 
on MMP-2/9 enzyme structure. After removal of the resin from the peptide 
sequence, the substrates were characterized by high resolution ESI mass 
spectrometry.    
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In order to complex the contrast agent, which in this study was Gadolinium with 
the oligopeptide sequences, work was undertaken to synthesize the paramagnetic 
gadolinium chelates (Gd-DOTA/ Gd-DTPA). Due to limitations such as poor 
reactivity, intramolecular cross-linking producing less stable chelation sites, along 
with clinical conditions such as nephrogenic systemic fibrosis (NSF-caused in renal 
impaired patients due to the use of Gd-DTPA for MRI scans) it was decided to use 
DOTA as the chelating agent in this research study. DOTA is one of the most stable 
lanthanide complexes. It is known for its solid rigidity, symmetric nature and 
kinetic inertness (Locin et al. 1986). Hence the chance of dissociation of the metal 
ion from the complex was found to be much less even at low pH, post injection 
(Wang et al. 1992; Bousquet et al. 1988; Lauffer 1987). 
Considering the advantages of DOTA as the ligand of choice an attempted 
synthesis of Gd-DOTA-peptide substrate was undertaken by conjugating the 
peptide sequence (76) to a hydrophobic alkyl chain (12-aminododecanoic acid) 
Ado (8). This was done in order to decrease the solubility of the complex after 
being cleaved by the target MMP. This sequence was then coupled to DOTA via a 
glycine residue followed by the coupling of DOTA. Due to the low yield and 
difficulties in purification of the sequence the final step of complexing the 
gadolinium ion to the peptide substrate was not possible. However, another 
attempt to synthesize a peptide substrate coupled to the Gd-DOTA (JL-87) 
complex was achieved following the design: peptide substrate 80-Lys(DOTA-Gd)-
Sp-AQ. This sequence was successfully characterized via low-resolution mass 
spectroscopy. Even though the probe JL-87 was successfully synthesized, further 
optimization of the peptide substrate in terms of efficient MMP-mediated activation 
to release the contrast agent is essential. From the mass spectrometric analysis it 
was found that the protecting group in the arg residue was still present and hence 
a longer deprotection procedure for their removal is essential. This problem can 
also be addressed by using Arg(Boc2) or Arg(Pbf) which are also attractive 
alternatives for Arg(Mtr) for the Fmoc/tBu strategy of SPPS (Stierandova et al 
1994). Also the protocol for the synthesis of the probe JD has to be altered in order 
to increase the yield of the intermediates for complexing the paramagnetic metal 
ion to the peptide conjugate. Finally another major issue would be the purity of 
the probes (JD and JL87), which would require purification by preparative HPLC. 
Upon successful purification of the probes-JD and JL87 which are engineered to 
carry a MMP recognizable substrate coupled to a gadolinium chelate, they could 
potentially be cleaved by the corresponding MMP-2/9 to release the contrast agent 
in atherosclerotic tissues or at the site of activation. On substrate cleavage, it is 
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hoped that the released contrast agent may increase the relaxation time of the 
water protons at the site of deposition resulting in signal enhancement. Moreover 
the presence of an anthraquinone moiety in probe JL-87 could possibly increase 
the hydrophobic nature of the released contrast agent causing an increase in the 
retention time of the CA at the site of cleavage. This could also influence the 
contrast of the image produced via a MRI scanner.       
 
2.2.4. Limitations  
Some of the limitations in this section were that, when the peptide sequences were 
analyzed for purity via analytical RP-HPLC they ranged from 76-97%. There is 
therefore a requirement to purify all the peptide substrates, intermediates and 
target compounds by preparative HPLC. The presence of the protecting groups in 
the peptide sequences 75, 76, 77, 78, 79 and 80, i.e., the N-terminal and side 
chain protecting groups were not removed, so that when coupling the peptide 
substrate to the contrast agent, as in compound 87, any unspecific binding could 
be avoided. However compound 87 still showed the presence of the side chain 
protecting group in Arg even after treatment with TFA. Hence the suggestion to 
use a different side chain protecting group that can be quickly removed has been 
stated in the previous section. The final step involving the removal of the Fmoc 
protecting group from the N-terminal of the peptide substrate is desirable.  
2.2.5. Future work         
Future work on these MMP (2/9) specific peptide substrates should focus on the 
determination of purity via HPLC analysis (75, 76 and 77) and the subsequent 
purification of target compounds via preparative RP-HPLC is recommended.  More 
work on the optimization of experimental conditions for coupling these peptide 
substrates to the contrast agent (Gd-DOTA) has to be developed. This can be done 
by following the procedure as demonstrated in scheme 9, although keeping in mind 
the need for better yield and purity of the target compound. The next step would 
be to evaluate the substrate specificity of the compounds to MMP-2/9. This could 
be done by using a FRET system as achieved for the legumain peptide substrates. 
The fluorogenic probes upon incubation with activated MMP-2/9 enzyme could 
release fluorescence and in this manner could potentially be used as a screening 
method for confirming those MMP-2/9 specific compounds. From here the 
successful substrates could be used for the synthesis of the target peptide-contrast 
agent conjugate. Finally biological analysis to evaluate the intercellular contrast 
agent release of the probes along with cytotoxic studies (MTT, LDH) on human 
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tissue extracts of atherosclerotic lesions is essential. Additionally, it is worth 
mentioning that both MMPs and legumain are found to be involved in the pathology 
of other diseases such as cancer and inflammatory diseases and hence the non-
invasive contrast agents engineered for atherosclerotic plaques could also be used 
to evaluate these conditions.  
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2.3. Structure library 
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3. Experimental 
 
3.1. Chemicals and reagents 
All chemicals and reagents where purchased from Sigma, Molekula, Novabiochem, 
TCI and Fischer unless otherwise stated; and were used without purification. 
3.2. Analytical methods 
3.2.1. Chromatography 
Thin layer chromatography (TLC) was performed on aluminum sheets (2 cmx 5 
cm) pre-coated with silica gel-Kieselgel 60 F254. Most of the compounds 
synthesized absorbed in the visible range however short wavelength UV light was 
used whenever additional visualization was required. 
Column chromatography was carried out using glass columns of dimensions 30 
cmx4.5 cm; 30 cmx2.5 cm; 30 cmx2 cm. The glass columns were packed with 
silica 60A; particle size ranging between 35-70 micron, suspended in the 
corresponding solvent system.  
The solvent systems used for TLC/ column chromatography were: 
Chloroform: Methanol (9:1; 19:1; 5:1; 3:1; 1:1). 
Dichloromethane: Methanol (9.5:0.5; 9:1; 19:1; 5:1; 1:1). 
Butanol: Acetic acid: Water (4:5:1). 
Dichloromethane: Ethyl acetate: Methanol (6:2:1; 4:3:1; 5:2:1; 3:3:2). 
Chloroform: Methanol: Pyridine: Ammonia (20:55:15:10). 
3.2.2. UV- visible spectrophotometer 
Helios-α UV-visible spectrophotometer (Thermo scientific) using VisionPro 
software, was used for all absorbance measurements with 1cm polystyrene cells 
for aqueous solutions and quartz cells for organic solvents.  
Fluorescence measurements were performed in 1 cm quartz cells using LS-55 
Luminescence spectrometer (Perkin Elmer), using FL Win lab software. 
3.2.3. Mass spectrometry (MS) 
All the samples synthesized (intermediates and final compounds) were 
characterized using low-resolution (ESMS) liquid column mass spectrometer- using 
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an Agilent column-ZORBAX 3.5 μm; SB-C18: 2.1 x 30mm guard column samples 
were prepared in HPLC grade methanol in a 1.5ml vial and analyzed in either 
positive or negative ion mode.  
All final target compounds were also characterized using a high-resolution (HR) 
positive ion/negative ion nano-electrospray ionization (ESI) as performed on a 
thermofisher LTQ orbitrap XL mass spectrometer. The high resolution mass 
spectrum values are mentioned as ESI-HR and the low resolution mass spectrum 
values are denoted as ESMS-LR.   
3.2.4. High Performance Liquid Chromatography (HPLC) 
HPLC was performed on a Shimadzu Prominence LC-20AD series fitted with a UV-
Vis detector (SPD-20 A), fluorescence detector (RF-10 AXL) and an auto sampler. 
Although 214nm is the most commomly set UV absorption wavelength for peptides 
(because the double bonds, such as peptide bonds absord at this wavelength) 
detection at other wavelengths (254nm, 245nm, 247nm and 300nm) was applied 
for detecting quenched fluorescent substrates and aromatic residues (Aguilar 
2004). Column: Eclipse XDB-C18 RP column (4.6X150 mm; 5 µm particle size). 
Conditions: solvent A was 0.05% TFA in water and solvent B was 0.05% TFA in 
acetonitrile or methanol. The compounds were analysed at a concentration of 1 
mg/ml with injection volume 20 µL and eluent flow rate=0.5 mL/min. The choice 
of the gradient conditions varied between samples and this was undertaken 
according to the separation pattern of each compound under investigation. After 
attempting a number of gradient conditions the following 8 were used for the 
compounds and the gradient conditions are as mentioned here: 
Gradient A (23 min; 254 nm)  Gradient B (23 min; 245 nm) 
Time 
(min) 
Solvent 
A(%) 
Solvent 
B(%) 
 
Time 
(min) 
Solvent 
A(%) 
Solvent 
B(%) 
0 100 0 0 100 0 
10 10 90 6 10 90 
15 30 70 8 30 70 
17 0 100 15 0 100 
19 0 100 18 0 100 
20 100 0 20 100 0 
23 (Stop) 100 0 23 (Stop) 100 0 
   
Gradient C (28 min; 254 nm)   Gradient D (28 min; 300 nm) 
Time 
(min) 
Solvent 
A(%) 
Solvent 
B(%)  
Time 
(min) 
Solvent 
A(%) 
Solvent 
B(%) 
0 100 0 0 100 0 
183 
 
5 10 90 5 10 90 
8 30 70 8 30 70 
17 0 100 17 0 100 
25 0 100 25 0 100 
26 100 0 26 100 0 
28 (Stop) 100 0 28 (Stop) 100 0 
 
Gradient E (23 min; 254 nm)    Gradient F (20 min; 247 nm) 
Time 
(min) 
Solvent 
A(%) 
Solvent 
B(%) 
 Time 
(min) 
Solvent 
A(%) 
Solvent 
B(%) 
 0 100 0 0 100 0 
5 10 90 3 10 90 
7 23 77 5 19 81 
10 22 78 7 20 80 
13 24 76 10 21 79 
15 27 73 12 27 73 
17 26 74 15 10 90 
20 0 100 17 0 100 
21 100 0 19 100 0 
23 (stop) 100 0 20 (stop) 100 0 
 
Gradient G (23 min; 254 nm)   Gradient H (23 min; 247 nm)   Gradient I (23 min; 247 nm) 
Time 
(min) 
Solvent 
A(%) 
Solvent 
B(%) 
 Time 
(min) 
Solvent 
A(%) 
Solvent 
B(%) 
 Time 
(min) 
Solvent 
A(%) 
Solvent 
B(%) 
0 100 0 0 100 0  0 100 0 
5 10 90 7 10 90  7 30 70 
13 20 80 15 30 70  15 10 90 
17 0 100 17 0 100  17 0 100 
19 0 100 19 0 100  19 0 100 
20 100 0 20 100 0  20 100 0 
23 
Stop 
100 0 23 
Stop 
100 0  23 
Stop 
100 0 
 
Before analyzing any compound the column was cleaned with 100% solvent B to 
remove any remaining samples absorbed on the column. This was followed by 
equilibrating the column with 100% solvent A prior to sample injection. Each eluted 
peak was manually collection in vials as individual fractions. ESMS on the collected 
fractions indicated the desired peak corresponding to the mass of interest.  
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3.2.5. Proton nuclear magnetic resonance (1H NMR)     
1H NMR experiments were performed on a Bruker, nuclear magnetic resonance 
spectrometer (400 MHz/54 mm, software-Topspin). Samples were dissolved in 
either deuterated CDCl3, deuterated DMSO or deuterated methanol.  
Note: Yields quoted in g refer to isolated product(s). Yields quoted in % refer to 
isolated product(s), based on the limiting reagent, except, when crude starting 
materials were used where % yield (approximation) is quoted as a guide to the 
efficiency of the reaction. 
3.3. General synthetic methods 
3.3.1. Solid phase peptide synthesis 
Method A: Resin swelling 
The preloaded resin (0.5/0.3 g) was added to a SPPS reaction vessel. To this 
anhydrous DCM (20 mL) was added and the mixture was stirred/shaken (750 rpm) 
for two hours at room temperature (rt).  
Method B: Amino acid coupling 
Fmoc protected amino acid (7.5 eq), HOBt (7.35 eq), TBTU (7.38 eq) or PyBOP 
(7.38 eq) were dissolved in DMF (~10 mL) and to this solution DIPEA (11.25 eq) 
was added. The solution was then poured into the SPPS reaction vessel containing 
the swollen resin and stirred/shaken at room temperature for 20-30 minutes. 
Reaction completion was confirmed by performing Kaiser test. Before coupling 
each amino acid, the resin sample was washed with DMF (3x20 mL). 
Method C: Peptide deprotection (Fmoc group) 
After each coupling cycle the solvent was removed and the resin was washed with 
DMF (3x20 mL). Piperidine:DMF (20:80 v/v, 20 mL) was added to the resin in the 
reaction vessel and was stirred/shaken at room temperature for 5-15 minutes. 
Reaction completion was confirmed by performing Kaiser test.  
Method D: Kaiser test 
After each coupling and deprotection cycle the solvent was removed and the resin 
was washed with DMF (3x20 mL). To a few resin beads, in a small vial, ninhydrin, 
6% in ethanol (2-3 drops), phenol ≈80% in ethanol (2-3 drops) and potassium 
cyanide in H2O/pyridine (2-3 drops) were added. This mixture was then heated 
using a heat gun for few minutes. The resin beads along with the solution turned 
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dark blue when a free primary amine was present indicating a positive result and 
a successful deprotection.  
Method E: Peptide cleavage 
The solvent was removed and the resin was washed with DCM (3x20 mL). A 
solution of TFA in DCM (1% or 5% v/v, 15 mL) was added to the resin in the 
reaction vessel and stirred/shaken at room temperature for 30 minutes. The resin 
was then filtered and washed (x3) with TFA: DCM (1% or 5% v/v) and the filtered 
solution was evaporated under reduced pressure. The resulting concentrate was 
re-evaporated with ethanol (x3) and the residue was then triturated with diethyl 
ether and then stored at 4-6 °C for 12 hours. The resulting precipitate was filtered 
and dried in a vacuum desiccator. 
3.3.2. Solution phase peptide synthesis 
Method F: Amino acid coupling 
The peptide sequence with the substituted aminoanthraquinone conjugate (AQ-
spacer-An-NH2, where A represents amino acids) at the carboxyl end was dissolved 
in DMF (5-15 mL). The solution was stirred at room temperature for 10-15 
minutes. To this solution N-protected amino acids (1.1-3.3 eq), TBTU (1.1-3.3 eq), 
HOBT (1.1-3.3 eq)/ PyBOP (1.1-5.2 eq) dissolved in DMF along with DIPEA (3.2 
eq) stirred at room temperature for 10-15 minutes was added. The reaction 
mixture was stirred at room temperature overnight. Reaction progress was 
monitored by TLC analysis. The reaction mixture was transferred to a separating 
flask and DCM/Chloroform was added. The product was then extracted into the 
organic layer and washed with water (3 x 100 mL), saturated sodium hydrogen 
carbonate (3 x 100 mL), water (3 x 100 mL), then dried over anhydrous 
magnesium sulphate (MgSO4), filtered and evaporated at room temperature or 
using a rotary evaporator (Magnesium sulphate (MgSO4) in the text referred to 
was anhydrous).   
 
Method G: Removal of Fmoc protecting group 
The Fmoc-protecting group was removed by adding 20% v/v piperidine in DMF to 
the peptide sequence. The reaction mixture was stirred at room temperature for 1 
hour. Reaction completion was monitored and confirmed by TLC. The reaction 
mixture was transferred to a separating flask and DCM was added. The product 
was then extracted into the organic layer and washed with water (3 x 100 mL), 
saturated sodium hydrogen carbonate (3 x 100 mL), water (3 x 100 mL), then 
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dried over anhydrous magnesium sulphate (MgSO4), filtered and evaporated at 
room temperature or using a rotary evaporator.  
Method H: Removal of tBoc, trityl and tert-butyl protecting groups  
The side chain-protecting group was removed by treating with trifluoroacetic acid 
(100%) at room temperature for 30 minutes. Reaction progress was monitored by 
TLC. TFA was evaporated in vaccuo and the resulting concentrate was re-
evaporated with ethanol (5 mL, x3). The residue was then triturated with diethyl 
ether and stored at 4-6 °C for 12 hours. The resulting precipitate was filtered and 
dried in a vacuum desiccator. 
3.4. Synthesis of 1st batch-FRET tetra peptide substrates (JC series -
leucine)       
3.4.1. Synthesis of Fluorescent labeled amino acids 
I. Synthesis of 5(6)-Carboxyfluorescein-Pro-OtBu (1) 
5(6)-Carboxyfluorescein (1.00 g, 2.66 mmol) and PyBOP (1.1 eq, 1.52 g, 2.92 
mmol) were dissolved in DMF (4 mL). To the solution DIPEA (5.2 eq, 2.38 mL, 
13.82 mmol) was added and stirred for 10 minutes. To this mixture, H-Pro-OtBu. 
HCl (1.1 eq, 0.61 g, 2.92 mmol) dissolved in DMF (2 mL) was added and stirred 
at room temperature for 6 hours. Reaction progress was monitored via TLC. The 
solution was then washed with citric acid (5%) in water and the resulting solution 
was partitioned between DCM and water (3 x 100 mL). The organic extract was 
then evaporated to low volume. The crude product was purified by silica gel 
chromatography column (7 cm x 4.5 cm) prepared with chloroform: MeOH (4:1). 
Yield: 1.27 g (90%). TLC (2): Rf 0.9 (DCM: MeOH-4:1). The purity of the compound 
was 92% on an analytical RP-HPLC system following the general procedure as 
mentioned in 4.2.5. (Gradient G, 23 min, 247 nm, Rt.10.23’). The molecular 
weight of the product (1) was 529.17, ESI-HR (+) m/z: 530.1804 (100%) (M+H)+. 
ESMS-LR (-) m/z: 528.0 (100%) (M-H)- , 1057.2 (2M-H)-.  
II. Synthesis of 5(6)-Carboxyfluorescein-Pro-OH (2) 
The OtBu protected compound (1) (1.12 g, 2.12 mmol) was dissolved in TFA (5 
mL) at rt. After 2 hours TFA was evaporated in vaccuo and the resulting 
concentrate was re-evaporated with EtOH (x3). The residue was then triturated 
with diethyl ether (75 mL) and stored at 4-6 °C for 12 hours. The solution was 
filtered and dried in a vacuum desiccator. Crude yield: 0.76 g (76%). TLC: Rf 0.4 
(DCM: MeOH- 9:1). The purity of the compound was 81% on an analytical RP-
HPLC system following the general procedure as mentioned in 4.2.5. (Gradient G, 
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23 min, 247 nm, Rt. 9.24’). The molecular weight of the product (2) was 473.11, 
ESI-HR (+) m/z:  474.1179 (100%) (M+H)+. ESMS-LR (+) m/z: 237.2 (60%) 
[(M+2H)/2]2+, 474.1179 (100%) (M+H)+. ESMS-LR (-) m/z: 472.0 (100%) (M-H)-
, 508.0 (40%) (M+Cl)-. 
III. Synthesis of 5(6)-Carboxyfluorescein-β-Ala-OtBu (3) 
5(6)-Carboxyfluorescein (1.00 g, 2.66 mmol) and PyBOP (1.1 eq, 1.52 g, 2.92 
mmol) were dissolved in DMF (4 mL). To this solution DIPEA (5.2 eq, 2.38 mL, 
13.82 mmol) was added and stirred at room temperature for 10 minutes. To this 
mixture, H-βAla-OtBu. HCl (1.1 eq, 0.53 g, 2.92 mmol) dissolved in DMF (2 mL) 
was added. The reaction mixture was stirred at rt following the same procedure as 
the synthesis of compound 1. The crude product was purified by silica gel 
chromatography column (7 cm x 4.5 cm) prepared with chloroform: MeOH (4:1). 
Yield: 1.03 g (77%). TLC (2): Rf 0.8 (DCM: MeOH- 4:1). The purity of the 
compound was 94% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient F, 20 min, 247 nm, Rt. 8.62’). The 
molecular weight of the product (3) was 503.16, ESI-HR (+) m/z:504.1642 
(100%) (M+H)+. ESMS-LR (-) m/z: 502.0 (100%) (M-H)-, 1005.0 (100%) (2M-H)- 
 
IV. Synthesis of 5,6-CBF-βAla-OH (4) 
The OtBu protected compound (3) (0.79 g, 1.57 mmol) was dissolved in TFA (3 
mL) at room temperature following the same procedure as the synthesis of 
compound 2. Crude yield: 0.56 g (80%). TLC: Rf0.1 (DCM: MeOH- 9:1). The purity 
of the compound was 51% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient F, 20 min, 247 nm, Rt. 10.70’). The 
molecular weight of the product (4) was 447.10, ESI-HR (+) m/z: 448.1025 
(100%) (M+H)+. ESMS-LR (-) m/z: 446.0 (100%) (M-H)- , 482.0 (20%) (M+Cl)-. 
3.4.2. Synthesis of anthraquinone-spacer conjugate (5) 
1-Chloroanthraquinone (3.00 g, 12.34 mmol) was suspended in DMSO (20 mL). 
To this mixture 2-2’-(ethylenedioxy)bis(ethylamine) (5.2 eq, 9.39 mL, 64.29 
mmol) was added and heated over a water bath for three hours at 60ºC. The 
solution was cooled to rt followed by the addition of a large excess of water. The 
solution was filtered and the precipitates were air-dried at room temperature. The 
crude product was dissolved in DCM and then purified by a silica gel 
chromatography column (16 cmx4.5 cm) prepared with DCM. The eluent was then 
changed to DCM:MeOH (9:1). The product was finally eluted with the addition of 
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TEA (5%v/v) to the eluent. Fractions containing the product were combined, 
filtered and evaporated to dryness using a rotary evaporator. Yield: 1.38 g (31%). 
TLC (fraction 7): Rf0.3 (DCM:MeOH- 9:1). The purity of the compound was 83% 
on an analytical RP-HPLC system following the general procedure as mentioned in 
4.2.5. (Gradient A, 23 min, 254 nm, Rt. 13.82’). The molecular mass of the product 
(5) was 354.16, ESMS-LR (+) m/z: 355 (100%) (M+H)+. ESMS-LR (-) m/z: 354 
(40%) (M)-. 
1H NMR (400MHz, d6-DMSO), δ ppm: 2.65 (2H, t, J=5.6Hz, CH2-NH2), 3.39 (2H, t, 
J=5.6Hz, CH2-CH2-NH2), 3.51-3.58 (4H, m, CH2-NH-AQ; CH2-O-CH2-CH2-NH2), 
3.62-3.64 (2H, m, CH2-O-CH2-CH2-NH-AQ), 3.72 (2H, t, J=5.6Hz, CH2-CH2-NH-
AQ), 7.28 (1H, d, J=8.4Hz, H-2), 7.44 (1H, dd, J1=7.2Hz, J2=0.8Hz, H-4), 7.62-
7.66 (1H, m, H-3), 7.81-7.92 (2H, m, H-6 and H-7), 8.12 (1H, dd, J1=7.6Hz, 
J2=1.2Hz, H-5), 8.20 (1H, dd, J1=7.6Hz, J2=1.2Hz, H-8), 9.78 (1H, t, J=5.2Hz, 
NH-AQ). 
 
3.4.3. Synthesis of FRET tetra peptide substrates (JC series-1st batch) 
3.4.3.1. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Leu-Spacer-AQ (8) 
I. Synthesis of 5(6)-CBF-Pro-Ala-Asn(Trt)-Leu-OH (6) 
A leucine pre-loaded resin for solid phase peptide synthesis with a 4-carboxytrityl 
linker (0.5 g, 0.21 mmol/g) was swollen in DCM according to method A and the 
coupling and deprotection cycles were performed as follows:  
 1st cycle: Removal of Fmoc protecting group was performed in accordance 
to method C. Presence of free amine due to removal of protecting group 
was confirmed by Kaiser test following method D. Fmoc-Asn(Trt)-OH (0.11 
g, 0.31 mmol) was coupled to the resin according to method B. Primary 
amine detection confirming the completion of reaction was checked using 
the Kaiser test kit (method D). 
 2nd cycle: Removal of Fmoc protecting group was performed in accordance 
to method C. Presence of free amine due to removal of protecting group 
was confirmed by Kaiser test following method D. Fmoc-Ala-OH (0.10 g, 
0.31 mmol) was coupled to the resin according to method B. Primary amine 
detection confirming the completion of reaction was checked using the 
Kaiser test kit (method D). 
 3rd cycle: Removal of Fmoc protecting group was performed in accordance 
to method C. Presence of free amine due to removal of protecting group 
was confirmed by Kaiser test following method D. 5(6)-CBF-Pro-OH (0.15 
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g, 0.31 mmol) was coupled to the resin according to method B. Primary 
amine detection confirming the completion of reaction was checked using 
the Kaiser test kit (method D).  
Upon completion of the third coupling, the tetra peptide was removed from the 
resin following method E. Crude yield: 0.04 g (36%). The purity of the compound 
was 44% on an analytical RP-HPLC system following the general procedure as 
mentioned in 4.2.5. (Gradient A, 23 min, 254 nm, Rt. 12.75’). The molecular 
weight of the product (6) was 1013.38, ESI-HR(+) m/z: 1014.3917 (100%) 
(M+H)+. ESMS-LR (-) m/z: 1012.2 (70%) (M-H)-. 
II. Synthesis of 5(6)-CBF-Pro-Ala-Asn(Trt)-Leu-Spacer-AQ (7) 
Compound 6 (0.04 g, 0.04 mmol) was dissolved in DMF (1-2 mL). To this solution 
compound 5 (1.1 eq, 0.02 g, 0.04 mmol), HOBt (2 eq, 0.01 g, 0.08 mmol) TBTU 
(2 eq, 0.03 g, 0.08 mmol), DIPEA (5.8 eq, 0.04 mL, 0.23 mmol) dissolved in DMF 
(3-5 mL) was added and stirred at rt for 5hrs. The solution was partitioned between 
DCM and water. The organic extracts were washed with saturated sodium 
hydrogen carbonate (3x100 mL), then water (3x100 mL), dried with anhydrous 
MgSO4, filtered and evaporated to a low volume. The crude product was re-
dissolved in DCM:MeOH (9.5:0.5) and then applied to a silica gel chromatography 
column (15 cmx2 cm) prepared with DCM: MeOH (9.5:0.5). The eluent was then 
changed to DCM:MeOH (9:1). Fractions containing the product were combined, 
filtered and evaporated to a low volume. Yield: 0.04 g (80%). TLC (fraction 8): Rf 
0.5 (DCM: MeOH-9:1). The molecular weight of the product (7) was 1349.53, 
ESMS-LR (+) m/z: 1350.4 (15%) (M+H)+, 675.8 (100%) [(M+2H)/2]2+. ESMS-LR 
(-) m/z: 1348.2 (60%) (M-H)-, 1349.4 (80%) (M)-, 1384.4 (15%) (M+Cl)-. 
III. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Leu-Spacer-AQ (8) 
Compound 7 was dissolved in TFA at rt for 2 hours. TFA was then evaporated and 
the resulting concentrate was re-evaporated with EtOH (x3). The residue was then 
triturated with diethyl ether (50 mL) and the precipitate was used without any 
further characterization. TLC: Rf 0.2 (DCM: MeOH-9.5:0.5). 
3.3.3.2. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Leu-Spacer-AQ (11) 
I. Synthesis of 5(6)-CBF-Pro-Gly-Asn(Trt)-Leu-OH (9) 
A leucine pre-loaded resin for solid phase peptide synthesis with a 4-carboxytrityl 
linker (0.5 g, 0.21 mmol/g) was swollen in DCM according to method A and the 
coupling and deprotection cycles were performed as per methods C, D, B followed 
by peptide removal from the resin according to method E: 
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 1st cycle: N-Fmoc-L-Asparagine (Trt) (0.47 g, 0.79 mmol). 
 2nd cycle: N-Fmoc-L-Glycine (0.23 g, 0.79 mmol). 
 3rd cycle: 5 (6), CBF-Proline (0.37 g, 0.79 mmol). 
Upon successful completion of third coupling, the tetra peptide was removed from 
the resin following method E. Crude yield: 0.08 g (80%). The molecular weight of 
the product (9) was 999.37, ESMS-LR (+) m/z: 1000.2 (100%) (M+H)+, 1022.0 
(25%) (M+Na)+. ESI-HR (+) m/z 998.3599 (100%) (M-H)-.   ESMS-LR (-) m/z: 
498.8 (70%) ([M-2H)/2]2-, 1113.0 (100%) (M+TFA)-. 
II. Synthesis of 5(6)-CBF-Pro-Gly-Asn(Trt)-Leu-Spacer-AQ (10) 
Compound 9 (0.08 g, 0.08 mmol) was dissolved in DMF (2 mL). To this solution 
compound 5 (1.1 eq, 0.03 g, 0.09 mmol), HOBt (2 eq, 0.02 g, 0.16 mmol) TBTU 
(2 eq, 0.05 g, 0.16 mmol), DIPEA (5.8 eq, 0.08 mL, 0.46 mmol) dissolved in DMF 
(3-5 mL) following the same procedure as described for the synthesis of compound 
7. The crude product was re-dissolved in DCM:MeOH (9.5:0.5) and then applied 
to a silica gel chromatography column (15 cmx2 cm) prepared with DCM:MeOH 
(9.5:0.5). The eluent was then changed to DCM:MeOH (9:1). Fractions containing 
the product were combined, filtered and evaporated to dryness. Yield: 0.09 g 
(82%). TLC (fraction 3): Rf0.5 (DCM: MeOH-9.5:0.5). The molecular weight of the 
product (10) was 1335.52, ESI-HR (+) m/z: 668.7648 (100%) [(M+2H/2)]2+. 
ESMS-LR (+) m/z: 453.2 (100%) [(M+2H+Na)/3]3+. ESMS-LR (-) m/z: 666.7 
(100%) [(M-2H)/2]2-, 1334.4 (100%) (M-H)-. 
III. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Leu-Spacer-AQ (11) 
Compound 10 was dissolved in TFA at rt for 2 hours. TFA was then evaporated 
and the resulting concentrate was re-evaporated with EtOH (x3). The residue was 
triturated with diethyl ether (50 mL), and the precipitate was used without any 
further characterization. TLC: Rf0.2 (DCM: MeOH-9.5:0.5). 
3.3.3.3. Synthesis of 5(6)-CBF-Pro-Leu-Asn-Leu-Spacer-AQ (14) 
I. Synthesis of 5(6)-CBF-Pro-Leu-Asn(Trt)-Leu-OH (12) 
A leucine pre-loaded resin for solid phase peptide synthesis with a 4-carboxytrityl 
linker (0.5 g, 0.21 mmol/g) was swollen in DCM according to method A and the 
coupling and deprotection cycles were performed as per methods C, D, B followed 
by peptide cleavage from the resin according to method E: 
 1st cycle: N-Fmoc-L-Asparagine (Trt) (0.47 g, 0.79 mmol). 
 2nd cycle: N-Fmoc-L-Leucine (0.28 g, 0.79 mmol). 
 3rd cycle: 5 (6), CBF-Proline (0.37 g, 0.79 mmol). 
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Upon successful completion of the third coupling, the tetra peptide was cleaved 
from the resin following method E. Crude yield: 0.06 g (55%). The purity of the 
compound was 46% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient A, 23 min, 254 nm, Rt. 13.44’). The 
molecular weight of the product (12) was 1055.43, ESI-HR (+) m/z: 1056.4388 
(100%) (M+H)+.  ESMS-LR (+) m/z: 539.8 (45%) [(M+2H+Na)/2]2+, 1078.2 
(25%) (M+Na)+. ESMS-LR (-) m/z: 1054 (100%) (M-H)-. 
II. Synthesis of 5(6)-CBF-Pro-Leu-Asn(Trt)-Leu-Spacer-AQ (13) 
Compound 12 (0.06 g, 0.06 mmol) was dissolved in DMF (2 mL). To this solution 
compound 5 (1.1 eq, 0.02 g, 0.06 mmol) along with HOBt (2 eq, 0.02 g, 0.11 
mmol), TBTU (1.1 eq, 0.04 g, 0.11 mmol), DIPEA (5.8 eq, 0.06 mL, 0.33 mmol) 
dissolved in DMF (5-7 mL) following the same procedure as described for the 
synthesis of compound 7. The crude product was re-dissolved in DCM:MeOH 
(9.5:0.5) and then applied to a silica gel chromatography column (14 cmx2 cm) 
prepared with DCM:MeOH (9.5:0.5). The eluent was then changed to DCM:MeOH 
(9:1). Fractions containing the product were combined, filtered and evaporated to 
dryness. Yield: 0.05 g (63%). TLC (fraction 2): Rf 0.8 (DCM:MeOH-9:1). The 
molecular weight of the product (13) was 1391.58, ESI-HR (+) m/z: 1392.5854 
(100%) (M+H)+. ESMS-LR (+) m/z: 1436.6 (35%) (M+2Na-H)+. ESMS-LR (-) m/z: 
1390.4 (35%) (M-H)-. 
III. Synthesis of 5(6)-CBF-Pro-Leu-Asn-Leu-Spacer-AQ (14) 
Compound 13 was dissolved in TFA at room temperature for 2 hours. TFA was 
evaporated and the resulting concentrate was re-evaporated with EtOH (x3). The 
residue was then triturated with diethyl ether (75 mL), and the precipitate was 
used without any further characterization. TLC: Rf 0.1 (DCM:MeOH- 9.5:0.5). 
3.3.3.4. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Leu-Spacer-AQ (17) 
I. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Leu-OH (15)  
A leucine pre-loaded resin for solid phase peptide synthesis with a 4-carboxytrityl 
linker (0.5 g, 0.21 mmol/g) was swollen in DCM according to method A and the 
coupling and deprotection cycles were performed as per methods C, D, B followed 
by peptide cleavage from the resin according to method E: 
 1st cycle: N-Fmoc-L-Asparagine (Trt) (0.47 g, 0.79 mmol). 
 2nd cycle: N-Fmoc-L-Alanine (0.26 g, 0.79 mmol). 
 3rd cycle: 5 (6), CBF-β-Alanine (0.35 g, 0.79 mmol). 
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Upon successful completion of the third coupling, the tetra peptide was cleaved 
from the resin following method E. Crude yield: 0.07 g (70%). The purity of the 
compound was 70% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient A, 23 min, 275 nm, Rt. 13.23’). The 
molecular weight of the product (15) was 987.37, ESMS-LR (+) m/z: 505.8 (25%) 
[(M+2H+Na)/2]2+, 988.2 (100%) (M+H)+, 1010.0 (40%) (M+Na)+. ESI-HR (-) 
m/z: 986.3593 (85%) (M-H)-. ESMS-LR (-) m/z: 987.0 (60%) (M)-. 
II. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn(Trt)-Leu-Spacer-AQ (16) 
Compound 15 (0.06 g, 0.06 mmol) was dissolved in DMF (2 mL). To this solution 
compound 5 (1.1 eq, 0.02 g, 0.07 mmol) along with HOBt (2 eq, 0.02 g, 0.12 
mmol), TBTU (2 eq, 0.04 g, 0.12 mmol), DIPEA (5.8 eq, 0.06 mL, 0.35 mmol) 
dissolved in DMF (5-7 mL) following the same procedure as described for the 
synthesis of compound 7. The crude product was re-dissolved in DCM:MeOH 
(9.5:0.5) and then applied to a silica gel chromatography column (14 cmx2 cm) 
prepared with DCM:MeOH (9.5:0.5). The eluent was then changed to DCM:MeOH 
(9:1). Fractions containing the product were combined, filtered and evaporated to 
dryness. Yield: 0.02 g (25%). TLC (frcation 3): Rf 0.4 (DCM:MeOH-9:1). The 
molecular weight of the product (16) was 1323.52, ESI-MS (+) m/z: 1324.5231 
(100%) (M+H)+. ESMS-LR (+) m/z: 662.7 (100%) [(M+H/2)]2+, 673.7 (90%) 
[(M+2H+Na)/2]2+. 
III. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Leu-Spacer-AQ (17) 
Compound 17 was dissolved in TFA at rt for 2 hours. TFA was evaporated and the 
resulting concentrate was re-evaporated with EtOH (x3). The residue was then 
triturated with diethyl ether (50mL), and the precipitate was used without any 
further characterization. TLC: Rf 0.3 (DCM:MeOH-9.5:0.5). 
3.3.3.5. Synthesis of 5(6)-CBF-β-Ala-Leu-Asn-Leu-Spacer-AQ (20)  
I. Synthesis of 5(6)-CBF-β-Ala-Leu-Asn-leu-OH (18) 
A leucine pre-loaded resin for solid phase peptide synthesis with a 4-carboxytrityl 
linker (0.5 g, 0.21 mmol/g) was swollen in DCM according to method A and the 
coupling and deprotection cycles were performed as per methods C, D, B followed 
by peptide cleavage from the resin according to method E: 
 1st cycle: N-Fmoc-L-Asparagine(Trt) (0.47 g, 0.79 mmol). 
 2nd cycle: N-Fmoc-L-Leucine (0.29 g, 0.79 mmol). 
 3rd cycle: 5 (6), CBF-β-Alanine (0.35 g, 0.79 mmol). 
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Upon successful completion of the third coupling, the tetra peptide was cleaved 
from the resin following method E. Crude yield: 0.07 g (63%). The purity of the 
compound was 41% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient A, 23 min, 254 nm, Rt. 16.01’). The 
molecular weight of the product (18) was 1029.42, ESMS-LR (+) m/z: 1030.2 
(100%) (M+H)+. ESI-HR (-) m/z: 1028.4071 (100%) (M-H)-. ESMS-LR (-) m/z:  
1029.2 (80%) (M)-.   
II. Synthesis of 5(6)-CBF-β-Ala-Leu-Asn(Trt)-Leu-Spacer-AQ (19) 
Compound 18 (0.07 g, 0.07 mmol) was dissolved in DMF (2 mL). To this solution 
compound 5 (1.1 eq, 0.03 g, 0.07 mmol) along with HOBt (2 eq, 0.02 g, 0.14 
mmol), TBTU (2 eq, 0.04 g, 0.14 mmol), DIPEA (5.8 eq, 0.07 mL, 0.39 mmol) 
dissolved in DMF (5-7 mL) following the same procedure as described for the 
synthesis of compound 7. The crude product was re-dissolved in DCM:MeOH 
(9.5:0.5) and then applied to a silica gel chromatography column (13 cmx2 cm) 
prepared with the same solvent system. The eluent was then changed to 
DCM:MeOH (9:1). Fractions containing the product were combined, filtered and 
evaporated to dryness. Yield: 0.06 g (67%). TLC (fraction 5): Rf 0.4 (DCM:MeOH-
9:1). The molecular weight of the product (19) was 1365.56, ESI-HR (+) m/z: 
683.7888 (100%) [(M+H/2)]2+. ESMS-LR (+) m/z: 1366.5 (95%) (M+H)+. 
III. Synthesis of 5(6)-CBF-β-Ala-Leu-Asn-Leu-Spacer-AQ (20) 
Compound 20 was dissolved in TFA at rt for two hours. TFA was evaporated and 
the resulting concentrate was re-evaporated with EtOH (x3). The residue was then 
triturated with diethyl ether (75 mL), and the precipitate was used without any 
further characterization. TLC: Rf 0.2 (DCM: MeOH-9.5:0.5). 
3.3.3.6. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Leu-Spacer-AQ (25) 
I. Synthesis of intermediate compound H2N-Leu-Spacer-AQ (21) (Method: 
F,G) 
Compound 5 (1.00 g, 2.82 mmol) was dissolved in DMF (10-15 mL) by stirring the 
mixture for 20 minutes at rt. To this solution Fmoc-Leu-OH (1.1 eq, 1.10 g, 3.11 
mmol), TBTU (1.1 eq, 1.00 g, 3.11 mmol) and HOBt (1.1 eq, 0.42 g, 3.11 mol) 
dissolved in DMF (10 mL) with the addition of DIPEA (3.2 eq, 1.56 g/ml, 9.04 
mmol) was added and at stirred rt. The progress of the reaction was monitored 
via TLC. The solution was then partitioned between DCM and water. The organic 
extract was washed with saturated sodium hydrogen carbonate (3 x 100 mL), then 
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water (3 x 100 mL), dried with anhydrous MgSO4, filtered and evaporated to 
dryness and was used for the following reaction without further purification.  
The extracted sample was dissolved in 20% v/v of piperidine in DMF (20 mL) and 
the amino terminus was deprotected as in method G. The solution was partitioned 
between DCM and water. The organic extracts were washed with saturated sodium 
hydrogen carbonate (3 x 100 mL), then water (3 x 100 mL), dried with anhydrous 
MgSO4, filtered and evaporated to a low volume. The foregoing concentrated 
solution was then purified by a silica gel chromatography column (13 cmx4.5 cm) 
prepared with DCM. The eluent was changed to DCM:MeOH (9:1). Fractions 
containing the product were combined, filtered and evaporated at room 
temperature overnight. Yield: 1.07 g (81%). TLC (fraction 4): Rf 0.3 (DCM: MeOH-
9:1). The purity of the compound was 98% on an analytical RP-HPLC system 
following the general procedure as mentioned in 4.2.5. (Gradient H, 23 min; 247 
nm; Rt. 11.38’). The molecular mass of the product (21) was 467.24, ESI-HR (+) 
m/z: 468.2488 (100%) (M+H)+. ESMS-LR (+) m/z: 490.2 (20%) (M+Na)+, 935.4 
(25%) (2M+H)+. 
1H NMR (400MHz, d6-DMSO), δ ppm:0.80-0.85 (6H, m, 2x[δ-CH3]), 1.14-1.21 and 
1.40-1.33 (2H, m, β-CH2-Leu side chain), 1.63-1.70 (1H, m, γ-CH-Leu side chain), 
3.11 (1H, q, J=5.6Hz, α-CH-Leu side chain), 3.18-3.30 (2H, m, CH2-NH-COO), 
3.46 (2H, t, J=5.8Hz, CH2-CH2-NH-COO), 3.53 (2H, q, J=5.2Hz, CH2-NH-AQ), 
3.57-3.64 (4H, m, O-CH2-CH2-O), 3.73 (2H, t, J=5.4Hz, CH2-CH2-NH-AQ), 7.29 
(1H, dd, J1=8.8Hz, J2=0.8Hz, H-2), 7.45 (1H, dd, J1=7.2Hz, J2=0.8Hz, H-4), 7.63-
7.67 (1H, m, H-3), 7.82-7.94 (3H, m, H-6, H-7, NH-COO), 8.12 (1H, dd, J1=7.6Hz, 
J2=1.2Hz, H-5), 8.20 (1H, dd, J1=7.6Hz, J2=1.2Hz), 9.79 (1H, t, J=5.2Hz, NH-AQ). 
II. Synthesis of intermediate compound H2N-Asn(Trt)-Leu-Spacer-AQ 
(22) (Method: F,G) 
Compound 21 (1.00 g, 2.14 mmol) was dissolved in DMF (15 mL). To this solution 
Fmoc-Asn(trt)-OH (1.1 eq, 1.40 g, 2.35 mmol), TBTU (1.1 eq, 0.80 g, 2.35 mmol) 
and HOBt (1.1 eq, 0.32 g, 2.35 mol) dissolved in DMF (10 mL) with the addition 
of DIPEA (3.2 eq, 1.18 g/mL, 6.85 mmol) was added following the same procedure 
as described for the synthesis of compound 21. The crude product was then 
purified by a silica gel chromatography column (16 cmx4.5 cm) prepared with 
DCM. The eluent was changed to DCM: MeOH (9:1). Fractions containing the 
product were combined, filtered and evaporated to dryness. Yield: 1.65 g (94%). 
TLC (fraction 4): Rf0.5 (DCM:MeOH-9:1). The purity of the compound was 91% on 
an analytical RP-HPLC system following the general procedure as mentioned in 
195 
 
4.2.5. (Gradient H, 23 min; 247 nm; Rt. 20.01’). The molecular mass of the 
product (22) was 823.39, ESI-HR (+) m/z: 824.4013 (100%) (M+H)+. ESMS-LR 
(-) m/z: 822.2 (80%) (M-H)-. 
1H NMR (400MHz, d6-DMSO), δ ppm: 0.80-0.85 (6H, m, 2x[δ-CH3]), 1.37-1.48 
(2H, m, β-CH2-Leu side chain), 1.51-1.61 (1H, m, γ-CH-Leu side chain), 2.38-2.46 
(2H, m, CH2-COO-NH-Trityl protecting group), 3.07-3.18 (2H, m, CH2-NH-Leu), 
3.35-3.37 (2H, CH2-CH2-NH-Leu), 3.45-3.53 (5H, m, CH2-O-CH2-CH2-NH-AQ, CH-
CH2-Trityl group, CH2-NH-AQ), 3.58-3.61 (2H, m, CH2-O-CH2-CH2-NH-Leu), 3.71 
(2H, t, J=5.2Hz, CH2-CH2-NH-AQ), 4.26 (1H, q, J=8.4Hz, CH-CH2-CH-2[CH3]), 
7.17-7.30 (16H, m, 2-H and Trityl protecting group), 7.45 (1H, dd, J1=7.2Hz, 
J2=0.8Hz, H-4), 7.62-7.66 (1H, m, H-3), 7.83 (1H, td, J1=7.2Hz, J2=1.2Hz, H-6), 
7.89 (1H, td, J1=7.6Hz, J2=1.6Hz, H-7), 7.95-8.02 (2H, m, CH2-NH-COO, CH-NH-
COO), 8.13 (1H, dd, J1=7.6Hz, J2=1.2Hz, H-5), 8.20 (1H, dd, J1=7.6Hz, J2=1.2Hz), 
9.23 (1H, s, NH-Trityl protecting group), 9.80 (1H, t, J=5.2Hz, NH-AQ). 
III. Synthesis of H2N-Gly-Asn(Trt)-Leu-Spacer-AQ (23) (Method: F,G) 
Compound 22 (1.65 g, 2.00 mmol) was dissolved in DMF (15 mL). To this solution 
Fmoc-Gly-OH (1.1 eq, 0.66 g, 2.20 mmol), TBTU (1.1 eq, 0.71 g, 2.20 mmol) and 
HOBt (1.1 eq, 0.30 g, 2.20 mmol) dissolved in DMF (10 mL) with the addition of 
DIPEA (3.2 eq, 1.12 g/ml, 6.41 mmol) was added following the same procedure 
as described for the synthesis of compound 21. The crude product was then 
purified by silica gel chromatography column (18 cmx4.5 cm) prepared with DCM. 
The eluent was then changed to DCM:MeOH (9:1). Fractions containing the 
product were combined, filtered and evaporated to dryness. Yield: 1.44g (82%). 
TLC (fraction 4): Rf 0.3 (DCM: MeOH- 9:1). The purity of the compound was 88% 
on an analytical RP-HPLC system following the general procedure as mentioned in 
4.2.5. (Gradient I, 23 min; 247 nm; Rt. 19.82’). The molecular mass of the product 
(23) was 880.42, ESI-HR (+) m/z: 881.4232 (100%) (M+H)+. ESMS-LR (+) m/z: 
903.2 (100%) (M+Na)+. ESMS-LR (-) m/z: 879.2 (100%) (M-H)-, 915.2 (M+Cl)-, 
925.0 (25%) (M+TFA-H)-.  
1H NMR (400MHz, d6-DMSO), δ ppm: 0.82 (6H, dd, J=18.8Hz, 6.0Hz, 2x[δ-CH3]), 
1.38-1.60 (3H, m, CH2-CH[CH3]2), 2.65-2.76 (2H, m, CH2-CONH-Trityl protecting 
group), 2.97-3.10 (2H, m, CH2-NH-Leu), 3.13 (2H, s, CH2-NH2), 3.26 (2H, t, 
J=6.2Hz, CH2-CH2-NH-Leu), 3.47-3.59 (6H, m, O-CH2-CH2-O, CH2-NH-AQ), 3.71 
(2H, t, J=5.2Hz, CH2-CH2-NH-AQ), 4.17-4.23 (1H, m, CH-CH2-CH-2[CH3]), 4.56 
(1H, s, CH-NH-COO), 7.18-7.29 (16H, m, 2-H and Trityl protecting group), 7.45 
(1H, dd, J1=7.2Hz, J2=0.8Hz, H-4), 7.62-7.66 (1H, m, H-3), 7.81-8.08 (4H, m, H-
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6, H-7, NH-Spacer arm, NH-COO-Asn), 8.13 (1H, dd, J1=7.6Hz, J2=1.2Hz, H-5), 
8.21 (1H, dd, J1=7.6Hz, J2=1.2Hz), 9.22 (1H, s, NH-Trityl protecting group), 9.79 
(1H, t, J=5.2Hz, NH-AQ). 
IV. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn(Trt)-Leu-Spacer-AQ (24) 
(Method: F)       
Compound 23 (1.44 g, 1.64 mmol) was dissolved in DMF (15 mL). To this solution 
compound 4 (1.1 eq, 0.80 g, 1.80 mmol), TBTU (1.1 eq, 0.58 g, 1.80 mmol) and 
HOBt (1.1 eq, 0.24 g, 1.80 mol) dissolved in DMF (10 mL) with the addition of 
DIPEA (3.2 eq, 0.90 g/ml, 5.22 mmol) was added following the same procedure 
as described for the synthesis of compound 21. The crude product was then 
purified by a silica gel chromatography column (16 cmx4.5 cm) prepared with 
DCM:MeOH (9.5:0.5). The column was initially eluted with the same solvent 
system. The eluent was later changed to DCM:MeOH (9:1). Fractions containing 
the product were combined, filtered and evaporated to dryness. Yield: 1.06 g 
(50%). TLC (fraction 5): Rf 0.4 (DCM: MeOH- 9:1). The molecular mass of the 
product (24) was 1309.50, ESI-HR(+) m/z: 1310.5081 (100%) (M+H)+. ESMS-
LR (+) m/z:  1333.5 (85%) (M+H+Na)+. ESMS-LR (-) m/z: 653.3 [(M-2H)/2]2-, 
1308.2 (65%) (M-H)-. 
V. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Leu-Spacer-AQ (25) 
Compound 24 (0.05 g, 0.04 mmol) was dissolved in TFA at rt for 2 hours. TFA was 
evaporated and the resulting concentrate was re-evaporated with EtOH (x3). The 
residue was then triturated with diethyl ether (100 mL), and the precipitate was 
used without any further characterization. Crude yield: 0.03g (75%)  TLC: Rf 0.1 
(DCM:MeOH-9.5:0.5). The molecular mass of the product (25) was 1067.39, 
ESMS-LR (+) m/z: 534.8 (60%) [(M+2H)/2]2+, 545.7 (40%) [(M+Na)/2]2+, 
1068.2 (45%) (M+H)+. 
3.4.4. Synthesis of 2nd batch-FRET tetra peptide substrates applying 
solution phase peptide synthesis (JC series-lysine)    
3.4.4.1. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Lys-Spacer-AQ (31) 
I. Synthesis of intermediate compound H2N-Lys(Boc)-Spacer-AQ (26) 
(Method: F,G) 
Compound 5 (1.00 g, 2.82 mmol) was dissolved in DMF (10 mL). To this solution 
Fmoc-Lys(Boc)-OH (1.1 eq, 1.46 g, 3.11 mmol), TBTU (1.1 eq, 1.00 g, 3.11 mmol) 
and HOBt (1.1 eq, 0.42 g, 3.11 mol) dissolved in DMF (10 mL) with the addition 
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of DIPEA (3.2 eq, 1.56 g/mL, 9.04 mmol) was added and stirred overnight at rt. 
The solution was then partitioned between DCM and water. The organic extract 
were washed with saturated sodium hydrogen carbonate (3 x 100 mL), then water 
(3 x 100 mL), dried with anhydrous MgSO4, filtered and evaporated to dryness and 
was used for the following reaction without further purification. 
The extracted sample was dissolved in 20% v/v of piperidine in DMF (10-15 mL) 
and the amino terminus was deprotected as in method G. The solution was 
partitioned between DCM and water. The organic extracts were washed with 
saturated sodium hydrogen carbonate (3 x 100 mL), then water (3 x 100 mL), 
dried with anhydrous MgSO4, filtered and evaporated to low volume. The crude 
product was then purified by silica gel chromatography column (12 cmx4.5 cm) 
prepared with DCM:MeOH (9.5:0.5). The eluent was then changed to DCM: MeOH 
(9:1). Fractions containing the product were combined, filtered and evaporated to 
dryness. Yield: 1.47 g (90%). TLC (fraction 3): Rf 0.3 (DCM:MeOH-9:1). The 
molecular mass of the product (26) was 582.31, ESMS-LR (+) m/z: 583 (80%) 
(M+H)+, 604.8 (95%) (M+Na)+. ESMS-LR (-) m/z: 581 (90%) (M-H)-, 616 (20%) 
(M+Cl)-. 
1H NMR (400MHz, d6-DMSO), δ ppm: 0.82 (6H, dd, J1=18.8Hz, J2=6.0Hz, 2x[δ-
CH3]),1.20-1.52 (15H, m, Boc protecting group; β, γ and δ-CH2 of the Lys side 
chain), 2.86 (2H, q, J=6.4Hz, ε-CH2 of the Lys side chain), 3.06 (1H, q, J=5.6Hz, 
α-CH of Lysine), 3.21-3.26 (2H, m, CH2-NH-COO), 3.46 (2H, t, J=6Hz, CH2-CH2-
NH-COO), 3.52-3.64 (6H, m, CH2-NH-AQ, O-CH2-CH2-), 3.73 (2H, t, J=5.6Hz, CH2-
CH2-NH-AQ), 6.75 (1H, s, NH-COO-Boc group), 7.30 (1H, d, J=8.8Hz, H-2), 7.46 
(1H, dd, J1=7.6Hz, J2=0.8Hz, H-4), 7.66 (1H, t, J=7.6Hz, H-3), 7.82-7.92 (3H, m, 
H-6, H-7, NH-COO-CH), 8.13 (1H, dd, J1=7.2Hz, J2=0.8Hz, H-5), 8.21 (1H, dd, 
J1=7.6Hz, J2=0.8Hz), 9.80 (1H, t, J=5.2Hz, NH-AQ). 
II. Synthesis of intermediate compound H2N-Asn(Trt)-Lys(Boc)-Spacer-
AQ (27) 
Compound 26 (1.00 g, 1.72 mmol) was dissolved in DMF (10-15 mL). To this 
solution of Fmoc-Asn(Trt)-OH (1.1 eq, 1.13 g, 1.89 mmol), TBTU (1.1 eq, 0.61 g, 
1.89 mmol) and HOBt (1.1 eq, 0.26 g, 1.89 mol) dissolved in DMF (10 mL) with 
the addition of DIPEA (3.2 eq, 0.95 g/mL, 5.50 mmol) was added following the 
same procedure as described for the synthesis of compound 26.The crude product 
was then purified by silica gel chromatography column (13.5 cmx4.5 cm) prepared 
with DCM:MeOH (9.5:0.5). The product was then eluted with further addition of 
MeOH (7%) to the eluent. Fractions containing the product were combined, filtered 
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and evaporated to dryness. Yield: 1.22 g (76%). TLC (fraction 3): Rf  0.2 
(DCM:MeOH-9:1). The molecular mass of the product (27) was 938.46           
ESMS-LR (+) m/z: 938.8 (100%) (M)+, 939.8 (60%) (M+H)+. ESMS-LR (-) m/z: 
937.4 (25%) (M-H)-, 1051.6 (20%) (M+TFA-H)-. 
III. Synthesis of intermediate compound H2N-Gly-Asn(Trt)-Lys(Boc)-
Spacer-AQ (28) 
Compound 27 (1.00 g, 1.07 mmol) was dissolved in DMF (10-15 mL). To this 
solution Fmoc-Gly-OH (1.1 eq, 0.35 g, 1.17 mmol), TBTU (1.1 eq, 0.38 g, 1.17 
mmol) and HOBt (1.1 eq, 0.16 g, 1.17 mmol) dissolved in DMF (5-10 mL) with the 
addition of DIPEA (3.2 eq, 0.59 g/mL, 3.41 mmol) was added following the same 
procedure as described for the synthesis of compound 26.The crude product was 
then purified by silica gel chromatography column (14.5 cmx4.5 cm) prepared with 
DCM:MeOH (9:1). Fractions containing the product were combined, filtered and 
evaporated to dryness. Yield: 0.71 g (67%). TLC (fraction 3): Rf  0.6 (DCM: MeOH- 
9:1). The molecular mass of the product (28) was 995.48, ESMS-LR (+) m/z: 
995.8 (100%) (M)+, 996.6 (M+H)+, 1017.6 (40%) (M+Na)+. ESMS-LR (-) m/z: 
993.4 (100%) (M-H)-, 1029.6 (M+Cl)-. 
IV. Synthesis of intermediate compound HN-Pro-Gly-Asn(Trt)-Lys(Boc)-
Spacer-AQ (29) 
Compound 28 (0.39 g, 0.39 mmol) was dissolved in DMF (5 mL). To this solution 
Fmoc-Pro-OH (1.1 eq, 0.15 g, 0.43 mmol), TBTU (1.1 eq, 0.14 g, 0.43 mmol) and 
HOBt (1.1 eq, 0.06 g, 0.43 mmol) dissolved in DMF (5-7 mL) with the addition of 
DIPEA (3.2 eq, 0.22 g/ml, 1.25 mmol) was added following the same procedure 
as described for the synthesis of compound 26.The crude product was then purified 
by silica gel chromatography column (20 cmx2.5 cm) prepared with DCM:MeOH 
(9:1). Fractions containing the product were combined, filtered and evaporated to 
dryness. Yield: 0.37 g (86%). TLC (fraction 3): Rf 0.4 (DCM: MeOH- 9:1). The 
molecular mass of the product (29) was 1092.53, ESMS-LR (+) m/z: 1092.6 
(100%) (M)+, 1093.6 (65%) (M+H)+, 1115.6 (M+Na)+. ESMS-LR (-) m/z: 1091.6 
(40%) (M-H)-, 1127.6 (65%) (M+Cl)-. 
V. Synthesis of intermediate compound 5(6)-CBF-Pro-Gly-Asn(Trt)-
Lys(Boc)-Spacer-AQ (30) 
Compound 29 (0.37 g, 0.34 mmol) was dissolved in DMF (3 mL). To this solution 
5(6)-Carboxyfluorescein (1 eq, 0.13 g, 0.34 mmol), TBTU (1.1 eq, 0.12 g, 0.37 
mmol) and HOBt (1.1 eq, 0.10 g, 0.37 mmol) dissolved in DMF (7 mL) with the 
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addition of DIPEA (3.2 eq, 0.19 g/mL, 1.08 mmol) was added and stirred at rt. The 
solution was partitioned between DCM and water. The organic extracts were 
washed with saturated sodium hydrogen carbonate (2 x 75 mL), then water (3 x 
75 mL), dried with anhydrous MgSO4, filtered and evaporated to low volume. The 
crude product was then purified by a silica gel chromatography column (23 cmx2.5 
cm) prepared with chloroform:MeOH:pyridine:35%ammonia (20:55:15:10). 
Fractions containing the product were combined, filtered and evaporated to 
dryness. Yield: 0.40 g (82%). TLC (fraction 2): Rf 0.6 (Chloroform: MeOH: 
Pyridine: Ammonia-20:55:15:10). The molecular mass of the product (30) was 
1450.58, ESMS-LR (+) m/z: 1451.4 (95%) (M+H)+, 1473.4 (M+Na)+. ESMS-LR (-
) m/z: 1449.4 (M-H)-, 1485.4 (M+Cl)-. 
V. Synthesis of 5(6)-CBF-Pro-Gly-Asn-Lys-Spacer-AQ (31) 
Compound 30 (0.40 g, 0.28 mmol) was dissolved in TFA (2 mL) at rt. After 3 hours 
TFA was evaporated and the resulting concentrate was re-evaporated with EtOH 
(x3). The residue was then triturated with diethyl ether (100 mL) and then stored 
at 4-6 °C for 12 hours. The precipitate was filtered and dried in a vacuum 
desiccator. The purity of the compound was 93% on an analytical RP-HPLC system 
following the general procedure as mentioned in 4.2.5. (Gradient A, 23 min, 275 
nm, Rt. 10.89’). Crude yield: 0.29 g (97%). TLC: Rf 0.1 (DCM: MeOH- 9:1). The 
molecular mass of the product (31) was 1108.42, ESI-HR (+) m/z: 1109.4252 
(100%) (M+H)+. ESMS-LR (+) m/z: 555.2 (100%) [(M+2H)/2]2+. 
3.4.4.2. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Lys-Spacer-AQ (34) 
I. Synthesis of intermediate compound H2N-β-Ala-Gly-Asn(Trt)-Lys(Boc)-
Spacer-AQ (32) 
Compound 28 (0.32 g, 0.32 mmoles) was dissolved in DMF (5 mL). To this solution 
Fmoc-β-Ala-OH (1.1 eq, 0.11 g, 0.35 mmol), TBTU (1.1 eq, 0.11 g, 0.35 mmol) 
and HOBt (1.1 eq, 0.05 g, 0.35 mol) dissolved in DMF (7 mL) with the addition of 
DIPEA (3.2 eq, 0.18 g/mL, 1.03 mmol) was added following the same procedure 
as described for the synthesis of compound 26.The crude product was then purified 
by silica gel chromatography column (21 cmx2.5 cm) prepared with DCM:MeOH 
(9:1). The column was eluted with the same solvent system. Fractions containing 
the product were combined, filtered and evaporated to a low volume. Yield: 0.30 
g (88%). TLC (fraction 3): Rf 0.5 (DCM:MeOH- 9:1). The molecular mass of the 
product (32) was 1066.52, ESMS-LR (+) m/z: 1066.6 (100%) (M)+, 1067.6 
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(M+H)+, 1089.6 (M+Na)+. ESMS-LR (-) m/z:  1065.6 (60%) (M-H)-, 1101.6 
(M+Cl)-. 
II. Synthesis of intermediate compound 5(6)-CBF-β-Ala-Gly-Asn(Trt)-
Lys(Boc)-Spacer-AQ (33)  
Compound 32 (0.30 g, 0.28 mmol) was dissolved in DMF (5 mL). To this solution 
5(6)-Carboxyfluorescein (1 eq, 0.11 g, 0.28 mmol), TBTU (1.1 eq, 0.10 g, 0.31 
mmol) and HOBt (1.1 eq, 0.04 g, 0.31 mol) dissolved in DMF (5-10 mL) with the 
addition of DIPEA (3.2 eq, 0.16 g/mL, 0.90 mmol) was added following the same 
procedure as described for the synthesis of compound 30. The crude product 
obtained was then purified a silica gel chromatography column (12 cmx4.5 cm) 
prepared with chloroform:MeOH:pyridine:35%ammonia (20:55:15:10). The 
column was eluted with the same solvent system. Fractions containing the product 
were combined, filtered and evaporated to dryness in vacuo. Yield: 0.31 g (78%). 
TLC (fraction 2): Rf 0.8(Chloroform: MeOH: Pyridine: Ammonia- 20:55:15:10). 
The molecular mass of the product (33) was 1424.56, ESMS-LR (+) m/z: 713.0 
(20%) [(M+2H)/2]2+, 1424.4 (100%) (M)+, 1425.4 (95%) (M+H)+. ESMS-LR (-) 
m/z: 1423.4 (100%) (M-H)-, 1424.2 (60%) (M)-, 1459.4 (60%) (M+Cl)-. 
III. Synthesis of 5(6)-CBF-β-Ala-Gly-Asn-Lys-Spacer-AQ (34) 
Compound 33 (0.31 g, 0.22 mmol) was dissolved in TFA (3 mL) at rt. After 3 hours 
TFA was evaporated and the resulting concentrate was re-evaporated with EtOH 
(x3). The residue was then triturated with diethyl ether (50 mL) and stored at 4-
6 °C for 12 hours. The precipitate was filtered and dried in a vacuum desiccator. 
The purity of the compound was 77% on an analytical RP-HPLC system following 
the general procedure as mentioned in 4.2.5. (Gradient A, 23 min, 275 nm, Rt. 
10.82’). Crude yield: 0.20 g (83%). TLC: Rf 0.5(DCM: MeOH- 9:1). The molecular 
mass of the product (34) was 1082.40, ESI-HR (+) m/z: 1083.4097 (100%) 
(M+H)+. ESMS-LR (+) m/z: 542.2 (100%) [(M+2H)/2]2+. 
3.4.4.3. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Lys-Spacer-AQ (38) 
I. Synthesis of intermediate compound H2N-Ala-Asn(Trt)-Lys(Boc)-
Spacer-AQ (35) 
Compound 27 (1.00 g, 1.07 mmol) was dissolved in DMF (10 mL). To this solution 
Fmoc-Ala-OH (1.1 eq, 0.36 g, 1.17 mmol), TBTU (1.1 eq, 0.38 g, 1.17 mmol) and 
HOBt (1.1 eq, 0.16 g, 1.17 mol) dissolved in DMF (10 mL) with the addition of 
DIPEA (3.2 eq, 0.59 g/mL, 3.41 mmol) was added following the same procedure 
as described for the synthesis of compound 26. The crude product was then 
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purified by silica gel chromatography column (15 cmx4.5 cm) prepared with 
DCM:MeOH (9:1). The column was eluted with the same solvent system. Fractions 
containing the product were combined, filtered and evaporated to dryness in 
vacuo. Yield: 0.84 g (78%). TLC (fraction 3): Rf 0.3 (DCM: Methanol- 9:1).  The 
molecular mass of the product (35) was 1009.49, ESMS-LR (+) m/z: 1009.8 
(100%) (M)+, 1010.8 (60%) (M+H)+. ESMS-LR (-) m/z: 1008.6 (65%) (M-H)-, 
1044.6 (40%) (M-Cl)-.  
II. Synthesis of intermediate compound HN-Pro-Ala-Asn(Trt)-Lys(Boc)-
Spacer-AQ (36) 
Compound 35 (0.42 g, 0.42 mmol) was dissolved in DMF (7 mL). To this solution 
Fmoc-Pro-OH (1.1 eq, 0.15 g, 0.46 mmol), TBTU (1.1 eq, 0.15 g, 0.46 mmol) and 
HOBt (1.1 eq, 0.06 g, 0.46 mmol) dissolved in DMF (10 mL) with the addition of 
DIPEA (3.2 eq, 0.23 g/mL, 1.33 mmol) was added following the same procedure 
as described for the synthesis of compound 26. The crude product was then 
purified by silica gel chromatography column (20 cmx2.5 cm) prepared with DCM: 
MeOH (9.5:0.5). The eluant was changed to DCM:MeOH (9:1) and the major 
product was eluted with the further addition of MeOH (5%) to the eluent. Fractions 
containing the product were combined, filtered and evaporated to dryness in 
vacuo. Yield: 0.37 g (80%). TLC (fraction 3): Rf 0.8 (DCM: MeOH- 9:1). The 
molecular mass of the product (36) was 1106.55, ESMS-LR (+) m/z: 554.0 (15%) 
[(M+2H)/2]2+, 1106.6 (100%) (M)+, 1107.6 (60%) (M+H)+, 1128.6 (15%) 
(M+Na)+. ESMS-LR (-) m/z: 1105.6 (35%) (M-H)-, 1141.6 (65%) (M+Cl)- 
III. Synthesis of intermediate compound 5(6)-CBF-Pro-Ala-Asn(Trt)-
Lys(Boc)-Spacer-AQ (37) 
Compound 36 (0.37 g, 0.33 mmol) was dissolved in DMF (5 mL). To this solution 
5(6),carboxyfluorescein (1 eq, 0.13 g, 0.33 mmol), TBTU (1.1 eq, 0.12 g, 0.37 
mmol) and HOBt (1.1 eq, 0.05 g, 0.37 mmol) dissolved in DMF (7 mL) with the 
addition of DIPEA (3.2 eq, 0.18 g/mL, 1.07 mmol) was added following the same 
procedure as described for the synthesis of compound 30. The crude product 
obtained was then purified by a silica gel chromatography column (17.5 cmx2.5 
cm) prepared with chloroform:MeOH:pyridine:35%ammonia (20:55:15:10). The 
column was eluted with the same solvent system. Fractions containing the product 
were combined, filtered and evaporated in vacuo. Yield: 0.34 g (69%). TLC 
(fraction 2): Rf 0.8(Chloroform:MeOH:Pyridine:Ammonia-20:55:15:10 ). The 
molecular mass of the product (37) was 1464.60, ESMS-LR (+) m/z: 733.0 (15%) 
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[(M+2H)/2]2+, 1464.4 (50%) (M)+, 1486.2 (M+Na)+. ESMS-LR (-) m/z: 1463.2 
(95%) (M-H)-, 1498.2 (60%) (M+Cl)-. 
IV. Synthesis of 5(6)-CBF-Pro-Ala-Asn-Lys-Spacer-AQ (38) 
Compound 37 (0.34 g, 0.23 mmol) was dissolved in TFA (2 mL) at room 
temperature. After 3 hours TFA was evaporated and the resulting concentrate was 
re-evaporated with EtOH (x3). The residue was then triturated with diethyl ether 
(50 mL) and stored at 4-6 °C for 12 hours. The precipitate was filtered and dried 
in a vacuum desiccator. Crude yield: 0.24 g (92%). TLC: Rf 0.5 (DCM: Methanol- 
9:1). The purity of the compound was 82% on an analytical RP-HPLC system 
following the general procedure as mentioned in 4.2.5. (Gradient A, 23 min, 275 
nm, Rt. 10.92’). The molecular mass of the product (38) was found to be 1122.43, 
ESI-HR (+) m/z: 1123.4411 (100%) (M+H)+. ESMS-LR (+) m/z: 562.2 (100%) 
[(M+2H)/2]2+. 
3.4.4.4. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Lys-Spacer-AQ (41) 
I. Synthesis of intermediate compound H2N-β-Ala-Ala-Asn-Lys-Spacer-AQ 
(39) 
Compound 35 (0.42 g, 0.42 mmol) was dissolved in DMF (5 mL). To this solution 
Fmoc-β-Ala-OH (1.1 eq, 0.14 g, 0.46 mmol), TBTU (1.1 eq, 0.15 g, 0.46 mmol) 
and HOBt (1.1 eq, 0.06 g, 0.46 mmol) dissolved in DMF (5-7 mL) with the addition 
of DIPEA (3.2 eq, 0.23 g/ml, 1.33 mmol) was added following the same procedure 
as described for the synthesis of compound 26. The crude product was then 
purified by silica gel chromatography column (20 cmx2.5 cm) prepared with DCM: 
MeOH (9.5:0.5). The eluant was changed to DCM:MeOH (9:1) and the major 
product was eluted with the further addition of MeOH (5%-10% gradients) to the 
eluant. Fractions containing the product were combined, filtered and evaporated 
to dryness in vacuo. Yield: 0.42 g (93%). TLC (fraction 3): Rf 0.5 (DCM:MeOH-
9:1). The molecular mass of the product (39) was 1080.53, ESMS-LR (+) m/z: 
1080.6 (100%) (M)+, 1081.6 (75%) (M+H)+, 1103.6 (15%) (M+Na)+. ESMS-LR (-
) m/z: 1079.6 (60%) (M-H)-, 1115.6 (70%) (M+Cl)-. 
II. Synthesis of intermediate compound 5(6)-CBF-β-Ala-Ala-Asn(Trt)-
Lys(Boc)-Spacer-AQ (40) 
Compound 39 (0.42 g, 0.39 mmol) was dissolved in DMF (5 mL). To this solution 
5(6)-Carboxyfluorescein (1 eq, 0.15 g, 0.39 mmol), TBTU (1.1 eq, 0.14 g, 0.43 
mmol) and HOBt (1.1 eq, 0.06 g, 0.43 mol) dissolved in DMF (5-7 mL) with the 
addition of DIPEA (3.2 eq, 0.21 g/ml, 1.24 mmol) was added following the same 
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procedure as described for the synthesis of compound 30. The crude product was 
then purified by a silica gel chromatography column (17.5 cmx4.5 cm) prepared 
with chloroform:MeOH:pyridine:35%ammonia (20:55:15:10). The column was 
eluted with the same solvent system. Fractions containing the product were 
combined, filtered and evaporated to a low volume in vacuo. Yield: 0.30 g (54%). 
TLC (fraction 2): Rf 0.8 (Chloroform: MeOH: Pyridine: Ammonia- 20:55:15:10). 
The molecular mass of the product (40) was 1438.58, ESMS-LR (+) m/z: 719.8 
(40%) [(M+2H)/2]2+, 1438.4 (100%) (M)+, 1439.4 (95%) (M+H)+. ESMS-LR (-) 
m/z: 1437.2 (100%) (M-H)-, 1473.2 (M+Cl)-. 
III. Synthesis of 5(6)-CBF-β-Ala-Ala-Asn-Lys-Spacer-AQ (41) 
Compound 40 (0.30 g, 0.21 mmol) was dissolved in TFA (2 mL) at room 
temperature. After 3 hours TFA was evaporated and the resulting concentrate was 
re-evaporated with ethanol (x3). The residue was then triturated with diethyl ether 
(50 mL) and stored at 4-6 °C for 12 hours. The precipitate was filtered and dried 
in a vacuum desiccator. Crude yield: 0.21 g (91%). TLC: Rf 0.5 (DCM:MeOH-4:1). 
The purity of the compound was 84% on an analytical RP-HPLC system following 
the general procedure as mentioned in 4.2.5. (Gradient A, 23 min, 275 nm, Rt. 
10.82’). The molecular mass of the product (41) was 1096.42, ESI-HR (+) m/z: 
1097.4250 (100%) (M+H)+. ESMS-LR (+) m/z: 549.2 (100%) [(M+2H)/2]2+. 
3.4.4.5. Synthesis of 5(6)-CBF-Ala-Pro-Ala-Asn-Leu-Spacer-AQ (46) 
I. Synthesis of intermediate compound H2N-Ala-Asn(Trt)-Leu-Spacer-AQ 
(42) 
Compound 22 (2.30 g, 2.79 mmol) was dissolved in DMF (10-15 mL). To this 
solution Fmoc-Ala-OH (1.1 eq, 0.96 g, 3.21 mmol), TBTU (1.1 eq, 0.99 g, 3.07 
mmol), HOBt (1.1 eq, 0.41 g, 3.07 mmol) dissolved in DMF (10 mL) followed by 
the addition of DIPEA (3.2 eq, 1.54 g/mL, 8.94 mmol) was added following the 
same procedure as described for the synthesis of compound 26. The crude product 
was then purified by silica gel chromatography column (15.5 cmx4.5 cm) prepared 
with DCM:MeOH (9.5:0.5). The eluant was changed to DCM:MeOH (9:1) and the 
major product was eluted with the further addition of methanol (5%-10% 
gradients) to the eluant. Fractions containing the product were combined, filtered 
and evaporated in vacuo. Yield: 1.40 g (56%). TLC (fraction 3): Rf 0.4 (DCM: 
MeOH-9:1). The molecular mass of the product (42) was 894.43, ESMS-LR (+) 
m/z: 894.8 (100%) (M)+, 895.8 (60%) (M+H)+, 916.6 (M+Na)+. ESMS-LR (-) 
893.0 (50%) (M-H)-, 928.2 (100%) (M+Cl)-, 1006.6 (40%) (M+TFA-H)-. 
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II. Synthesis of intermediate compound HN-Pro-Ala-Asn(Trt)-Leu-
Spacer-AQ (43) 
Compound 42 (1.40 g, 1.57 mmol) was dissolved in DMF (15 mL). To this solution 
Fmoc-Pro-OH (1.1 eq, 0.58 g, 1.72 mmol), TBTU (1.1 eq, 0.55 g, 1.72 mmoles), 
HOBt (1.1 eq, 0.23 g, 1.72 mmol) dissolved in DMF (5-10 mL) followed by the 
addition of DIPEA (3.2 eq, 0.86 g/mL, 5.01 mmol) was added following the same 
procedure as described for the synthesis of compound 26. The crude product was 
then purified by silica gel chromatography column (14 cmx4.5 cm) prepared with 
DCM:MeOH (9.5:0.5). The column was eluted with the same solvent system. 
Fractions containing the product were combined, filtered and evaporated in vacuo. 
Yield: 0.95 g (61%). TLC (fraction 3): Rf  0.5 (DCM:MeOH-9:1). The molecular 
mass of the product (43) was 991.48, ESMS-LR (+) m/z: 496.4 (15%) 
[(M+2H)/2]2+, 991.8 (100%) (M)+, 992.8 (M+H)+, 1014.6 (20%) (M+Na)+. 
III. Synthesis of intermediate compound H2N-Ala-Pro-Asn(Trt)-Leu-
Spacer-AQ (44) 
Compound 43 (0.40 g, 0.40 mmol) was dissolved in DMF (7 mL). To this solution 
Fmoc-Ala-OH (1.1 eq, 0.14 g, 0.44 mmol), TBTU (1.1 eq, 0.14 g, 0.44 mmol), 
HOBt (1.1 eq, 0.06 g, 0.44 mmol) dissolved in DMF (5-10 mL) followed by the 
addition of DIPEA (3.2 eq, 0.22 g/mL, 1.29 mmol) was added following the same 
procedure as described for the synthesis of compound 26. The crude product was 
then purified by silica gel chromatography column (20 cmx2.5 cm) prepared with 
DCM: MeOH (9.5:0.5). The eluant was changed to DCM:MeOH (9:1) and the major 
product was eluted with the further addition of MeOH (5%-10% gradients) to the 
eluant. Fractions containing the product were combined, filtered and evaporated 
to dryness in vacuo. Yield: 0.14 g (33%). TLC (fraction 4): Rf  0.6 (DCM: MeOH-
9:1). The molecular mass of the product (44) was 1062.52, ESMS-LR (+) m/z: 
532.0 (40%) [(M+2H)/2]2+, 543.0 (20%) [(M+2H+Na)/2]2+, 551.0 (15%) 
[(M+2H+K)/2]2+, 1062.8 (100%) (M)+, 1063.8 (70%) (M+H)+, 1084.8 (60%) 
(M+Na)+. 
IV. Synthesis of intermediate compound 5(6)-CBF-Ala-Pro-Asn(Trt)-Leu-
Spacer-AQ (45) 
Compound 44 (0.14 g, 0.13 mmol) was dissolved in DMF (7 mL). To this solution 
5(6)-Carboxyfluorescein (1 eq, 0.05 g, 0.13 mmol), TBTU (1.1 eq, 0.05 g, 0.14 
mmol), HOBt (1.1 eq, 0.02 g, 0.14 mmol) dissolved in DMF (5-10 mL) followed by 
the addition of DIPEA (3.2 eq, 0.07 g/ml, 0.42 mmol) was added following the 
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same procedure as described for the synthesis of compound 30. The crude product 
was then purified by silica gel chromatography column (17 cmx2.5 cm) prepared 
with DCM:MeOH (9.5:0.5). The eluant was changed to DCM:MeOH (9:1) and the 
major product was eluted with the further addition of methanol (5%-10% 
gradients) to the eluant. Fractions containing the product were combined, filtered 
and evaporated to a low volume in vacuo. Yield: 0.10 g (53%). TLC (fraction 2): 
Rf  0.7 (DCM: MeOH-9:1). The molecular mass of the product (45) was 1420.57, 
ESMS-LR (+) m/z: 711.0 (15%) [(M+2H)/2]2+, 1420.4 (45%) (M)+, 1421.4 (40%) 
(M+H)+, 1443.2 (95%) (M+Na)+. ESMS-LR (-) m/z: 1419.8 (80%) (M-H)-. 
V. Synthesis of 5(6)-CBF-Ala-Pro-Asn-Leu-Spacer-AQ (46) 
Compound 45 (0.10 g, 0.07 mmol) was dissolved in TFA (2 mL) at room 
temperature. After 3 hours TFA was evaporated and the resulting concentrate was 
re-evaporated with EtOH (x3). The residue was then triturated with diethyl ether 
(50 mL) and stored at 4-6 °C for 12 hours. The precipitate was filtered and dried 
in a vacuum desiccator. Crude yield: 0.06 g (75%). TLC: Rf 0.5 (DCM:MeOH-9:1). 
The purity of the compound was 64% on an analytical RP-HPLC system following 
the general procedure as mentioned in 4.2.5. (Gradient A, 23 min, 275 nm, Rt. 
17.16’). The molecular mass of the product (46) was 1178.46, ESI-HR (+) m/z: 
1179.4674 (100%) (M+H)+. ESMS-LR (+) m/z: 590.2 (100%) [(M+2H)/2]2+. 
ESMS-LR (-) m/z: 1177.6 (60%) (M-H)-, 1213.6 (20%) (M+Cl)-. 
3.5. Synthesis of Gadolinium-DOTA-Peptide substrates [Leucine-JS Linear 
sequences] 
A. Synthesis of Gd(III)DOTA-Pro-Ala-Asn-Leu-Spacer-AQ (49) 
I. Synthesis of intermediate compound DOTA(t-Bu)-Pro-Ala-Asn(Trt)-
Leu-Spacer-AQ (47)  
Compound 43 (0.30 g, 0.30 mmol) was dissolved in DMF (5 mL). To this solution 
Tri-tert-butyl1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA-tri-t-
Bu-ester) (1.1 eq, 0.19 g, 0.33 mmol), TBTU (1.1 eq, 0.11 g, 0.33 mmol), HOBt 
(1.1 eq, 0.04 g, 0.33 mmol) dissolved in DMF (7 mL) followed by the addition of 
DIPEA (3.2 eq, 0.17 g/ml, 0.97 mmol) was added and stirred at rt overnight. The 
solution was then partitioned between DCM and water. The organic extract was 
washed with saturated sodium hydrogen carbonate (1x75 mL), then water (3x 75 
mL), dried with anhydrous MgSO4, filtered and evaporated to low volume. The 
crude product was then purified by a silica gel chromatography column (20 cmx2.5 
cm) prepared with DCM:MeOH (9.5:0.5) and the major product was eluted with 
206 
 
the further addition of methanol (5%-10% gradients) to the eluant. Fractions 
containing the product were combined, filtered and evaporated to a low volume in 
vacuo. Yield: 0.20 g (43%). TLC (fraction 2): Rf 0.8 (DCM:MeOH-9:1). The 
molecular mass of the product (47) was 1545.85, ESI-HR (+) m/z: 1568.8402 
(100%) (M+Na)+. ESMS-LR (+) m/z: 784.9 (100%) [(M+Na)/2]2+. 
II. Synthesis of intermediate compound DOTA-Pro-Ala-Asn-Leu-Spacer-
AQ (48)  
Compound 47 (0.20 g, 0.13 mmol) was dissolved in TFA (2 mL) at rt. After 4 hours 
TFA was evaporated and the resulting concentrate was re-evaporated with EtOH 
(x3). The residue was then triturated with diethyl ether (75 mL) and stored at 4-
6 °C for 12 hours. The precipitate was filtered and dried in a vacuum desiccator. 
Crude yield: 0.13 g (87%). TLC: Rf 0.2 (DCM:MeOH-9:1). The molecular mass of 
the product (48) was 1135.55, ESI-HR (+) m/z: 568.7844 (100%) [(M+2H)/2]2+. 
ESMS-LR (+) m/z: 587.7(100%) [(M+2H+K)/2]2+.  
III. Synthesis Gd(III)DOTA-Pro-Ala-Asn-Leu-Spacer-AQ (49)  
Compound 48 (0.10 g, 0.09 mmol) was dissolved in water (3 mL). To this solution 
Gadolinium(III)chloridehexahydrate (2.8 eq, 0.09 g, 0.25 mmol) dissolved in 
water (2 mL) was added. The pH of the reaction mixture was adjusted to 7 by 
adding a solution of ammonia 0.35% drop wise. Reaction progress was monitored 
by TLC analysis. The solution was evaporated to low volume. The crude product 
was then purified by a silica gel chromatography column (10 cmx2.5 cm) prepared 
with chloroform:MeOH:pyridine:35%ammonia (20:55:15:10). The column was 
eluted with the same solvent system. Fractions containing the product were 
combined, filtered and evaporated to a low volume in vacuo. Yield: 0.10 g (91%). 
TLC (fraction 3): Rf 0.2 (chloroform:MeOH:pyridine: ammonia-20:55:15:10). The 
purity of the compound was 72% on an analytical RP-HPLC system following the 
general procedure as mentioned in 4.2.5. (Gradient B, 23 min, 245 nm, Rt. 
14.77’). The molecular mass of the product (49) was 1290.45, ESI-HR (+) m/z: 
646.2351 (100%) [(M+2H)/2]2+. ESMS-LR (+) m/z: 657.2 (20%) 
[(M+2H+Na)/2]2+, 1291.4 (90%) (M+H)+, 1313.4 (100%) (M+Na)+. 
B. Synthesis of Gd(III)DOTA-Pro-Gly-Asn-Leu-Spacer-AQ (53) 
I. Synthesis of intermediate compound HN-Pro-Gly-Asn(Trt)-Leu-Spacer-
AQ (50) 
Compound 23 (0.54 g, 0.61 mmol) was dissolved in DMF (10 mL). To this solution 
Fmoc-Pro-OH (1.1 eq, 23.00 g, 0.67 mmoles), TBTU (1.1 eq, 0.22 g, 0.67 mmol), 
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HOBt (1.1 eq, 0.09 g, 0.67 mmol) dissolved in DMF (10 mL) followed by the 
addition of DIPEA (3.2 eq, 0.34 g/mL, 1.96 mmol) was added following the same 
procedure as described for the synthesis of compound 26. The crude product was 
then purified by silica gel chromatography column (12 cmx4.5 cm) prepared with 
DCM: MeOH (9.5:0.5). The eluant was changed to DCM:MeOH (9:1) and the major 
product was eluted with the further addition of MeOH (5%-10% gradients) to the 
eluant. Fractions containing the product were combined, filtered and evaporated 
to a low volume in vacuo. Yield: 0.51 g (85%). TLC (fraction 3): Rf 0.2 
(DCM:MeOH-9:1). The molecular mass of the product (50) was 977.47, ESMS-LR 
(+) m/z: 489.8 (15%) [(M+2H)/2]2+, 978.4 (100%) (M+H)+, 1000.2 (25%) 
(M+Na)+. ESMS-LR (-) m/z: 976.2 (100%) (M-H)-, 1012.2 (15%) (M+Cl)-. 
II. Synthesis of intermediate compound DOTA(t-Bu)-Pro-Gly-Asn(Trt)-
Leu-Spacer-AQ (51) 
Compound 50 (0.20 g, 0.20 mmol) was dissolved in DMF (5 mL). To this solution 
DOTA-tri-t-Bu-ester (1.1 eq, 0.13 g, 0.23 mmol), TBTU (1.1 eq, 0.07 g, 0.23 
mmol), HOBt (1.1 eq, 0.03 g, 0.23 mmol) dissolved in DMF (5-10 mL) followed by 
the addition of DIPEA (3.2 eq, 0.11 g/mL, 0.65 mmol) was added following the 
same procedure as described for the synthesis of compound 47. The crude product 
obtained was then purified by a silica gel chromatography column (16.5 cmx2.5 
cm) prepared with DCM:MeOH (9.5:0.5) and the major product was eluted with 
the further addition of MeOH (5%-15% gradients) to the eluant. Fractions 
containing the product were combined, filtered and evaporated to a low volume. 
Yield: 0.16 g (52%). TLC (fraction 2): Rf 0.6 (DCM:MeOH-9:1). The molecular mass 
of the product (51) was 1531.84, ESI-HR (+) m/z: 788.9055 (100%) 
[(M+2H+Na)/2]2+. 
III. Synthesis of intermediate compound DOTA-Pro-Gly-Asn-Leu-Spacer-
AQ (52) 
Compound 51 (0.16 g, 0.10 mmol) was dissolved in TFA (2 mL) at rt. After 7 hours 
TFA was evaporated and the resulting concentrate was re-evaporated with EtOH 
(x3). The residue was then triturated with diethyl ether (50 mL) and stored at 4-
6 °C for 12 hours. The precipitate was filtered and dried in a vacuum desiccator. 
Crude yield: 0.10 g (83%). TLC: Rf 0.3 (DCM:MeOH-9:1). The molecular mass of 
the product (52) was 1121.54, ESI-HR (+) m/z: 583.7 (100%) [(M+2Na)/2]2+.  
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IV. Synthesis of Gd(III)DOTA-Pro-Gly-Asn-Leu-Spacer-AQ (53) 
Compound 52 (0.10 g, 0.09 mmol) was dissolved in water (3 mL). To this solution 
Gadolinium(III)chloridehexahydrate (2.8 eq, 0.09 g, 0.25 mmol) dissolved in 
water (2 mL) was added following the same procedure as described for the 
synthesis of compound 49. The crude product was then purified by a silica gel 
chromatography column (9cmx2.5cm) prepared with chloroform:MeOH: pyridine: 
35%ammonia (20:55:15:10). The column was eluted with the same solvent 
system. Fractions containing the product were combined, filtered and evaporated 
to a low volume. Yield: 0.02 g (18%). TLC (4): Rf 0.3 (chloroform: 
MeOH:pyridine:ammonia-20:55:15:10). The purity of the compound was 77% on 
an analytical RP-HPLC system following the general procedure as mentioned in 
4.2.5. (Gradient B, 23 min, 245 nm, Rt. 15.43’). The molecular mass of the product 
(53) was 1276.44, ESI-HR (+) m/z: 661.2134 (100%) [(M+2Na)/2]2+. ESMS-LR 
(+) m/z: 659.7 (100%) (M/2+ACN+H)2+, 1299.4 (100%) (M+Na)+. 
3.6. Synthesis of Gadolinium-DOTA-Peptide substrates- JS Lysine 
sequence 
3.6.1. Synthesis of Gadolinium complex using 1,4,7,10-Tetraazacyclodo 
decane-1,4,7,10-tetraacetic acid (58) 
I. Synthesis of Fmoc-Lys(Boc)-Spacer-AQ (54) 
Compound 5 (1.00 g, 2.82 mmol) was dissolved in DMF (10 mL). To this solution 
Fmoc-Lys(Boc)-OH (1.1 eq, 1.46 g, 3.11 mmol), TBTU (1.1 eq, 1.00 g, 3.11 mmol) 
and HOBt (1.1 eq, 0.42 g, 3.11 mol) dissolved in DMF (10 mL) with the addition 
of DIPEA (3.2 eq, 1.56 g/mL, 9.04 mmol) was added and stirred at rt. Reaction 
progress was monitored by TLC analysis. The solution was partitioned between 
DCM and water. The organic extract was washed with saturated sodium hydrogen 
carbonate (3 x 100 mL), then water (3 x 100 mL), dried with anhydrous MgSO4, 
filtered and evaporated to a low volume using a rotary evaporator. The crude 
product was purified by a silica gel chromatography column (17 cmx4.5 cm) with 
5% methanol in dichloromethane. The fraction containing the required product was 
filtered and evaporated to dryness. Yield: 1.85 g (81%). TLC (fraction 2): Rf 0.8 
(DCM:MeOH-9:1). The molecular mass of the product (54) was 804.37, ESI-HR 
(+) m/z: 805.3811 (100%) (M+H)+. ESMS-LR (+) m/z: 827 (M+Na)+. 
1H NMR (400MHz, d6-DMSO), δ ppm: 1.17-1.40 (13H, m, tBoc group, γ-CH2, δ-
CH2 of lys side chain), 1.46-1.62 (2H, m, β-CH2-Lys side chain), 2.82-2.89 (2H, 
m, ε-CH2 of lys side chain), 3.17-3.29 (2H, m, CH2-NH-COO), 3.45 (2H, t, J=5.8Hz, 
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CH2-CH2-NH-COO), 3.49-3.61 (6H, m, CH2-NH-AQ, O-CH2-CH2-O), 3.70 (2H, t, 
J=5.2Hz, CH2-CH2-NH-AQ), 3.90-3.95 (1H, m, α-CH-Lys side chain), 4.17-4.29 
(3H, m, CH2-CH-Fmoc group), 6.76 (1H, t, J=5.6Hz, NH-COO-tBoc group), 7.26-
7.33 (3H, m, H-2, H-10, H-15), 7.36-7.45 (3H, m, H-4, H-11, H-14), 7.62-7.66 
(1H, m, H-3), 7.70-7.73 (2H, m, H-9, H-16), 7.81-7.95 (5H, m, H-6, H-7, H12, 
H13, NH-Spacer arm), 8.12 (1H, dd J1=7.6Hz, J2=1.2Hz, H-5), 8.20 (1H, dd, 
J1=8Hz, J2=1.2Hz, H-8), 9.78 (1H, t, J=5Hz, NH-AQ).  
II. Synthesis of Fmoc-Lys-Spacer-AQ trifluoroacetate salt (55) 
Compound 54 (0.42 g, 0.52 mmoles) was dissolved in TFA (3 mL) at rt. Reaction 
progress was monitored by TLC analysis. TFA was then evaporated and the 
resulting concentrate was re-evaporated with EtOH (x3). The residue was then 
triturated with diethyl ether (100 mL) and stored at 4-6°C for 12 hours. The 
precipitate was filtered and dried in a vacuum desiccator. Crude yield: 0.20g 
(54%). TLC: Rf 0.1 (DCM: MeOH- 9:1). The purity of the compound was 95% on 
an analytical RP-HPLC system following the general procedure as mentioned in 
4.2.5. (Gradient A, 23 min, 254 nm, Rt. 16.59’). The molecular mass of the product 
(55) was 704.32, ESI-HR (+) m/z: 705.3280 (100%) (M+H)+. ESMS-LR (+) m/z: 
1409.64 (100%) (M+2H)+. 
1H NMR (400MHz, d6-DMSO), δ ppm: 1.27-1.32 (2H, m, γ-CH2-Lys side chain), 
1.51-1.61 (4H, m, β-CH2, δ-CH2 of lys side chain), 2.74-2.76 (2H, m, ε-CH2), 3.24 
(2H, q, J=6.0Hz, CH2-NH-COO), 3.46 (2H, t, J=5.8Hz, CH2-CH2-NH-COO), 3.51-
3.61 (6H, m, CH2-NH-AQ, O-CH2-CH2-O), 3.70 (2H, t, J=5.2Hz, CH2-CH2-NH-AQ), 
3.92-3.98 (1H, m, α-CH-Lys side chain), 4.19 (1H, t, J=7.0Hz, CH-Fmoc group), 
4.26 (2H, d, J=6.4Hz, CH2-CH-Fmoc group), 7.26-7.33 (3H, m, H-2, H-10, H-15), 
7.38-7.48 (3H, m, H-4, H-11, H-14), 7.62-7.73 (5H, m, H-3, H-9, H-16, NH2-Lys 
side chain), 7.81-7.91 (4H, m, H-12, H-13, H-6, H-7), 7.94 (1H, t, J=5.4Hz, NH-
Spacer arm), 8.13 (1H, dd, J1=7.6Hz, J2=1.2Hz, H-5), 8.19 (1H, d, J=7.6Hz, H-
8), 9.77 (1H, t, J=4.4Hz, NH-AQ). 
III. Synthesis of H2N-Lys(DOTAtBu)-Spacer-AQ (56) 
Compound 55 (0.20 g, 0.28 mmol) was dissolved in DMF (4 mL). To this solution 
DOTA-tri-t-Bu-ester (1.1 eq, 0.18 g, 0.31 mmol), TBTU (1.1 eq, 0.10 g, 0.31 
mmol) and HOBt (1.1 eq, 0.04 g, 0.31 mol) dissolved in DMF (2 mL) with the 
addition of DIPEA (3.2 eq, 0.17 g/mL, 0.91 mmol) was added and stirred at rt. 
Reaction progress was monitored by TLC analysis. The solution was then 
partitioned between DCM and water. The organic extracts were washed with 
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saturated sodium hydrogen carbonate (3 x 75 mL), then water (3 x 75 mL) and 
dried with anhydrous MgSO4, filtered and evaporated to low volume. The crude 
product was then purified using a silica gel chromatography column (12 cmx2.5 
cm) prepared with DCM:MeOH (9.5:0.5). The eluent was then changed to 
DCM:MeOH (9:1). Fractions containing the product were combined, filtered and 
evaporated to low volume. Then followed by treating the pure sample with 20% 
v/v of piperidine in DMF (3 mL) and the amino terminus was deprotected as in 
method G. The solution was partitioned between DCM and water. The organic 
extracts were washed with saturated sodium hydrogen carbonate (2 x 75 mL), 
then water (2 x 75 mL) and evaporated to low volume. The crude product was 
then purified by silica gel chromatography column (15 cmx2.5 cm) prepared with 
DCM:MeOH (9.5:0.5). The eluant was changed to DCM:MeOH (9:1) and the major 
product was eluted with the further addition of MeOH (5%-10% gradients) to the 
eluant. Fractions containing the product were combined, filtered and evaporated 
to low volume. Yield: 0.08 g (28%). TLC: Rf  0.2 (DCM:MeOH-9:1). 
The purity of the compound was 90% on an analytical RP-HPLC system following 
the general procedure as mentioned in 4.2.5. (Gradient F, 20 min, 247 nm, Rt. 
8.34’). The molecular mass of the product (56) was 1036.62, ESI-HR (+) m/z: 
1059.6071 (100%) (M+Na)+. ESMS-LR (+) m/z: 519.4 (100%) (M/2+H)+, 1037.4 
(85%) (M+H)+, ESMS (-) m/z: 1035.2 (50%) (M-H)-. 
IV. Synthesis of H2N-Lys(DOTA-OH)-Spacer-AQ (57) 
Compound 56 (0.08 g, 0.08 mmoles) was dissolved in trifluoroacetic acid (2 ml) 
at rt. Reaction completion was monitored by TLC analysis. The solvent was then 
evaporated and the resulting concentrate was re-evaporated with EtOH (x3). The 
residue was triturated with diethyl ether (70 mL) and stored at 4-6 °C for 12 hours, 
filtered and dried in a vacuum desiccator. Crude yield: 0.03 g (43%). TLC: Rf 0.2 
(DCM:MeOH-9:1). The purity of the compound was 95% on an analytical RP-HPLC 
system following the general procedure as mentioned in 4.2.5. (Gradient F, 20 
min, 247 nm, Rt. 8.82’). The molecular mass of the product (57) was 868.43, 
ESMS-LR (+) m/z: 435.2 (100%) [(M+2H)/2]2+, 869.2 (95%) (M+H)+. ESI-HR (-
) m/z: 867.4259 (100%) (M-H)-. 
V. Synthesis of H2N-Lys(DOTA-Gd3+)-Spacer-AQ (58) 
Compound 57 (0.03 g, 0.03 mmol) was dissolved in water (3 mL). To this solution 
Gadolinium(III)chloridehexahydrate (2.8 eq, 0.04 g, 0.10 mmol) dissolved in 
water (2 mL) was added. The pH of the reaction mixture was adjusted to 7 by 
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adding a solution of ammonia 0.35% drop wise. Reaction progress was monitored 
by TLC, which showed a single new component and no presence of starting 
material. Crude yield: 0.02 g (50%). TLC: Rf 0.4 (Chloroform:MeOH:Pyridine: 
Ammonia-20:55:15:10). The molecular mass of the product (58) was 1023.33, 
ESMS-LR (+) m/z: 1024.2 (30%) (M+H)+. ESMS-LR (-) m/z: 1022 (60%) (M-H)-
1057.2 (20%) (M-Cl)-. 
3.6.2. Synthesis of JS-Lysine series of tetra peptide substrates 
A. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-Gd3+)-Spacer-AQ (62) 
I. Synthesis of Fmoc-Pro-Gly-Asn(Trt)-OH (59) 
An asparagine pre-loaded resin for solid phase peptide synthesis with a 4-
carboxytrityl linker (0.5 g, 0.21 mmol/g) was swollen in DCM according to method 
A and the coupling and deprotection cycles were performed as per methods C, D, 
B followed by peptide cleavage from the resin according to method E: 
 1st cycle: N-Fmoc-Glycine (0.23 g, 0.79 mmol) 
 2nd cycle: N-Fmoc-L-Proline (0.27 g, 0.79 mmol) 
Upon successful coupling of the second amino acid, the tri peptide was cleaved 
from the resin following method E. Crude yield: 0.06 g (75%). The purity of the 
compound was 70% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient A, 23 min, 254 nm, Rt. 15.36’). The 
molecular weight of the product (59) was 750.30, ESI-HR (+) m/z: 751.3120 
(100%) (M+H)+. ESMS-LR (+) m/z: 750.8 (100%) (M)+, 772.8 (100%) (M+Na)+. 
ESMS-LR (-) m/z: 250.2 (80%) [(M-3H)/3]3-, 749.4 (15%) (M-H)-. 
II. Synthesis of Fmoc-Pro-Gly-Asn(Trt)-Lys(DOTA-tBu)-Spacer-AQ (60) 
Peptide sequence 59 (0.06 g, 0.08 mmol) was dissolved in DMF (3 mL). To this 
solution compound 56 (1.1 eq, 0.09 g, 0.09 mmol), TBTU (3.3 eq, 0.08 g, 0.26 
mmol), HOBt (3.3 eq, 0.04 g, 0.26 mmol) dissolved in DMF (5-10 mL) followed by 
the addition of DIPEA (9.6 eq, 0.13 g/mL, 0.77 mmol) was added and stirred at rt 
for 5 hrs. Reaction progress was monitored via TLC analysis. The solution was then 
partitioned between DCM and water. The organic extracts were washed with 
saturated sodium hydrogen carbonate (1 x 75 mL), then water (3 x 75 mL), dried 
with anhydrous MgSO4, filtered and evaporated to low volume. The crude product 
was then purified by a silica gel chromatography column (15 cmx2.5 cm) prepared 
with DCM:MeOH (9.3:0.8) and the major product was eluted with the further 
addition of MeOH (10%-15% gradients) to the eluant. Fractions containing the 
product were combined, filtered and evaporated in vacuo. Yield: 0.06 g (43%). 
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TLC (fraction 3): Rf  0.7 (DCM:MeOH-9:1). The molecular weight of the product 
(60) was 1770.92, ESMS-LR (+) m/z: 885.0 (100%) [(M+2H)/2]2+, 1792.4 (15%) 
(M+Na)+. ESMS-LR (-) m/z: 1803.6 (15%) (M+Cl)-. 
III. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-OH)-Spacer-AQ (61) 
Compound 60 (0.06 g, 0.03 mmol) was dissolved in TFA (2 mL) at rt. After 3 hours 
TFA was evaporated and the resulting concentrate was re-evaporated with 
EtOH(x3). The residue was then triturated with diethyl ether (50 mL) and stored 
at 4-6 °C for 12 hours. The precipitate was filtered and dried in a vacuum 
desiccator. Crude yield: 0.04 g (80%). TLC: Rf 0.5 (DCM:MeOH-9:1). The 
molecular mass of the product (61) was 1358.62, ESMS-LR (+) m/z: 680.0(95%) 
[(M+2H)/2]2+, 1358.4 (100%) (M)+, 1359.4 (85%) (M+H)+, 1381.4 (40%) 
(M+Na)+. ESMS-LR (-) m/z: 1357.2 (20%) (M-H)-. 
IV. Synthesis of Fmoc-Pro-Gly-Asn-Lys(DOTA-Gd3+)-Spacer-AQ (62) 
Compound 61 (0.04 g, 0.03 mmol) was dissolved in water (2 mL). To this solution 
Gadolinium(III)chloridehexahydrate (2.8 eq, 0.03 g, 0,08 mmol) dissolved in 
water (2 mL) was added. The pH of the reaction mixture was adjusted to 7 by 
adding a solution of ammonia 0.35% drop wise. Reaction progress was monitored 
by TLC analysis. The solution was evaporated to a low volume. The crude product 
obtained was then purified by a silica gel chromatography column (15 cmx2.5 cm) 
prepared with chloroform:MeOH:pyridine:35%ammonia (20:55:15:10). The 
column was eluted with the same solvent system. Fractions containing the product 
were combined, filtered and evaporated to a low volume. Yield: 0.03 g (75%). TLC 
(fraction 2): Rf  0.6 (Chloroform:MeOH:Pyridine:Ammonia-20:55:15:10). The 
purity of the compound was 45% on an analytical RP-HPLC system following the 
general procedure as mentioned in 4.2.5. (Gradient E, 23 min, 254 nm, Rt. 11.81’). 
The molecular mass of the product (62) was 1513.52, ESI-HR (+) m/z: 1536.5082 
(100%) (M+Na)+. ESMS-LR (+) m/z: 768.7 (60%) [(M+2H+Na)/2]2+, 779.7 
(100%) [(M+2Na)/2]2+, 1514.5 (30%) (M+H)+. 
B. Synthesis of of Fmoc-β-Ala-Gly-Asn-Lys(DOTA-Gd3+)-Spacer-AQ (66) 
I. Synthesis of Fmoc-β-Ala-Gly-Asn(Trt)-OH (63) 
An asparagine pre-loaded resin for solid phase peptide synthesis with a 4-
carboxytrityl linker (0.5 g, 0.21 mmol/g) was swollen in DCM according to method 
A and the coupling and deprotection cycles were performed as per methods C, D, 
B followed by peptide cleavage from the resin according to method E: 
 1st cycle: N-Fmoc-Glycine (0.23 g, 0.79 mmol). 
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 2nd cycle: N-Fmoc-β-Alanine (0.25 g, 0.79 mol). 
Upon successful coupling of the second amino acid, the tri peptide was cleaved 
from the resin following method E. Crude yield: 0.06 g (75%). The purity of the 
compound was 83% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient A, 23 min, 254 nm, Rt. 14.41’). The 
molecular weight of the product (63) was 724.29, ESI-HR (+) m/z: 725.2967 
(100%) (M+H)+. ESMS-LR (+) m/z: 724.8(40%) (M)+, 748.8 (100%) (M+Na)+. 
ESMS-LR (-) m/z:  723.2 (20%) (M-H)-. 
II. Synthesis of Fmoc-β-Ala-Gly-Asn(Trt)-Lys(DOTA-tBu)-Spacer-AQ (64) 
Peptide sequence 63 (0.06 g, 0.08 mmol) was dissolved in DMF (3 mL). To this 
solution compound 56 (1.1 eq, 0.09 g, 0.09 mmol), TBTU (3.3 eq, 0.09 g, 0.27 
mmol), HOBt (3.3 eq, 0.04 g, 0.27 mmol) dissolved in DMF (5-10 mL) followed by 
the addition of DIPEA (9.6 eq, 0.14 g/mL, 0.80 mmol) was added following the 
same procedure as described for the synthesis of compound 60. The crude product 
obtained was then purified by a silica gel chromatography column (15 cmx2.5 cm) 
prepared with DCM:MeOH (9.3:0.8) and the major product was eluted with the 
further addition of MeOH (10%-15% gradients) to the eluant. Fractions containing 
the product were combined, filtered and evaporated to a low volume. Yield: 0.08 
g (57%). TLC (fraction 2): Rf 0.7 (DCM:MeOH-9:1). The molecular weight of the 
product (64) was 1742.90, ESMS-LR (+) m/z: 872.4 (100%) [(M+2H)/2]2+, 
1742.4 (30%) (M)+, 1764.4 (15%) (M+Na)+. ESMS-LR (-) m/z: 1777.6 (40%) 
(M+Cl)-. 
III. Synthesis of Fmoc-β-Ala-Gly-Asn-Lys(DOTA-OH)-Spacer-AQ (65) 
Compound 64 (0.06 g, 0.03 mmol) was dissolved in TFA (2 mL) at rt following the 
same procedure as described for the synthesis of compound 61. The precipitate 
was filtered and dried in a vacuum desiccator. Crude yield: 0.03 g (60%). TLC: Rf 
0.4 (DCM:MeOH-9:1). The molecular mass of the product (65) was 1332.60, 
ESMS-LR (+) m/z: 667.0 (100%) [(M+2H)/2]2+, 1333.6 (40%) (M+H)+. ESMS-LR 
(-) m/z: 1331.4 (55%) (M-H)-. 
IV. Synthesis of of Fmoc-β-Ala-Gly-Asn-Lys(DOTA-Gd3+)-Spacer-AQ (66) 
Compound 65 (0.03 g, 0.02 mmol) was dissolved in water (3 mL). To this solution 
Gadolinium(III)chloridehexahydrate (2.8 eq, 0.02 g, 0.06 mmol) dissolved in 
water (2 mL) was added following the same procedure as described for the 
synthesis of compound 62. The crude product obtained was then purified by a 
silica gel chromatography column (13.5 cmx2.5 cm) prepared with 
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chloroform:MeOH:pyridine:35%ammonia (20:55:15:10). The column was eluted 
with the same solvent system. Fractions containing the product were combined, 
filtered and evaporated to a low volume. Yield: 0.01 g (33%). TLC (fraction 2): Rf 
0.2 (Chloroform:MeOH:Pyridine Ammonia-20:55:15:10). The molecular mass of 
the product (66) was 1487.50, ESMS-LR (+) m/z: 1520.9 (100%) 
(M+CH3OH+H)+, 1533.9 (85%) (M+2Na-H)+. 
C. Synthesis of of Fmoc-Pro-Ala-Asn-Lys(DOTA-Gd3+)-Spacer-AQ (70) 
I. Synthesis of Fmoc-Pro-Ala-Asn(Trt)-OH (67) 
An asparagine pre-loaded resin for solid phase peptide synthesis with a 4-
carboxytrityl linker (0.5 g, 0.21 mmol/g) was swollen in DCM according to method 
A and the coupling and deprotection cycles were performed as per methods C, D, 
B followed by peptide cleavage from the resin according to method E: 
 1st cycle: N-Fmoc-L-Alanine (0.25 g, 0.79 mmol). 
 2nd cycle: N-Fmoc-L-Proline (0.27 g, 0.79 mmol). 
Upon successful coupling of the second amino acid, the tri peptide was cleaved 
from the resin following method E. Crude yield: 0.05 g (63%). The purity of the 
compound was 66% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient A, 23 min, 254 nm, Rt. 14.68’). The 
molecular weight of the product (67) was 764.32, ESI-HR (+) m/z: 765.3280 
(100%) (M+H)+, ESMS-LR (+) m/z: 764.8(40%) (M)+, 786.8 (100%) (M+Na)+. 
ESMS-LR (-) m/z: 763.6 (20%) (M-H)-. 
II. Synthesis of Fmoc-Pro-Ala-Asn(Trt)-Lys(DOTA-tBu)-Spacer-AQ (68) 
Peptide sequence 67 (0.05 g, 0.07 mmol) was dissolved in DMF (3 mL). To this 
solution compound 56 (1.1 eq, 0.07 g, 0.07 mmol), TBTU (3.3 eq, 0.07 g, 0.22 
mmol), HOBt (3.3 eq, 0.03 g, 0.22 mmol) dissolved in DMF (5-10 mL) followed by 
the addition of DIPEA (9.6 eq, 0.11 g/mL, 0.63 mmol) was added following the 
same procedure as described for the synthesis of compound 60. The product was 
used for subsequent reaction without further purification. Crude yield: 0.09 g 
(75%). TLC: Rf  0.7 (DCM:MeOH-9:1).  The molecular weight of the product (68) 
was 1782.93, ESMS-LR (+) m/z: 892.0 (100%) [(M+2H/2)]2+, 1782.4 (40%) 
(M)+. ESMS-LR (-) m/z: 1816.0 (40%) (M+Cl)-. 
III. Synthesis of Fmoc-Pro-Ala-Asn-Lys(DOTA-OH)-Spacer-AQ (69) 
Compound 68 (0.09 g, 0.05 mmol) was dissolved in TFA (2 mL) at rt following the 
same procedure as described for the synthesis of compound 61. The precipitate 
was filtered and dried in a vacuum desiccator. Crude yield: 0.06 g (86%). TLC: Rf 
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0.5 (DCM:MeOH-9:1). The molecular mass of the product (69) was 1372.63, 
ESMS-LR (+) m/z: 687.2 (100%) [(M+2H)/2]2+, 698.0 (40%) [(M+2H+Na)/ 2]2+, 
1373.0 (15%) (M+H)+. 
IV. Synthesis of of Fmoc-Pro-Ala-Asn-Lys(DOTA-Gd3+)-Spacer-AQ (70)  
Compound 69 (0.06 g, 0.04 mmol) was dissolved in water (2 mL). To this solution 
Gadolinium (III) chloride hexahydrate (2.8 eq, 0.05 g, 0.12 mmol) dissolved in 
water (2 mL) was added following the same procedure as described for the 
synthesis of compound 62. The crude product obtained was then purified by a 
silica gel chromatography column (13 cmx2.5 cm) prepared with chloroform: 
MeOH: pyridine: 35% ammonia (20:55:15:10). The column was eluted with the 
same solvent system. Fractions containing the product were combined, filtered 
and evaporated to a low volume. Yield: 0.02 g (29%). TLC (fraction 2): Rf 0.3 
(Chloroform:MeOH:Pyridine:Ammonia-20:55:15:10). The molecular mass of the 
product (70) was 1527.53, ESI-HR (+) m/z: 764.7751 (100%) [(M+2H)/2]2+. 
ESMS-LR (+) m/z: 775.7 (100%) [(M+2H+Na)/2]2+, 1527.5 (100%) (M)+, 1528.5 
(90%) (M+H)+, 1550.5 (60%) (M+Na)+. 
D. Synthesis of of Fmoc-β-Ala-Ala-Asn-Lys(DOTA-Gd3+)-Spacer-AQ (74) 
I. Synthesis of Fmoc-β-Ala-Ala-Asn(Trt)-OH (71) 
An asparagine pre-loaded resin for solid phase peptide synthesis with a 4-
carboxytrityl linker (0.5 g, 0.21 mmol/g) was swollen in DCM according to method 
A and the coupling and deprotection cycles were performed as per methods C, D, 
B followed by peptide cleavage from the resin according to method E: 
 1st cycle: N-Fmoc-L-Alanine (0.25 g, 0.79 mmol). 
 2nd cycle: N-Fmoc-β-Alanine (0.25 g, 0.79 mmol). 
Upon successful coupling of the second amino acid, the tri peptide was cleaved 
from the resin following method E. Crude yield: 0.07 g (88%). The purity of the 
compound was 63% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient A, 23 min, 254 nm, Rt. 14.68’). The 
molecular weight of the product (71) was 738.31, ESI-HR (+) m/z: 739.3124 
(100%) (M+H)+. ESMS-LR (+) m/z: 738.8 (60%) (M)+, 760.8 (100%) (M+Na)+. 
ESMS-LR (-) m/z: 737.4 (20%) (M-H)-. 
II. Synthesis of Fmoc-β-Ala-Ala-Asn(Trt)-Lys(DOTA-tBu)-Spacer-AQ (72) 
Peptide sequence 71 (0.07 g, 0.09 mmol) was dissolved in DMF (3 mL). To this 
solution compound 56 (1.1 eq, 0.11 g, 0.10 mmol), TBTU (3.3 eq, 0.10 g, 0.31 
mmol), HOBt (3.3 eq, 0.04 g, 0.31 mmol) dissolved in DMF (5-10 mL) followed by 
216 
 
the addition of DIPEA (9.6 eq, 0.16 g/mL, 0.91 mmol) was added following the 
same procedure as described for the synthesis of compound 60. The product was 
used for subsequent reaction without further purification. Crude yield: 0.15 g 
(88%). TLC: Rf 0.8 (DCM:MeOH-9:1).  The molecular weight of the product (72) 
was 1758.92, ESMS-LR (+) m/z: 879.0 (100%) [(M+2H)/2]2+, 1758.4 (40%) 
(M)+. ESMS-LR (-) m/z: 1790.4 (45%) (M+Cl)-. 
III. Synthesis of Fmoc-β-Ala-Ala-Asn-Lys(DOTA-OH)-Spacer-AQ (73) 
Compound 72 (0.15 g, 0.09 mmol) was dissolved in TFA (3 mL) at rt following the 
same procedure as described for the synthesis of compound 61. The precipitate 
was filtered and dried in a vacuum desiccator. Crude yield: 0.08 g (73%). TLC: Rf 
0.08 (DCM:MeOH-9:1). The molecular mass of the product (73) was 1346.62 
ESMS-LR (+) m/z: 674.0 (100%) [(M+2H)/2]2+, 1346.6 (80%) (M)+, 1347.6 
(60%) (M+H)+, 1368.6 (20%) (M+Na)+. ESMS-LR (-) m/z: 1345.6 (80%) (M-H)- 
IV. Synthesis of of Fmoc-β-Ala-Ala-Asn-Lys(DOTA-Gd3+)-Spacer-AQ (74) 
Compound 73 (0.08 g, 0.06 mmol) was dissolved in water (2 mL). To this solution 
Gadolinium (III) chloride hexahydrate (2.8 eq, 0.06 g, 0.17 mmol) dissolved in 
water (2 mL) was added following the same procedure as described for the 
synthesis of compound 62. The crude product obtained was then purified by a 
silica gel chromatography column (20 cmx2.5 cm) prepared with chloroform: 
MeOH:pyridine:35% ammonia (20:55:15:10). The column was eluted with the 
same solvent system. Fractions containing the product were combined, filtered 
and evaporated to a low volume. Yield: 0.07 g (78%). TLC (fraction 2): Rf 0.4 
(Chloroform: MeOH: Pyridine: Ammonia- 20:55:15:10). The purity of the 
compound was 65% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient G, 23 min, 254 nm, Rt. 11.81’). The 
molecular mass of the product (74) was 1501.52, ESI-HR (+) m/z: 1502.5225 
(100%) (M+H)+. ESMS-LR (+) m/z: 751.7 (100%) [(M+2H)/2]2+, 762.7 (90%) 
[(M+2H+Na)/2]2+, 1524.5 (55%) (M+Na)+. 
 
3.7. MMP (2/9) targeted gadolinium based contrast agents for MR 
imaging of atherosclerotic plaques 
3.7.1. Synthesis of peptide substrates designed to be specific to MMP-2/9 
via solid phase peptide synthesis (JJ series) 
I. Synthesis of N-Fmoc-Ala-Pro-Leu-Gly-Ala-Ser-Gly-OH (75) 
Glycine pre-loaded resin for solid phase peptide synthesis with a 2-chlorotrityl 
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linker (0.5 g, 0.64 mmol/g) was swollen in DCM as in method A and 
coupling/deprotection cycles were performed as follow:  
 1st cycle: N-Fmoc-L-Ser (tBu) (0.92 g, 2.40 mmol) was coupled to the resin 
according to method B. Primary amine detection confirming the success of 
the reaction was checked using the Kaiser test kit following method D. 
Removal of the subsequent Fmoc protecting group was performed in 
accordance to method C. Presence of free amine due to deprotection was 
confirmed by Kaiser test (method D). 
 2nd cycle: N-Fmoc-L-Alanine (0.74 g, 2.40 mmol) was coupled to the resin 
according to method B. Primary amine detection confirming the success of 
the reaction was checked using the Kaiser test kit following method D. 
Removal of the subsequent Fmoc protecting group was performed in 
accordance to method C. Presence of free amine due to deprotection was 
confirmed by Kaiser test (method D). 
 3rd cycle: N-Fmoc-Glycine (0.71 g, 2.40 mmol) was coupled to the resin 
according to method B. Primary amine detection confirming the success of 
the reaction was checked using the Kaiser test kit, following method D. 
Removal of the subsequent Fmoc protecting group was performed in 
accordance to method C. Presence of free amine due to deprotection was 
confirmed by Kaiser test (method D). 
 4th cycle: N-Fmoc-L-Leucine (0.85 g, 2.40 mmol) was coupled to the resin 
according to method B. Primary amine detection confirming the success of 
the reaction was checked using the Kaiser test kit, following method D. 
Removal of the subsequent Fmoc protecting group was performed in 
accordance to method C. Presence of free amine due to deprotection was 
confirmed by Kaiser test (method D). 
 5th cycle: N-Fmoc-L-Proline (0.81 g, 2.40 mmol) was coupled to the resin 
according to method B. Primary amine detection confirming the success of 
the reaction was checked using the Kaiser test kit, following method D. 
Removal of the subsequent Fmoc protecting group was performed in 
accordance to method C. Presence of free amine due to deprotection was 
confirmed by Kaiser test (method D). 
 6th cycle: N-Fmoc-D-Alanine (0.74 g, 2.40 mmol) was coupled to the resin 
according to method B. Primary amine detection confirming the success of 
the reaction was checked using the Kaiser test kit, following method D. 
On successful completion of the sixth coupling the polypeptide was cleaved from 
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the resin following the procedure in method E. Crude yield: 0.16 g (59%). 
Molecular mass of the peptide sequence (75) with tert-Butyl protecting group on 
serine was 849.97, ESI-HR (+) m/z: 850.4349 (99%) (M+H)+. ESMS-LR (-) m/z: 
849.2 (50%) (M)-. 
To a few resin beads TFA (100%) was added and the procedure as in method E 
was followed. Molecular mass of peptide sequence without the tert-Butyl protecting 
group on serine was 793.99, ESMS-LR (+) m/z: 816.4 (99%) (M+Na)+. ESMS-LR 
(-) m/z: 793.2 (50%) (M)-. 
II. Synthesis of N-Fmoc-Ala-Ala-Leu-Ala-Nva-Leu-Gly-OH (76) 
Glycine pre-loaded resin for solid phase peptide synthesis with a 2-chlorotrityl 
linker (0.5 g, 0.64 mmol/g) was swollen in DCM as in method A and 
coupling/deprotection cycles were performed as follow:   
 1st cycle: N-Fmoc-L-Leucine (0.85 g, 2.40 mmol) 
 2nd cycle: N-Fmoc-L-Norvaline (0.81 g, 2.40 mmol)  
 3rd cycle: N-Fmoc-Alanine (0.74 g, 2.40 mmol) 
 4th cycle: N- Fmoc-L-Leucine (0.85 g, 2.40 mmol) 
 5th cycle: N-Fmoc-L-Alanine (0.74 g, 2.40 mmol) 
 6th cycle: N-Fmoc-L-Alanine (0.74 g, 2.40 mmol) 
On successful completion of the sixth coupling the polypeptide was cleaved from 
the resin following method E. Crude yield: 0.06 g (22%). Molecular mass of the 
peptide chain (76) was 835.39, ESMS-LR (+) m/z: 836.4 (100%) (M+H)+, 859 
(70%) (M+Na)+.  
III. Synthesis of N-Fmoc-Lys-Pro-Ala-Gly-Nva-Ala-Gly-OH (77) 
Glycine pre-loaded resin for solid phase peptide synthesis with a 2-chlorotrityl 
linker (0.5 g, 0.64 mmol/g) was swollen in DCM as in method A and coupling/ 
deprotection cycles were performed as follow:   
 1st cycle: N-Fmoc-L-Alanine (0.74 g, 2.40 mmol) 
 2nd cycle: N-Fmoc-L-Norvaline (0.81 g, 2.40 mmol) 
 3rd cycle: N-Fmoc-Glycine (0.71 g, 2.40 mmol) 
 4th cycle: N-Fmoc-L-Alanine (0.74 g, 2.40 mmol)  
 5th cycle: N-Fmoc-L-Proline (0.81 g, 2.40 mmol) 
 6th cycle: N-Fmoc-L-Lysine(Boc) (1.12 g, 2.40 mmol) 
On successful completion of the seventh coupling the polypeptide was cleaved from 
the resin following method E. Crude yield: 0.21 g (81%). Molecular mass of the 
peptide chain (77) was 820.93, ESI-HR (+) m/z: 821.4191 (100%) (M+H)+ ESMS-
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LR (-) m/z: 819.2 (99%) (M-H)-. 
IV. Synthesis of N-Fmoc-Gly-Pro-Arg(Mtr)-Glu(OtBu)-Ile-Thr(tBu)-Ala-
Gly-OH (78) 
Glycine pre-loaded resin for solid phase peptide synthesis with a 2-chlorotrityl 
linker (0.5 g, 0.64 mmol/g) was swollen in DCM as in method A and coupling/ 
deprotection cycles were performed as follow:   
 1st cycle: N-Fmoc-L-Alanine (0.74 g, 2.40 mmol) 
 2nd cycle: N-Fmoc-L-Theronine (tBu) (0.95 g, 2.40 mmol)  
 3rd cycle: N-Fmoc-L-Isoleucine (0.84 g, 2.40 mmol) 
 4th cycle: N- Fmoc-L-Glutamate (OtBu) (1.02 g, 2.40 mmol)  
 5th cycle: N-Fmoc-L-Arginine (Mtr) (1.46 g, 2.40 mmol)  
 6th cycle: N-Fmoc-L-Proline (0.81 g, 2.40 mmol) 
 7th cycle: N-Fmoc-Glycine (0.71 g, 2.40 mmol) 
On successful completion of the seventh coupling the polypeptide was cleaved from 
the resin following method E. Crude yield: 0.25 g (58%). The purity of the 
compound was 76% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient D, 28 min, 300 nm, Rt. 19.76’). 
Molecular mass of the peptide chain (78) was 1345.40, ESI-HR (+) m/z: 
1346.6681 (100%) (M+H)+. ESMS-LR (+) m/z: 673.8 (90%) [(M+2H)/2]2+. 
ESMS-LR (-) M/Z: 1344.4 (99%) (M-H)-; 1345.2 (75%) (M)-. 
V. Synthesis of N-Fmoc-Ile-Pro-Arg(Mtr)-Thr(tBu)-Leu-Thr(tBu)-Ala-Gly-
OH (79) 
Glycine pre-loaded resin for solid phase peptide synthesis with a 2-chlorotrityl 
linker (0.5 g, 0.64 g/mmol) was swollen in DCM as in method A and 
coupling/deprotection cycles were performed as follow:   
 1st cycle: N-Fmoc-L-Alanine (0.74 g, 2.40 mmol) 
 2nd cycle: N-Fmoc-L-Theronine(tBu) (0.95 g, 2.40 mmol)  
 3rd cycle: N-Fmoc-L-Leucine (0.84 g, 2.40 mmol) 
 4th cycle: N- Fmoc-L-Theronine(tBu) (0.95 g, 2.40 mmol)  
 5th cycle: N-Fmoc-L-Arginine(Mtr) (1.46 g, 2.40 mmol)  
 6th cycle: N-Fmoc-L-Proline (0.81 g, 2.40 mmol) 
 7th cycle: N-Fmoc-L-Isoleucine (0.84 g, 2.40 mmol) 
On successful completion of the seventh coupling the polypeptide was cleaved from 
the resin following method E. Crude yield: 0.40 g (91%). The purity of the 
compound was 97% on an analytical RP-HPLC system following the general 
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procedure as mentioned in 4.2.5. (Gradient C, 28 min, 254 nm, Rt. 21.52’).   
Molecular mass of the peptide chain (79) was 1373.15, ESI-HR (+) m/z: 
1374.7366 (100%) (M+H)+. ESMS-LR (+) m/z: 1396.7 (20%) (M+Na)+. ESMS-LR 
(-) m/z: 1372.2 (99%) (M-H)-; 1373.2 (85%) (M)-. 
 
VI. Synthesis of N-Fmoc-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr(tBu)-Ala-
Gly-OH (80) 
Glycine pre-loaded resin for solid phase peptide synthesis with a 2-chlorotrityl 
linker (0.5 g, 0.64 g/mmol) was swollen in DCM as in method A and coupling/ 
deprotection cycles were performed as follow:   
 1st cycle: N-Fmoc-L-Alanine (0.74 g, 2.40 mmol) 
 2nd cycle: N-Fmoc-L-Theronine(tBu) (0.95 g, 2.40 mmol)  
 3rd cycle: N-Fmoc-L-Leucine (0.84 g, 2.40 mmol) 
 4th cycle: N- Fmoc-L-Arganine(Mtr) (1.46 g, 2.40 mmol) 
 5th cycle: N-Fmoc-L-Arginine(Mtr) (1.46 g, 2.40 mmol)  
 6th cycle: N-Fmoc-L-Proline (0.81 g, 2.40 mmol) 
 7th cycle: N-Fmoc-Glycine (0.71 g, 2.40 mmol) 
On successful completion of the seventh coupling the polypeptide was cleaved from 
the resin following method E. Crude yield:  0.45 g (92%). The purity of the 
compound was 83% on an analytical RP-HPLC system following the general 
procedure as mentioned in 4.2.5. (Gradient C, 28 min, 254 nm, Rt. 19.94’).   
Molecular mass of the peptide chain (80) was 1528.35, ESI-HR (+) m/z: 
1529.7147 (100%) (M+H)+. ESMS-LR (+) m/z: 765 (70%) [(M+2H)/2]2+; 1551 
(25%) (M+Na)+. ESMS-LR (-) m/z: 1527 (85%) (M-H)-. 
 
3.7.2. Synthesis of Gadolinium-DOTA-Peptide substrate designed to be 
specific to MMP-2/9 
3.7.1.1. Attempted synthesis of JD- (Gd(III)-DOTA-Gly-12-aminodode 
canoicacid-Ala-Ala-Leu-Ala-Nva-Leu-Gly-OH) 
I. Synthesis of 12-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)dode 
canoicacid (81) 
Fmoc N-hydroxysuccinimide ester (Fmoc-OSu) (3.00 g, 8.89 mmol) was dissolved 
in dioxane:water (60 mL, 4:1). To this solution 12-aminododecanoic acid (1.1 eq, 
2.11 g, 9.78 mmol) dissolved in dioxane:water (50 mL, 4:1) with triethylamine 
(TEA) (2 eq, 2.48 mL, 17.79 mmol) was added and stirred at rt for 12hrs. The 
solution was concentrated and the mixture was partitioned between DCM and 
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water. The DCM extracts were washed with saturated sodium hydrogen carbonate 
(3 x 100 mL), water (3 x 100 mL), dried, filtered and evaporated to low volume. 
The crude product obtained was purified by column chromatography. The column 
(13 cmx2.5 cm) was eluted initially with DCM. The eluent was then changed to 
DCM:MeOH (9.5:0.5). Fractions containing the product were combined, filtered 
and evaporated to dryness. Yield: 1.29 g (33%). TLC (fraction 3): Rf 0.2 
(DCM:MeOH [9.5:0.5]). Molecular mass of compound (81) was 437.26, ESMS-LR 
(+) m/z: 438.2 (99%) (M+H)+.  
H1 NMR (400MHz, d1-CDCl3), δ ppm: 1.30 (14H, s, 7xCH2), 1.45-1.52 (2H, m, CH2-
CH2-NH), 1.65 (2H, quin, J=7.2Hz, CH2-CH2-COOH), 2.37 (2H, t, J=7.4Hz, CH2-
COOH), 3.20 (2H, m, CH2-NH), 4.22-4.28 (1H, m, CH-Fmoc protecting group), 
4.42-4.47 (2H, m, CH2-CH-Fmoc protecting group), 7.34 (2H, td, J1=7.6Hz, 
J2=1.2Hz, 2xH-2), 7.43 (2H, t, J=7.4Hz, 2xH-3), 7.62 (2H, d, J=7.2Hz, 2x H-4), 
7.79 (2H, d, J=7.6Hz, 2xH-1). 
II. Synthesis of HO-DOTA-Gly-12-aminododecanoicacid-Ala-Ala-Leu-Ala-
Nva-Leu-Gly-2-ClTrt resin (84) 
1stcycle: Compound 81 (0.15 g, 0.35 mmol) was coupled to the resin according to 
method B. Primary amine detection confirming the success of the reaction was 
checked using the Kaiser test kit, following method D. Removal of the 
corresponding Fmoc protecting group was performed in accordance to method C. 
Presence of free amine due to deprotection was confirmed by Kaiser test (method 
D). 
2ndcycle (82): N-Fmoc-Glycine (0.10 g, 0.35 mmol) was coupled to the resin 
according to method B. Primary amine detection confirming the success of the 
reaction was checked using the Kaiser test kit, following method D. Removal of 
the corresponding Fmoc protecting group was performed in accordance to method 
C. Presence of free amine due to deprotection was confirmed by Kaiser test 
(method D). 
3rdcycle (83): DOTA-tris-(tBu) (0.20 g, 0.35 mmol) was coupled to the resin 
according to method B. The reaction mixture was stirred for 2hrs at rt.  
On completion of the three coupling the polypeptide was cleaved from the resin 
using the cleavage solution, TFA: H2O: EDT: TA (87.5:2.5:4:6). After 3.5 hrs the 
solvent was evaporated and the concentrate was re-evaporated with EtOH. The 
resulting product (84) was triturated in diethyl ethyl and stored at 6°C overnight. 
The molecular mass of the compound (84) was 1253.57, ESMS-LR (-) m/z: 1252.4 
(99%) (M-H)-; 1253 (75%) (M)-.  
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3.7.1.2. Synthesis of JL (87) 
I. Synthesis of DOTA-tris(tBu)-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr 
(OtBu)-Ala-Gly-Lys-Spacer-AQ (85) 
Compound 56 (0.10 g, 0.10 mmol) was dissolved in DMF (5 mL). To this solution 
peptide sequence 80 (1.1 eq, 0.16 g, 0.11 mmol), TBTU (2.2 eq, 0.07 g, 0.21 
mmol), HOBt (2.2 eq, 0.03 g, 0.21 mmol), DIPEA (6.4 eq, 0.11 g/mL, 0.62 mmol) 
dissolved in DMF (5 mL) was added and stirred at room temperature overnight. 
The solution was then partitioned between DCM and water. The organic solution 
was washed with saturated sodium hydrogen carbonate (3x 100 mL), then water 
(3x100 mL), dried, filtered and evaporated to low volume. Crude yield: 0.17 g 
(68%). TLC: Rf 0.8 (DCM:MeOH-9:1). The molecular weight of the product (85) 
was 2547.48, ESMS-LR (+) m/z: 857.0 (10%) [(M+2H+Na) /3]3+, 1274.2 (100%) 
[(M+2H)/2]2+, 1285.2 (15%) [(M+2H+Na)/2]2+, 2547.8 (15%) (M)+. 
II. Synthesis of HO-DOTA-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr-Ala-Gly-
Lys-Spacer-AQ (86) 
Compound 85 (0.17 g, 0.07 mmol) was dissolved in TFA (2 mL) at rt for 7hours. 
TFA was then evaporated and the resulting concentrate was re-evaporated with 
EtOH (x3). The residue was triturated with diethyl ether (100 mL) and then stored 
at 4-6 °C for 12 hours. The resulting precipitate was filtered and dried in a vacuum 
desiccator. Crude yield: 0.08 g (50%). TLC: Rf 0.05 (DCM:MeOH-9:1). The 
molecular mass of the product (86) was 2323.07, ESMS-LR (+) m/z: 775.0 (75%) 
[(M+3H)/3]3+, 1162.2 (100%) [(M+2H)/2]2+, 1184.0 (15%) [(M+2Na)/2]2+, 
2323.2 (15%) (M)+, 2347.0 (10%) (M+Na)+. 
III. Synthesis of DOTA(Gd3+)-Gly-Pro-Arg(Mtr)-Arg(Mtr)-Leu-Thr-Ala-
Gly-Lys-Spacer-AQ (JL-87) 
Compound 86 (0.08 g, 0.03 mmol) was dissolved in water (2 mL). To this solution 
Gadolinium (III) chloride hexahydrate (2.8 eq, 0.04 g, 0.10 mmol) dissolved in 
water (2 mL) was added. The pH of the reaction mixture was adjusted to 7 by 
adding a solution of ammonia (0.35%) drop wise and stirred at rt for 12hrs. 
Reaction progress was monitored via TLC analysis. The solution was then 
evaporated at rt. Crude yield: 0.05 g (56%). TLC: Rf  0.2 
(Chloroform:MeOH:Pyridine:Ammonia-20:55:15:10). The molecular mass of the 
product (JL-87) was 2477.97, ESMS-LR (+) m/z: 826.4 (60%) [(M+3H)/3]3+, 
1239.0 (100%) [(M+2H)/2]2+, 1250.0 (35%) [(M+2H+Na)/2]2+, 2477.4 (15%) 
(M)+.  
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3.8. UV-Vis Absorption Spectra 
3.8.1. Materials 
Water was used as the control; compound: 9, 1 mg/mL stock in water, similarly 
stock concentration was prepared for compounds 11, 31 and A (5(6)-CBF-Pro-Gly-
Asn-OH); UV-Vis absorbance spectra were recorded on a Helios-alpha UV/Vis 
spectrometer (Thermo Scientific, software-VisionPro,UK); 3 mL quartz cuvette.  
3.8.2. Method  
UV-Vis absorption spectra was performed to determine the absorption area 
between wavelength 200-600 nm. The compounds were dissolved in water and 
the final concentration was 50 µM (for each compound) in the cuvette. 
  
3.9. Fluorescence measurements 
3.9.1. Materials 
Water was used as the control; compounds: 9, 11, 31 and A (1 mg/mL stock in 
water); Fluorescence spectra were recorded on a LS-55 luminescence 
spectrophotometer (Perkin Elmer, software-FL Win Lab, UK) using a quartz cell of 
1cm path length at rt. 
3.9.2. Method 
Fluorescent measurements are done in order to evaluate fluorescence intensity of 
FRET compounds. This is a quick and simple procedure to compare fluorescence 
intensities between the FRET compounds and its fluorophore. The fluorescence 
spectra for the samples were measured using an excitation wavelength of 490nm 
and emission wavelength scan over the range 500nm-600nm. In order to have a 
final concentration of 0.5 µM of the fluorophore 5(6)-CBF 15 µL of 5(6)-CBF (stock 
conc. 100 µM) was mixed with 2985 µL of water; and 16.6 µL of compound 11 was 
mixed with 2983.4 µL of water to make a final concentration of 5 µM and the 
results were recorded.  
3.10. Legumain activity assay 
The legumain assay for the FRET compounds (JC series) was done in order to 
evaluate the substrate specificity of the compounds when incubated with legumain. 
This can be analyzed by the gradual increase in fluorescence when cleaved by the 
activated enzyme (legumain).  
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3.10.1. Materials 
Recombinant human legumain/asparaginyl endopeptidase (rh Legumain) was 
purchased from R&D Systems (UK) as a pro-form 49 kDa enzyme. Reagents and 
materials required for the legumain assay were: activation buffer consisting of 50 
mM sodium acetate, 100 mM sodium chloride, pH 4.0; assay buffer consisting of 
50 mM MES (2-(N-morpholino)ethanesulfonic acid), 250 mM NaCl, pH 5.0; 96well 
black maxisorp F16  plate; FluoStar Omega multi-mode microplate reader and test 
compounds (selective compounds from the JC and JS series).   
3.10.2. Legumain assay on JC series of peptide substrates   
A stock solution was produced by taking rh-Legumain 10 µg and diluting with 100 
µL activation buffer (pH 4.0) and stored at -78°C. The enzyme was activated by 
incubating the aliquots for 2hrs at 37ºC. The activated enzyme was then diluted 
to 1 ng/µL using assay buffer at pH 5.0 Each compound (8, 11, 31, 34, 38, 41 and 
46) in the substrate library (stock solution: 1mg/ml dissolved in DMSO) was 
assayed in triplicate at a final concentration of 10 µM per well against the activated 
enzyme (40 µl/well).  
Figure 64: Template for assay conditions. 
Enzyme assay was performed in a 96 well microtiter plate and the final volume in 
each well was made 100µl using assay buffer (figure 64). The gradual increase in 
fluorescence was measured at 5 minute intervals using FLUOstar omega multi-
mode microplate reader (BMG Labtech, software-Omega) with excitation at 485 
B 
B
B
B+F 
B+F 
B+F 
B+P 
B+P 
B+P 
B+L 
B+L 
B+L 
B+F+L 
B+F+L 
B+F+L 
B+P+L 
B+P+L 
B+P+L 
For e.g., in each well: A1-C1: 100µL assay buffer (B).  
                                A2-C2: 90µL assay buffer (B) + 10µL 100µM 5(6)Carboxyfluorescein (F). 
                A3-C3: 98.9µL assay buffer (B) + 1.1µL 902.1µM probe (P). 
                                A4-C4: 60 µL assay buffer (B) + 40µL 1ng/µL rh Legumain stock solution (L). 
                                A5-C5: 50µL (B) + 10µL 100µM (F) + 40µL 1ng/µL (L). 
                                A6-C6: 58.9µL (B) + 1.1µL 902.1µM probe (P) + 40µL 1ng/µL (L). 
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nm and emission at 520 nm based on the fluorescence properties of free 5(6)-
CBF. 
3.10.3. Legumain assay for JS linear/JS lysine series of peptide substrates 
The same procedure as mentioned in section 3.9.2. was followed for rh-Legumain 
storage, preparation activation and incubation with compounds. The major 
difference was, the assay was performed in sterile eppendorf tubes with the final 
volume in each tube being 600 µL (e.g., Assay buffer: 352.3 µL, Substrate (10 
µM): 7.7 µL, rh Legumain: 240 µL) for compounds 49, 53, 62, 66, 70 and 74. The 
compounds were incubated with the activated legumain for 2 hours at 37°C. The 
resulting enzyme digested product was neutralized with triethylamine and then 
extracted into chloroform (500 µL) and washed with water (500 µL) (x10). Both 
the organic and aqueous solutions were air-dried at room temperature and 
characterized by high-resolution ESI-MS.  
3.11. Cytotoxicity assay  
3.11.1. MDA-MB-231 cells 
Human breast epithelial cancer cells (MDA-MB-231) were purchased from 
European Collection of Cell Cultures (ECACC) (ECACC: 92020424). MDA-MB-231 
(1x104 cells/well) cells were cultured in Roswell Park Memorial Institute 1640 
medium (RPMI-1640) containing GlutaMAXTM-1 with 25 mM HEPES supplemented 
with Fetal calf serum (FCS) (10% v/v) and penicillin (1%,100 U/mL)/ streptomycin 
(100 μg/mL). 
3.11.2. Maintenance of MDA-MB-231 cells 
The MDA-MB-231 cells were incubated (HERAcell 150, Thermo scientific, UK) at 
37°C in a humidified atmosphere of 5% CO2. Cells were passaged by washing twice 
with phosphate buffered saline (PBS) and detached for 5 minutes with trypsin-
EDTA at 37°C. Trypsinised cells were neutralized with RPMI medium and 
centrifuged (Heraeus Primo R, Thermo scientific, UK) for 5 minutes (1500 rpm) at 
room temperature. The supernatant was discarded and the cell pellet resuspended 
in RPMI medium. The cells were then counted using a Neubauer Haemocytometer 
under a Leica DMIL- Inverted microscope (Leica Micro systems ltd, UK).  
3.1.2.3. Colourimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-(diphenyltetrazo 
liumbromide) (MTT) assay 
MDA-MB-231 (1x104cells/well) cells were seeded in a 96 well plates. After 24 hour 
of cell attachment, four compounds- 62, 66, 70 and 58 were added to each well to 
produce a final concentration of 0.01, 0.1, 1, 5, 10, 15, 20 and 40Μm in DMSO 
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(100 μL/well) and incubated for 24 and 72 hours (figure 65). DMSO was used as 
the control solvent. After the preferred incubation time, the cell culture medium 
was removed and replaced with sterile filtered MTT solution (1 mg/mL in medium, 
100 μL/well). The cells were incubated for 4 hours at 37°C. 
 
Figure 65: MTT assay condition for the drug compounds. 
After the incubation time, MTT solution was replaced with DMSO (200 μL/well), 
which solubilizes the metabolized MTT product (formazan). The plates were shaken 
(Polymax 1040 wave platform shaker, Heidolph) for 15-20 minutes at room 
temperature and the absorbance was measured at 560 nm (Synergy HT microplate 
reader, BioTek, software-Gen 52.04).   
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5. Appendix  
 
Appendix 1 
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Figure S1: 1H, 1H-COSY NMR spectra of compound 5 in d-DMSO. 
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Appendix 2 
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Figure S2: 1H, 1H-COSY NMR spectra of compound 21 in d-DMSO confirming the coupling 
between δ-methine (9’) and β-methylene (8’); amino group proton of AQ with 1’ and the 
α proton of leucine with β-methylene (8’). 
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Appendix 3 
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Figure S3: 1H, 1H-COSY NMR spectra of compound 22 in d-DMSO. 
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Appendix 4 
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Figure S4: 1H, 1H-COSY NMR spectra of compound 26 in d-DMSO. 
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Appendix 5 
High resolution mass spectrometry results for compounds were obtained via 
positive ion/negative ion nano-electrospray ionization (ESI) as performed on a 
thermofisher LTQ orbitrap XL mass spectrometer. 
Compound 9 
Molecular weight: 999.37 
 
Compound 12 
Molecular weight: 1055.43 
 
 
 
(M-H)
-
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Compound 15 
Molecular weight 987.37 
 
Compound 18 
Molecular weight: 1029.42  
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Compound 34 
Molecular weight: 1082.40 
 
Compound 38 
Molecular weight: 1122.43 
 
 
 
(M+H)
+ 
(M+H)
+
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Compound 41 
Molecular weight: 1096.42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 46 
Molecular weight: 1178.46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(M+H)
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(M+H)
+
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Compound 47 
Molecular weight: 1545.85 
 
 
Compound 48 
Molecular weight: 1135.55  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(M+Na)
+
 
[(M+2H)/2]
2+
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Compound 59 
Molecular weight: 750.30 
 
Compound 63 
Molecular weight: 724.29 
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+
 
(M+H)
+
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Compound 67 
Molecular weight: 764.32 
 
Compound 71 
Molecular weight: 738.31 
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(M+H)
+
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Compound 78 
Molecular weight: 1345.40 
 
 
 
Compound 80 
Molecular weight: 1558.35   
 
 
(M+H)
+
 
(M+H)
+
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Atherosclerosis is a serious medical condition wherein the arteries become 
blocked by fatty substances such as cholesterol, leading to hardened or 
narrow blood vessels.  Early diagnosis and treatment of these atheromas is 
necessary as they may result in either the damage of organs or they may 
rupture, releasing a blood clot instigating a heart attack or stroke [1]. 
Recent studies have implicated the role of legumain- a cysteine protease, in 
the progression and activation of plaque rupture [2]. In addition, over 
expression of active legumain is found in unstable regions of atheromas. 
These findings suggest that legumain may have the potential to be 
exploited for targeted delivery of drugs/imaging agents.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM AND OBJECTIVES  
The aim of this research project was the design, synthesis and evaluation of 
selective non-invasive imaging agents for atherosclerotic plaques. To 
achieve this, the study was split into three objectives.  
• The synthesis, purification and characterisation of a small discrete library 
of peptide motifs, designed to be substrates for legumain. 
• The covalent attachment of imaging agent (e.g., Gd complexes).  
• Evaluation of in vitro cleavage and release of imaging agent.  
 
INTRODUCTION 
 
 
METHODOLOGY 
RESULTS AND DISCUSSION 
Legumains are found to exhibit restricted specificity for peptide hydrolysis 
on the carboxyl side of asparagine residues [3]. By exploiting this 
condition six peptide substrates containing asparagine at P1 position of the 
tetra peptide sequence were synthesized [4]. These were characterized by 
high resolution mass spectrometry.  
 
 
 
 
 
 
 
 
 
 
 
Each sequence contained a fluorophore (5(6) carboxyfluorescein) at the N-
terminal. The peptide’s fluorescence was measured prior to and after 
anthraquinone coupling. The results indicated that the anthraquinone 
system effectively quenched the peptide-fluorophore. It is hoped that this 
phenomenon can now be used to further elucidate peptide substrate 
specificity for legumain.   
 
 
 
 
 
 
 
 
Moreover enzyme studies on these substrates clearly showed their 
specificity to legumain by the relative increase in fluorescence intensity 
when hydrolyzed on the carboxyl side of asparagine for e.g., JSLP1. 
 
 
 
  
 
 
CONCLUSION AND FUTURE WORK 
Six anthraquinone-peptide-fluorescein FRET systems, designed to be 
specific to legumain, have been synthesized and characterized.  These 
peptide substrates may be exploited to not only deliver site specifically, 
contrast agents for magnetic resonance imaging but also pharmacological 
actives in a range of disease states.  
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SOLID PHASE PEPTIDE SYNTHESIS 
The peptide was synthesized by sequential addition of amino acids using 
PyBOP and DIPEA.  Reaction completion was determined by a Kaiser test.  
The tetra-peptide sequence was then cleaved from the resin using 5% TFA 
in DCM. Coupling of the anthraquinone-spacer moiety was achieved using 
similar coupling conditions. 
SOLUTION PHASE PEPTIDE SYNTHESIS 
An anthraquinone moiety was coupled to the peptide using HOBT, TBTU, 
DIPEA in solution.  After each coupling and deprotection the samples were 
purified by column chromatography and characterized by mass 
spectrometry. On substrate optimization, the final step of coupling an 
imaging agent will occur on a ε-lysine residue. 
ENZYME ASSAY 
These peptide sequences were then incubated with rhLegumain/Aparaginyl 
Endopeptidase at 37ºC for 2hours. 
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Atherosclerosis is a slow process, where a plaque develops at a very early stage of 
life and ultimately leads to narrowing of the blood vessel, impairing the flow of 
blood in susceptible patients (1).  Research on MMPs has indicated that they play a 
vital role in the development of atherosclerotic plaques. Their expression is not only 
part of atherosclerosis pathogenesis, but may also be predictive of plaque instability. 
With characterization of peptide substrates specific to certain MMPs, their role has 
been exploited to not only deliver site specifically, pharmacological actives in a 
range of disease states both in vivo and in vitro but also as a device to localize 
imaging agents (3,4) .   
 
Introduction, aim and objectives 
0
Methodology 
0
Results and Discussion 
0A library of six peptides designed to be MMP-2/MMP-9 substrates have been 
synthesized and characterized by mass spectrometry. For example ESMS (+) which 
showed a signal at m/z 850.4 (M+1)+ corresponding to molecular mass of 849.97 as 
shown in the scheme below. 
 
Conclusion and future work 
0Conclusion  
The overall aim of this study is the development of a non-invasive imaging agent 
that can be deposited site specifically, via MMP cleavage, in vulnerable plaques. Six 
peptides designed to be MMP-2/MMP-9 substrates were synthesised. The structure 
of these peptide substrates was confirmed by mass spectrum analysis. Synthesis of a 
peptide based contrast agent was also undertaken. However, the complexation of the 
metal ion is yet to be done. 
 
Future work 
• Optimisation of conditions for mono substitution of DOTA/DTPA. 
• To develop a library of oligopeptide MMP-2/MMP-9 substrates. 
• Evaluate susceptibility of these peptide substrates to MMP-2/MMP-9 cleavage. 
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Synthesis of Gadolinium-DOTA-Peptide complex (JD4) 
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MMP-2/MMP-9 Region of cleavage/ hot spot AA4 Gd/DTPA or Gd/DOTA complex AA3 AA2 AA1 AA 1 AA 4 AA 2 AA 3 
AA 1 AA 2 AA 3 AA 4 
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Aim and Objectives 
The aim of this research project was the design, synthesis and evaluation of selective 
non-invasive imaging agents for atherosclerotic plaques.  To achieve this, the study 
was split into three objectives.  
• The synthesis, purification and characterisation of a small discrete library of peptide 
motifs, designed to be substrates for MMP-2/MMP-9. 
• The covalent attachment of imaging agents (e.g., Gd complexes). 
• Evaluation of in vitro cleavage and release of imaging agent.  
Resin AA Resin pre-loaded with amino acid (A) Resin AA Peptide sequence
(B) 
Resin AA Peptide sequence12-Ado acid (C) 
Resin AA Peptide sequence12-Ado 
acid AA (D) 
Resin AA Peptide sequence12-Ado acid AA Chelating agent  
(E) 
Peptide sequence12-Ado acid AA Chelating agent/ Gd3+ AA (A)Sequential coupling of amino acids. (B)Conjugation of Fmoc-12-Ado-acid. (C)Coupling of glycine residue. (D)Coupling of chelating agent (DOTA/DTPA) 
(E)Cleavage of resin and conjugation of Gd3+.  
 Synthesis of JD1 
The peptide sequence was synthesised 
by the sequential conjugation of the 
amino acids, Leu-Nva-Ala-Leu-Ala-
Ala using coupling agents HOBT, 
TBTU, DIPEA. After each coupling 
and deprotection the resin was washed 
with DMF (X1), DCM (X1), DCM/i-
Pr-OH (X3), i-Pr-OH (X3), DCM 
(X3). Reaction completion was 
confirmed by Kaiser test. 
 
Synthesis of JD2 
Fmoc-12-aminododecanonic acid was 
coupled to the peptide sequence using 
coupling agents HOBT, TBTU, 
DIPEA. This followed an adapted 
procedure by Espelt and co-workers 
(2).  
 
Synthesis of JD3 
A glycine residue was added to enhance 
the yield and facilitate efficient coupling 
of DOTA to the peptide sequence. 
DOTA-tris(t-Bu) was coupled to the 
sequence using coupling agents 
following the same parameters as JD1 
and JD2. The resulting sequence (JD3) 
was cleaved using TFA:H2O:EDT:TA  
(87.5:2.5:4:6, v/v/v/v) for 4hrs at room 
temperature.  
 
Synthesis of JD4 
The complexation of gadolinium 
chloride hexahydrate to the sequence 
will be undertaken at neutral pH.  
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Peptide sequence
a) Coupling- fmoc protected amino acids (n1,n2,n3..),
    HOBt, TBTU, DIPEA in DMF.
b) Deprotection- piperidine/DMF (1:4).
c) Removal of resin and side chain protecting groups
    1% TFA in DCM.
Peptide sequence
Characterization by LCMS
An attempted synthesis of Gadolinium-DOTA-Peptide (JD4) was also undertaken. 
Furthermore, the successful coupling of a hydrophobic moiety (Ado) was achieved. 
It is hoped that the addition of Ado to the peptide substrate will decrease the 
solubility of the cleaved contrast agent in vitro resulting in deposition of the imaging 
agent (5). The addition of a chelating agent and subsequent complexation reaction is 
now underway.   
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